var title_f35_35_36400="Spot magnification MLO view";
var content_f35_35_36400=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F74424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F74424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 489px\">",
"   <div class=\"ttl\">",
"    Medial lateral oblique mammographic view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 469px; height: 242px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These images illustrate the benefits of spot compression and magnification. In the left panel (A), a medial lateral oblique (MLO) mammographic image, there is a mass at the posterior edge of the film (arrows) which is incompletely characterized. The borders of the lesion can be better characterized with regional spot compression and magnification. The spot magnification MLO view (B) shows that the lesion has irregular borders and spiculation. In addition, associated microcalcifications are seen. The lesion can now be characterized as suspicious, BIRADS 4c, requiring biopsy. Pathology revealed infiltrating duct cell carcinoma with papillary features.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_35_36400=[""].join("\n");
var outline_f35_35_36400=null;
var title_f35_35_36401="Patient information: Temporomandibular joint (TMJ) disorders (The Basics)";
var content_f35_35_36401=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?23/12/23746\">",
"         Patient information: Chronic pain (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Temporomandibular joint (TMJ) disorders (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/temporomandibular-joint-tmj-disorders-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H13954786\">",
"      <span class=\"h1\">",
"       What are temporomandibular joint disorders?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Temporomandibular joint disorders are problems with the jaw joint and the muscles around it. The jaw joint, called the &ldquo;temporomandibular joint,&rdquo; is located in front of the ear where the jawbone connects to your head. To feel the joint, place your finger on your cheek just in front of your ear and then open and close your mouth.",
"     </p>",
"     <p>",
"      When doctors refer to temporomandibular joint disorders, they often call it &ldquo;TMJ,&rdquo; for short. TMJ can be caused by many problems, including arthritis. More often it is due to a combination of stress, jaw clenching, teeth grinding, and other things that strain the jaw joint and the muscles around it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13954801\">",
"      <span class=\"h1\">",
"       What are the symptoms of TMJ?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptom of TMJ is a dull pain in the jaw muscles that doesn&rsquo;t go away. The pain is often on just one side of the face, near the ear. Sometimes the pain also affects the ear, jaw, or back of the neck. It is usually worse when chewing. Some people just have headaches with TMJ. Others might hear a clicking or popping sound or have a &ldquo;crunchy feeling&rdquo; in the joint when they open and close their mouth.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13954816\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the pain in your face or jaw is bothering you and does not go away, you should see your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13954831\">",
"      <span class=\"h1\">",
"       What tests might I need?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There is no single test that can show if you have TMJ. Your doctor or nurse should be able to tell if you have TMJ by learning about your symptoms and doing an exam.",
"     </p>",
"     <p>",
"      Unless the doctor finds something unusual in the exam, most patients will NOT need X-rays or an MRI (an imaging test that creates pictures of the inside of your body). &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13954846\">",
"      <span class=\"h1\">",
"       How is TMJ treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No single treatment for TMJ works for everyone. Most of the time, medicines and simple lifestyle changes can help. Most patients get better over time, even without treatment, so patience is important.",
"     </p>",
"     <p>",
"      Your doctor or nurse will help you find the right mix of treatments for you. He or she might refer you to a dentist who specializes in TMJ. Treatment options include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines to relieve pain and relax the muscles &ndash; There are several types of medicines used to treat TMJ. These include nonsteroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, and certain medicines used for depression. (Medicines for depression can relieve pain even in people who are not depressed.) Your doctor will decide which medicine or group of medicines is best for you.",
"       </li>",
"       <li>",
"        Jaw exercises &ndash; There are simple jaw exercises that seem to help some people. Ask your doctor to show you how to do them.",
"       </li>",
"       <li>",
"        Bite",
"        <span class=\"nowrap\">",
"         plates/splints",
"        </span>",
"        &ndash; These are special devices that fit in your mouth and keep you from grinding your teeth at night. They are made out of either a hard or soft plastic and might be made specially to fit your mouth. If you have sleep apnea, be sure to tell your doctor as the bite plate or splint might make your sleep apnea worse.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If these treatments don&rsquo;t help, your doctor might suggest that you see a specialist, such as an oral surgeon. The specialist might use medicines given by injection (shots) to treat the pain. It is rare that people need surgery for TMJ.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13954861\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You might feel better if you:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Avoid doing things that make the pain worse, such opening your mouth too wide.",
"       </li>",
"       <li>",
"        Eat soft foods that don&rsquo;t require a lot of chewing.",
"       </li>",
"       <li>",
"        Practice relaxing &ndash; You can learn methods to relax your body, such as doing deep breathing exercises. Ask your doctor or nurse about these methods. Relaxing the mind can help with how the body feels pain. People can learn to quiet their pain or make it less bothersome.",
"       </li>",
"       <li>",
"        Use ice packs to ease the pain &ndash; Use a bag of ice, bag of frozen peas, or cold gel pack once every 2 hours, for 20 minutes each time. Put a towel or cloth between the ice and your skin. Do not put the ice directly on your skin.",
"       </li>",
"       <li>",
"        Put heat on the painful area &ndash; Wet a clean washcloth with warm water and put it on the area. When the washcloth cools, reheat it with warm water and put it back on. Repeat these steps for 10 to 15 minutes every few hours.",
"       </li>",
"       <li>",
"        Avoid stimulants, such as coffee, tea, colas, or decongestant medicines, since these can make your anxiety worse.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13954876\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/12/23746?source=see_link\">",
"       Patient information: Chronic pain (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/35/36401?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 82988 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-115.25.216.6-090AABC1AD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_35_36401=[""].join("\n");
var outline_f35_35_36401=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13954786\">",
"      What are temporomandibular joint disorders?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13954801\">",
"      What are the symptoms of TMJ?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13954816\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13954831\">",
"      What tests might I need?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13954846\">",
"      How is TMJ treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13954861\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13954876\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/12/23746?source=related_link\">",
"      Patient information: Chronic pain (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_35_36402="Rotator cuff tear US trans";
var content_f35_35_36402=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F50236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F50236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Transverse sonogram of rotator cuff tear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 358px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFmAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDzRImwrysiP1GO9V7mW93GNQ0it0CiobeUnYDC31NT/aZllKxOQc8YoArA3kCsGWaMEY5XisfUJJAwxcMcnkEV2tlp2r6ihzI7R4zyKu3Hge7+ymUtGwxnBxQB5iV8yQDzsnvViKEoc+YD7Gty50JIpmWa4iiI7LVKbT7aFGPnk+9AFNnDZUhVP1qKa3k3oY93uRU4SID92rSZ/iqlPLsc7WdSPU0ADSsJxh5FlTpnpWhbXM0Q82dpMf7JqktxE4HmxmQdzT4/Jlz5beWvoTQBp/2ve3X7u2upVQ9j1pQLpCBMQ4PXecE1QiV4lIilUnP3qtw2V1durSEMAOCW60AaTvF5QIjYECi0adcuFV09CMms+5truIbVCj6PmrENxLDbFJzIPdRQBPd+VJKoZtrn+ECo3YlhHu6dqga7iniImMgUDhtvNU/tEUbHytxH95qALL3M0TERxDPT5qpCTF2MxDzW6tUxKS/f3AnuKakPkH964ZDyM9RQA5o3gzmQoW681FZxhpWbznJ9qum7h2g+UjADjPNVIbspKzrDGvbigBmoBFkBjklM39/tWhbTK8QWWeNaznZ+ZEIZCeVq2GVIwRb8n1FACSCCKcOk+Wz1z1qWSed/k+Rwe7cUzb51uSYYkYHjNRmxZ3DkgbRjAPFADkmSB8HMZ9jmmzXbGTayuyn0FRwLi9+4AgHJPNX3s7q4bMEMzxZ6IvWgCvOsstsr2wcHp0qCO2fOZYnOB3NbVjpGoTNiO0uQPQ8Vuw+ENVkiw8a727s3SgDiJLhBCVUSJg8qO9Ot50d+TPGn+0K9Bj8CXNtHtlmhLEZOe1XrLwW4s9zTblB5wmRQB5tcTxtGAshVM9cdagWcJKUkAIxwFPWvT4dF0qHIuI2duw2cE1LcR6Elr5bRRR3I6naOlAHlVqQ0o+VwPpV+eNi48naT6Z5r0d7LRJdNY2cghlHZlFcqulGWRvKuogM5zjmgDn50ZjtcKrjn5TzVdgN6t50jOOuOQBXUHwrdyP5qyI/bIFNOgTxExsjlm4yi0AYEzJcbAQ8i5wSoqxCkdvzbxsw7gnpWymg3EamJFn5HJ24xV6y8PkRGPzW8zuCBQBz3k+YryHncMAZqoNPeKISLGpY9QzV3tl4XtXjYXV8yMPRaz/7F0y2umMlzc3Mf9xVoA46wtGnuZA424GcdqsrYljt2liOm012ypo9thrLQ72eT/ayAKgurm+ux5UGii3zwG6EUAYNpBd26AQRzBj3fpW3YadqEgMsoV/fcOKgfQNe2CSNHIHOHfilXTNSzgTojHqN9AFmSOSBz9pugFzwuKZ/Z1vcOsgbcR6ikl0WZkXzZg7juDkVJPazQRRhGDEdcHFACXejXLL5kUKqq8jjrVCDRb24lJlgQKeMCttJfMhEc92yeq5NILIyxskFy8agfeYkZoAyW8MzwOcxRqh7q2SKry6QkByyMVP8AeU1pyWt/aqXF4HA6Y5quL3WW4Dll/hDKMUAZbWIkSXyWVcDoBWNLBKG2FwfTI6V28upX6QqJLSISd2RRzUby3E4VprRWHbaoBoA4lI0DeXIsbSHocU4TvbfIjIW9K7Ke3huAoEBif0Kjmqtx4ecws6pbnPT5uaAObtNRljZx5Y3E9RxWpB4o1CFRFbyhX6YPatKHwg8tuJpJo029AGzj61Wm0WS0IMlmXU/dZf4vegDS0/xheWa/6SVkc8/dzVpPHdwAwiWCTP8ADtrk9Qs44gGiWSNyMlC1ZU9nOq74YJHzycHGKAOtl8WXtxc4WGIc8ripk1qL7QjSW+EH3wtcOZpEwwQxyjgA9c0/zXXDSyyh27Y4oA9Em1vTetvbsM9cms19Q0+SYlokLnoDXKfbYGZUjIeTHO7NG47ixQZ9QOKAMf4lSwy6xbm3RUQQjhfXJorO8XuHv4iCP9WOn1ooA6hbu5KDMqZ9AKktmcSFpmUL144rEDlc7CpUehojuIhz+8Le5oA6geJ57P8AdW7ukfrmof8AhJrmSUYurggnBXqKwHu4pVxMCB2IFEDwp80btkdAR1oAvzSb7oy3Nwdp7d6c6vcYjhdMN3aqU8hdA4AYjtVY3crMgMZUD0NAGteRy2kCxgJuPdTWLdxyeWeCx75rVtrtFBJjDsO5NR3d400ih4cjsUNAGZDIgVUELmX3PFPjdgzD7ON3rWlFYwyY3O0Uh6Z6VaTRbtzgSRFPXdigDKCFsZbGeoA61eiDKqjDgdsmrlvYPayYuEDR54IatmSyhkiQKeGGQM5xQBm21lDMheVgWXoFOM1PPc2yKsJDJx9aHhEMTgLhx0wKzbuCWULI44HvigCw0SuwjE2Yj1BXmoLm0WJg2xpEHYCmRpuGInLH1bjFa8Fu0cQYXC7/AO6eaAMc3UbYSJTGPdM0gAZGDMrk9iK3oNRuHOw2AuV6HanNaNrptpdjdPpFxCD2zigDhFaISFGXY3ba3WpIoIZXIYSB+3zV6enhLw6Yt7xyRy44yc1Tbw9pMALgvJJ/CpOKAPPrWwlE5wSyelactlcSIrAvwcbQtdpaaOqDNrGqk/3ucV0VnapDDgzwux/hCigDgtM8OPIiNcxFY25+Yda24/Dtms65XamOiscmuqubSNIDJJLz127s4/CsqKeBpSXkGF4BWgCxp+jWFrcrPFYxOoGNknJJq/cahglHtIrJOmUUdKyb27V48G+WPHQqMms/z/lEsN15zL/z0U4oA67TXtN2Q0jnrkCnakZJWBtra4f9KwLfXr2OA+WImcdAiYqimu6xNKwZ5Iz9aAN8yX0MO6TT55e3Paq0niDVrK2KJZSC3P8ACVrLtL7Vppij6m+0npjpWhNFKEJ/tclscqy0AVv+Ema7hNtdPFbD+8I+aiNhpWpbYxqsSPnJZxhqrCOVnYGa3kHbemKltLOMEia1tZXP8SvzQBtxeDY7lf3WoW8i+quBQngaRCRFPCCejE5rMTTtLizuW7hbsqMagBjtX3QXt0ozjacnH40Abb+D723TdNrEar6RqaqR6Zscr/a0r++3FRi9vT8ltrK57pItUrifUg/zalbjnnMf/wBegDZutHuDB/o96xyOSXo0/wAMxJGZ7283P/dWasNobibmW9Lr6RrgGqyW1lbSM811Mvscn+tAHYww29u2YbcHPH7ybNN1CeNVGyO0gb+9vBNcZJNZSkG3lnYDsTTRfWu8o9rwP4nfOaAOrttWSNyJNRhcf3EXNQvqNpNOWMjsw6ALXMHUYASsVnEuerL1qQ3mlxwlgJVlPUA0AdKdUfO2NNyH1FVp1hbLhmib0ZAa5htWg2kJ5wP1zSWepQvku07Oe+aANK+kaMEvqLhPRYQAKq2lxZTsc3UzbOrHiql/ezwJgbzbnsRk4qO2ltrmJioAI654oA3kFhIuftik9sr0qq6R7yPtxZR2xWIlxbW7bQC5PG1TUsl0pHeP2xn9aANuzwjMyTl8dAy8VHNfT78zWSzD1VsYrDj85yTDcqf9nNQSNKknMrox7BsigDqo75yFwixoeMHqKbdW95uEsM6lBzgEVzkV0FzuG9u+WpqyIjmRnlUH+EdqAN6PU7pH2SRxyr3yvI/Grw1qxA2XNjH9QSKyLG4hQb4Lkxk9dy5qUzRK+64dLgt2AxQBal1PToyTZ24Rj235FZ9xrNzI2DHnP3faidbFuWVonP8ADisS6QTTEQtKhQ45XrQBadIp599xEdw6lnrY023s5o2EiYT2fmucc3XllXj+T+8aaNQtV2rKWjK8HAoA6W+0zS9m6OR4nHTcuRWFd2ALjypYp4+4PGKQ6hBM6ssrFF9amNwjkMskYT0AoApm1iUHZGAB1YdqikhVg3lTl/XdxWqdQCJiONT9B1qOTUQAcWa7sddtAHm3ihAl+igY+QfzNFWPGrbtSjbAGYxwBjvRQAkZJjJVSCfSrUSL5YBfaffmmptjQBM/Q1EwfeCME+lAF2IRIu1j5uew7VHNMm1k2FQO4piJl1aVCrf7PenupkO1UIHcHjNAEcMYlBIdhjtmtG1ikMTKoQntyKzzlJFG3I/ujrUsc0ayj5HSgDdt7ZIrf95CNx71Xwkb/MhAPTFVnvSVIQFh2Jp0csxK7cKx7HnNAF62SKUktJkjoDV2yifEnypJjtmsuRbrI8xVwe4qsJZYZfKRZAzdwaANlzI2VkjWLHQE5qdJJngym0MnA296zVSeVdrRyADqTW7po8iJU2Z49KAK1vfXzAoYlZu2FoK3s8oUqgHcMOlbQvljG1YYwx7mmSXMSurl41buM0AU4rERjdcqrn/YFbGn2ol5WKBQOm+qE2oWwU4bDHuKrS6hO64iIx2IHNAHS2stxZ3OEmtY8+gFWdRa8kG837Px91F4rhbQXzSmRlkl5710FtPeyRY89If9kjmgAkv5kyrsFfsW71nX98Z2CSNz6qafqFvCpEl1eCRvQDFZzrAeRIFHbvQBcsLoruSa6f2AzRc3R3BoLhwR2IIo07XFsm2qlvIR/eXNbyeI7i4TEekwf8BTNAGMdWleLbO0mcYGznNZz3EmdsIcg9ycVvXVxqT5aKy8vPXKAYqnHDqMzEmJXHfjpQBWtVv2OxFPP8WM1eji1OM7C4YHtgCprLT7hZT9puI7aPHUmq+pWlpG5K6rLIRzhelAD7jT9SaPdh1+kmKpwpqiMVduPUHNFtcBzseaYxj+LdVyW8tYYttolxnuRzQAtqt4g+W7KE9iKLl2UYubtnP+yOaz3urpiWhSUL/tjBqtJPIU33Ksee1AF4aiUQx2okkfPSRc1Ztb28U740RD6heazbK72yFreJ146t1q4plkBmeQwy9vSgC1c69c3DCO6uFjA6EJjP41YtNWlj2mLy2/66YOao22k3uoZLFJk9OBira6GYoAixgyDsW6UAXL7z7seY8FsjY+8g5qhGbWDJuUkJHfmmbUtmKzTkSf3Aa0LAWLxlpxJu/2jxQBUbUUK4sRIg7jdUT28t8BgMzdwDWpLPpykCSFXTPAj4Jpk50+dQYbZ4iP+mmDQBXlsDa2YYxTJjqTWNP9gOWeeTzD6it4PZeQy3RvJR6buKw5TpxkKrZSbV5G49KAIEukUCKIjJ70+Szd9oc5J7qRWgl5ppg2taoj9A3rTygkgHlKpI5yDzQBnLolr5gJadZf97intod1DKZcrjt8wFU78N5paF5XkH8OaZBFqV0MtbzMB37UAWrmW5ChGcNt4K4zVORQzLuKqD1UHrWpa3ktggF1aKQBzkVFPf6XduBLbAe4OCKAKEK24mKxxlWH8WahvjEH2ySun45zWt9l0oxs1kz+YezGqN5bxtEBJGNw6epoAq2gm2MIY18r+93NWLLTJ55PndlU92NVoQyZ8uCYD68UPLk/IJVI7FqANC+0UxjEU0Zk9c81Vm067ii/1yu391e9RxXbRnbK7Qq38XUmrlvcxxN+6ldj7r1oAggtLieH96vlY7Zq3bRW8KnzJCHHQ9KsvdowG4tk/wB0U/z4HUKqNM3oVoAqLqDgnlXI/iYc1HPdNKQ0hYKe4XGaJ4UkZt0Dw496jhaDd5bStkccngUAMkunVl8tiy9w1RC4UBzJBE2T3YVfVLNW23DCRTzkcY9qhul01VKxIvPfOaAGCztbpMxypA5HTqKoXGkzpIPIu0ZvpirEhlIXyYUEK8ZHWgPICN6P7HNAFIW2oRA+ZESP7ymnxzfNtbzw+OhNWnu5oj+6kbb3yM1TvbsPkq/z46haAOX8W7vt8e9SD5Y6/WiofEbs93GXYk+WOv1ooA1/sjFh/pMK/h1qKeFY2P7zcfUUkcdzFHu2Jj0Pak+zSSDdtUk+lADANpBjmYN71O7yyDbIQ49R1FXLKxU8yleO1SXMMcZ328RyO3rQBj3LCBkyWJ7H0qwk8j7cKpp86q43T2+wetPiit8x+XLj2IoAkhuHOU8sbqSYPt3MxDDoFqaWJkwyspX0C0oid9rQR73PUEUANt3dsZkk3dgRxWhbpIsysUMgpgilBUPCFP8AKrEjtCV3yYHoDQB0UF7biHaYijHC811Oo6Fo2m6jd2N34vtYLu3cxyoLCZ9jdxkDB/CvMp7oRsh535+Xn3rpvindQj4jeJYwDu+2tkfgKAL1xpvh2Q7T41gJ/wBrS7j+gqGLw34bmbE3jC0Pof7MuB/MVyInt1X7r59+lOjnLOD5qRigDtYvDPheDLnxlatjt/Z05/pVjyfDEabV8X2oI9NLuP8ACuHa7jT5BDuPdgKoy3KjdmFz+FAHbPa6GZN0Xja2B/7BN1/hTzpuisu8eOLfPqNKuf5Yrz+K9lWbKuwX0Iq8sk07AQjOetAHWnQ9EuQTL41hcD10m4/wp9r4b8LxNifxnbuD/Cum3A/pXJkXMI2PKwLdF7VUHn2825iMHnpQB6PaeHPA/wBqXb4njZu5+wT/AOFbT6V4ZgVTbeLljx2Wylryaa+VsN+8XHHyCpYUmO1oPtTE99pNAHp17a6LJCF/4S6NiRwX0+4P9KgtJNKsEKf8JhYgNzxpdx/hXH21nqTTISJvLYc7xin3FpNbt+/jkf0J6UAb9zH4flmL3HjO2Ibt/ZVx/hVZtG0R1Lx+MrLyj/CNKuM/yrClZIl3+Uj+x5qm0z3KstsqQH24oA6X/hHvDpJZfGEQB9dMuQP5VraNoWhRp83i+Nh1/d6dOP6V5rDJdwFkmmyM8DOa0bCS8cMdu0+pNAHot7Y+Gnwkni2Pju9hNn+VY97o/hiYqF8ZRLg9tOn/AMK5Uabe3Z3qYsk45bpV1vD0ojBfUYIW7igDoYtA8O+buHjSEsB/Fps/+FNufD+iv+8k8b2rKOw06f8Awrm5tNlijAXUI3Pcr1p8VjGrAm4wp7HpQBuw6boUSYj8cQAH0024/wAK0Ley0gLtj8aWjk9zp1xn+VYUmhSMitF9nkGeiPTJdOnt+tqRjuGoA6Y+H9CcZn8VWbOejCwnqOTwzpUafN4ttBEeB/oE+f5Vy0sYOAyMnGd2ckGnR+bF85ld1Hc9vwoA6Wz8MaG7bF8XwFj62E4qS98OeHLZQJfFkG8d/sMx/pXLXM4IDJM5z1BFUJmllztkC49TQB2D22hLFgeMbYJ/2DJ/8Kry23hfaB/wl9qWPU/2Xcf4VxTRSMuDcFvbNMtQYndZWG0cqCKAOufS/Cryj7T4xgeMdAul3HH6UtxYeEkB8jxeiKPXS7k/0rkS6NjfGWOeApqX7W8W1oisOOxXOaAOhTS/DUpEg8ZwoB66Xcj+lXUTwykZEfjhlLf9Q25x/KuXGpLe/u5TDkf7GKnGnW6wmS6lidfQNQBoXGjaJOS58fwkHr/xLLjP8qaPDXhsIgHja1J9W0u4/wAKwLgWcUZa3ZQD171RMtvcEBAxI6tigDsP7N8Lwjy28aW5YdNulXH+FPudO8LNAofxpCD6rpVz/hXDtGiyZEzp6gjFSiVUcbN0q9+aAO0tdK8Kuu0eN0ZffTZ/8Kenhvwu8h2eM7Rz2zp1xxXGtHDMpKI8Z9QKZa6XOX/dTDJ98GgDtJNG8N2j5m8aWuB2XS7hv6VdhtPDE8RWPxdbkHv/AGZOv9K4d9Nv7fLIA4785qE3TRYVgu48GgD0VPD2gKmU8ZW5J6Y06f8AwpraNo0K/N4wtEbsRpc+f5Vw0WpCAqN34+lTz+Ilk/dhFZuxIoA6K60nRNjfavG9vsP/AFCrkf0qqvh/wptDR+NLb6/2Xcf4VgtqDum2VVCns9NE6LjJiCjsB1oA6CfSfDZUf8VtalRwQdJuT/Sqg0/w2Ucr43tVVOw0e5B/UVlfaLDzkZ4WzjqoqPVJtNeGTyiUYrngUAXPFemf2Hqr2UeopcR+TFMsyoyB1kQODhuejCuae5lzuLrIw6V2vxSMf/CTW6rICv8AZdh8p/69Y64h5ATxGvHcUATw3M0y7lwmOuTTWunkJAOG9aoyIrnMcshb+72pp+0KuNu76mgDK8RSNJdoWbcQmKKi1lGW4Tcu0lKKAOpsbnbv8xFfPPI61JFMZnKwQqPXPFZ1ncSbvnRiPpWzp7WDv++Rw3qOKAAWE7DIjA+pqJpBETFJOqseMHtWjcpCBmAyD0BNN0/TLe8uFe43K2aAKX2Y7S0l0jRnsFqaG2sRg+YwPstdaPDemNFhNQAkx9ysy8sbWzU7Lo5H+yDQBm+VA2QZZCD0wMUi2pt28wzbB2xTTegFhCxkPqy4qq1w7N+/x+HSgCW4uWZsvJ8vr61CnmS5EQDg96kkvIfKO2MMR2IqH7Wu392PLagCvPZzrKrSAjaRjJ966T4suIfij4n3HJN8+MduBWGBcTONxMmSP511/wAU7KWX4k+JWZdqtesRgZ7CgDhvtUzyBVwy98CiW3kc5WLGO+a3obHywAIWcHqcVK0Ma4CRnPQ0AYls04+VN2R3FWVhvJGGVkK+uK6C3gs1iy5EbeoqxFcQW6/8fA2dqAOROmXcjkmEgg8ZNb2maVfCMGOEMfZq0jf2J+aOB3PckjFB8QLDGVigRQPegBi6fdiYG48mMe5yalks7T/nqjzdsjishtV86UvI6genWiW7gblYJGPtQBtQTQ2i7nhhcjtitO28WfY8NEkIP90pXIpM7NxCBH/tGrCCPzB5yoq/3hQBu3/i9ruXfcuI8dlXArIvNW/tBcfaUCA4weKuf8SbywJVd2x97bxVB4IHYtZ24lHTBGKAKkrxpjBTPcqetNVI5l3sjFe5WtNdE1O5i3RaaFX14pINGnhBWeCQMOcg8UAZLS2aybI7d2b1JpDNE5ywcN/dU1tw6PJM+GgKqP4jU7aCWkHlFceoBoA55ZoD8q29wG/vA1Ktmlww3zzADsRmurtdEVBgswk9SOKkNnDESkzw59aAOVl06COPzIZJy49uKS2hiIxJJOa7GBbCOMpPcxbfRRVZ7/RbElXw6HvigDnon+zuothLj6cVsR3GpToFEYZccc9ajk8QW8D7LOy3I3UuKlt9VsiPM8iQP127qALkGnXcoPmwbR7VFqdlPZ2Ek1vskkUf6ojk1ND4xMAxFb4Ho/Oar3viiS5JP2SHNA1ozFWW7e3VrgRx7wQYwvIqjc2MqqzxI8ue3StxtbjkGZLKISDowHNQ3HiGBIgJbbaTwCaAZn6XYNIn723njI/Gta10y0lc/ao52U9Cq0WmrskW5dpU9s0y51BLmRJHSMvHypPagRX1fS7G2ANnFchj3essiVUwyM3puWtSfxPcGXbPGroP4gBTovElox5jU4/hZcZoAwJbW+X98kC4NBkujFsmsgV/2a35dXsrhx5hS3H161eGoaSkeJG3Z/uUAcR5kKvsWNoWB+bI4rQtJbXoqSMfVcCty4XRbsH94Yz/ALWKbaeGI5m3WEu9f9o4xQBzmqXEBG2SMYHvzVZDEIN9tFk+pauuvvCbop3W8THu2/msObwwvOGmjPovIoAw7m7wVG9kPcA0955fJBiySfetYeGZhFmOeNwOzg/4VGNBvWjfbCXA7r0oAgtLm5jjBJIz6kmrCPDJIWuYx/vAVWFvNaIRJBKcdQRxUL6mqgK+VT0K0AaY0+zlDMl2iZ6Z7VA9knIF5Dx0KjmqUV7GUYBNwPQgdKkWNQocOAT2xQAk0IYjfcbsfrVmGS3aLZLCwYDhhVGV2aQLkyMfYACo2a5gzl+OwA5oAtW1+Ibgg/Mo6b1p2pX3mRSAwRYKnlRVRGlYcluf7wqpJE4ZyrnlTmgDtvicI28W248ok/2Xp5/8lY645rcM5G54x7V2fxTtLv8A4SuCWJyU/srT847f6LHXHF2AOXct7rQA4yRRjbIAOMZ71XPkAsRL17Ux5pww8+EMvY4pGv4gCDEo+goAxte2/aU2kkbOpoqPV3DzoR020UAdHpTGYqY4JCR1A6V2Omz2pZVudNIYd65y1mfYN0flgd1PWtqx1BIY87Gb3NAHTvqGmJDtbSXJ7NiqS6tYpuMNoEI7ntWVNrYZSBGc+/SqzXSSIGaIZ74oA1PNjup94UIP73Ss/U7WJZC0Ry3ruzU8HmMgaNPk9qoyyBZiGtlH1agCkRlypVmPqBUEsM8bjau5fUitUyRZUgxxt6A1HJIJtwedQB2HegChDE7ne7IoHYVpx2sLxBpOD9KbDdW0Aw0IJ9TTZ793/wBXEAB0oAtW08EQK5AwQATx3rpfijqm34heIoVTLLeMMjnsK4jzpJuJgq4YYx9a674myRL8RfEwdSGF64B9eBQBgXGr3EIVRuC45JFURevLIdsqnPbNVZg8jHaSR6VWuVSKLcRg+xoAuTyMkmXcEemadBCX/eGUkHt6Vi290A+SC3PFa0FyFAIZsnsRQBpW1tFcNtMrr7LU80NhagebBPJ7gVTtb2SNvlKEVDLczzSERHBJ7nigDQkubViohtML6midN+PJbYD6dqbYaZcySKZAXB/umtex0zF2F5X13GgClZWc8MRdZAydTurTsLWS6+aLY2OxFbUmnwW6YnQMvWpY9ZtbRClrbhX/ALx6UAUba5e1mMVzp67Rxv2cVZnlhkTemxccfLxSX2tPJCTcXkYBH3UXpXOTX6qG8h3kHfcKANwassClZLiYR/7J4qoNdty52NIV6ZY1yV/qMr5WDA9TmseS4lkk2+a4x1AoA9RsfFNpbuR5Msjeh6VFe+KpWB2wrGhPYc15o/nHBjZsDqTVsTgxgKzu3qelAHWXuvSsN0E2446DrWPPqd3MBtQs/vWfCkzAl3QZ7inSbkjK5DH1B6UATveXB4nVAPQHmq5nTce3s5qluYE7pAvv3qSN1ccguR0NAGhaTwzczXLKewA61p+baQ7VxIx/vYrFtEkk5PlAj1q/GxUbZbiJT2oA3YJrVY9zR7vdqf8AbrJP+Wan6VjC5jRdtxcRyqa7T4TanoWn+LLWbWZLRLfzoTGZYySr+YpVg+4CMKcMxORtBGOaAOdbU7N2ZUhIOPSsu/KTsQiAkdM10HxG1nRbrxRM+hpA1owIAihKENvbO5izb2J53g4II4GMDntzbN8USgehoAp7mjjInhwvqDxVR5IXA8piR32tVl7xySGgLDvWfJJEXO1THQArRhJAVlfB6AHNUri5mikI2My9uKlOAWZC2760LKDH+9f5h7UARGaLZm5jdiewp8E6bVWPcE7g02KTDljIwX3Wobm9kMpVFBUegoA057y38tY1GSBVnTNZeElI/MH44rngVf5ncq3pirSTxQgAux3egoA3ZtWu5ZfnnYL6b+aswa4IztSeXf3BGa5l5RnMOdw67qYsrli4nAPcAUAdXL4icRsq3OGP+zViw8WRW6BXkeRj1xXFFmlkHzZHcipjJCOCMH1oA7iTxYkyurIoBHG9aopNa3pIaO2Y9cZ5rlY4ZrmZIbZWkkchVAGeSQB+pA/Gnalb3ei3c1teK9vdRSNFIjcFWUkMPwIIoA6Q6QZJf3PlxLVC+0+8hfaxDKOmKy7XV5olB80lj0BqeXWZGcEsSfSgBhsJDIDmVH+lQ3ELq4BlYEcDNX012ckKQ3sdtRtqCXDMJFV2P97igCCW0ldU/wBI68kUy5tbnyXCyrgKeB1qTYgf5pypPRRzVe7EiCRoywAB+Y9KAO++JSXKeJ7RwzhRpVhweh/0aOsCCe6+8bPI9SK1fifd3I8WW6LMAo0rT+o45tY6597m+UAyOjR46rQBLqF3NIhU2O33xXP+Y0EhYqhHpWnO8srDZMF9iaz7qKfDfIG96AMjW51nuEZQoG3HFFQahC8MoEnUiigDoLe4CKDMWXHYc1dhuDL8zOWTtiqSTKi/MNxPbFTQhQNwR1HcL0oA1TPCsOVyxHY1TXUTuACsBnB9KhS5gLFDG3/AqtW6W87hBhM+tAFiDVZEXHm7RTknhkUmUO30qK5skgXd5kcoP8IODVSCW6kVxBGEA6d6ALnm2SnIVk/3quRf2e0e/d8/+yM1gy29xKw8wEtSrbSIcQhw/fFAGyXMzYGNo6FhiqV55isQp/Kp7axvblRxh+241o2vh5sg3N5EhPUZoA51HO9VYkcjAz7123xOkjHxM8Thj/y/P1PsKrx6LpUDFpZvMkyMY6da6X4mR6bJ4/8AEAYKX+2NuOO+BQB5hexxuf3csi/SqYiiYFRKS/8AtV6DbadofHnXTr7YpbyDw3bphY5Zm9QOlAHn0Fu/mhFjx/tAVfGlXjuHG4gdOK66zvNHjjOyN1kH3Qy0g1aAuVRMe9AGTa6BeLGXli4POelWLfT4ljbzIxu9c1buNYJwjyFh6A1k3WqxQkkhifTFAGvEkUUJ2SsH7bTTY5gvzTzMTmsX+2p3iPliJAf9kZqjLdv1dm98UAdi+ueWu0SuygdMZrJm1OO5cxl8Maxbadi+9JT5fdTU0UETyh4xuYe+KAL7gxnKhZPxrPvrl3xvTaPRTVq8JjhGFAas64uCig+TlT1J9aAGZBIHlPg96nZfKjysa8+nWoUmZeY3HPY9qW2VmkLzTJj+6OKAGRvknCsR3AqaFWMbbGCezUx5Y0nKGTavtSCaGNyI3BHrQBGGKOS7nI7AcVIXjmGcuCOvGM0xJVlJLOwHtxR9rVQUyGHr6UASRxR7S24KfehBvXJcHHYcVmtMSx7/AFpLeeZiflVcd6ANWAJvYqd2B0PFMje3mlMcihMdgaqtLO8W6IBx34xmo1fB5g2P3OaANuLTvNG+KFlA7g5qyLQIuZSxYdjiqlhNI0W37SE56VZdIWGJbp2f2oApTjE48oNuz3qedJTFukLgAdFqrcyOj7Y0z6EnrTUkvc8cA9RnNADLaV5GJjMuR2IqRxPIdzwcj2qG8uposfNs9eKoPqUyPkXLbR2oAsXTqwzkLIvaq6s0qBhKBjtimSyvc5aPlm65GKgkeS3jCtCQf7wFAF0SM2QXyB7UouEUbdhC9iBVK3uwAd6sCfanGcmPYpwfXFADbiRhIWjJJbpxUMYd5P3jYI7GrNuAVJmLbh6UwlwxIVWB9etACkKMs56d802JtzFtyhPTHWiR5HQAAL68dajUO4zyMdBigCY5X5l+Q9jUcsrggySoR6CpWjkaL59zj/dqCMRRhhKmT2oA7X4Y+LYPCviNNSe3nnj2eW0aTbEcFlz5i4O9AATt4yQvIxVr4w+MLTxp4pkvrWGeO3jklWIPLmMoZCVdUwNhYYLDJyxJrz9E3ByMiPsBxSxMB6gDrQBOjiFs5DE9yOlJlWYncBSvOhjJiXLD+8c1Vbn5nwM+hoAnUuflE+B9aUxFDkOGx1b1qKGPaM8UyZ2GVbHtjigC/FMoG7PzDuateak8L+bIfunpWGGUrtYFieetSo4WGTYFGFPWgD074nWaz+K4MK7D+ytP6f8AXrHXJS2E9sN0QfaOxNdV8Q9Se08X22YwU/snTj/5Kx1knUUuyoCgZoAyRqjwIRLaIfcjmoP7WhL58v5j+VbN9pzPHnfGw9K5q/sfIfcZAuB0AzQBm69cfaLpHAAG3tRVW/VFkUIxPHeigDaErBQeCO3y0qXMzNwzKR6Cks0kl4QgD6VYlgMYzuw1AEZ3SkYDlxyTir8SpFFukfc2Oh4qpD5qISzZHtT4BLId5g3KOee9AEkAjln3o3TsTWhbXghcrHAhJqss8a/MsCrjrmpmlt5AJN20jrgZoAuIzvL++Tap/uirM8sFsoZfmc9K5yfV3jk2RNvUfhR/aAcguDkdqAN2HUriUkDaoHtTDNlyZSCT3rLjvY2B4I9xU8bq/TJHqRQBrW8kQfezh8EcDjvXU/FS7WL4geIVghXcLtsk/QVxllawysQXySR93612fxK0+d/iJ4jeIqU+2MRn0wKAOMNy7AlsflU9rAZBvklIX0FJdL5ZC7Qx7kCs+eaRT8kwUelAGhdzxQjKRs2PWs251KDGdj57gDpVW+u5jCVMq9O3es+O6YtsyM/SgC79vSUExoyN2yahh82SQ+bkjtk1EQR80nH0pjks+6MMce9AFyV8D5I8he+aY7M4DLketVVRyDhz9DSwxTbj821fWgDfs9Pvp9PuLq2tXktoNnmyKudm9iq/mQR9aqwNCrfOZmB7qMV6f8Pvirp/h3wLc6JcQX0t2oQRTG4G8ZkYt5L7f3QUEMoO75iTXmRJlMkkly2SScDkn6nvQBZlitHw6SyA+jGmtGpUu5JxwPTFZoumEhjEZk5xkjmpfNdT8zED+7QBC84SU4XdTFbdJvxg+lSzTRMOY9p9hUBkjbKgkH8qAJjjzg/yq3o3ekmkYvyigf7NQpDvzuPmH0zimyJLGQwjcLQBajK4+Yke2KgljQPu81RnsBUsG6VMsrKvTGM0s2nvH84Rhn1GaAIo2iUlsqT6Gno3BYyR7fQVEish+aNWB7YqN44o5AwXAPWgC/E6SRhRIFHsMVOgjRgJFynY9arRzwyMFAZf+A1pwRwouWbdnsaAJ7eGxkI24J9M4pLzyo+Iox+LUkdvA8m6NWVvpUE9vMsxZAHPoTQA5DujPmQj65qqxAkYxMw9ql8qaQbZFKH2PFRiHyvl25J6mgChdTliMg4HdqhnKhVIdCD1wKt3ishAwHWq0jSMAFt1WMd8c0AQtdHAWMZHqRjFQyM0nALMf97irEUUszlUjcg/7JqG7tLqBvlhZQfUUAQOmwfM7MfQU4/MuQGH4Ug3wYMqliegFSDIwWYg+nagAsS4lY7+e4IpbiaVWJIVfcU7cGJZsAdsd6qzuHJBQgDvQBPbzAsWkZT+OKkWXlmBHsAazhESOF+WpIECk78gj2oAtia4HAJCnvmo1YFjvAPvmoJVfBYSnHpTE3bcshOfQ0AW3mXhUHHrSQyCJ2DAsp9qrquc8MhHqaY0jsMFhgelAFyTyHJVM7j/AAg1G5SMAZ/A1DGSgzx/vd6jeT58/e+tAE7y/KAnWm4fyyZP1qNSpG/BFO84HqC340ALEofJU89+akkt2WGRgy/dOeaijk3HbgBT6UsxRY3VATwaAO6+LAY+L7ZScKdI07nP/TpHXLW1yYG2hty10/xaaMeL7YTKeNH03p/16R1x42OQI12j1NAG3FqpUhdu/PYnFTzzs0RYwQ/ic1hRkIctiQCpH1JnQpFGi49aAM3WyTcqSqrkZ4FFQ6hK8sql8ZAxxRQBrPOYwohcKParlrzgyyByaq2cIU9UZPQ1qQwqeVCke1AEy+UqnMir9R1rRso3dV8o598cVmqYY3+cZ9q3bK6Ux4iUD8KAG3VnE6ATKpPsKyb22tUQpCxDf3QK3BM75DharA5c/KjUAc9DpLsQxiI56k1sWujpJgSAZPpWjbTR/ddQB7VVvCqNuglKj09aALDadpliBvGWp1vJao37q1SQH3rOhAc4cOc1ajEVo2QTk9qANa1t443aUIiEkcY960PivdyJ8RPEIjlKkXjcY46CsOTVpEUbFXbwP1rQ+LWoSL8Q/EyGJCReuAfwFAHJzXZmDKZ8P7CsmSBjJvMwf1UmpknJY8hc9RVa4eMkkKQR1NAENyyQ8NHlj0YHpTy0YjVsAn9aZJGmA4UuOpBqOV9wAWLB7UAOUB253Y96cQYWyGG30psblEKtGWb1ojQOxZ1O6gCxlnwcgA+tPG5eEGT79KqOFkIWRGx60vyEZiZsL2PegDQVokXM0Yz7UkYWNi8RwvvVFZccmT5f7rU/DFcBjtoA1YmLHIAye9OktxKdpYI3rWfbPhQNzEA4q+REwAHmbzQBKmlRjG65APqar3VhErgNMjDtjvSmO5gYbSGU+tOkYBh5kalvWgCFLdYmG4DI6VcimjlnEcoIX1qJ5GcBVRaekLj5twC91oAsefYwzCOKN5D69qvNNLJFmNAB6NWR5R835MYPWp1jVFARnY55XtQA2eV4zmaJB9KRYkm/5Zr+VX7cRiQfaIlK1oyW+lFQ7zSJnsooAxLSwXOXAHtV9bSLbxFvatG3i02MgRzSM3+1Uk0tp5BCwurA9QetAFCCwdiQEZD9aH0xlOWYk1EzN5+6K7kjX0Jqy0iyIoSdmkzj/wCvQBHJZIEDO7CkFtZqNzSyN7You7aaSMqkhz3Yms8afOo+WaRz7GgDRZ7DyzsgLN9KzgLMysXUqP7uK0bdLyO3AjKA+hqSW3uWTdJCu/1agCCyuYSdtpAPl6mpL2eFnAndRn+HFV2gnOT8qsOgUdans9F+1fvbwspHegBl1ptlLErx7Q30rM/seOR8yKw9eK2GaK0n25dsdOK0YzFKm6S3Yn0zQBzjeG7GRMRyFT7ms6fwxKoOzMo7Ba66RIlGVg2k9mPSpLSULx5+0+iDFAHDx6DcJG37tlI7EVmzabfLk7OntXpV3G/LC4P/AAKsqe6I+Vl3GgDz6WzlJw6urD2pJIbiMKV+Yewr0KMm5UpJGiriop9MTYAhVfpQBwLeY6jcpUepFV3WMnAJrubzT3WLrEw96xWsJHf5IojQBjsirDh/wxVVgMdDiujewkyA0SKfaqN7YSZ5NAGX8+wHAK00H0wB6Vb+xuV/dhifpVeS0kU5Yc980ARFiHGeKcwyjsCc4pWjOfun8qcwbyWHGMdKAO2+LhJ8YWxOf+QRpv8A6SRVxTyY+6c+wrufizGT4rt9xx/xJ9N/9JIq4ryjtxuGPXFAD0dDH8uc1XaTbnGAffrSpGQcR7vrikeJ8EnJNAFWZizc0Us6lWAINFAG7ArKc+WGq8DcRjKI34VFpsZ2qSRjsK3LaI+vFAGXb3j+ZtkhDN7irkd5OJNohCj1x0q7Pp6PiQNyvJGalht/OXBIC9OtAFcM7DO4E/WrkWlBkEm4bjzgGpLfTLWJv3sxyankPkkC2DOfXtQBV/s5UOWba3pSSwGMBg+VHXjNTta6jcDePLx71Ture5RlDOCO+D0oAY9wQd8bthfbAqNLlJW3SxF8VC0ahiBIGb/aNIpkTJGzHoDQBDf3CTSokUbqCwyfxroPijaTz/FLxXjKqL98H8BWIjjz1Mh28j5cZHWu6+J5c/EbxCY9pzeNkfgKAPLp4GVjvI3jgUtrG8ikSRqw/nW5q+mpIolcsjAdBWJcWs8QXyHGD3oAjuWjJ2eU8ZHQ9qropaTtt9qllDlf38rMRUUfyZYjAoAEJVmAJz71XcuHO2VgfQU+Und5hJA9qkhmgPUHd6gUAKk5VcszFqQETDBIB+lTpZtc9BwelXLbTpUOHAVfU80AVLW3DttVRIfUitEwSRJtcBQf0pLdfssxRWQg9WPWp2RVG6Ry3tQAy2tYwcmQtnk+lTOYlkHVF9Vquow3mFwIx0So8xzk7N6D+tAF9DHI22Nmx/eakexQkncWbsSap2ltKxKifbn1Fa1v4evCN5dHXrnJoAzFhZG5mVGHb1q1bi5cEloWUe1SS6bJFNl0DD0FXbPTrfn9/wCWx/hagDNLyknaMN2K9DSRmcph5kRs9zWtNYlW+Tay+uavabpMTgNOkbL6t1oAwYkUOGedWb/erShvTEuDHGy+vWr2q6TpyRkiNd3+zWJZ6FfTuzWyN5PYE0ALd6wCCiQRonriqKXMkg3RuVb2NbH/AAjlxLDtudqEd6pnQjDLhp2Kg9EFAylLJPMwUSlWHerKTXUKgTGOTHTHWt6LTAbXiD8TWHe2KrN8zKOegPNAixFLLdYVfNXPB2nitO104gYadhn1p2jQRrEfKzux1Jp939pUnuPagDQitBaQ73uInPbJqpPNLNyXRo/QVgTxXAO91Yr7k06K4XZ8jMm3t2oA6CB5wR5ccbL9KZf372nzSMV9lqrZX9y8Z8mHIA61UmEs8pa7LBc8jGaAJRqTXb5jAB9e9PLlGHnGZzVmC1sUQOkhX602VrVuBcOxHoKAIb65C248uHa5H3mPT8Kr2168cQ3o0jH+JVxTpjCjiUJISOQWNZuq6ncS4wQijsvGaALN9qMhHMJHuxqK21TcD50G8DpisOZZJ2DlZSM56k1qW6x+UN6yk/3SMCgBJtTRZThCgP41Ct00r4jkwD3Y1HJqEIlZI4VQr/e5pwKXWB5UZf24oAmmmSIDeRIaYRBImQrRn1FSR2TnhlCD86jnSSHHDsvrQBEVx9yU/jQls7klnDfVqYFmfJjTAPdqijBWULJESfUUAOa5ayfYIdwPcUySOK6cM8coJ5wKuBVVssT9DV+BEcKd6L6etAGe0MSx48kg9PmFU57CKSJyVXOD7VvXEM0pAQ4UfxNUY0S5YlorqLkHO7mgDS+LGnA+KbeTBIGlaePvelrHXGzBo1ABiCjt3r0v4sabdtr8TCeMj+zLEEAdcWyV5wbNkY77fefUmgCl9qjUHaUHviq0jCR/lnAq81jNMxCxJGPes+4hFvLt4LD0GaAKF8CJAC27iikvCxk+YfpRQBsWUl2rExqpTtitWK8uSApKqaqxwSHmF0UfWrlrbtLJgt35xQBMHLKfNZv+A1Ha3XlSnG8r9a14LOFRjJL46Gl+yQKxMgAYdBQBJCyTlNwf861PtNvaoNwVj2ya51pGiclV2p706WbzVyBHxQBrS6x5wdIzGoHoawb+7csQFJA64PWmh0y27arDuKjUTXD7Uj3AdCKAIEYyEkKVb3qxArg7WQc9ya0Y9MKQlpThvSlS38objHu+hzQBDDHucDeEwR8vXvXW/EtwnxK8TF3/AOX1+n0FcoIy8wby3jIYYz35rpfim8SfEXxQZ+P9NfBH0FAHNX2qKqbAjPkdxWI8jSvjcy57VLcSxjkPuXtSQ3EbLyAT2oAhmhaOFpGBPHXvWexlc4yCPQ1flleQkOSEqjNw/wC63MR6UAIm4qcrg1c03ThK/wC9kVB71HaW0ruHcN+VbkVujgfKN3vQBNDaxW+AG3+47U2beWKGN5FPdTV62s7p8KI0CDuTVpofJU/ugSP4lNAGdDpUMMfmyDJPOG5rO1HcAWwCvovWtqQqUO9yD6VnrHEX2tHK4/2aAINOsRcRErbylj69KupoFy8Zd4yiDpzV2GdYYwsQkRRxgikm1WMxFdkxbpy2KAMj7Hsk2PdBGBrZt5vssYUTNJ6FarW5tpsmSJtx9aeIo4WL5Kgc80ASm7lJyOQf71SC0kaVXGz1I3Csi7njZeHc8/wilto/MYMEkI92NAHUPAEj3lY1bHdqwr2WdjsR2UZ4IzirsVsAofa7D+6DnFbWl2Oh3UUR1C51eG4ydyRW8bIOeMEuD0x2oAx9NsZpk3PcoSOgJrRhS+hfJJ8sf3K6uLR/D6ovk3Gquf8Ar2j/APjlXorHSQn719V2DubaMf8AtSgDiJL0S7Q5ZCPUU9ZN5ARQ3ue9e33Gl/DN/DWnvqd0kF41uhZrdz5+cfxIu4BvqK8q8Q2+mWd1v8NX13cW46i8hVSPoVPP5CgDBvHlhQlV+XHTNcvLMZbrd9mzz2PWtzU726nQqyoo6HHesmFFVt3mFXz2oA6DS0ur0pbWOnSyTuMKkalmb6Acmut0v4SeOdZIItU06A/x3kmzH/ARlv0rhS0ix71kYsoyGDYIrY0n4o+MtAwLPWbl4l4EdywmXHoN+cfhigDM1Dwr4qstQurP+zdTuPJlaPzEs5Cj4JGVOOQcZFQHwv4gC4l0HVmPX5LKT/4msXUb/VdSv7vU5bqYPcSvK6xuwUFiSQBngc1Daanej72oXCr/AHS5oA2/+EY8VjJg0bWAp/hNpIP6VkmXULWVobgyo6sVdGXkEdQc9DV1dVRU/fahc5PTDms6e8AZjAWk3HJJPNAG1ah5Y8nLD0biodhMhaN2GOw61lreMiAkSAnrzU9o01y+6FlA7kmgC08rMSJ45Sg6HHWqrCCZittbOx77qsXUc/A89ifQVHBDNE+/bIWHfOKAIrjfBHtWNonPeoEluWwjOXY8AL3q9PL9oYC6Eiimy6cyDzbW4UAc4J5oApGyvI3LtYlhU9jHFMfmheNx16VXnub3mI3Bx7Gm2IdH/fyE596ALt3BHFyWl9sNUTRxyw/ekZ/TNTtDCylmc4+uarpdW6sVjY7vWgCmtnLAxYCXFMeWdpOGZVX25q2/nTScXP4Un2e0DkXUzhvagCtNelYsCPn1ao7SS6J3qyAdt3Sp5rZBkxSF17FhUUCOSfl3AdloAne8vH4kZnUf3BxU0d28UTPiVUCnqKpK1w0m0RsgHQZxmrc1lem2djlV2ngnNAHU/Fm/lbxTbRpMVH9mWLHj1tozXFNcJC26W4lb14rv/iMbSLxVCboAEaVp/wAxH/TrHXDa3NYTJ+5lDf7ooAnt7pJFyseVPdqytTSLzDtAXv1qG2lRMDz3I9AKbdNGx+WTr/eFAGLe7hLyc+nNFF6oWQYKnjtRQBvYkAXylKn3q3bJMjF5HI+lZsEm0/PKc9xVoSK5yu7j0NAGvaXVu0vPms47HpWiz7yGJWM9s1i6a5kc84IrS2lnzuUkf3qAJpcNwQsn0FRrIFz/AAj0xTFlbfiIKSOuDimGNpn3S5Ug9qAG3G2RTsUZ/nSwpPGUZfk9qvWk/lj/AFQcDvipi0d04IjZGX8qAK07yyYDvwas24xGMyE49KlltDMuCUGPfmq7QmJcZwKAIppCZAwDNhgMscd60vi3dsfib4mjaMEfbXAP4CsCZyHPy5GR/OtP4uux+J3ixVyo+3v1+goA4ttySPk4ycjNQsxLdQPcU+HdIrrLKAAagdARsWTIoAVkcHCSls1d07du5OCPUVWs7CSRl2ucZ59a3bbT0XHmO35UAS3Uc8ka+WAqd8VpaVFEiDKFn75qOKFQRlWZRSy3EETECNk980AXr2VkiJhUhvQVnC+nEZ+0oyj+dV/tTb9yy/J3FRXN6XBG0unfJoAuJqloIj5lurn1Jqo2pOZMwABPTHNRx28M0ZYw4/GoppGt1BijO36UAaQmeZAyo/vxUVw8IIMgZW9abaXssoCwqVPckUt6kskeZmXPtQBVaWfzP3VxlOwx0qJZLgykPI5+lXdOsoZOWL5+lbFrpcKvuwSKAMm0YqPm81vwrWglhU/vVYL71Ykht4yNiMp9c1Vd5lkADpj/AHaANSKaF7Xzbdm8skjjpxUatPy8R3D0aoBvYD5wfZeB+VSGO4IClcj2NAMuWOsXNux89vLUf3eatf2uZGJWd3XuKxpIUVD5rlB9c1lpcJBOQjq4z3OKAOlMkUr/ALuOZD69ar3bOqFFeTPqRVKLz5gXhJVfY1SuLh4Cd8jZz0JoAinuXjYq2XPqaYt0MDzI32+wqu9/Bv3l/m/Oo5tRTy2IkY+wFAGjJcQXKFYVkVgOvpWfIVHyuzt9aqQ3qFPMYsp/KrQuUkj3Ahh6YoAHuGhj2wYb2HNVppd65eBufSm/KZCeF+nFSMsgQmOJmHrmgCnheqtt9mqxAZi37tUI9R1qBUMrFJEIJ9qtW8KWh+VCSe+aALgSfYPNI2+wpUlghU+WzD2rNvjds2QzBPQU0zT/AGf7oA9cUAbVnvmJl3MQeR7UsokJJSZQ3+0aw9PuZEfLyMVH8Iq9eXcM8e1Y2V/7xoGpNEqzTq+1wjN/eFW0cMVEiEc9c9KzLTaAPMfcKtXEscQBjyT2oEaFxbwyw5jbB9elY8sY85VADc9Qaha5RgxkZwfSqwc+cvlI2M+tAHRGBI4VJUZ9+lUrg7F3RCJfp3rSs1RrceawH+yarzWyFshlwPagDLDM5zIoH0NKsAlbgOp9aviIbs7htHpVS+vCp2ozAD0FABJE6x7Rl/c8VWiNxE2I3X/d9KlgkaRSPtDfTFVZ0niJZVbHZsdaANBt4w0x+btg4ps8ivbuJZXA2no1VIZZWH70qx7Zpt0DLbyZMYAB6UAdn8VIIpfFtuMlVOlaf8x5/wCXWOuLntYLUkpchvbFdd8VTKPFluqlio0nT+g/6dY64yaaMDa8ZzQBGCoB+cH6LVG5b5+C35Vs2U2OF2kH1WnX4t2H7wjcR0AoA5S4zv5oqS+RUlwmdpHeigDRtoHc7iR83PNaCQhB8zqPYCqKTugGAwx7VIblyMuOntQBoWp8tyY3VCOue9Xf7TLEKsat2LCsMMZly4AHtV+yCQIW68UAaAuI5SR5OcenFTCPK/u9303UmnBHJcqAD71cl8mQbFyG9aAKW+W3bEZG49R1q3A9yF3DaM++KjgitoWO9/m/2jTJJQznYd6jtQAXCXcpzuVPcNUFzLMiCOQs3uKcLuHkMoPqM1Xu7q3KH923HvQBVlnkO1EY43DPHvXQ/F+At8UPFbMWZft78A+wrlxPE7jYrgkjv711XxcyPil4qCOQTfPwfoKAOIddg/ur6YzVizt2m5XAA7Yp1rC0su2U9+9bMVv5Sj7p9McUAFlCBgKm1v71WvsJd90tztNMeV0TG3aMcnNVwN5y0mR78UAasl0yRbMxnjGRWNcM+SxYMvpmorpkRv8AWKTWbcXM8UmEAdPUUAaoUXERCKqkfrVeWzmgQsihh9aht9Qmx80IC9yDV0X0bJhgVJ96AILe68tcZJYdjQdWeWUKYwF+lVZl3PkMAD7UhhUMA8oGfQUAaUt9vQBUzj04qzYeZcLhlKgH1zVGG3gYALI5Yegq9ZybH8tmKL7jrQBrW8bRH5JFx7rU8tzcIuCEx6gUkEqRIBHtlb0NF3czrETLaJtx2bFAFdbt1f8Aen5fpVsX1o/Tdu91rJE/m5PCj+6TmqMyk5xccegFAG3PeFiQsSkducVm3N1NGM+YyA9lOaoAOAApLe5PWklE7jYq898UATG7ldflaQ+70sN59mfNxFE+e4XJpLayj3bWllZ/THStOz0mWZ8AjHutAANcQKViZEPoOKyp5muJS0rggnsK37jwvMfnit0cd8cU+x0FQAskvlSHohGaAOdFpEy5Vgw+lM+wSCTIBZD2Fdf9jh0+TFyFkHXirtobZ13RIgz3PpQBxP8AYksxDAlF75FXE0RvLHlTIAOvFdmzZQgbGGOwqBDanKSRY98UAc4dEUx5eRH/ABq7p2nggqzIiDpg1cneKEbItmw+oot72O2BLBHHoFoAyNU0l9+YmH1ArLutOmhiEgLO3qK3tR1BZh+6+QHtip7CaMWw8xWGP4iOKAORgDXHEvnDHoKkeMnMaQOyDqTXULqtrBIwBjwO5WqktxBqErssoweiouMUAcvI0aZjQeU/qxokUCAeYpYn+LditLUdJL5kXnuCetZnmKg2Soxx6igCnGzwPlWAU8dc1akmldMKxqaJ4f4YVGe+KZcrBngO3rjigCsoijBdpCX9Cau2EltIcNvX3BrLlVGJ8rg/7VTQ3MkYCloh75oA7K3srd7fzIpJS3v0qpNGxBEisc9COKy7O8nRCVm3j0U4qb7fIq7iGU+rHNAFpNNLpmNJSD1wxqrcaXH0ZnU/7TmnR6tLLGUMoRR1OarTXMKnmUMT70ASRWiWqny5Fd/rmq9xcSBgspLj+6KRJreJMqvzH1egMsmG2g/jQBJKZDD/AKPAq+pJzWZd+Z5Mgk3ZweicVpZxwWwP96qt1EzxvtuSAQeOtAHVfFSZk8WW4WbH/Ep07gD/AKdY65OON7g/d59a7D4p2k0ni+3KMuP7J04dP+nWOudWwmVQWDFfrQARWsscZOQf+BCsa/E0UpIG4/XNXL6aSJSFgAH+9WJLdyDK9D6CgCvduzyZfg0UyZi75Yc0UAasRB4yxz71MwIxgZHoaqRunA5XHTirG98DAGKALq3EKrtZMN6AUqsJRgHbnoKrREPzIMDtUhdUkGz5j2oA29NMSLtYsG/OrkgXPGWJ7jisSGR1+YECtKC+VQCdhx6mgB7oyHdJBuX1J5qI3EcRyYjt9FNTPqyNgb0we1RSxJJiSN1JPUE0AULh7eSTzI4nQjvmqu9HJVcnmrtxGzAgqi/Q1R+zyF+D+VADltWZgzHZhh3966/4rWzSfFDxXyTi/fBz7CuTigmkJ6jaR1+td78SCIvih4p811yb59ox7CgDj4reSEqVdW77SMmrLX2whXt1B9TxV1FRiX8wK9ZuoESPtchh/exQAtxf4GSg298HNZ93qERT5WKn3FOmRo0xDtZD1qqIJJTwq59xQBVed2I54+lTB2CfNgHsKbJa5cB2K/SpmijQZ88H6igCIylSNzDB7VG06Mw6fWmPhpMBlYfSrsEEci7W2kn25oAWEmTAKhh7HNasNgu3eQgI9am0zSJWUfZiqn3rVfTdi/vpFLe1AGXbwu3G9FHbHFXo4rKFd8+ZHHcmmJYM7HZHuB75qzBockjcHHsOaAK66lCsuIkUj/ZHNVdRvhOcfPj0roofCjEbssD9Kjfwm6S72ZitAHNwwQy4Ko27uM1riwR4sFQnHUYq+bK3tflk8wD1Ap09rZqi7BPjqSaAMVLCP7T5bl39wKuS6GY5FeFZCDW/p15p1tANigsO7dai1DWI5lKRuVP+zQBVgsnt2D/Z+vdq1Vu4LaEPJGob0FcxcagY1Ia4dj6Zql/aCoCXnB9jQB2setwzREx/uj6Gsu91FRuZ41YjuvWuWfUWBDo6EZ7ir0WrqUG+KJjjtQAj37PIzMp2nrmqcmpq2I0Yxjpmnz3UTHf5WD6Csi/nWXgQlVPfFAG3BK8K5S73A9agm1cxuQtwGb/a6VzqKbdWaN3PsaIiZCftELMp7gUAbL6xcIQXkhYfSpotbSUbWkC/RaxnVEjOwIo/2+tZ5lRHLBsn2HFAHSzX6xglJtxPQbc02K9nlU792306VzDXrl15BUVO1wGAJ8wfQ8UAa00z7tqouD1JoS6kt3HkOfyqlFLFtzuIPuajkdixYTAr7UAdnpl0JowbghnI5B4pbw2rfLKFx2wK5O1vvJJKtvPuamOpyXD7Ujz7jtQBZ1BBtPkxtsz2rPEbY+XcD7mun075IgZEDnH3aj1FftI2/YxGDwSDQByMsUjE/ID75piQRnluvoa6JNDMozFJt9iaz7zTo4MhyS496AKlvcpE5UpwPQ1Z+3wurKIXI9SaogPGTtjQj1PWkM8r5VVRSPwoAlaWHnYSD6YqW3tPOO4Nj6jFVFZkO6RBkd6e1/MjAsQU9MUAdJaaF5qE7EYj3qO5sZYvkSPGOOOlSaPryxx7FhBJ75ovr4yvksMnqAaAM9omTP2hPpVV2VFkbaqjaeSas3UpK/Ifm9zWNdSSvHJvUAAGgD074mPu8XWw8xcjStOOB/16x1guXMX3Tj2arfxSvEj8W2qsAM6Rp2cf9ekdc99sjkg2x+Z+dAEV9c7MqtuWPqTWJOHmfd5YQelXJFIlyVlP/AqZNKnTyST7mgDLuVIcAkUUXPMhOAPaigC625vuBj7VPbkqAHi5pLflRnf+dTJtMgDF6AHtmQBQQD701wyoVxlqne2bcpiJP1qOSB/NXepUZ5IFACxeSE/fNKD/ALNaENtHIoKMpX3qss/kjaSrD/aFS2zw53JyaALsdnbxDdJtaoyIQ4YkBR0Apyz2z5WQkH3pHtIZAGUqRQAjtBIwCp1/CkS3ijJYHb+NV7gqh2BwPYUom2BVkbAPfFAFu3kxIR5gI3DtXV/FUqnxP8TSb1I+3PkE+wrmbDTY2Pm9eR/Our+K9jHJ8TPEbPGeb1j19hQBzE80OFePk47dKqzXb4+ZF2+wpZ4jCxEeFT0NUZZJSPmlTZ6DrQAtzKXQ+SozTYLmSBcyRlvpUMcwjJ5JHpitKyxMuCrGgCNdRjb5Uts59abJb+eCTGEzVsWu2TaI2U+xrU0+CPpcQHHrQBz1lawLNiXPsfStuO3t8gQMu6tlLDSHUljj1DVNbNpVuT5cMbsOmaAKVvG8mI2BVf7wNadnY2sI+WQyt/tUNrMUoMYhgRR6Csu+vogh2BlPtQBtTPBDExSAvIOwNFprnkJ+8iRG7CuMW7leclVkx67qe0jydWb86AO+TxGXjOXUDtis2bX1DESzfLXIecsOd28/U1m3eoyBv3cIYe4oA62fWj525dxT1PSoL/Wg8eFmX6VzizTzR5lXYtUSUD/Kz49aANqTUQVJaME+tQjUl2kbAPrWf5hI+Us/1qJpQDzFz24oAdcXbNMNi7eeuaVmQS72bJ9hSmQOv73ao9hUJkMf+qAb60ATPcrKQgUH2xVhXNvg/u1/DmqC3QBxKi7vVaLhnI3RKSPegC1cXW4j98fwpjXW0AtLke9VAfMX94CMURCHJVyGHoaAJpZ45F4uQtV5JHIxDclvpRdC1jGEiUk1UWFmO+PKj0FADys4P735h7mq0xCtxgewqSYuD8zkfjTVdXGCi/XFACxLkbsDFPR0RvmqBpMEKp4HpSOARlqAJJZMngHFRq+37rEClUkjCqcUucAgnNAEbMHPUmrdnMVJUMwHtVRAQeDmnEkH7ooA3IZnUqY7tgfc1s2d8GIEz7h6jrXHRjcRu4HapI5poZBs3KM9jQB6M0tkYAY0kZ/c1jX4up1IhgTHt1rK0+/Zz++fOPU1vQF2TMMioD3DUAcytlPHKxmjYN+lWFtocfviqntxW1cWd26H55Hz0OayWhuoZMOm4H+/2oApXEKgkJMuOwxUDAfxuh/Crl9E2RuGR3C1B9lVlzynsaAC1lCNgqWT0Wr7vbvHiO3kVvUmqSKY0wiBvcmoRIiOfOVifrxQBL5UYYmc4PYe1MnSKSGQK2cKTip2u49u2BE3H2qOcyJA5LRKxU0Adh8W4o28V248xEI0jTgMj/p0jrjNxRQPOiYe1dX8YGkfxhbLuQ50jTu3/TpHXFPbuB8zKB9aAJt+7IUN9QapzDBOc1Miqo4VifXNRSHHRTj35oAqzfeFFLcZLcjFFAGir7BnDU5bhkYEBsfSoHMzLx0qW2ZwNpoA1IbwtH1cH3FJ9ouJm2q4AHc1FbxytkE7VPcCrS2ceD+8YmgC1bwROMSsGb3pWtxE37tYl/GqpiKgbHAx6moZpGAwyqfoTmgDUYQ7f3qxlv8AZqNYAx+QlVqnbTyKAVtyPetOK8uCQGjTb9OlAFWSGKPOTvb0xzU9s0O0eYp/EdKuTIk0eJHjXPp1qp5EIUhZ8Y9aALW4FgbeRj8wyO3Wup+K8+34ieJc5yLxh+grhkeSNwY5lYbhkdzzXUfFwyn4l+Jv3mxftz8fgKAORkudzn+P6VWeNi4fy9p6U6XarDOWOOoqa0UySgqwx/tUAEcM7MrGMAZ9K17O0VsM0hj/AA4qe38hSBPOq/SroliCgRTK49MUAOisrOTGbjc3+yDV3yooocCRtvutZx1RbT7pCn3UVnajr905Plyrj6UAX51tyc+bz7is17hIGOTHt9eay5NUkmyHlGfaqXnOxYMQy+9AGnJfxedmMr+FR3t64UY59qzS0Sntu9qJXO3JjJ/GgC3BcSynYiBc98085gOTIxb0zVC3lBbiNtw9DVo+XL/rRtYdyaALC3UrHaYdwqK4mZRxHg1VukwAY5jj0BpqSug+ZiaAH/bpXO1k+WkDPyFUYPrVaeVieDTInlGQRmgCwUljl3F8D0FOkuH6Aj8RUSI7sMlhU0/nRqMRqw9aAId5zlj+VSh0POGNU5ZJSDuUD2FWIZ3EWFVc+9ADZT/EFQfSo/tMmMAjFDCQAF0H4GpYrdZBkyBT6elAELyu64JGKiUkg7VBPrVqS3WLmRlYexqBY3kkPkqMUARAMpBkTI74NSyTBk/dqwp4tZYzkqTQ8Vyy/JtUUAV/MQKQ4O40xwoGVJpGDhsMuW9ad5THHAoAiBAYcHFTSIDymQB2amyFiAu0fhUIDY/+vQA8sQOCVPtUZYk44P0p4SULlRTcOBxgUAGAvU80+Mqx+Z8CkQZ+8MmkZMH7tAD5f3bABw3fimhnY8mmNuJ6U5Ec88UATxKVYEYz71eguJEcZGF9RVKOKYnI249zVlc9GYD8KAOk065LEKZpvoMVdlhDNmQSPjpmue02UxnCS4+oq82pXCvtW5Q/71AFiW2jeQYjKe9SPa2SJmVmB+lPsZ5T88rxv7dqtyXdtOCkmEPsKAOfuoo+tuzOPQLVN42I/eQmNfUjmustrIB8s8mz1AFWLzSLeeMss7OT2JxQBwMqw/8ALKXB+lQyQhonLSZIU9a6KfSxGxWKB/qBmsm9tZY0fMLn5T1FAHYfFu0L+KLbayKf7I07n/t0jrgJbUJ/rJ1Ptmu5+LrSf8JXbMF2p/ZOnf8ApJHXDsWfAESk+tACRgkYjiLfjUcyyofmTaPSr8DTwjiJSPeq97PI33o1H40AZ0rFmyaKaxyaKANJGGR85Aq/DcQJjehc+oqhC2HUM+VB9K0GaLHGfyoAv21zC3+rAU+jVK90VBBRD/KqNvcRowyOPcVpFkePcACcelAGeboGTHlxf99VOcsBmNFX1Xk0imOOUs6LVyKWNiBEjE+xoAhihRRujacn0K1btXeSTB4A67hU379gF3PH/wABoa8ktuHKsPUigC3N9mWLLquayp1hVWfChaWbUYJPvE59AKo3ModdxDhOwxQAhkUMHiDMikEqMfMM5xntXb+IfEHg3Xtc1DVb3Q/EYubyUzSiHU4FQMQM7QYiQOOhJrz75m+YfKlMWYBjtGT60AdhHc+AmB/4k/isHPQ6lAf/AGlVmO+8Exr8mgeKCf8AsJQf/Gq4+1be2HlRfbFOuysany3DNQB2kV74Hc5m0bxMv11O3/8AjVSyal4GVP3eleJsf7Oowf8AxqvNYpnJ/eIo+pqwZVUZDAH0BzQB2M974DuGw+meKyf+wlb/APxqoJ7r4fIuG0jxUcf9RO3/APjVcO7EyZBPXtU7iFkyeD7mgDpBefDtidui+LM+2p2//wAZpwvfh8BhtH8WqP8AsKW//wAZrjJI1U5VgPSrVtaLIuXbk0AdWJ/h+RuGi+LSPUanb/8Axmm/bvh+px/ZXi7Hvqdv/wDGa5p7UhdqPmoEjKNhoxQB1yXnw8U710jxaT6DU7f/AOM0SX3w/ueG0XxbkempQf8AxmuSYohO0gH0pnz4JQ59xQB14l+HiDP9keLgR66nbj/2lTvt3gBxj+xfFnH/AFFLf/4zXGGdtuOCe+aiQZJJfb9KAOykuvh9jLaP4tH/AHFLf/4zTl1H4fsPl0jxZn1/tS3/APjNcVt+b5iWFPLxHgAigDsjefD8nnSPFxb21SD/AOM077d4A/i0nxeB2H9pwf8AxmuOjgjIyXIpxZFIC/MPWgDs0vfh/kA6J4sOfXUrf/4zU4/4QGTkaN4qX/uJ2/8A8arhrhN6DaSDUUQlB5lIFAHbSf8ACARj59H8XMP+wpb/APxmmpe/DxV2/wBj+LRjt/aVv/8AGq5IRyMMCUGmeQ8ZzuUk0AdU978OuQdI8W5/7CluP/aNSQTeAmIMWj+Lx9NUt/8A4zXHyPk4lVCfUU4YC5DYHtQB21zP4CKgvpfi7jsNVt//AIzVQX3w+Ukf2V4uH/cUt/8A4zXIl+uzLVFGWZjheaAOz/tD4eFudH8Wf+DO3/8AjND3fw7YZGj+Lfr/AGpb/wDxmuOkTP3sCo3CgYB/KgDsGu/h5/0BvFv/AINIP/jFJ9t+HPfRvFn/AINIP/jFcUep5NKGPQLQB2wvPh4Rxo/iz/waQf8Axmm/avh130fxZ/4M7f8A+M1xZHXJIph7fLQB2xu/hyP+YP4sH/cTt/8A4zQLz4cn/mEeLP8AwZ2//wAZriie22lBOeBigDtDd/Dr/oD+Lf8AwZwf/GKQXnw56/2R4s/8Gdv/APGK47zHHAK0zcc4IGKAO2+3fDvtpPi3/wAGkH/xmnrqHw+HTSfFx/7icH/xiuLjGCWEeRSOzFsBMUAd0upfD3p/ZPi3Ptqdv/8AGasW83gGX7uieLCB3OpW/wD8ZrgE+Q845q3FcsuEDbaAO9N/4CiIQ6P4rH11ODH/AKKqQ6p4DOA2ieJifX+04P8A41XEb0EZYnc/YmmoJpRkHH0WgD03TtV8DqCItN8UAeh1CA/+0qkuNR8GqSx0XxO4J6jUYR/7TrzyzWRT/pBf/vrFW5NjriN/zbmgDu7fV/AqkFtK8Sk/3Wv4T/KOrNzqPgWeEg6Hrqg8Z+3RZP8A5DrzmBFRj5rDHsasZjLjyVcn1oA2PH97ZeIPEDX1laTRQrbwW6RzSB2xHGqDkAf3a5C4imhHyx7FHfFdZZtPtAER+pWm6hZyyxkuhIoA4CedjkNIx+lVWBY5+bHqa1tStTDLjZjnsapyF9uAnHvQBnyDB7UU6fO7kAUUAbMIjVdzsPcYpXzJ/qhkVTjdiMFcircTHI2KwHfFAFm1iz8rIwb1FWJYJFUjzH21Gl6qDaA6t6mnLezM2CN4P4UAEdvI4xFAZD/tGr0VpeKvy2e36GkglmyDEoU+7Zq4b27RQfNVvbAoAhSGcMPPWRPxJFOkt4i3+tyfRqm/tS5kUKI93vt4rJvllMytIcDnpQBNIoSQZQEeopzus2E2GqoI25UsTT4y8fz5BPvQBYbTLcx/PNxVQ2VvGf3TZUe/WpHn81T0z7Cqn2iRJPuqMUAWEjCHMa/N2JFQXM0+drbc/QVFdXszrw4H0AqmsjyDLvuPoOKAJ1Xc4NzECo71O8VoV/dR/N9aoth1IO8fjUJDIw8sn8TQBOR5LHCjFQNMrud6fiKfh26sDVmOOMp87KPwoApLOImBCZHuKtNctPH8qfN+VMlgtjjM5H4ZqsxVCRHISPXpQBOUlIznb+NQggZ/eHP1poYkYBJ+pppChdpyfegCWR1PBfn6U0bhja+BTVhOQcbhU7ligVI8H3FAEUpYsMEGjY33sH8BTg8inlFY/SrMV0rfI6FQfagCqEkk4H608WhTDZyfSrx8nGQ3PvUQu2ibCoGHqRQA9LYTR4wEPvUD2/kcHa3pzS3LzyjIwB7VVUPnDH8zQBKHY5yQB6DrUQlHPyH6mrAhGwtkA+uarhSCfnX8TQA5GVx85wO2KY7qhwCSfemyOxPG0CoiWJ/vUATthl3HFNVVbq5zUfzLjoc08BmGCuO+aAFO9QQjDFOiE4GVA+tRqBg5P0podweCcfWgCV2lAyyqajaUsANoApSXI9aiOQfmGKAFZc84zSqwxjoabu7DNGKAEf2NKuSM9aCox15o8xlGBjH0oAO54owTSFietIpoAXAzzSjbnHNDH0pdxAzxmgB67h9xTmhg+fm4NMDue5pCzZ+8aAJ9rY+YfL60iSGNjtOR7io9zd2JFHmNjAxj3FAEnmM0mQ+KlV2zh52A9qgV2X0x9KXzyGyAPxFAFu3Vd37yRmHbJNTS3IQbFGB0zWcZS/Lt19BT0zjCqXHvQBchISQOZs+xrUjv59uI9qj1rAMkiHgKPwqaO4Y/eyT7UAa639yWO66ZR7VZgu7hztjleb/eOKyYJiXGEUH1Patq1t4ZQPMuVU/7JxQAlxpryxl5jGh6/ernry3EUm2ObcPrXZjSNOZMyXgP1c1japY6fET5MoJ9jQBylyoV8A5op14oWU7SMUUATxvIny4A/pVm3eYvjeAKrQxuxy7KKuxgKnAVz7HFAF5Y3C5ba4+tRGTaeFA+pqDeUILxvg/3TmryiJo8iNun8QoAsWaiRPmVPruq15TxjcmxvbNZ8TEHCBfxGK0orhVXO6NT7UAI0su3CtsI6jFU57hVJaRgx71om6BTkpj121k33lNkkZ+goAryyNcfNEQAO3SovtLxDaUZjTUUHPlvsHuM09IWJ/14/LFACrdFxjaFb61WlSUyEueM+tSTwtHhjIhNNiMhGSAw+tADUVUP3uvY1MxiC5Ow/SoJXYfejGKgaRScquD9KAJpDgErtHpUDEMwLvj8KcJFcbSvPrUqJGF/eDPtQBUViGx0B7ipjESuVbP40rNGM5BC/So42Ukhfl+tACRu8bHbgn6ZpzzOwywA/CpCdowHXJ9utOGGXDFc+uaAKoYyHKjFOZ8gBuferKxrGpEcq59xVWRmH3tv4UALhc/6winNI64/eZ+tVx8x6Gp8EryBQAq8sGMoq2w2R7kAY4rOZAO4/Cj5wPm3gfWgCw0ruPmX8qkEpVcEgfrVHcQf4qlR+MBeO+aAHvuByJMr6U0lHwCrZ9c09wMDaBUDseAQaAFkO3puIpy3JCbRED7kUwMV6A/jQXP97H4UAKwLHOAKMuvAIA+lPEzbMDb+IqPHmMctg+woAaxwQdufxpQZCOCMUjnacGkbBHAIoAVmXuOfrTcA9Cc04Iu3JIpBtPFAC5x92gF2PPNN74XmlG7d0oAR/l6ilC5XO6h8ntTR6EkUADYA65pn0pzDn2pDjFAAfSgCigY/GgAbPU804EFcHimnP1oPrigBy8dM4oIyetBGBn1oyuOtAAeuB0pVGDSAEjgU0kjigCR27ACkXGORSxEBhnrUjMOxA/CgCPew4wPyp6TOeOg9qjJYHPalDjGM80ASsGODmlDlBwOfWmJNgYY8UrOCeDgfSgCbz5FXjaT71Na3zqfmMY+oqoiLnIO6pRDH1dRigDU/tNduAkbH6VSur2RwSI0A+lRJJBH93k07zkcEeWPqTQBnTli3zYz14op9426QfLiigC5G8BxkHOOauwCDg+X171kxptO5v0rQgulQAKCTQBbcqf8AVybMeop8SyMMl2kXvgVSuLjcvyqQadaXtwqbQpx60AXJEAIPlZ/3mxTldiRl4lHsM1DGJJ3zL0q2LBANysR+FAE6MrKB5yY+lQXUasmBKv4VDOMfKBv+tQLaqx+Z9h9M0AN8xohtCKV9TTXlEwwoUCnywp0B3+1QRwANgqR+NACeQ0hARSwp8kLwx9cH0qwGW2X5ZD9MVFJcrICWbH/AaAKizswKkfjSOABuLDHoKGc5O0bh9KhZgxwB0oAJXUjKgrSou4hg5H40mwsOBUe3YaAJ3BPRt1RM209NxqeERbOetObYq52j8aAK4TzBxwfrSBAp68+uaa7ksABipCsfl9eaAGFU3cvn2pysufuZFRlB/DzSkFBwCKAJN27hBjHamOu08tk+lCNzwMk02RCDkDH1oAczADlMe9NG7PUsPSplY+WAQpqJmB68UAAbPAQgikIbPPAoRlJwWIFSbUY/K4P1oAjDZGM/lQVI+8TjtTmcL8oUZ9RTMoeWYk+lABnI74oVgOozSb88KOKUKCOuKAFJHcEmmjlhtyKTY2cLS7Wz84xQA8HcwGM0GME5zx6VIohGMu2abKoY4jJagBML2FMZD1BFPSAgjeB+dSyRRqAd2D7UAVQCDzSqrMCR0p5WI84JpkjD+AYHvQAYwOc5pjA9waepJA56UrHcuGNAEeBjvS846cUm4p0NLkseTQA08H5TRx+NKeDxQcEZPWgBKUk7elKRkcUHjtQAhVio5pAD3p2MDpSDJ9aAHqABzmmnGeKQN2NISegoAftHtRt9BmmA4PIzUwZ8fKAKAEO4LwMigKWUnaBikYSe+KQA9zgUAIQTjjFKCMY2k0u1dpO7JpAR170AKivnIyKkO4j5nFML+9G7d2zn0oAcpXoBn6UojdvuxtQFYMMYWryLkDfIx47UAZVwrK2GXFFTaiEEw2buneigByoRjkVZTAGcnPtVd84AJGfanwxO/wAoY59qALIilmIEYb3yasGOeJNuBiq6W92vIc4ppNwW+bcQPXpQBN9qkibG5QfcZq3HK7rkzkD2FQW5DDlUB96siS5HCxRMvrQA0LEeZJ3z7moZUgAJjYlvXNOmRycvBn/dNAZUALW4FAFNWGcM5B9Saed5I2BW96mLxOdwh5H5Un24x8LB+QoAhllkT75VPXApYxFKMmYn2xST3rOMCBV+opkMwUnKjP0oAldVxhTmq8iBf4Bz6UXE6MMBPxFNhnQD7hP0oAbuVCT8y+1REhsknipJgrhnAfI6A1FtDDpigBMbTypx9al35THIWo+cgMaRiDwuTQA5AWbG7imOgRsbs0oJHoKcVDclhQAK237y4HtRKSRwc/WkBB4JNOcqF6nNAEKjnpg0EHqATT13MMbePWh0K4G7APPFAC5ATmPHuKYvOecUEDHDH8aaDz0BoAXBzxzUmV29x703gDjrQCTxuXFADc/N0JFO2AnJ4pMHPLA0EnGKAEducKKsQhPK5QbvWoFO0Z60jMxOSKALJJBwoH501gOdzHd3FQdgf5UBfU0APP3hg5oDjPQ0xVJbinDcGw4OKAFbDfwn86ayELkkU/5GPyg/jTGU4+6R70AMj7808Jvyc4pANppCB1yaADb6EmkYjGMEUHr1oBB60ANApw6daQ0ZxQAoXjqKQqR2pygHpSsCpGTmgBnP4UpzjNBPrSnAGaAGkk96M44oORQAT3oAVRxmkA9adz04pOnoaAAdelGSPWlAB70/aPUUAIGb/wDXTc8nNO25H3uaTZjHNADB16GnHniggL0PFJ1OQaAEP405VbGc80AH1oOQevNADgSOckmnGaT+EkUwyZGMYpm4+tADrguWBc5opkhJIJooA0pGhcAqdrU6KVEOCcH1qJcTkGKPFT+TNj51jx7mgCcSgkclh6A1MZAF/wBS5H1qqI41UF2Rf901Mrqg+RyaAFj2kk/Zz+dI8pziJCPxpsjsR/rADVVSyNk5I9qAL6vIq8xkn61WEbyyEsXQenrVu0lSRejVJJsUjBdT9KAGxRIqEMXP4U2RUj5EbY9TUjTpFGS82foKpmVZCdrsw9DQA2SRHPzJx600xgDKng8iif8A1e3aQKrAIFxvNADXlYsV2gGmFHC7i22nlgCAy5HqKcWixxk/WgBiEufvE0kqgDFOaSMKdqkH1qAgsw6ge9AAoJYApxSMME7eBT0facYJpNy5J55oAaPzNNIOeBT8AnJ4pPlHegBVQg5IP4UokAPC5+tBHdWzUYzu64oAmMxYYxj6UwJuPPSgNgdqQnOOcUAGznC5NPCMBjZ1o2gjk496aGUHlmoAQqVPJGfSkCEnkAU6RgcYP40qjdyW5oAjI2n7tLnn0pWLd+lAOegyaABmGMd6blumaQsc9KdjdigBSDwvGacEOecGkCkEZUmpf3eO+aAAME6ioz87ZySfSpGC46H8agbIPAIFACncDyKTORyTQQcZ5pO1ABwRwaTnrkUBaB+GKADPGKQg4pSMHjFGcsATigBBRgdKVl+bjkUbeeKAAnHGKQZzQw7UoHqcUAIR6UKKDgHrRnHSgCT5QMZ5phwTxSZ96Bg96AFOMcdaOwxRxQp56UAGfWnZx2pCcmjPX0oAQ8kY6U/I981GOfu04sRwaAAEZp3Vc4/Ko88HNCtjgHigBQT2zSHnrS5780Z7mgBwGVzn86bkEdMGg8Cmg80AI1FDdaKANCKQKRtBFWcecDliKKKAGSWu0A7s/WhGZeOPwFFFADCxduSasBjGh7/WiigBLacsWAyp9qnkLBcl2NFFAECMzHAxu9TQ9xJD/DH+VFFADftDsm58GoWctzgAUUUAReYxbAwBTWLAjnNFFACgZU5qNpAFK7c/WiigAMmWXAxTgAynNFFADVQMDkn5aQA5wMUUUAK2BHz1qJTzzRRQA5hmlROM5oooAeznG2o2AB55oooANoPA4qReBzRRQBE7fNwKcAMZGQTRRQAIQDluaUSL/doooAcrY6jPFR7/AGoooAC3FJuINFFAC8mjBoooAavJyacPn9qKKAEZNvejAAoooAQnFNzzRRQA4GlNFFADT1oNFFACE8U7tRRQAlGcHNFFADs8HNIuCeaKKAB8KeBSdeaKKAEzS0UUAFBoooAQU7iiigBj9aKKKAP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This transverse sonogram of the shoulder shows a full-thickness rotator cuff tear (arrows) and associated fluid-filled subdeltoid bursa (asterisks).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of George AW Bruyn, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_35_36402=[""].join("\n");
var outline_f35_35_36402=null;
var title_f35_35_36403="Female cystectomy PI";
var content_f35_35_36403=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F54274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F54274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Surgery to treat bladder cancer in women (cystectomy)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 652px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Some people with bladder cancer must have surgery to remove the bladder and nearby organs. In women, the surgeon removes the bladder, the uterus, the ovaries, and the tubes that connect the ovaries to the uterus (shown inside the dotted line).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_35_36403=[""].join("\n");
var outline_f35_35_36403=null;
var title_f35_35_36404="Marginal cord insertion";
var content_f35_35_36404=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Marginal cord insertion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 344px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla J Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_35_36404=[""].join("\n");
var outline_f35_35_36404=null;
var title_f35_35_36405="Flurbiprofen (systemic): Patient drug information";
var content_f35_35_36405=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Flurbiprofen (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/19/30008?source=see_link\">",
"     see \"Flurbiprofen (systemic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/46/7911?source=see_link\">",
"     see \"Flurbiprofen (systemic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8101443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alti-Flurbiprofen;",
"     </li>",
"     <li>",
"      Ansaid&reg;;",
"     </li>",
"     <li>",
"      Apo-Flurbiprofen&reg;;",
"     </li>",
"     <li>",
"      Froben-SR&reg;;",
"     </li>",
"     <li>",
"      Froben&reg;;",
"     </li>",
"     <li>",
"      Novo-Flurprofen;",
"     </li>",
"     <li>",
"      Nu-Flurprofen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700782",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of very bad and sometimes deadly heart and blood vessel side effects like heart attack and stroke. The risk may be greater if you have heart disease or risks for heart disease. The risk may be greater with long-term use. Do not use this drug right before or after bypass heart surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700792",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of ulcers or bleeding from the stomach or bowel. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691473",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop migraine headaches.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691600",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain and swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691733",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat arthritis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease painful period (menstrual) cycles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691861",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat gout attacks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702149",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to flurbiprofen or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 24 weeks pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696862",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take colestipol or cholestyramine within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697889",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain or heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood in the urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11687 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-A1721555EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_35_36405=[""].join("\n");
var outline_f35_35_36405=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101443\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029716\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029718\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029717\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029722\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029723\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029725\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029720\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029721\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029726\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029727\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?22/29/22995?source=related_link\">",
"      Flurbiprofen (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/3/38963?source=related_link\">",
"      Flurbiprofen (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/61/42962?source=related_link\">",
"      Flurbiprofen (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/19/30008?source=related_link\">",
"      Flurbiprofen (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/46/7911?source=related_link\">",
"      Flurbiprofen (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_35_36406="Epidemiology and pathogenesis of and risk factors for surgical site infection";
var content_f35_35_36406=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and pathogenesis of and risk factors for surgical site infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/35/36406/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/35/36406/contributors\">",
"     Deverick J Anderson, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/35/36406/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/35/36406/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/35/36406/contributors\">",
"     Anthony Harris, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/35/36406/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/35/36406/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/35/36406/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical wound infections are the second most common nosocomial infection. In one survey from Switzerland that excluded asymptomatic bacteriuria as a cause of nosocomial infection, surgical site infections (SSIs) were actually the most frequent infection documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36406/abstract/1\">",
"     1",
"    </a>",
"    ]. While usually localized to the incision site, surgical wound infections can also extend into adjacent deeper structures; thus, the term surgical wound infection has now been replaced with the more suitable name, surgical site infection.",
"   </p>",
"   <p>",
"    Among surgical patients, SSIs are the most common type of nosocomial infection, accounting for 38 percent of nosocomial infections. It is estimated that SSIs develop in 2 to 5 percent of the 16 million patients undergoing surgical procedures each year (ie, one out of every 24 patients who have inpatient surgery in the United States has a postoperative SSI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36406/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The definitions, epidemiology, pathogenesis, and risk factors for SSI will be reviewed here. Both established and controversial methods to prevent SSI are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10805?source=see_link\">",
"     \"Controversies in control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMPACT",
"    </span>",
"    &nbsp;&mdash;&nbsp;SSIs are associated with substantial morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36406/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SSIs increase the post-operative length of hospital stay by 7 to 10 days.",
"     </li>",
"     <li>",
"      Hospital charges increase by $2,000 to $4,500 in patients with SSI.",
"     </li>",
"     <li>",
"      Death is directly related to SSI in over 75 percent of patients with SSI who die in the post-operative period.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one paired case-control study of SSIs following orthopedic procedures in both a community and a tertiary care teaching hospital, the occurrence of an SSI accounted for a median 14 day increased total hospitalization, an approximate doubling in the rate of rehospitalization, and increased total costs of more than 300 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36406/abstract/8\">",
"     8",
"    </a>",
"    ]. Cases and controls were matched by hospital, surgical procedure, NNIS risk index (see below), age within five years, date of surgery within one year, and operating surgeon.",
"   </p>",
"   <p>",
"    Another study found significantly increased costs associated with SSI diagnosed after discharge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36406/abstract/9\">",
"     9",
"    </a>",
"    ]. Using patient questionnaires and administrative databases to assess impact during the first eight weeks following discharge, the average total cost for patients with SSI diagnosed following discharge was $5,155 compared with $1,773 for those without SSI. Infected patients also utilized more healthcare resources, including outpatient and emergency department visits, radiology, home health aides, and were readmitted more frequently.",
"   </p>",
"   <p>",
"    The definitions, epidemiology, and risk factors for SSI will be reviewed here. Control measures to reduce infections rates are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Centers for Disease Control and Prevention (CDC) has developed criteria for defining SSIs, which have become the national standard and are widely used by surveillance and surgical personnel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36406/abstract/2,4,10\">",
"     2,4,10",
"    </a>",
"    ]. These criteria define SSIs as infections related to the operative procedure that occurs at or near the surgical incision within 30 days of an operative procedure or within one year if an implant is left in place.",
"   </p>",
"   <p>",
"    The clinical criteria used to define a SSI include any of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A purulent exudate draining from a surgical site",
"     </li>",
"     <li>",
"      A positive fluid culture obtained from a surgical site that was closed primarily",
"     </li>",
"     <li>",
"      The surgeon's diagnosis of infection",
"     </li>",
"     <li>",
"      A surgical site that requires reopening",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    SSIs are classified as incisional or",
"    <span class=\"nowrap\">",
"     organ/space.",
"    </span>",
"    Incisional SSIs are further divided into superficial (ie, those involving only the skin or subcutaneous tissue) or deep (ie, those involving deep soft tissues of an incision). An",
"    <span class=\"nowrap\">",
"     organ/space",
"    </span>",
"    SSI may involve any part of the anatomy (other than the incision) that was opened or manipulated during the operative procedure (eg, meningitis following an elective neurologic procedure or mediastinitis following coronary artery bypass surgery). Although",
"    <span class=\"nowrap\">",
"     organ/space",
"    </span>",
"    SSIs account for only one-third of all SSIs, they are associated with 93 percent of deaths related to SSIs.",
"    <span class=\"nowrap\">",
"     Organ/space",
"    </span>",
"    SSIs are also vastly more costly than incisional SSIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36406/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rates of SSIs for individual procedures vary widely depending upon the patient population, size of the hospital, experience of the surgeon, and methods used for surveillance. Nonteaching hospitals generally have the lowest rates of SSI compared to small (&lt;500 beds) or large (&gt;500 beds) teaching hospitals (4.6 versus 6.4 and 8.2 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36406/abstract/11\">",
"     11",
"    </a>",
"    ]. Several studies have noted an increased risk of SSI in patients with cancer who undergo surgical procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36406/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The type of procedure is also associated with different rates of SSIs. The highest rates occur after abdominal surgery: small bowel surgery (5.3 to 10.6 percent), colon surgery (4.3 to 10.5 percent), gastric surgery (2.8 to 12.3 percent),",
"    <span class=\"nowrap\">",
"     liver/pancreas",
"    </span>",
"    surgery (2.8 to 10.2 percent), exploratory laparotomy (1.9 to 6.9 percent), and appendectomy (1.3 to 3.1 percent). High volume surgeries associated with higher rates of SSI and therefore more common infections include: coronary bypass surgery (3.3 to 3.7 percent), cesarean section (3.4 to 4.4 percent), vascular surgery (1.3 to 5.2 percent), joint prosthesis (0.7 to 1.7 percent), and spinal fusion (1.3 to 3.1 percent). Eye surgery is associated with an extremely low rate of SSI (0.14 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36406/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS AND MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most SSIs are acquired at the time of surgery. The most common source is believed to be direct inoculation of endogenous patient flora at the time of the surgery. For clean procedures, the most common pathogens causing SSIs are normal skin flora including the staphylococcal species, Staphylococcus aureus and coagulase negative staphylococci (CNS). When the surgical procedure involves opening a viscus, the pathogens causing SSIs reflect the endogenous flora of the viscus or nearby mucosal surface. Such infections are typically polymicrobial.",
"   </p>",
"   <p>",
"    The species of microorganisms isolated from surgical site infections have remained relatively stable over recent decades [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36406/abstract/14\">",
"     14",
"    </a>",
"    ], but the percentage of SSIs that are caused by antibiotic-resistant pathogens has increased (eg, methicillin-resistant S. aureus [MRSA], methicillin-resistant S. epidermidis [MRSE], vancomycin-resistant enterococci [VRE]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36406/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/53/8026?source=see_link\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27721?source=see_link\">",
"     \"Epidemiology, prevention and control of vancomycin-resistant enterococci\"",
"    </a>",
"    .) In addition, fungi, particularly Candida albicans, have been isolated from an increasing percentage of SSIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36406/abstract/16\">",
"     16",
"    </a>",
"    ]. This trend toward resistant organisms and Candida species probably is due to the widespread use of prophylactic and empiric antibiotics, increased severity of illness, and greater numbers of immunocompromised patients undergoing surgical procedures.",
"   </p>",
"   <p>",
"    While most SSIs are due to normal endogenous flora, there are also exogenous sources of infection. These include contamination of the surgical site by flora from the operating room environment or personnel. Anal, vaginal, or nasopharyngeal carriage of group A streptococci by operating room personnel has been implicated as a cause of several SSI outbreaks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36406/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Carriage of gram-negative organisms on the hands has been shown to be greater among surgical personnel with artificial nails [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36406/abstract/19\">",
"     19",
"    </a>",
"    ]. Rarely, outbreaks or clusters of surgical site infections caused by unusual pathogens have been traced to contaminated dressings, bandages, irrigants, or disinfection solutions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether a SSI occurs is dependent upon a complex interaction between numerous factors including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The nature and number of organisms contaminating the surgical site",
"     </li>",
"     <li>",
"      The health of the patient",
"     </li>",
"     <li>",
"      The skill and technique of the surgeon",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Wound classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;A widely accepted wound classification system was developed over 35 years ago. This wound classification scheme, developed by the National Academy of Sciences and the National Research Council, was based upon the degree of expected microbial contamination during surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36406/abstract/20\">",
"     20",
"    </a>",
"    ]. It stratified wounds as clean, clean-contaminated, contaminated, or dirty using the following definitions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clean wounds were defined as uninfected operative wounds in which no inflammation was encountered and the wound was closed primarily. By definition, a viscus (respiratory, alimentary, genital, or urinary tract) was not entered during a clean procedure.",
"     </li>",
"     <li>",
"      Clean-contaminated wounds were defined as operative wounds in which a viscus was entered under controlled conditions and without unusual contamination.",
"     </li>",
"     <li>",
"      Contaminated wounds included open, fresh accidental wounds, operations with major breaks in sterile technique or gross spillage from a viscus. Wounds in which acute, purulent inflammation was encountered also were included in this category.",
"     </li>",
"     <li>",
"      Dirty wounds were defined as old traumatic wounds with retained devitalized tissue, foreign bodies, or fecal contamination or wounds that involve existing clinical infection or perforated viscus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several studies found a moderate correlation between the wound classification and the SSI rate. SSI rates according to wound class were [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36406/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clean &mdash; 1.3 to 2.9",
"     </li>",
"     <li>",
"      Clean-contaminated &mdash; 2.4 to 7.7",
"     </li>",
"     <li>",
"      Contaminated &mdash; 6.4 to 15.2",
"     </li>",
"     <li>",
"      Dirty &mdash; 7.1 to 40.0",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While widely used, this classification scheme turned out to be a poor predictor of overall risk of SSI. Other factors, such as the operative technique, length of surgery, and health of the surgical patient, were as important as wound classification in predicting infectious risks for SSI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other defined risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other patient-related characteristics have consistently been identified as risk factors for SSI in well-designed studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36406/abstract/25\">",
"     25",
"    </a>",
"    ]. These risk factors include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diabetes",
"     </li>",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      Cigarette smoking",
"     </li>",
"     <li>",
"      Systemic corticosteroids or treatment with other immunosuppressive drugs",
"     </li>",
"     <li>",
"      Malnutrition",
"     </li>",
"     <li>",
"      Preoperative nasal carriage or colonization at other sites with S. aureus",
"     </li>",
"     <li>",
"      The presence of a remote focus of infection",
"     </li>",
"     <li>",
"      Duration of preoperative hospitalization",
"     </li>",
"     <li>",
"      The preoperative severity of illness of the patient",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many of these patient-related factors cannot be altered preoperatively.",
"   </p>",
"   <p>",
"    In several studies, the extremes of age (infants and older individuals) were identified as a risk factor for SSI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36406/abstract/26\">",
"     26",
"    </a>",
"    ]. However, a prospective cohort study of 144,485 consecutive surgical adult patients found that increasing age independently predicted an increased risk of SSI only until age 65 years (risk increasing 1.1 percent per year between 17 and 65 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36406/abstract/27\">",
"     27",
"    </a>",
"    ]. In contrast, at ages &ge;65 years, increasing age independently predicted a",
"    <strong>",
"     decreased",
"    </strong>",
"    risk of SSI (risk decreased 1.2 percent for each additional year). The authors hypothesize that the decreased risk of SSI in patients &ge;65 years may be a selection bias (more healthy elderly patients undergo surgery compared to the frail elderly)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    due to a \"hardy survivor\" effect (persons who survive to older ages may have a genetic make-up that enables them to better withstand threats to health than some middle-aged persons).",
"   </p>",
"   <p>",
"    Several factors related to the surgical environment and practices during the procedure have also been defined to be significant risks for SSIs.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Preoperative hair removal (particularly shaving)",
"     </li>",
"     <li>",
"      Inordinate personnel traffic during an operation",
"     </li>",
"     <li>",
"      Excessive use of electrosurgical cautery units",
"     </li>",
"     <li>",
"      Presence of a prosthesis or other foreign body",
"     </li>",
"     <li>",
"      Prolonged duration of surgery, degree of tissue trauma",
"     </li>",
"     <li>",
"      Need for blood transfusion",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     NNIS risk index",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1985, Haley published a statistical model using four risk factors that had better predictive value than models based on the simple wound classification system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36406/abstract/22\">",
"     22",
"    </a>",
"    ]. These four independent risk factors included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The presence of three or more underlying diagnoses",
"     </li>",
"     <li>",
"      Wound classification",
"     </li>",
"     <li>",
"      An operation involving the abdomen",
"     </li>",
"     <li>",
"      An operative procedure lasting longer than two hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The National Nosocomial Infections Surveillance System (NNIS) surgical patient risk index, now called the National Healthcare Safety Network (NHSN) risk index, was developed in 1990. This risk index score was a simplified and better predictor of SSI rates than Haley's model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36406/abstract/24\">",
"     24",
"    </a>",
"    ]. The risk index stratified patients undergoing surgery into four risk index groups by assigning each of the following a value of one, if present:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An American Society of Anesthesiologists (ASA) preoperative assessment score of 3, 4, or 5",
"     </li>",
"     <li>",
"      A surgical wound classified as either contaminated or dirty",
"     </li>",
"     <li>",
"      An operation lasting over T hours, where T depends upon the operative procedure being performed",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rates of SSI for the different strata were 1.5 for risk index 1 (zero points), 2.9 for index 2 (one point), 6.8 for index 3 (two points) and 13 for index 4 (three points) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36406/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reanalysis of the Study on the Efficacy of Nosocomial Infection Control (SENIC) conducted by the CDC in the light of the NNIS risk index found that: the ASA score was more predictive than age or number of underlying diagnoses and that the determined length of the operative procedure (T) was more predicative than an arbitrary two-hour cutoff point [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36406/abstract/24\">",
"     24",
"    </a>",
"    ]. The NNIS surgical patient risk index is a more predictive model and also provides a system to make valid comparisons of SSI rates among surgeons, among hospitals, or across time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MINIMALLY-INVASIVE PROCEDURES AND LAPAROSCOPICALLY-ASSISTED SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;These procedures have been used by general surgeons for multiple intraabdominal operations including gastric fundoplication, inguinal hernia repair, and colorectal resection. Perceived benefits include less patient discomfort, shorter hospital stays, and more rapid return to work. Additional benefits included lower rates of SSIs. With regard to cholecystectomy and colon surgery, the SSI rate was significantly lower when the procedure was done laparoscopically within each NNIS risk index category. However, for appendectomy and gastric surgery, use of a laparoscope affected SSI rates only when no other risk factors were present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36406/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190974707\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among surgical patients, surgical site infections (SSIs) are the most common type of nosocomial infection and are associated with substantial morbidity and mortality. SSIs are defined as infections related to the operative procedure that occurs at or near the surgical incision within 30 days of an operative procedure or within one year if an implant is left in place. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Impact'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rates of SSIs for individual procedures vary widely depending upon the patient population, size of the hospital, experience of the surgeon, and methods used for surveillance. Nonteaching hospitals generally have the lowest rates of SSI compared to teaching hospitals. The type of procedure is also associated with different rates of SSIs, with the highest rates occurring after abdominal surgery. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most SSIs are acquired at the time of surgery. The most common source is believed to be direct inoculation of endogenous patient flora at the time of the surgery. For clean procedures, the most common pathogens causing SSIs are normal skin flora including the staphylococcal species, Staphylococcus aureus and coagulase negative staphylococci. When the surgical procedure involves opening a viscus, the pathogens causing SSIs reflect the endogenous flora of the viscus or nearby mucosal surface. Such infections are typically polymicrobial. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis and microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The species of microorganisms isolated from surgical site infections have remained relatively stable over recent decades, but the percentage of SSIs that are caused by antibiotic-resistant pathogens has increased (eg, methicillin-resistant S. aureus, methicillin-resistant S. epidermidis, vancomycin-resistant enterococci). In addition, fungi, particularly Candida albicans, have been isolated from an increasing percentage of SSIs. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis and microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Whether a SSI occurs is dependent upon a complex interaction between numerous factors including, the nature and number of organisms contaminating the surgical site, the health of the patient, and the skill and technique of the surgeon. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A wound classification system has been developed based upon the degree of expected microbial contamination during surgery. It stratifies wounds as clean, clean-contaminated, contaminated, or dirty. Although widely used, this classification scheme is a poor predictor of overall risk of SSI. Other factors, such as the operative technique, length of surgery, and health of the patient, were as important as wound classification in predicting infectious risks for SSI. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Wound classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patient-related risk factors for SSI include diabetes, obesity, cigarette smoking, systemic corticosteroids or treatment with other immunosuppressive drugs, malnutrition, preoperative nasal carriage or colonization at other sites with S. aureus, the presence of a remote focus of infection, duration of preoperative hospitalization, and the preoperative severity of illness of the patient. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Other defined risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The National Nosocomial Infections Surveillance System (NNIS) surgical patient risk index (later renamed the National Healthcare Safety Network [NHSN] risk index) stratifies patients undergoing surgery into four risk index groups and can be useful for predicting the risk of infection in surgical patients. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'NNIS risk index'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laparoscopic approaches for certain types of surgeries (eg, cholecystectomy, colon surgery) have been associated with lower rates of SSIs than open surgeries. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Minimally-invasive procedures and laparoscopically-assisted surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36406/abstract/1\">",
"      Pittet D, Harbarth S, Ruef C, et al. Prevalence and risk factors for nosocomial infections in four university hospitals in Switzerland. Infect Control Hosp Epidemiol 1999; 20:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36406/abstract/2\">",
"      Consensus paper on the surveillance of surgical wound infections. The Society for Hospital Epidemiology of America; The Association for Practitioners in Infection Control; The Centers for Disease Control; The Surgical Infection Society. Infect Control Hosp Epidemiol 1992; 13:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36406/abstract/3\">",
"      Horan TC, Gaynes RP, Martone WJ, et al. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol 1992; 13:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36406/abstract/4\">",
"      Horan TC, Gaynes RP, Martone WJ, et al. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Am J Infect Control 1992; 20:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36406/abstract/5\">",
"      Boyce JM, Potter-Bynoe G, Dziobek L. Hospital reimbursement patterns among patients with surgical wound infections following open heart surgery. Infect Control Hosp Epidemiol 1990; 11:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36406/abstract/6\">",
"      Poulsen KB, Bremmelgaard A, S&oslash;rensen AI, et al. Estimated costs of postoperative wound infections. A case-control study of marginal hospital and social security costs. Epidemiol Infect 1994; 113:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36406/abstract/7\">",
"      Vegas AA, Jodra VM, Garc&iacute;a ML. Nosocomial infection in surgery wards: a controlled study of increased duration of hospital stays and direct cost of hospitalization. Eur J Epidemiol 1993; 9:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36406/abstract/8\">",
"      Whitehouse JD, Friedman ND, Kirkland KB, et al. The impact of surgical-site infections following orthopedic surgery at a community hospital and a university hospital: adverse quality of life, excess length of stay, and extra cost. Infect Control Hosp Epidemiol 2002; 23:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36406/abstract/9\">",
"      Perencevich EN, Sands KE, Cosgrove SE, et al. Health and economic impact of surgical site infections diagnosed after hospital discharge. Emerg Infect Dis 2003; 9:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36406/abstract/10\">",
"      Draft guideline for the prevention of surgical site infection, 1998--CDC. Notice. Fed Regist 1998; 63:33168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36406/abstract/11\">",
"      Hughes JM, Culver DH, White JW, et al. Nosocomial infection surveillance, 1980-1982. MMWR CDC Surveill Summ 1983; 32:1SS.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36406/abstract/12\">",
"      Guinan JL, McGuckin M, Nowell PC. Management of health-care--associated infections in the oncology patient. Oncology (Williston Park) 2003; 17:415.",
"     </a>",
"    </li>",
"    <li>",
"     CDC NNIS System. National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986- April 1998, Issued June 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36406/abstract/14\">",
"      Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993; 6:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36406/abstract/15\">",
"      Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991; 91:72S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36406/abstract/16\">",
"      Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995; 20:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36406/abstract/17\">",
"      Schaffner W, Lefkowitz LB Jr, Goodman JS, Koenig MG. Hospital outbreak of infections with group a streptococci traced to an asymptomatic anal carrier. N Engl J Med 1969; 280:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36406/abstract/18\">",
"      Stamm WE, Feeley JC, Facklam RR. Wound infections due to group A streptococcus traced to a vaginal carrier. J Infect Dis 1978; 138:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36406/abstract/19\">",
"      Pottinger J, Burns S, Manske C. Bacterial carriage by artificial versus natural nails. Am J Infect Control 1989; 17:340.",
"     </a>",
"    </li>",
"    <li>",
"     Altemeier WA, Burke JF, Pruitt BA, Sandusky WR. Manual on Control of Infection in Surgical Patients, Lippincott, Philadelphia 1984.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36406/abstract/21\">",
"      Cruse PJ, Foord R. The epidemiology of wound infection. A 10-year prospective study of 62,939 wounds. Surg Clin North Am 1980; 60:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36406/abstract/22\">",
"      Haley RW, Culver DH, Morgan WM, et al. Identifying patients at high risk of surgical wound infection. A simple multivariate index of patient susceptibility and wound contamination. Am J Epidemiol 1985; 121:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36406/abstract/23\">",
"      Olson M, O'Connor M, Schwartz ML. Surgical wound infections. A 5-year prospective study of 20,193 wounds at the Minneapolis VA Medical Center. Ann Surg 1984; 199:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36406/abstract/24\">",
"      Culver DH, Horan TC, Gaynes RP, et al. Surgical wound infection rates by wound class, operative procedure, and patient risk index. National Nosocomial Infections Surveillance System. Am J Med 1991; 91:152S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36406/abstract/25\">",
"      Anderson DJ, Kaye KS, Classen D, et al. Strategies to prevent surgical site infections in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29 Suppl 1:S51.",
"     </a>",
"    </li>",
"    <li>",
"     Kluytmans J. Surgical infections including burns. In: Prevention and Control of Nosocomial Infections, Wenzel (Ed), Williams and Wilkins, Baltimore 1997. p.841.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36406/abstract/27\">",
"      Kaye KS, Schmit K, Pieper C, et al. The effect of increasing age on the risk of surgical site infection. J Infect Dis 2005; 191:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36406/abstract/28\">",
"      Gaynes RP, Culver DH, Horan TC, et al. Surgical site infection (SSI) rates in the United States, 1992-1998: the National Nosocomial Infections Surveillance System basic SSI risk index. Clin Infect Dis 2001; 33 Suppl 2:S69.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4041 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.65.66-4367187BB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_35_36406=[""].join("\n");
var outline_f35_35_36406=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H190974707\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMPACT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS AND MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Wound classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other defined risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      NNIS risk index",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MINIMALLY-INVASIVE PROCEDURES AND LAPAROSCOPICALLY-ASSISTED SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190974707\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10805?source=related_link\">",
"      Controversies in control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27721?source=related_link\">",
"      Epidemiology, prevention and control of vancomycin-resistant enterococci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_35_36407="Abdominal aortic aneurysm with crescent sign";
var content_f35_35_36407=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 592px\">",
"   <div class=\"ttl\">",
"    Abdominal aortic aneurysm with crescent sign",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 572px; height: 495px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These images&nbsp;show a&nbsp;large infrarenal aortic aneurysm in a 77-year-old male.&nbsp;The lumen of the aorta can be appreciated&nbsp;in panel A&nbsp;(arrow) and is surrounded by mural thrombus. A hyperdense crescent can be seen within the thrombus in panel B (arrowhead) suggesting acute hemorrhage within the thrombus. This finding suggests an unstable AAA with impending rupture. Narrow windows (C and D) are used to accentuate the high density crescent sign (arrowhead in D).",
"    <div class=\"footnotes\">",
"     AAA: abdominal aortic aneurysm.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_35_36407=[""].join("\n");
var outline_f35_35_36407=null;
var title_f35_35_36408="Pelvic veins";
var content_f35_35_36408=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Veins of the pelvis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 593px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patterns of the portal and systemic (vena caval) venous systems of the abdominopelvic cavity are shown. Venous drainage from pelvic organs flows mainly to the caval system via the internal iliac veins. The upper rectum normally drains into the portal system, although the superior rectal veins anastomose with the middle and inferior rectal veins, which are tributaries of the internal iliac veins.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, Dalley AR. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_35_36408=[""].join("\n");
var outline_f35_35_36408=null;
var title_f35_35_36409="VIN histology";
var content_f35_35_36409=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvar intraepithelial neoplasia histology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 690px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAKyAYsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAoorzuXXvGWp+K9e07w5H4eW10ySOPdfibe29A3VDg857DtUTqKFr9TqwuEnieblaSirtt2W6X5tHolFcJ/xc7/qTP8Ayao/4ud/1Jn/AJNVHtv7r+46P7N/6fQ/8C/4B3dFcJ/xc7/qTP8Ayao/4ud/1Jn/AJNUe2/uv7g/s3/p9D/wL/gHd0Vwn/Fzv+pM/wDJqj/i53/Umf8Ak1R7b+6/uD+zf+n0P/Av+Ad3RXCf8XO/6kz/AMmq6zQv7T/suD+3vsX9pfN5v2Ld5P3jt27ufu4znvmqhU5nazRhiMJ7CPNzxl6O7L9FFFaHIFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXCeBv+R+8e/8AXzbf+iq7uuE8Df8AI/ePf+vm2/8ARVY1fjh6/oz0sF/u+J/wr/0uB3dFFFbHmhRRRQAUUUUAeSx/GVru81GLSPA3ivU4bK7ls3uLS3R4y8bYbB3fQ/jU3/C2NU/6Jn43/wDANf8A4qj9nn/kBeLP+xm1D/0Ja9UoA8r/AOFsap/0TPxv/wCAa/8AxVb/AIK8b3niXVZbO68IeItERITMLjUrdY42IZRsBBPzHdn6Ka7WigAooooAKKKKACiiigAooooAKKKp6pqmn6TFFLqt9a2UcsqwxvczLGHkbOEBYjLHBwOvFAFyis+TW9JjuL6CTU7FJ7CLz7uNrhA1vHjdvkGcouOcnAxVmxvLXULOG7sLmG6tZlDxTQuHR1PQqw4I+lAE9FFV7O9tb3z/ALHcwXHkStBL5Ugfy5F6o2OjDIyDzQBYooqul7ayXslmlzA13Eod4BIDIinoSvUA+tAFiiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4TwN/wAj949/6+bb/wBFV3dcJ4G/5H7x7/1823/oqsavxw9f0Z6WC/3fE/4V/wClwO7ooorY80KKKKACiiigDyv9nn/kBeLP+xm1D/0Ja9Uryv8AZ5/5AXiz/sZtQ/8AQlr1SgAooooAKKKKACiiigAooooAKKKKACvO/wBoHQ5Ne+E2uxWqsby0jF9blBlg8LB/l9yoYfjXolFAHxZ4iPiWbSLnxlb2ly1z8QGutLe32n9zH5sSQgjH92OQfQ13Xxivp/D19B4a0LUtY0mbSPD6NaPHqU9vFcGINgRQxIRK/ADF2AwO2CT9M0UAeC6LN4i8XePPC9jeeItd020uPBFpqd19gdYvNujMN2dykKTnnABwMZxkVzXgfSZGf4paDpXifXbLxeNT1CaysxcsnmoGjaO4I28s5G0vnkN0r6fqO5hW4t5YXLqsiFCUYqwBGOCOh96APIvgJ4l1rx7cat4r1Oa5h07yoNPtrJmxGJkjVriXb05dsA46Aiue1SysoP2kdXh1XxBrOkSapYWwsTbztGLmQnYYwQpyoPOM8HJr2zwp4d0zwpoFro2h2/2fT7YMI49xYjLFiSTySSSea1qAPnn4V694u8QeJZtM1m+vox4Msrm21GTzCBfXbO6xFv7wEabgT/Fz3zXMeAvFmsagPAMugeJtb1nxXcNN/a2nT3DyWy2434aRSNqn7mGzk5619IeH/CekaBFqyabA6HVbmS7vHeRnaWV/vHJOR9BwKseFtA0/wvoFno2jRNDp9opWJGcuQCxY8nk8k0AfN3wp8S+JLrxt4fbVPFbDVJbiSLVNIvLy6klfOeBamARw7eCCGxx15xX1NRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVwngb/kfvHv/Xzbf+iq7uuE8Df8j949/wCvm2/9FVjV+OHr+jPSwX+74n/Cv/S4Hd0UUVseaFFFFABRRRQB5X+zz/yAvFn/AGM2of8AoS16pXlf7PP/ACAvFn/Yzah/6EteqUAcP8QJ9Qj1HT49O1MWXmRSBw0RZTyuGyCMEVy11FqE0atc6xPcWaJveGAsu9scHcrggZ7bvwNdd8QzIBaiCdIJpFeNGlUsmWwBuA564rlbi7aK1tfkjaHy90zRttRccEhTzjnI61Dm01Y9KhGPIrlIeJr4wmJdSjtpo2SM/bVkERBGWzIpJVguOoHX8a6GPxTqFxZSW7GWBCqhLmJA5MbD5ZUYblYe/b0rndW02LWLOaG4Vo7SWGNS9tIQ6nOCwIGOOh5FVdA0f7Fo0OkS3lpqdnG7QGOeFomiDdFimUlkxwSD19aUuVpu9ipRStpc66w1Lxdoa2rXcR8RWE0eVWIIl2pOSCeQrrjvheO2a7nRb6TUdLt7ueyuLGSVctbXAAkj5Iw2CRXFfDN7jUYZL+51DTr6ztLia1tXEJ+0RhTtCSOx+8oyuRncCDn176ZRNFLEJGQspUsh+ZcjqPerSa3PPqNN7GLrfinTtGvorS7W9eaRd48i1klAHuVBA/Gsmb4gWj3SW+m6ZqV5M6lxuiEClR3DSFQR9DXmd3pYttcv9Dk1XWYdUhTMjx3kiNfQkjYyiQGMt2O0qeDW5Bpk0V5emVkF4WUROIwGgjxwqsC3GepB5pa21Z106FJ+ZvzfEp4NQis5dCnaeVSyIt3ACcdvmcZP0q5D8TtDXyF1FbywmlUttlhLKuOoLrlQR3Ga4uP7fZSulpe6neCSRECeY04Q5AYn5ThcZJLDvxTBY6dp2sQSwxSWl3cuVeW2sY0R8Asd7YBHPpg1as3oxuhT7WPWNN8T6Jqdi15YarZz2ynDSLKMA4zitS1uIrq3jntpFlhkG5HU5DD1FeMuI57tT9ihubaNcCfYrtC55BKspccYwwOOajTXr+1tojpt1qJniZBdQ+TKsrJjGUjZGBxx90gHHWptLsZywsbe7I9vNZel6/perXl5a6bfQXM9o2ydI2yYzkjB/EVwcXxB1CLXl0prVbnz4GmhvZU+z26FQSyyHLMOw+73q4vxJsrSG2N/b2kUtypaNob+AxzsODsJYE9uSBRfujGWHnHoeiV5hqWvyT/E670+0lMlpFZAySLOQIpVPKhQcE/OmfTIqrd+KtX8VNcR6bdw6No0LqrXlvNFcTzY5dVwSqY6ZOT6CuZ8KafZ2Wk6vBpDrHDNI9zp0t1qCzG5wcu5KjzACwUFfTnrVRSerOrD0XSfNPqdQmq3jyTwwTiOKTK+bPdNvRuwA6Yz3rMtNX1D+xdVbffapK0ix2yh3UyOT1wMHg56YHFZLzXWt6Jpk0ws5JY2kllubKP5dy7uIw4+9kKpLA8ZrZ0GWe8kmgv5tkjjOVUp5XygHHAOQT6nk1co8sTomlJ6I27SXVp552vZ7gsqhEtzMIvMXBGZAMlckZGCCOh5FXBfXFpao13M1pGilUM0u3eoHHUkg4Hc9qqaTFbWhYKyoGYQnzfkZ2X+7nrySc5PXrVWOKD+3Da3FzPIImM0Y1EARxyYO3y8KM/99Hufaud6swaUEmlqS6/ql9Z6I9zpk12NVuGEUM0cTXCEcEMVztCgdSOetWdJ1ee7t7EGe5eaUIXYpJFtkI+bCsuQhIbGc1Qtku7HT4Li7d1nhCw+Tp+WhjXOBiLIOOeSfSrmob4DdiZ3m1Boxax7rgiNlbnIXru6c4znjOKT2sJq8m0vkXnuyZ5rW2uHWYhl3i4JZugJKnOCMjp61gWes3VrBdCfU77UJVBEcFwyQn92Tv8AmX16knHAHrWtPDt1KaSzMLtHKWPmriRcqqEgjrkZGT6Vmz2lxqOnanFPblJXA2zRS+Q0oGOC3OACTz3A6VUHbRsppWV13LOqSxy3FnNdXM8MzR5hj+2NGCrewPzfU1Wn1W4inutU077feaqm2II8xMYXJBIjyoYD5ucZ4qhp+nwwW7prFvYlYFaOOSJ5rqXGOctIoP8A3zU+lWEVpDdm2uVhiuJFkjaGJ9yMO5L8KeOlW7FXjK3ulrRPiBqjXM13qh0pdAjgRmunm8plfByQMsCpOO4I54Na2l/ES0tdOim8ZS6dpE80mIzDdefCUIyrGTAAzzwfSucm0tJrXULa0u4YdQuELq00KMrrncwZO+/Lc1n2qWsc9y7SWTzuGtYLa7soz5SgYELkDJAUdMnr+FUlFrQylhk3orHs+lXg1CyS6RNkchJT51cMueGBUkYIwfx5q3Xh2gSW2pQ2t9JJLpUrborZNKvSLc7QeVgA7c5G386tW3iDxJa+dG/iewn1VQWlikt90CIOjAfK6+5OeTU2le1jH6tJ7Hs9FeQ6Z4/vf7HW68RxC7mW4BsToj7lvMD5gQegHfJH4Vu6R8WvC95PLbX9xLpN5EwSSK/TywGPQB/uk/Qmm01ujOVCceh6DRRRSMgooooAKKKKACiiigArhPA3/I/ePf8Ar5tv/RVd3XCeBv8AkfvHv/Xzbf8Aoqsavxw9f0Z6WC/3fE/4V/6XA7uiiitjzQooooAKKKKAPK/2ef8AkBeLP+xm1D/0Ja9Uryv9nn/kBeLP+xm1D/0Ja9UoA5PxuqNcWG5Yww3FZXcLsIIPeuJeK6S7jdbO1u9OiZxNNFcmMxRnayrsJKud27J44Irt/G6zyNbRQW8crSJIAzNyGAyBtx0OOueK4u10281W2lkmu7u1+1DYjxQmNot2FYr0O0Dn8M5rGS95s76L9xK42K+jtRp8dw5U6ncNaruXcsVxt3iNsHkN0znng1bmt1az2pbxymO3BeJEG6P5uSgbBByDzyahu7SK10GfTdXMU11Fcx3P7ly7ylGBjY4A2scDOPYc1n6VeWttqc2oaiySX0lqJERZN2yNwWPy5OBgADdg5VuOaHZ/CPmf2vkamoawBpMFrfoZDbTLBMtsAP3rEgOcDqTzwOtSaL4gS18SIbyKSGB9iWswuc/bd6/L5gYD5xhuB6GrFzcXFnskiHl25fY77eSSQMHtj1JNVdStzb6qjQ6at0JGjjlmlfbmNcurL2Lq3AHXmlGS3CVNW5ex2nje3hu/Dk07ztHHbYuQybSG284OR0NcN4Qih/syB7c3Pl3AaX92oJHJ+YFdwC8nBJJ6dK3vBWsmby0kiuLLTVjlQQ3hXcjAg4JycjaGIPTnB5pJrOWy1GFdPgge2uCZrR4pCDjGWXPQqVycflVNuxnSfLeJixXVlpdrsWdY7ff8jzPuL7jn5SOpOM4xThd3UV4LGCKKXS7iMzNIZ1dyc4ChMZOfXoKybZbXX7ptLuTpty1oQzRi6UvvUnY4Xh43HOefUc10UV7pwlm0uO8lszbQDzbeJd/lDIwxFJ/ezdSv5Ipf8I5HLrUd7bPcRt5BheFlVoyv+wTyuMDgHHHSqE9xMurxo6Wlxb7HjtxJlJFbAbyw2c5yrEjBGF69a6J4ohbwzy3TIEZyih9vPYkd8g9KzNUtLmM295vs4YIFLS3F0q+bjnDKwBwBnHJGQTyKIz7lST3XcyZNUsNU08QaotvDbXC7pYJpCmRu4YOh4APHOPWi30iFNNjtpYIkt7OUNFbWTOnlvu6+YpVsEEcnrzWnrFlLqeoWcl4baOGFThJY45sq4IDbsnAPHB4PTvVRLBbK7kvwLuOeGI2saSSqkc65ZuMkKAWbrz0GelbKfRML331Rj6iE0+/vNSlmvIrmFyPJY+ZEwkbG7bHGGYdMFskc1a1mG11OaK7nh86K2zOl5Fbs7ZxyitsOVPcZB4q4ZtWjulVNHMZZXDyvcrhOPlQKhKuxOBgf3qh05FsI1t53lglurX7bDYyMWjiKBPMVXIzlST8pJ4GRitOd79R8/LonoOu/Ln0tWsY49KSHCxtsESqCfmAjxlW9MjvUmm3KLrNrB9iuHuWj8lr1ogpXA34kGRkEHOR0z0pfEunaJqmlLPrURN7b7FjmZhhCRyrZHQ9cH8CDzVWDT7TUtImuzf8A9oabdqpkmhnW3ijwxJuMggk8KhUAkbAOQTmOZNa/1/mRUqSi9F/X9aFzW7CDUL55Li9swwQJHviScAq4IwSCUySF455+hrXjd77T7i8ZTeWzkO9sEZRsxyOuRzjBGD61lXWsWUNhCbloZmVDu1Gzhd44vNYlFYIPu4xuJ46VbtNQmk0lLuXUrXUZRL9jFyiNF5wKqwYKCSVywBx71k32IcouVn1J4Qk1p9rsYIeJHiuOdjoxkDMpbPzY3GsmDWr+3h1ESWMizWrCKG5a1KpIpUneUyShHPynk9R1rdsLDUHv55nvjcaldqgMe8vaKq4JMQIG049++ayG0y/0bxXBprvcTWVzdSXqTQyt/o+Y+VkyCGBI24JBw3HIppJ9SW2rFyG6NtrDW8ls7hkYSXCocsykYG5RjOMnBbOc96iurm+j0OJr+UpcZZ5Z7KRolQhs4JYMRleDkc84xVO4ttS0yzjjtrVmAvfMWKwWISOpfLtIrDGCCPm+93xVu8eDw5fzssLbZWacfZMP5YI5z03FS2dvJxk9BTVk9ClLo/8AIdqNzdX0tnbtJDFCMia2liLtKONuHJ+XjPzfyqzBbWlppaSKXiU/MTJcFnOMDAA6gcc9azrnbG9prgeeeDT4m8yG0US/a2ZcZJX5lCnLY5GD0qLUGuP7Nga0m0mLUruQPAhuCVWHjOwuOT65A5oteyWxXNZ3sadxa22oWccrwyWUc6qJA8PzlCCA24Hch5OCCMZ6VgWzeRrl0iRXlxa2ThvNnaMsWweGkJ3BQFDYAyM5zzit+dYLW+kmlm8mOKwZJoUlJ+bj5lXBBGenIIJGKpardwGKBbyTMUztaNC8BjaVyF4djjbhSCM5zTjJ7Cdrroylbavf3Ut1JKkCskqJaBUXzCrqdzxtuzs+7liRn5uKx7qK6S2jhtr23t7xy0rCIfvZCMEouByQWGVbqMGumtrJLeW+mZoklXiOe2cDKBQoDLgAMMAY6DFYNzql7cRX017Z2S2095HaWsVrukLoFzJ5zgE5yV5HfI96uLs7lJuKXn/XkMt9Otb5Tc32nmSOeMTfYjsZBKhzvH9x2BIOOCPpVmyI1QQxT+VqFzE/mIlymRbP1KgjjjIGRmpo4rQW81vbz3SnzHto33xu8W1RjBA6gDv75FRf2kVjsZbO901Vkjyzldpmk3LwDuAGQSSR/d7VspM10SvY91ooornPHCiiigAooooAKKKKACuE8Df8j949/wCvm2/9FV3dcJ4G/wCR+8e/9fNt/wCiqxq/HD1/RnpYL/d8T/hX/pcDu6KKK2PNCiiigAooooA8r/Z5/wCQF4s/7GbUP/Qlr1SvK/2ef+QF4s/7GbUP/Qlr1SgDgPijdIjWNpI6nzctHCkzxTTOGXCqVHIwTkZ/rXO+IrYW+oQXdlIZBAxdEs4VkkdGPIwzDYVPcdmrsfHeoQQT2dnJNMk0ys0axqCWIZRkZxkjdnbnkZ4Nc5q2nmXRwkyThreTz/KjdlVXT+IBWViCOdp/SspO0ldHbR+DRkVxpy6nqMOojUHSFds0lsU4dwQyuzDnK7eB2JNQX1tDpHh6KKztla4kZIjv3B2UtzI5GGcBWJ5J4Bq3A1nNp0TXFzdTtINoWJSWYk4xk5B9Byap3GoXl5qGnHSZPMcbg0YuYjGY0YK6yHn7pYE7efY4qY3dl0Rc3FK/X+tg0/TtRvJVvLi/nhN08E6wJz5TlWDhsgqVIOOnTB4NW41t7fVZru9ElvPFGIh+8LwgDnft6KpYAiotWl8m7s0a/wBliySObbyGkkkO4COQMOmCRweuSKydS1FdN0WO/Wy1Mp5IVrYjJ8t3XerbjyMSZHPGNvbFP3pWsF4xdma09rql7oFq13DZ3zTzGC4ZRyYHBBZQepAOcEHIrV8NmH+w7fTtPEsEuksI7eQvvTftwRzlghyQMnoR6VntKLe7mvV1P/Q7aAie3faYWXlck/eRlwQeT0/GlntzYaO9rpk9vprSgLbmeQy52oAiLyoIwMAE9uc0NtKwpRvruVbl2TxVPLc6No80aIr5tLUPeW8n3nVnHzE4PGB371pW0mtW9/eu2nxJal1WCeaVGaVdoz8qqGHPQZJ9aluL6bRtPja71QLEjKJZfvguSOE3HOM5wMEjpmqE+i23iV4ZdfN1JcWsjyQrBbeQYgR9xgxYE8A7gAQehFK91d7C1jolqXtSv7/TYme009Lq8lKxJ+6OUJzlmJ4SMckt/Oq0bveSRrJDZXdu0JjuLppWZWfAx5aAYKA7skgcAd+K1nht3iMktqRPtZDKuySWNewDHPOQCfpWNbWmqWUq3UusPLaW8XlwwTIsSHjaXYqWdjg9AAM46UotW8/mVK7lfWxYks72fTXgudWEF27LunsiG2AHG0q2Qcj6H6VT1jRbvUIIHsL2aGW1dW83akuQBjBB2hgw6twQelJq9ro2l+GJ50iibT7RvtJx5spaUsCGDZ3HnBz2o+16nc3NrqNn9ntrGWQFp532ExEtvVoyNzMWUbeg+bNUr7oTcVe/X+v8jI/sGys9Gu7m0l1eye6mVVhupisschLoANw45fIZiQcLk8ZqWKOd9AuJ9l7cWuER4lgVpJSimKYf7LNjov5nPG5pVrcabFPblb29gv5JJp7iaQTiBzz5bA8rGTkAAEL61JLbTz6tvF60luieXPZZBaNjgpuGBjIXj/eqnO4R00+RUvbUQ222w32dssYQrNAFMabQFdS+RuXjhu47dah0HTGt4Z/s80MUaweUiuimLzgRvZogOu48kMR2rLtrq31VP7A0+WzmM07RXSX0jee0SM4dQikksNgAZjg5zXT2iMYbeTb5dqlsCkd9uE6AHDEk5xx245HvTba0Y4tSd2ZsWnapb31vbieztrZgEtnsgYQhIBbcpyuCQCFB7VSuI5L/AMT21zJd3umzW5MTSqpnWe1LEFAcfK7FASeeAK6DStNRNSn1K4upmhurf7CyLIfLIUllZoyODg4yDzmqEWsNaTwrB/rAVRwH3gtygSNSflJHbjNS5XIcVaxtXFtGrhhNOtxC6ypclgAI14bkcEsOMEd6wXGm6hpiaq2ialNdWdzK0PnpI7qwPEoCnDqeCpOfaoL+axtH1u9FuZ4YVjFzPayOzmROdpRsheMElR9afFbW+nahZWkB1JSZp7C0hhl3xThkEhmc9cLluT0I/CqjG2o5S7kWkyxW+n3b6FZw3GsySJI9nPfkMdzAfMx+VGCgkKPx5q1q9rJcXx07TrK1Fmx82C7nt2kRHw2XyCAOQBjIJDE5PSrNxawtrU807vLYTWYluZJJBkGJlIVFXpvGSSOm0Vm3KHxCY7PU9CZPD0cIuYZiWYXMbRgIEcEFXDMeDyQM007u4rtLleg6wvZFmmS5a3hhjJjb7LZlTLMByy88ruwOnpzzmqtnMl7c2eqWMUpl1ECS4trzzNsTYI3KhQ+XnjnIBNakelR3Edpq32BtLu4kS3h8wkyQwZ2hthDAOFJIJwc9elZ8enIJ421XWY/P1AQ/ajeOENxJDJsiKodyhW3HKg4Jx6mi61sGt0Le6pb2B1G31F9LFwYkube2mmRZS2doD5JHJxjPGTUGo3gm1KVtG01L77NbNuCxr5Dyo6qYs5yjrkZ68KPqKEq6rpWoafpWo+H43/tR7sTalagpJZ2u7MalsEZBJYZOBwBWlqscOo2ktjbaxJFd7QyrH+7YuPnIwDtO7GCWyeODzVe6nZ/8Aak3qFuy3cqrbRPZzS2kE2X+ZN7FpGUr2BO4E5zninaasmu6ndXt00KCKT7IAreYsKqvysmOSSTg59KNKttQ+xW1mt3GdQ02ZRJIrBopMhmPy8HGGGM8gY681W0PUk0I6lei0uIZLNgl4I49y3Uf/PRc/fAQMcDkbMHtRJe7ZG8ZWNa4t4/EVjb6jocdqwBiltpSWimZ1chkfIBBO0gAg9OawdFa21iVJTpzQSybzJDcoGUNnZJCW68MvHsa2EvL02dldWOkiRbiUyRXiXkaJIEA8sxoSBvkOF2Hpg5PrDqqNY3ttqt1eXVuupXkEy2lxEALZ2ARomIJ+Vjg56AjPerjKy5UCmpOz/r+v68/Z6KKKg8oKKKKACiiigAooooAK4TwN/yP3j3/AK+bb/0VXd1wngb/AJH7x7/1823/AKKrGr8cPX9Gelgv93xP+Ff+lwO7ooorY80KKKKACiiigDyv9nn/AJAXiz/sZtQ/9CWvVK8r/Z5/5AXiz/sZtQ/9CWvVKAOA+JVxaR6ppVtfeR5F0kkcgeRFJTKlshmB28ZJXJGBWRYNc6LY3009wdRZ5JJUWO2dZFXBbGAxLEAADHX8a2vilZ2NzDYS6s8KWsDlhuzuZyQFXjgqc4ZSMEGuGhvraCxvPtVpezxaUXna7tWDicqq4iLYHXdgIox8h5wKzkubRHXS0V2bYudNlvtPS9Vku7kn7OXDRNkYcgoMjC8Eseh4z1FVRfaF4ettOto5bYaV5rwAwTqsdv8AxkBSS8jMTnjjjnFal3LeRWMBtdLeV5hH5lpJMIoreNsbvNHPIBOVGeagt7TTRbW9q+nC3tLdytrZS2qMZSOjgSEsMDHJ57CpVktfuNG7vR/Pb/MnSW5u78Q29uLOG1cBpZ02q0bbmfyCAfmG0HuM8Vk2qafrFk1pIq3dtCzJ5v2gO/mbydjMvCEDB6cEcVbtbycvqgUW91qdsN8E62MkaKXLAKWDMzEY+YgZGelPkvptPYyzWuraiEjST7Nbw/OgJG7qoLKDnqM4xwKSTWi3C736BY3LSMmdEv43laVZRLCmxHXdkcAZDbiQR94Nz1NSwxXlrHZ3UtzC8lpGVuoLW03ecBwDGM/IByCB7elUGMmpZfznl03UQXiiDC3ukcHgoHA2su0nHOQOnrZTVJpNKih0/wC2maVhbpLLbKfIV8/vXUkdGBBOMgnkCm0+hKa7liWfTpfI1CSY2yJIsZKbh5TZB2EDjkH9c1a8R6UNU0qS1jGoJHDMry/ZrjyWJzwHOCSvXPtVTw6L+3u3kFqsXmI0ksjOuWcAgAsAA2BnBwOD7VPH5kd7NJ54upmC4s7ZmZjFwNzDvjI/AZz1qba6PYrm0s9mWbCwmUTTXmnQDTYIYfs8vnmWSc4yQR2C9OeTWdrF4RZw3nk2sXhvyZWvyY9piAGSNo5znPIz27VY1WeHR7S4vZpb14PKVVgjK+XC5YHcDxycD8/esWy0h9U8NG0mk1Z5XkS9gZ7vcJU7oeAQCCQQc/jTST97p/X4jSlfU0tLhe3trGLQZlhsp4jc290du2XcuSEUdDjacY9fetCeU2NjLdRW8Fzqb7bdLZpGfDMRjcSSFJ7nAqhJDbeGLbSH1FEs9KiVmaaWcD7O4/1YWPr8wyuAenFYWhwQ2eoaTZ6VqcbGXzbwpbbVN9vPmCSRxzlQxwD2I9qHvdickzT0K4l/tRtM1KCaxuXj+1wwg5R4Mpn/AIGpJXb6ckGtHRdAXSXnmkuJb28mUR3N2/7oyBc7CU5+YYAyOvpUDWcdtJp1pdRX0rLJJO1xNIxaCMr1LehYfd96lvbO4t4rn+xpLnd57eSXkR/Nd5wzDaxAwNhHUHGcU3r8yb2d7DNTtdZGsae1jJp1vFDK817+6+aRSck5C4GFxnP3sCptAsdHt7S2sLK6aZbiC4lS5Z95dHcuwBHAw3OO23jvVjU7S51LTrqzuR5DSpKr3CBXVAyhcle/+76dateTJpkSR2FpHBZxw/IiHyxHhTuyvoTjAGe5pX0Fy62MHQZrCxlGgPcXWo3tjYpLPLd5Z2R3bEm/ocE/gKqRada3Ot2irZzNZtAJ11iScSIWDKUVGDH5gwGB061YN8TBfNeQw3UpQW4tEhxLGNmfImPUjOcY4xg+9UrLVdLTTLRU05s2VjDfW+jW9mS1vEQxRsqTnJGee/Wqs9WDaaV2i5ba3HLqxmtL+9vLydJY7aBJI0Q7WLYAbOHY5Xk8Y7U3Sr+58RWuoy2iLFYxzC0QwzIJgpT9/GQCdrqwyD3z6Vq6EfEFxBd6hrd0sdvdXaLYQLjCWwwVkJ+9ubIyDjBWqOlWNvNNcahpE4t2vLxbq7IO4TeX8siopGBnbg+u5jTulcI3aTX9f1+BmQXtpYeFZBpC7510trqDTrqPE3l7n81ZOgLMzcAADjjirFjf276JpV5eRiHSZdPiW30vOGWbapU7yePkXAGe/NJa2KXVxLqFjetf2F1amM3UEzB7R1BJPspHY9Dkd6ktNDuNQ0/TY7tYprcta3cV0rBxiJw+zyyQxLAsScdPyourFWtFPc0olvFuft15cCOK5uElt7WVmV1dk4jkU8AhiuApOTWRrVv9qsZBqF1Z3MX2yRpbSWaNVlBHmQodw+R9wUHpxnvg1o+INchLXCok8czN5cF1tVjG5yfNAY4O04x3OPaksdL0K9aaKeyt9R1EGMXMyqw3OGYo56DOQ3PbpmknrzMmSa91lXUtS1DUdI02ddLnvry0R7v5pVRd4cIySZypBRmIXPOKl8UadDqpwmm3Ect6oU3lkIwICvziQnOMYPB7/jWctnq9vqcsFpPb6ssd26sZLhY5LJZY9zxyrjEgBZcAY657Vf0y2+2aZcahLb3VpNqNhErR20yERFFb5Y2GQXK8bgBwQMVS91qxKbevUnU3VhHeCz025WbT1WT7QkKqL9yoAwBjnjnA4AwcZFYmq+FZL+KS88P6pNp1xqMMbTrb7QvnldzOmeQRjJXrg8e+pEtja6fBcW15cWkupxQQWlvcMUCEIwWJAxB3EHnucCsuOy0uaeHVo75ikl7sh+yzhG8yNRhzxlGOGjdTnI9KcZNbfkaRm7q25T+131rpWhW+pRy67qtnKtw8cdosquUmwZYipXYwLAnJ5CnI61Jq9xq2oXumPqcdrp+kWN9Mmpw3QK+fGGHlyxN6c5GDkHHpU3iu3j0i1uJ7fR5pGe88+5hQBzb7+GeND1Vs4bB96ba6PfaV4lW9k1v7KmqukEOmXcRkiV1UfJuzwCoOCcEk96tON9Pl9+voapJLm/r/AIJ7jRRRSPMCiiigAooooAKKKKACuE8Df8j949/6+bb/ANFV3dcJ4G/5H7x7/wBfNt/6KrGr8cPX9Gelgv8Ad8T/AIV/6XA7uiiitjzQooooAKKKKAPK/wBnn/kBeLP+xm1D/wBCWvVK8r/Z5/5AXiz/ALGbUP8A0Ja9UoA4fx9IDrOk2zI0SzrJ/pYi8wRlcMBjBA5AIbttrltMuLqz1q7s7eWOeG2dUDwxKnkpt+Vs5+bcxkBwD05Ndh8RFnhsxf20uyW2jcphWY5OOw/LJ9a4fW7WE6PHFbP9jiv1WW5msZHUXHyscB1DFVBO7jvWctXY6qbShdFjUBHeeI9GgspDHBa5klRZB88rNw7gtlgNrA8Hr2pbe9lTxoItVh0SS2ukaPRXa1LXZdQC7M7DCLw3pnIxmq0cN1YeJo4r+/8AM0y7tRZKFdh5LFclicY4YDkYPzZOaupef6BqtwNGvX1uzuoraVY0acsR8qTIpOAhBJOCOhpW093XQ0l2l/wCe51vTLCyENjqmmwqJGQW1nCuTJ/EQqnLNgHPfg1YtL2Ddc3YuJ7WOW5MTyOGKSfLwrK2QASQc8E5xWPpmiQrNqGoaeYV1S5iLW4uFHkW7q5AIAG9clmzgnALc1pa1af2q2jG6leO3+1i4FsYiwd0QkxksMleCQ3HPHGam0U9ytdU0Z1tG180aW0dlHbmAxxOgKeVKg5BAUqCGzyygjIIzzWxazarHIsMySXEflB/PmCMomIIZCwx3HDbR1HpWH4b17UbTRdNuNet7j7ZdzTzSxw2291XLFRIqng7V7A9qt3Wbi0eDxMYbN2uvs0Qd/LFwrH5drDo2VPA52nnGaqSe3Qm6Tv1IrhrvUdQ0yK/uXgFzBMk9jcOBNAzKFDxspx8rBSMgnD+tXtP04WsMN3FHb3Otx2McN5dW8GZJDsA3DH3+jcjBA49qtzxSy2x06WcRy2zrl2U5cAAglgcr8yg8Zzg+tZkNhPFoSyWyrNE97HcSxWl2YUjRpFZwj5y4Lhmxnncw9qV7rTQiS5dWXmW21PxVb2bzSJq8Fg0j27K/k+S3ygvkFPT5Tzx7VU8I3es6dcJY6yYLm8blBFNGFFuGCsyMoGRkZx79uK3NQa6uF1CGe3eV43LtDkgTREH7jZA6euemPesG8TT9B8O6dPNpjWenabKoC2kgg8gEYG4s2SrHAK4689aSd1Ypb7XGXdtY3tpcXmo61dz6c7vcw3DMv8AoRRNzQvgFXHf5hkDpzzW14SQw+D47j7NbwTz24aT7LbeQpUKNuFzycYwTzg46ill1aVtGhurSxAtbqRHlhliC+b5nAVlAIJOV5PFY9zfTanGlpqN02n3YRjKijbGIgzEHn/Zx/un2ovzaJAo2abZZ+yXpuY3e4jWwCxm5Fzc/fJwAgQrxx3z19a1tRScf2U9mFdVYtMMqAo8p9h+odlz61j2OnW8t/pdzpsslvHbI7eS0XmLeAIux/NckhV3ckDk554qSz1eO50K4h0aaG91FQZVWdhH5yA4Eg4H7sFgA3fb+NHK90LnTdmHhS21aDTZn1ZTby+TAzRvJ5zGVAfNkPJwH+XC9ueBWYIPEUc5m1DWtPjvTcGQTQFljjs1bLhon6tgBQy888nFOs9V0K08V319ezsNWmhS2ZzI7A7FDEJGeEyHUjrn25rsp7SOVvOIi81N0jtt2gRtzgjp0A6+9U3y7rchRdlqc5dy6u1n9t0u3s4dRvZJTH9oZQSMARuT1A2jOPUCptdu4oLmSaz1pbFLGf7TevDb+bNcQqu7yiRkkAuPfB4rbnhtWdry7WJZVZSkiRD5V4O0N12jIPGKrytp+lwS6lZ6ZAl021JmEeZGzwDnG4nBxz7Z6Uk9dipLm23/AK/4YpyaU17pMmn6tI0kkj+c6W7FdnIYbScHtzn+9V9DbJHaz20xlFsTHuZvNOD2Y+o/rVC8fWTrkn2LY2mNaFvMO1y7bT8oQMHLbh06c9eKyYXmstFjntPNsbuZftVxbXEYUjAIVSrfdGByOT70mm1uaKSvoXNGkntLnXIbazcXVvbShERcMoZ8qvHUckg9vm6Vy/hu+ikfTtL8N3d7b6ldxNc202tuZjMsDv8AIpGdpGRuBwdpHcV0+pwyf2Z4q1G11CDT0vLRIoriOExeVKVw7yEZJIwuGPQZ4rDspbC28SafNrKyXeoaJGVsLuylaeRoXhdtkqDq+xC+R97A78VottDGTa1tY6/UoYri/Sa3NtNHKv2hQ0QkEbqQrYz07jt3rLstYstIe6i1O1jKsA80ltbhQuBx5hUfdBOM9vwNM8L2dwfDv2nUtR/tpbkpfW0qoI1VWdnXgAEcbMqeMjvSafZWnlK0cEV/DHKWllaLOzu3QnoFxjnJqFpc0d5QVzLivrm4v4XuI5dJtvKnW6iMWfOdFjEUnmEDLfNgE5DAHrUthfalq0Oh6n4Nhij0a5Do8FyEjeBhkYIOMqpGMLzx36VZ1ySFy2pXLpdwXcawi1lPlmRG7MD9wKTnpnKgVcl1GJZrVLyEG2cGZWHyMu9SCMAfeBJJx9aptdFqSk09GXLG8L6LDceJEsVvrPElx9lcSpHMMMGJI4IwTxXPR2mi3GpXkNjBciLUBHrQZQcOWUDzEUEDA6lcZO4k1Lp9jounSXuoaa95eTz2SRNCZ/NilhUqRIFPLN8wycnG7tmpZLptR1EWcN1Jp19YxLMEjBceTlRhk+VQPmGAD2PvSStt/XyL7GT4o1iQeJPsGtgJHHcW6xRGLcZojndMh+8Wzt+Vc4KnIwc10Vi2q6lpojFppUEDXskM6zO7G4gUfK64GUbOflPHB9arpFHqd7BJDr4v9KM5k8iWBSuAp3xlgdyuCysCMYwOD1rNvNQNnps39qaWtt4ZeSOATWcm4SJK+wZXAZWUsHyARgnvVO2llsTdo9ooooqzjCiiigAooooAKKKKACuE8Df8j949/wCvm2/9FV3dcJ4G/wCR+8e/9fNt/wCiqxq/HD1/RnpYL/d8T/hX/pcDu6KKK2PNCiiigAooooA8r/Z5/wCQF4s/7GbUP/Qlr1SvK/2ef+QF4s/7GbUP/Qlr1SgDlvGscVx5VpPMEjuUMTIDh3Usu4A56YznHNcbdxx2+kz20mjRixiA+zx22MnGQw2g54HzAZ+bniux8aWUV28DeQWu443MDxFY5c8ZVZTyoI646gVxeqC102PXLqe8m0K4kMT3EtvcieSQfKoO0htgPIyB3zWMviOmm2oaD4oDe31pJfhF09ZW3xS25O2RC22RDnADblbGD3FMewlJvBd6vLGDEsM88ZaNlCAMkgAx8uevJOGIrUsHW50XT7iJ5bhNpG+T5fORifn/AAJH+FVLqRUuNRfVdMjOlW9oXa8WUyNMAACghUZGBk5HORUqT5rG0trgbWw1qxltpZfnEciSSRTBWlXbhisnGRhj1AwTWFFY3q6rcX+nX0bvdRJEllNdP5v2LcsbnAzhsqMSDrv5rUKadayvd/ZrabSpNMRyXG52RyMBwezqxOcZ4xS2fhVjc3mr6XN9na3it7TS4opyFNqjJIAd3csCM5wVI6VcWluS3ezLGkRR6ZMlrY2r21qJZUuC0pcyIkbsoLZ67uB7VkWeoJqWj2M/iGC6a31WJLg294iyRRSGRVjVAuGyN3f0zngCtfWTDpniezaCya5srom0lMhZ/LA3MW8v/eO4uwxgcHmq8OuxrHKJFudUh0+G2mjaG1BldpQQhRwSGbK4PAAB6nFJXsnuyajTl2LGs35Gr3Wm2tktxdlN8ltJJiQKWO1xhSMHDHDEdOlP1DRFu7+ztGEI0KKQTS2wgVC7DLA+YGAUBjkjAOckVdgsb2PVL65uzbFSqqZgFZygIO3AH8Pz9z1rJ0PRrtPDOp23iK7s9dltpfMtGRnWZ3OSisflw5J+6DgZx0pJWtb+v+GCb5lr/X/DmjqNzq93NpN0IXslkndLm1khaWUoSRlHjbC8AnJyOetZun6fYW91/ZempezXVrEZRNMSwljLk5ViAr7WYjBzjP41Bq39reKtLtNOWa68OahLbLdGa3BGMYLwyKDmPpwRnp74Oi2vz38S3Xh9v7R003gtrp9PmSZocj75VQc4OMjjjJqrNKxKaerNyKa7ltbi4htpIryWMrl2K/muccEgZxXL3l3HaRrpkWl3zNfKC0j2ZM7jOHAXjO0An0Ix1q34ftp7F1GoROmmeUZLu4+0qIZpi21Y/JOWUFee3JA5rRvLeW5tNKmSe5tVhlMyQxXuEmAOVLnBZh7ZHvUqyZd29Igl1ewQW7ulqt4FVYbVgts5Tg9OQCcHjPalt9Otba4lu7iW3inv2VZGGQzlR8q5zggZPQDPFVIZJL++N1dyXCSNIIY7eSE4LLkh1c4Az6EdveuP+IXiNJ9YsoLN3FtpDJe3TJEXLzNLmOHg8j5Tx3wMVUYOT5TShTdSVo/1udj4ZQtrJ1MpFIl3M620ySsVRVGD98jLsF5wvsDii60TUfEMko1q7iXSbsbktraQo7SBsBGYDBjK9ec59KfY29vrM2ka3cx6gLmwjmlt7G4TaFmZdu2QHJLgZwRjg5qGLUD5Xh6x120kttSupHEYhyq2zukpHOR/CpyCCcnp6PXpuc7VnZmrA1zbaHF/bktt9tVT5xts+ScudoXPPCgA+9QpNcy6hqUmrEtCozGjQkKrqfk2nox65HPIFU4Y59I0Oy8zyblbi6MjlEJAGB8oHvgnnoTWgsUt2b1brfFE2JIZoyA+MZyDznmoe5rGOn9fcVY7t5bfVr1rsXFgwYRCFSHjGBng985P/wCqmtZxS2Bgu0kuGmRlUqjZWJhyDkk8fjzUUWqpBa3Etr5wbY7SSyZLEkjkHGDjP4YxTN8l1OnnTTLbwqrtckODLxnqAOBgg98iixSK+jxoPCV3aaNHN5Mcbukt+u5XlHGJE5bBHOO2BU2t2cSPqNzeapHaWrT26LJpiBXhcEBd5x864YDaeME1qWt1EZPNhPyIdvlDgkcDP5enXNZmm3MVy8zX+oJpUt1ciO10+adWRZY2J3o6tyGAGU6ZUiqjJ6tEziov1+4NEgl0rwzdTWV7Hf2MojktiFCMU8td20AYAyNwQDjJ9aXT7vdNaGJUgs3mKSljhZBgnIDYPr2zmrnjBIpdNaFLuaMwkFPJ2hi3QnnoOR9Kox7p0AvDPbwbiyBZg6BcYIaQ9Tk9jUr3ldlpOKsR2kcgEbN9lnuCfIhWHds8skuFKkZJGMkewwetTW2pXkltcxWsYsplJYlnwrnIU52hsckdjTHW3aFgbiWFkZERJsFY23nLoRjk5/Kg/ZdNu7WG4uJY793e5BgRYY7hsYEbjDfLjHGe3WjRsl+RnnUpbfVBDbW9vPJBFLJNIEaICTAVUVduDu45yM4OBxV3QNRutSnuXV4/LUlhBu3LuAAIODhSCejdiCKraTM+mR3c0tveatG6SXckKMZXeTapaONTgKMqSB3zVdri01HW7eWxhn0nUPMJktSmyPU4DEGbHQGRVJHXIKmqte9kU0o2TLOs2X2yO2tdIs4bKRCt/a3QjDwNMG2NG6g/fKtwc8/hW3FDDa2iSaZJbWptd4URLsjifYQSyA4I6nA4rI/tGCDTF+3M8l3J/pBMxETs5AcKqg/eVV5wD0NNtL68tNM06SxNtZwJcebL5bIyvF824qOhUuwPGCdxos2S9L2PW6KKK1OEKKKKACiiigAooooAK4TwN/yP3j3/AK+bb/0VXd1wngb/AJH7x7/1823/AKKrGr8cPX9Gelgv93xP+Ff+lwO7ooorY80KKKKACiiigDyv9nn/AJAXiz/sZtQ/9CWvVK8r/Z5/5AXiz/sZtQ/9CWvVKAOR8faYmqRxxS28EuI3KM0xhkVsj7rryOM5xXKTE3TyaxpukRPqjxJEJGuTC5dCP3RbOWHO70Peul+IK26NFdXkN28MFvK4NrMySFhghFUfeY4PHtXNiS8j0DS73SLCWExiJLeC4m2ytE3J3DOCw54rKW50Q+FEWmsBexXd/cC5ubh0tdsUT7LOVc7vfDcdeCRnPNXb+5tNAlXWm+3SR3jfZ5EjP7qJv7x9OnX3qS+ntbW8jtlmSwuL5SI4pX2vdH5s5A6Y3DGOeag04x2dtpul2EMVzA5EcjOxlKMcgknH8OevHH0rO93dm3SxNeafY6pb3SMLcySqbb7RJABJJGG3CMnggDHBBx3FZ0okCRot0mnzeXGxgkXzVlABVImySQM4JCjPHWmWeiTRefYw20FvELtZLbZdNK9xHtO8Ek9VbLYGAc9Otaet6bHcXKy3VrJLJCxWJoUwIhj7zqPmPOCeO31p6J2voEb2Iha3d15v2q4t3juLWTZOqCR8vnKqpAYqCOBxnHNX1U2WmxxC6RzaxRGJQuJCVx9/HTnoPfFUdNvbS/0dLm2857wAW5nMBXAJ5JUcge5x9KXTNTtGur/SQ8ks9harcXUksa7VLn5Y2cfx45x6Umnt2C6VpMrQjQPDojtllWEi8LXWLpnWKaUrIY3B43H5cDk/nzR0W2/sbxZbaFJrN9qDRzz3zPfQyZ8rKkIj4Kvs+YA7gQTkDtXQW1tbnVNRm1Gzt4LWKcXSSXC7cz4CmUe5AHHtRJq62mnXd5++mt2yiBJArkk53DLAdh35zVc/REezb1ZmeHrLU0muLtjBpU51RzNHFIsy39qu7y+pyhIcZOScj8K1o7OW2uJzp+n2dtYzN/pXlqlu0xIOWynLEZ4P1qveWltqEWnxQx/2SwuYr9fs8Cr57ghirjod2T3yDzzVnUrdbiOK4tbpojau6sEbITIzg+pHHB4xSlK7KjGy13KEym41uGz0/TRNpajy7oyTZ2OwBJkhIwRgAhwSc1HLo82lyM8N9cNI0scs05j8wvEzNiKIucRuxYAscAAcAYqT7C/mSTxxysEmMqKzOZIckkeVsZlOeeDgcDitKLbqfnNLbN5AYrcQzgFOBuw68hhz278Gq5rbbCS5r3ZQ02xs2lR4beCzgLstxGkRC/KrAHcpKlgHUbsnPNR3nh7TtNsvNnlv7niKKdoo1RnVMiMDAG0DOM9enNWrmSNbazjgeytLONBJcQKBHiLJyFAHGQOg7+nWnPqlz50lnC0xuIIvtP7hFCSAsNke9uN3PpSTlumXFuD0epREtyXvtK0aeZJI2yiiPd5asMs28gjfuyMHr+NdHoklpPIyLLHOIpWhZ1bzNtztBZSeqkA/+PY9qqtqWyC0tvsUzagqGdIApQLIvK7+eM9cGqGiJZxaUdNijh0u81See6EEMh825kxmSRRJyDxnA6fSi11fqZu66lnz49MnNoA0f2m5c7TLvViRg4I+7nnj2qlbQ6jol7Bp8MRuYxKB8m6QrAVPOO3zAHPuatW8MV7bpc/YJ4WbDgXCkOrKcZI6g8da1BqCwI322+tLX7VN5EUkkoBdQgJ2nru4bj2qU29Eat8mpzFremfV9ZsIrFDZhFkBjgKloyMMM98npj0oE0EIi3SyqWVZ4Yu4Vzgx7SeSQCemKhaa61fV5dMtJzbussWrNNHI7xXdmWGGjborH5dy9Dwe5qea9sZdPl1OBHmiUO5nTOZCDjywT1Bz24wK0YotSV0PEiR30080a2ixHb9pdGVZFAK8D7o7dKkg0rTHN2jRxTXEhSWaK7H2hUwPlCqwO0fNkY9afcXD3CyR3kTPbSOSVukRvLPDFMHIyMng+nFMldRdokKW63d51gm3oGwAMrjOAdo7AHFLUa89h19c2loUlmSM3MqsoZ1OGA6cVNDp4toZbe+mRgYhJbwwRndgfMc543HH0FUBPaXuox6VbmCXU4AJRBkv5aFshnXHI/8ArVZna8hvL64u2894G3x732MiFgCwVfmwq+vUkcUoroOUidYYLizhkwy/ayJkj2gGLjO3ByB1Ge56iqupT3KNaI0duA0n7mSfayKoAX5T13ZzgA/nUehWzi3SzsrqwmguoHZ7mGbdIOqq+GADEkfMfWmwJYmFr+1lvImaz8kWEoVolaJyFZSM7TyeQSMEd6drMhSWhWivbx7i+sLea2+32lzFPdWIkjWSaDIMy4PBVl5B4rH0LQfDUuvXFx4Yd00oXFvdxWyRuIVkxKjMGPG1lDLt/vDmum1drkXSapp0UUs0O1k8qNGkkXODEXILBTzk1ZiuE1aytf8AhHL6LTbOO5Pn2yRAGZkP7yIkkBQD12g55IpqWnqOaalzFRVht9Q0yKZ7GNwzQ2qNEZH3AEK2SBj5doOPwp91pwGt6TdIY7No/kkjCoySwFgTEBnoSoPGccjFZi3l9eiEWVlDcpb3YEDyxsxijT5fL35BBwN27J/E8VetHhgCW9sr2WmxsEgdVEpKMQzAkk7yXJJI5FJK3UU7t2Z6vRRRWxwhRRRQAUUUUAFFFFABXCeBv+R+8e/9fNt/6Kru64TwN/yP3j3/AK+bb/0VWNX44ev6M9LBf7vif8K/9Lgd3RRRWx5oUUUUAFFFFAHlf7PP/IC8Wf8AYzah/wChLXqleV/s8/8AIC8Wf9jNqH/oS16pQByvjeWO3m024lRyY5co4jLKjdixHQVxs1zcpqV9cGK5v3vJomhtLqZFW2TGDKoOCB7c5zXT/EcS7bLa+bZtyTx5CEqf4vMPAx6Y59q5u8g1BrS3ZtOW5Pm+WnkyhwYAOCzAZ3E8dcAVjLc6qfwonvGv7XUVs/sdvd6Mu55ZWHzBiGB2OT8hHHXs3Wjw+9ta6PE8ZviIpfKe5kK3BKqpVchcZVSfT6mnXTarFHEttZQTiW4WKaO4uUVIYjne27HzgDAAxn61bmXbHbwWcaNG8xieRm8rZEcndGApDP0wO9Qm9inZO4y3gh0ue3gm1CO5uUyyP5IRVOPmkTIO3J6gHGelUoL1NS16dYJnjn0u5WK4SWFg0jsCeG3KMMBnJBHoKbpcllNpgl0qWPU7m3Vkcgh8kMRubuDnPTA61ah+1yzx3TssMcjAyMgTy1wmPnz8wbP3TyPajq+5fRXJ9RtJ3so43kvQiyrcM1k4jSR1PEbMRkrnBwoBqDULO4uNOVLiJI7u5LSlLNAGndBlVkYDggcDJ4wKkt2ZbqyeaR51VgI2libcHJ/ujgHGfmrNGmx2MlxZxWzafYQSvMk8b5LO7BmduSck8c9qE9LXFy63sXVumuNLEGtg2bToFjhYhpRxjJb19Mmobe8WDSbmBre6v0jlW1MYhUDk5OMEdARnmmixsrvVNpuZIzEgG5HMaFWP3WYEhjxx+FJP4Q1qS0u9ctbl7HVZYcCB5PMCYkJYgLlfmQLgYzzgnvVJJvUq8Vu7FrVkGn22oXklpcXto5UzRW+TIoXAwgBBBHsemaW2SWTVrqNrK6ghSFBE5cbJlYZ3AAEhlxgg+veqbW7C7sdQe7MJ8hNmA2TI2ctjPU56diK0YJ4X1IPcWqx+TuXAYs3sWz1JPapTVu45Rd+wxIv7HgS7Mxkt4okWdIGAJkI5OAoyoPO4DoDVeC5uZkSzjS1guZmaXymcArbk8sdp4APORnNTuwvdYUMthPbBsK/8X2gnC8dQQSwJyMcjmnWl9qEe601W7tWvJ5j9neFFYsFPzIQCR6cdeelUldXM22na5ijxL4Yn03UNcsb+5vLGyX7NeR20TOZYyTtG3Gdp3EhhwQM54ra1+3tpdGiEct3LNMifZktJIrecgrxhpMD5VPGeRj1qn4IWxsbF7yz8OvpEMrzTm0eAWszYwPMK7iSPmIHIwCeBVqa+TUt5OnW8YjheS2N3I3lmUdN7DPy+/NN6PToSveTd9/69R+gXGnQ+Ibm3gnun1FLWJbiOc7toVV4aQDDOcckHGc4q1dW5tmW5nvTd3MVxJJb3M6oHhVxgxx7R0AyOeuTStq9vYaS2uTSW3lOEEjwZcmQ4yoYA5XdkAkcc9KrTajpfie1ka1hFxMuxxGkkcctqzqCpJY/KSvOD1HY0rN6jjyrdGVq9vLBrou7a9u5p/NXzYS7sAAPuKF4GfcVteJ30xtLsp9ags4oZJCB9vjU+XIeOpBAJxgdDz1qu8NwtzEiNb3UkxDTQgKJUYdG8zoR04A55qO9Y6np13BK8UaxTRl1uUW4WTawOzac43DIPcZzRdytcuSum7amD8P8ARNdvvh5d6JrOqyIbaQRWs1uuyWIwysDgfxR4EZA6kEg5rfubdII7PTdHFlb2IaQIhG0EkFgsY7HO/r/dxWvf20rTWsEM8lrDDdKshkVQGjC/KhJ6oxCjjnNZ+pXtle288eppBNJYli6eSZZLeVYwfkwdx7tkdvem/e1MYN03Yz7S5VHiuIZbdrdEKOZCcO24n7v97/aqJ7+9uNPIWxXdKGXzIA4ZVIHILcjqc4/Ci00N4NP89reC5WQiW3MU25DnGwZPzdOhOKddpLbzSxXMO2SWMR+cZdm8kfdRfUdABReL0R1WTV+gkdvHp8TTi7jijm2CWSJWXYg52bh8xJ9Ks2Mdrc6jdvd/ZsyyMsVu0wYuCOSCAGB479MGsmzwt/Lapd35kkZJXtRCrCIKmNrSHnk889OK1LN2El1dRWCG+34SHymjWPkgNvJ2k7VGcAde9N6IkpQfv783empbSRxMRHM4z5KkNuXH3jufBDDOc9BU7HYsMdowtWgQtcOCilU5I2AjcRkYI68VKkStd3k11bz2sJjw+zIj52g7QuMsecEHjGagMBa7WCR51+zBkSBpF3AD5gcr0HC4JyeSOtLclX2KssEUl4Va2ZnRsh0LIWbbnI2DOcE4VsDrWhcaheQzTRpZSzRoixqiFGdA3Q4JBJ65qnFIlvdSm3kgLsoZ1DEyI7MRuUnPAJyTzSXUC2MI1m1SW/uJmRXjl2ReQSMFg+0tkjjrj6U1FN6lbD2uZks5bKyQw38hVhEMnbx3LcDAP5+taFteWqQaU2+O7kuJPJ8xBv2zY+83qAOPxqtfEArHdSvcW0zBB5MTDrwAXB7YPrVy2tmt2KxssMSybYpNwcHOOWJ6YwOlSmmDuel0UUVuecFFFFABRRRQAUUUUAFcJ4G/5H7x7/1823/oqu7rhPA3/I/ePf8Ar5tv/RVY1fjh6/oz0sF/u+J/wr/0uB3dFFFbHmhRRRQAUUUUAeV/s8/8gLxZ/wBjNqH/AKEteqV5X+zz/wAgLxZ/2M2of+hLXqlAHJ+NL20tL7TVv76GKGbzIxazR7lnYjjntj9a5O4aGHV0hS+lnM0bI8ZcAFW4yGxnjPToMV0/xAv5rX7HbxWIvUut0TQk7dwOP4u3r9RWTDcreQrbWojkgt5Ss8rgjyCrgspbktJ8xI4x61jNa3OmnpExbee5gtRqmgSnWba5KJ5lq6lTHkqCORkDBHboa1bSZo7mCPRwtw0V4UvHnkCCOHB+ZAeW+YDj3qK2WazsXgsrSBdPgjCRfZlES/vHJxgE456+maihkisLUSCKK1nuZQqBHH7xyMBcE/ePHTHSobXY3Sdty3baTp9peX9xaaalvcX2DO8ClFdF5AUA4BzyaJP31232eFUaRPMxcxLgAAYPH3hkYPpmq9utraXWp3IN099dOJrqIS4ACDG9I2IKkgDPWpXmQ3cIa2EwcsVkwQYMjjOe3XOPSk73vuNWfkW4xHZg2iRXCu23zIQcquRkhWP4kL+VUbqTybWG5to7N/tEmJ1knALLyOPfA6f4VUuDHbyG5lSG6mjOf3lw8YcAYK88OfRhyD6VNeW92s3l/YZbhDKoAV0SRI2JG4Bs7lAODkZzmnbW5PM1oQPa6dqNveaLeW7W6zf6uVW3kAYYDdjsR0p99qviC9v9MXQ9d06PTrpHiGJFUqdgVsbhljGw3D1DEEDAysGqs2mvJqsUNmtrcRRlMAn7w4PU47ZqTxv4bu7tdMk17W7ttKaZGubG1gX7MxQbwHfhgpICg/QYq4Npv/hwqWJrqPUb46nbpDCz2TqljJPMGkuHUEuzKQGQgkHHIIIxiobbWW1rVQNFhnYWk3k3Zni8jCnOXwwyy8HG3p3qxd+dpusILRbW4sGlkF/NevukjumjUIU77XxswB7+tOk8OLbyq1tp6QW9vbpHbwxjdHEzgh/Lbuc8MDwRg9c1Fra7gpLSN7f1/X4mZem10d/tEdtJKkrx3CK84ypTJUruIC8nOBnPvV64s9D0WC0s7CS20i81q7c2wwXE1xJh5DnJI3bQMAgelUrhL1vDKrqNk8kslwCNxAZFwMEHbgj6DvgVsvb2t09vZtFY3EdgySWzBjvgcRsAyZHLBto5I4JJqvUmqraxRas1NvpU8zRSXF/Gk2NxLKMcbQxyQOnfmucvNWuryxWd4rK301oD5dnPMImeQMPuE4+UkgdDyTVjw5BLZ2qXt1Fd2kVrJJb3EM8TK0gEmfMAzypDMQ3U5zVC60/+1LmGz8U6jpd7rcl7LqmktEhRoreIqVRXK/NjIyPTdz6EYrW5MqlrNF6C6ng8M6nH4i0O30uzSRBFA7GeS6Q/fZxjPcDPrmqeuw6dcPqz3WkHT2N5EIrxt0iXqxw7o5AB2GWXgelb11bPdRK9jaSXwuXlKG/Lhox5mHUKRwOCQDnoKjvXhOq2+mNcwNqNxC13ZwXllsY7MbgDwNwB5BHfOOKalvZDdtG2Z0iR2WpTwvqDm+t2Es0EcbAyRlgd5ZjhmHPY46VatX2Xc0awDecyqzt8zgnKkDpjHWn2t3NLrztdyW8EkxBtEml+VyUIYRr0PzEhs9mFYt3JfN/Zlza6VY3zxyrALm1m2+UxdgwAxt2qOpJ65xStzI1hLkeppeJb+SHVtM0m9tZLyz103Dee2MWsqxqUhQ9CWKkhTjk+1c/58PiDxRpfi3QtWtdOvzZXdkltNC6lLhELOlwAcKFO5jnuBjOa1NQ1Rb2CawukdPtF80MU9upYwGPBE3PodvT1OOman8VWkmn3EVzaW8EWjfZpLm7ktLYFrltyeYkir1Ei7jkd1BzTTtvuYyjZ3Wxtl5bTw1/askSald3NiktxHp+AbptuQYP7zHnH1HNcbqsEVloOkXYkuobG0Uj7TqcxFxZO5LFZw3fOAG5PQD31Z7iPUz9otdLhlHhqaNbawdG85JEXLrGAQCfLxtJ4z+NdbZXdlqlgt1aXELyXTeW7eWu7j/lnKvUlc4PcE1W2qJTcHqcXLfT3WvWklo0bQ7BLCyu6faMKCccgMcHpzjvWzaLDPiKe484XaSNEuSyhcg4PPA3D8ayvEs2o6bqct3fw/arRrffDMbZT5W7AkjEvBUkYx/eH0qKC2VQ0UbRpG1qPNEuWMbEgqpIz6AgdKmytY6FquYktgzwR2i3Vz9qtQT/r8KxOAV7HAOcceozVe4vbY6il+rPcTFBEICxiUhRhmLAcnHIz/SrmqXEdrpK3rxLdQHaJFtUUvM+AF54AIbPJNRwLDqVvHcGKd2vFeA3TqqtbtyMrztzyPXpxTvbUElsZcsem6Tb3NnZ3sq3ts6TK1wMfLgsUD/xELknAzgdKv6pcC20+P7ZBHGt3I/8AolpOX8xich1dsH047VM2jeHofGGneSLQamEdBcTXjeczooCgRjhxlhkcEbunNZ8mqTaMRYeIbhYruGULJJOhJvJH+Ym3PGFycAccCnGTeskNWekWXVnn3Qw6O0azKp82W4JZ9ucZ3HCjr9TWhiaDUIRG0EhLAPbLhkYdPMZ+cH0xWRf2H2q3nTZPuSRXeBV3mRT0GCMbevYjmrVoQuvWjYXzbcJD9ljjYpER3DkYY4/KhJdAZ69RRRWh5oUUUUAFFFFABRRRQAVwngb/AJH7x7/1823/AKKru64TwN/yP3j3/r5tv/RVY1fjh6/oz0sF/u+J/wAK/wDS4Hd0UUVseafPnhX4ga9qGvW1rd64ZtSutSsgdOSBU+zoZJ1uYSMZwiKhLHnOPXn6Dr5u0jxZHp2q6Z4jvfGGnz6tdXqwapYfZI0WKEuVba4G75AAc55x+f0Tp97bajYwXljMs1rOgkikXoynoRXo5jT5ZJqNl+v3I5cNK6abv/XqyxRRRXnHUeV/s8/8gLxZ/wBjNqH/AKEteqV5X+zz/wAgLxZ/2M2of+hLXqlAHEfEu2+0QWqmO6uAxC+RbEKT8ynLt/c45GO/UVji9hht53hmaKU3KxbLpAUZmAwUIOOcYHPat7xzfLY6jpx8tsypIjTKufLXgnPB4yBxXMW9uEvZHd3WIRCVpYoF2ynPCspzuI6gds8YrCpvZnZRvyqw6+1KKwtjNcSfZJDsX/U7oyX6Egc4znk02/jivLW4t7qGSe6tJTc2tsmA1xgDEiAdEy2M+oqu0tvLe2ltDqAc3DSPKZiF8zaAFDKVwRz1GK6qwtbeLUkuIYo9kO+3EzZBCADP4F8cVna3Q6H3OVju7ueZJpLO5mDZkjl8ry8ZzyV3ZVjjHX35q/q0gW0eK8YRrJBuy2F8rjJG7jv+dWdU0+Z7Q6lb2kUusBTGqRyMq9ySMcnOSQTWFbJNc6XBatcfZQgzvLJdSGQHnIbORj24pq0vL+v66CemqNnQxZpYhLd1MhiXzJCwcSqxJDbsnr+Y4ptxCbUFrcBIrSMiMZLAIW+fJY9sk4J9KLW9Ntqk1rZBBut8vE8O1JyB95SO/PT3qFb14r0JcSGO61C2Z7WDyyIi0XL4bkg4zwR2Jo1bbJbtozNS5v006Z9J02K5eRFKnyo2jKbuoCsd5xzk9PWuqbX7BdO0LQfEkCQXmp25SPzId0KyoB8pzkBs9AepHGawdaN/9g+02V1BA+QTNNITEiEkYCbck9hx3q1a6La6h4d8N3FzfXEr2N79pmYkoJ3VnCl1/uq7g4x2FXCW7ZlVhdKxSsdNgMkdrevc399BIl7DcmYRSTSRSmIswJAwuVz25FO065vrK58SwXOvQ3bWtvGv9nu+YdP+QE+Y4G4u2CeOBmrupmL7XnXdOnitUUxz6krrGF27HIAzlkdgDx2BzjFUNU8L219rGtQ65cX8WlahawySvFHHFHGY3QbWnGS+4YJB6rmhbasU9Zaq+wa250i51Hyrxt9y6rbQIw4XC/d3fKODwcdzWrZzTPZ6ZFPes81kW+3okIYXBKEBQ+MAhipJGOlSaxaSC6uZriC0ljhWJIiqlGj67yR0AwF249Kz7SfT4NR0azWO+Se5juJ4mKYhBX7yOQSASORn0680r3WnQ1kk0nI0dOjkOuXtxdag7xW9mIG03cNhkc71kJODvIXGOeMdKz9M1mGawF54h0SW31O305rgXtxBuiVXYqYUbru2hSQOoNReIdNk1G4SQaFFqcKSnUTctcqpiuUXagWMkbtyjH93mpNWs4Ta2Nqt3aWFjZSRX2pW0wWVpIAgj2ledhyowy4Hy8U0k0jGV4trzKWvafr+lzahq+jX19fXExsvO0qWRdke2QK7I+fkVkVwRj1Oa0LG5mtfEl9Bq1lBbRXchhg1CWc77mYrwIUP3coOSCAdtF9q9rdXWteHNSSea2toVnu4ZYv3T27kqfLk744PPXP1qzpFt/Yun6bYRTyXtvCT9lupUy0SH/VgnnJAbGRjjg0+bT3hKGr5SW3Fwk0kRWMWsbRvaSHDoUx6n5lIPOe/Ss6K30sRK0du0ii5dwsLNh2kGdxBJwOCSD0xVfS5NVS0spbUyXNnDdXMF3ayx/POwJO4EkgLnLEe+BjpSHU1Fo9mltBBpw3Pesq/dRvmGOAenVcZ59qSi1/X9f0zVPsV7iK0ittRsFnvNNtXRxHc/KIsuMblbJbjGcjFW/D+tvZW+n2FjHHqjwM0Ul3DIVVEKSSMFHJYrsUYP94UTXBmspE0vT0FlEu5PJLKGXPIAUjac54HYU6ye5s9Qiv57SCGxtdxUJExfDjAChc598jNEn1/r/hy2uZWJtNudP1WdbbU7K809JtOiuZHuHCxM8hzjzFw5dSSCCRwelVvAnhf/hGo9Uv7iey1C/E8t5a3MRkASKdVL5zkEHZkdenWs/4teCL3xt4Tj07R7yGzure8jvEeTARhtP3iPu4ySOP4QDW/bBdA8N2I1q/Fze6fb7Zb9UeMGRuBsQfKRghQcdB+FLm93QnkvK3b+v1sZutxWXiCykuLK7uHvp/IuJH5aKDYSUzGfublYqfccciqukyfZrFJ7jUpL+R55Wk+QFkCrtCEEL0U52nnnvUNy+ty6cVNhZO0t1uuJ5CWZoV5j5Xbnbk45NWks5LhJbuZ0jup3iaQmNELlCTmXAIz1HynPSmnezbNLNKyQirHBY2wsXgLLAfNSaDasg3dCFJUEH8earX9ha6rA8GsREWzuk21t/lBdw2qvQA528cGptUvp4JZpNCWyubhp1X7C175bT4GGVSQRuHdePrnimxQullBpRujazXkf2iFruWMzRtnd5RUnceRj8atpqN1v+IlNXszN1nwq19rmla74VtoHuLO5uhI1wpl8iST5kmA3Abdy43dR+FbHhe9tPGSajYam5n1DSGgQzeQAsNwIwrqj7v3m11PJ7tjmp/CF1eyF7q60iazuJ5jDJHK0YCLGrhTIF5YHPQA4zn3LtQsD4d1f7ba6ZPeCaSUymyRRNEsioGUxdZl3Luz97OOtRGXNHle5NuV88Tlgbjwprcc+sXk1xDcyiOCaBMC5YdfOY/dIbtx04FdBaX/ANrhtxDBHBazzMbiWSZssu4dFHbqMn6VL4csbjVE12w1myZrQNbFJbm2IeZzCgMrK2VByGDADgiuasbue01SGTVJbOG3iufLW2tmMkky7uFOQSoHYcdacL8z5mbX543R9CUUUVseSFFFFABRRRQAUUUUAFcJ4G/5H7x7/wBfNt/6Kru64TwN/wAj949/6+bb/wBFVjV+OHr+jPSwX+74n/Cv/S4Hd0UVQ12e/ttJuJtHs0vr9QDFbvKIg5yMgsenGT+FbpXdjzG7anhth4xurLxBNptro+meObSNm8y60zTTFNDg9H+QxsfTaefWvctBuor7RrK6trWW0hmiV0t5Y/LeIEfdZexHTFeWeD1+Ij6doOmz6JBpVpBepNdXn2pA7wiQs6eUo/iHy/r717FXdjnG6SS+Tv8AlojDDp2u/wAv6YUUUVwHQeV/s8/8gLxZ/wBjNqH/AKEteqV5X+zz/wAgLxZ/2M2of+hLXqlAHIeOmuRLZrbh2R1ZXWNtrEcdCeP6+lcfJG7XcbRWkG20LSJ5su6R5CBh1zx26YrqviA0xvdLis5pEnZicRFd23I+baeSucA47GuWt57u4MFrHpuydmK3ssu1omX+8mM5PzcDI6GsJ6O530FeKsM0W2OoeIf9JWG5jsm3edLbtDNFIVwxQDhg4OOSRkZxTtI8QtqF3ZyzXkkCx31xbRR7wI7hQ4VXYHBJ3BlGODtJqzZQ/YLDfd3cFq0MQjvJo33bBn5UjDZG5uOOce9cZ4EsLLVvEmqapfWFnBZ6QVe3tkbaOQRGdoxtPU9uTWlOKkm3skd1CiuSVWekYr1vJrRf15HouqQKxSOd7qARTtcieDhuzrxzkdRjHIBrmbHT5ba1nkeSzmWaY3VndJbPCsQOcrLjAXrha7SWOaOJAhcgMRI7N/q2BwoHtjp9a4+zcSPM+pv5OLo5M16Jop2B42+gwAcEDFYQb2RzNJLX+tS0Sr2jW9jcXbIQHJgG3Ep6EMTgjIIyOaUrNbzmxtInaxFqzNJON4muHOAEfIKnBJPGCDihp5IInmnaOJEYLbyySKY/mGQDgAkc+pqe6stQltI0tVNwZCjyvE5K4znk5zj04p3t6ENX9SGYoluhIW5sUYQyw/MpfJ/uk/Kc9DxjHWtfU9ZtvDXh++1GKylkj0+D97bxqWkCN1OCegOCSfesMz+fdzQLPHFcGcqjXcLFW2rwHHBUZAIPP0ra8PO92L1zPDJdSRsLqe3AILphQpXsPmb8AKLW1ZMldWMKfTLiO68Ny21x/bGiol3dGCaNizwSDIRTg73AdgoyMqfQVtm7trldT0bSo4/s6WFu0ME6earKN6shBbORhVJPQ4rRE0EcNq9tNE00MkREcRCxuZF28A546lazbLw9oBinfR0eBPtjT3BjZVfzztk8pmILbckNgEc03LR3J5drP+tyrrRkh1EPLK01tGVRFVlXcyr8xYk4AAGcHr0psKqtteA3ds2hhz5xuJSkgm4IQKF+ZT0PI9qefs1/qctvc4jeLc6wqRhgc5LADGQMYINUxaaM81lZW1tNJaTzmQkDBZgpB3nuBnpxUxs1qazu1oaN0PJ0+4gsrom7milltpbpVljtCyhlBKjlAc4HXmoNRSG5u9MvReJDqEIS1uVe2RTqXy5aI7yMLk7sGrV7FdWtnGY2guLzAiuEjh8r7Tk4XaoLAAZGee3WmWcqtqcUFz9jntorwsG8px0BwEc8Fg2AcnHBqk+pny6FI6hP/Y8NyllPrN3as1pdWFrcKoWFzjJi4UlcYCjOBjmptU01DY22l2t1cwQS3TeTe2iEm38v7+87v4sFcnp6VVvtKvJtP19LZZNUnnvY1hhaYWNwiq2WbzuN2Acr6hcV00eq6fDZ3dtqL3MK22IFub/KJKuB0boxHf1q3fdf1/XoZp2djNudYyouNSdDMXY20URLGeMjcqhWx83vWT9pu55LO6lilS5uQ/mfZrdUhuAWIUSGTksFwNuR3P0bp0lpfahqOjWWnyxCxYSxXuSclgMlFbO3AcYHTirl+l59oSS/3XdjGAEdXYtEUGC7MuMsRkY780tIvY1WuhVv1htdTs7yFHtre1ADLI6xwj/dXIwME8jOSBxWXqiR3MMMd9Y6hDYR3ReO8dkjbeARlQw4XB4bGT9ankaKK9ljuLzUmS4i82KJ7YKkUYxwBuJPQD8aj1Swa90u1d7ZdU8tkmtApZbjHQlw2T3609tGaKxftvEMcujm7ub2AeXM7ot8RFlSwGwgnA5ZFBPqKadQ1nVbzT7KzhsrWyEKz3TRX0c0sPzsuCpIBUBeCO/FSamole6uLmcz6XFaFpdIhtUMhcAEgyHjjA98gVh7pCWEGnQW1vcx+UA0W9p15ATdkbckg5GOQOtQoxSZXvS26FO6nF14i1K9sY9KSJZN+LmZZYs7gMgn+HGGIGeSRW+JrW/+0QI1ldXFmqSpa2lrxHKV+8/bGNo46cVzsFumlyW9hc/bTcqhjSxmQuruw6FgcABsAYHOBWgUv9X0+GC48nSncR/ZryC4Ty3cNxAf4yTjB9DWjV3f+rf12E7JE7GzLWdpPp9vHJKgkhg2uqpKBkt5hzsXAPbrWdcIs2nWi6fOEM1w7WyF2KPtzuHmlQqNkHbuIyc0umeF9RHhx7ae3MEciyO+JCognkVW3pzz27YzwKoLbT69f2EtnBIumalpUA1C6n3R7yhZNw3kLv3hW245+lNWlrfRf1+ISvHS5pRv9q8Ui91piNRtIwUiiviUYZIRwMFeSuGCt74r0qz1C5ubPYRJG6x7vKKHepHXBzypHT2rj7Hw8w1ezNnfeXai2EF1EhCM7chZhnjOQX4zW7plpf2u+5vZLW5vZ1JjljdgCqcDLY5PU9O/euebu00XBaWF8OadcWVpdh7w3tvLcGW1HllfKVh86NzkgnkdOa5LxXpDHXJ76eceRNMrpbwkJIQPvHnOSeAeOgrrdW1jTdIllN/cXTTeSs8TRWsj8Fwo+5975mGR171PZzagNZuvNtkj01NhhJykrsdpYEEcr8xG4EcgjHeqlzPVvz7XKutkeg0UUV0njBRRRQAUUUUAFFFFABXCeBv+R+8e/wDXzbf+iq7uuE8Df8j949/6+bb/ANFVjV+OHr+jPSwX+74n/Cv/AEuB3dZPia+1TT9KafQ9I/ti9DqBa/aVt8qep3txx6VrUVvFpO7VzzGro4XSfEvja51O2g1DwB9htJJAstz/AGzBJ5Sk8ttAy2PQV28xdYnMSh5ApKqTjJ7DNfPPh74c6xpXifw9fXnh+W51KW5t7q61CS83C3dZJPP3ANhty+Wy/l6ivomuvGQpwkvZ2+X/AA7/AEMaEpST5vx/4ZHlf/CU/Fb/AKJ1pv8A4PI/8KP+Ep+K3/ROtN/8Hkf+FeqUVxm55F+zRJcS+EvEUl9Ctvdv4ivWmhV94jcldyhu+DkZr12vK/2ef+QF4s/7GbUP/Qlr1SgDjvH8C3cmnW4dI5i7SI6GPz1wOSiurZHqBzWGdPlOkzOby2sJ9+1bm0G5Y4v4f3ZITJGex5NegahpVhqLwvfWcE8kJ3RO6AtGfVW6qfcUsem2cf8Aq4FT125Gfr61ElJ/Czop1YxjZo4TVNOTWNLks5xfPbkx3CHAjCMuPlGc4+7jB4+lLZ6Zp2lRCVpv7NsLeNlmtp0XfMSCA7sPvYyNvpzXWzeGNFmtLi1fToPs9whjkRQVDA5J6dOp5FX5dPtpoGhkjzG3UbiPyOcip9m11N5Y1uHsrvl3+Zxil51SGaKY/wChNLJeR/8AHvKu4DGeofncPYGua13Q5PJeWHSINc8p444opwVliYMA5fAClQjcdT716wLC2DhhEMgY6nB+o7/jVUaBpyhwsMi75fNO2eQfNkHj5uBwOBx7URptO6M3iU0eezObiyvLeK1t0sg5aGdwWhXgYHyjPHTFVl1tIDbafHdWkM8gUiUI+yYgZ2rH6Y75r02TQ9Ol3eZbB1Zt5VmYqT64zin/ANkWPkJD9nAhT7se47R+GaFCwOvE83e/OoaxIkkaXvlwgw27AHcTj59uNwOcjIyPbNSeEvsx1Y3MFu1hcsGS9g8xT5TgcBx1O4A4b2ru18M6Ot5b3a2MYuLdSkTgnKjOfX1NWotJsIZ5porWNJZm3yMBgufU+tJ09NA+sROelEV5pYMUKLdRTRJuUDDtEdwX6DJHtUUdy7aTJ9lhRWhkcSK0eBJgDbk9fuso3e1dXFYW0RjMcKr5bMy4zwWzuP45NIthbKpVYgFL+ZgE43cf4DjpUulJ9RRrxXQ8bns5HtLxbjRrtNO2rLIyyBpnfhsKem3LHr6Vr2tvfQR6XCkl5ND5gkKLKQyxiMAhgBtBHoDya9Ak8N6TJdtcyWYaZuSS7EflnFLD4d0mEqYrGJCp3DGeDjGevpV8jta43Xizg7r+1ZpLF49RgsVtr3z7tZVDfarUA/JnHyH8vrUq2SpefbJrPDxIGMkTFw4I5UA8Z9x+NdvdeHdJu4pI7myjlSThg5Jz+tSw6JpsBYw2cUZYANtGM49fX60vZuwLEK/U8+nklgSY6jbiWAXAeyUgbIztym4Dlecgnpz1qCWG20m1jn1O1uTC84u3aGTcYLk5HAAzg56njHevQ18O6SuoyX62Ua3ckflPICQXX0bnBHHep10iwWaaZbWMSzYEjd2A6flVcjWxPtovc8014SX1pf6dNe2l3rFnefaLYTytGm1sbUIXGSATjPtSFbmC2gXSLdtMuHYvqD25WREcAgCQZzhhnkA16PdaDpl1D5dzaJIpcOdxOSR05zmny6Jp0plL2qbpcb2UlS2OmSOaaTVgVaJ5dfzzvFJFHdR2umuA6vCSMlfvIF6jP65rO0i2OtXEI1a01RRbThlO7eykZHzjZnv2OMHmvXl8P6UoKrZRqhBBQEhWB65XOD+NLbaDpdtt8myjXaMLnJwPxpSi2rI0WIh5nAaZpckOv6iEk82C4iCPO16wmkwOioBhVG7GRg5q59hv9P05YdJubi3tIRIBHd/vfMLdPmB3gZPbmu1t9C0q2upbmDT7ZLmVt7yiMbmPqT1puqeH9I1WyktL/T7aa3kxuUpg8cggjkH3FLklffQTr03vG5xdto0dpPHM/h63kLR7HYRuZJGI5O5z8g3ZPUmszRdPuNL+y2yNpukWESELpWnwvcFpDk7mkcArg46A559q9RisLeKCOFFfy4wAu6RmPAwOScn8aelpbo25IIlbrkIAaOWS00F9Yg90/k/+HPNEsrqJEu76fydUlaIzmGaUwbkBG6NCDgkH7p46Z6U7VP7NitLtdUvrC7tbCcPO15OHWCVvmVWGPlPzKFAzxivQNP0aw0/zfsluE82ZrhssW/eN1YZJxn2qaHT7OAOILaKISOZHEa7Q7HqzAdTwOTSdN31Y/rSj8COCtNUgvYbS50txqcVzKsRazG7yc9Wkb+BAO/XtirVyUtIkWO2mlt3nkk84yiRUUDhjz3PAUetdSdB07zLpzA2bnHmr5r7W4I+7nA4J6D3606LQ9Mit7eCOzjWO3jWGIc5VFAAGevQCh0layKWM968tjj59ZsrKONbvUorN55fKWEusbFv7i7uh7469sVW8OatF4ja+FhA0kVncm2YKwDyMpwSy9AnUc/hiu8l0jTpY1jmsoJFUkjegYgkYJye5pdI0nT9GtBa6VZ29nb5zshQKCfU46n3PNNU0loKWKTWiL1FFFanEFFFFABRRRQAUUUUAFcJ4G/5H7x7/ANfNt/6Kru64TwN/yP3j3/r5tv8A0VWNX44ev6M9LBf7vif8K/8AS4Hd0UU2SRI0LyOqKOrMcAVseaeA2XhKFvGGh3Gg/DvUNInt9TjuLi+u7xmj8lSd/wApc89CPcDtxX0BXz94Z8M+Ljr+kXV2k3m6Vd29qjxXyyLLCZXe5nYbujKQMEZ5A7cfQNehj5XlFc17ebf5tnNhlZPSwUUUV550nlf7PP8AyAvFn/Yzah/6EteqV5X+zz/yAvFn/Yzah/6EteqUAFFFFABRRRQAUUUUAFFFFABRRRQBR1nWNM0OzF3rWo2WnWpYIJrudYU3HoNzEDPB49qj0PX9H1+KWTQtW0/Uo4iFd7O5SYIT0BKk4ryv9qtHf4eaYUO3brNszP5RlCAB8sVHUD0715tomqvot98SdaslvNcsX0uB21fRrN9KKyB0TyUXDBThi7OMkBSaAPq+ivlPQvEviOLSvHkFp4vmjshp1rcWWozXFzfRW7PKFbbK8YkwQSCwXCk7v4eDSfG91H8PtakuZ/EksK6nZWY1GPXppLYbw5aRbnyzIka4G8AE5KAYzQB9Oa3rOnaHaJdavdxWlu8qQq8h4LscKv1JrQr5LGoa3qXw91my1O/u9VisvFFgLWaV5Jj5ZYE7ZJFDsvoSK2fiD4l1W217xoLzxJ4g03xTaXcaeHNKs2cQ3UOF2kRBSsu7Lbs5x7UAfRdlrOnXurajplpdxS3+neX9rgU/ND5i7k3fUDIoh1nTp9budIiu431O2iWaW3B+ZEb7rH2NeA+M/E/jG0n+KXk3eoW4tP7FAMAZ/sMckObl4Rz3zkjp17ZrW+DA0+T4v+JJ9D1XUtZ0t9ItRFf38rzPKdxz+8cAsAf8KAPcEvbWS9ks0uYGu4lDvAJAZEU9CV6gH1qxXgF9a2Np+0vqaavr2saW2pWVr9hWGdo1unztMQIU5UHnGeDk1V+HGueL9Y8XSeHdW1C/C+DILwajc+YR/aEruy2+/wBQEG4Z64oA+iaK+V/hx4r1TUrj4dyaP4n1zWPEtzLKNZ0+e4eS3S2+b53Ujap+7hupz1pnw58TeKLnxnoMmseKTb61JqDQ6no93eXTO6sxXYtp5Hlx4GCHD49T2AB9V0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVwngb/kfvHv/Xzbf+iq7uuE8Df8j949/wCvm2/9FVjV+OHr+jPSwX+74n/Cv/S4Hd1zXxHGkHwZqI8R2Nzf6V+7862tgxkf94u3G0g8NtPB6A10tFdEJcslLseZJXTR856NZ+GZ/F3htvh14Z8QaZqMWoRyXVxOsqxC1GfNDFnYcjjtnpX0ZRRW+IxDrteXd3f3mdKl7O//AAwUUUVzGp5X+zz/AMgLxZ/2M2of+hLXqleV/s8/8gLxZ/2M2of+hLXqlABRRRQAUVy/xMbZ4F1mQTywSRW7SRvFIY2DDkYI96+a9V8Ra20tun9r6gr+Su7bcOoHpnnrimlc+iybh6ea03UhNRs7aryufXlFfHTazrTEAa9qIdSHP+lSAFQeec1z174o8Vwa3J51zrCF9pgMl9JGgjz1AJwxIzWsaLkdWM4VnhbXqp3dtEz7mor5D8Oa/qT2aTza3fhLaMuizzTj7XGXOGVs4aRW4x0Iq8mqa9aa5pVrqniOeK1uGF1Dd290XjaNlGwSKW3LluCCfXFU8PbS5w/2J0dTX0ve3mfV1FfNPgzWtUls5pNY1G6e0d5LOzMc0jGMkmRSx3ZYjaQD6da3dJ1O5muZbHUL67hby/Nhja7bfOVY5cYJKgrzjkcZGKUqPLuyXkdSPxSs/wCvM95oryZ5dTF7ZGXUQbJZiZ5XuDEY1MbDGCfnG7HTnvWXa6vfakbxJ7SWO9uDtllt72XmFGA3KpYKCcA5XqM/jChfqZf2TN7S06nttFeJ6nqeqSajazRaw2kQafaM1w0zMyyRK3zSLnIYhQepz3puneItR16a21Pw3evfaQWVN/luh6/vfMy+FOOVwCOo4o9myXlUl9tHt1FeD6hfXmkxXNzZaxqN/BqLNDZ21rIZCpPG3LE4Zcn+LnHFDa3e+G7fUodUvBqD2hSW3LXkijIXPlZByzkHPIwelNUr7Gjyh9J3+X+fY94orxS08R65aeFobqO5+2yajdl4oNQDQN5Tn7gkU4yCcbumBXOt4je71p4Na8Qy6RGl2ltbx2M0jPIyEny5AwOACSDIDg8ZyKFRk7mX9l1LXbPo2sLQ/CekaJJrUlhbususXDXN7I8jO0jsMHkngDnAHAzxXh9v4t1Bb271x7C7lsFcW91JHqpkijfcFxHghBjIJJ/StXwz4l1S3tNd1nxHe6cVvYRJYq1+0LDBIEewkhcgZ3Dr9DTlRkipZVNbSv8A16nsfhbQNP8AC+gWejaNE0On2ilYkZy5ALFjyeTyTWrXzNeeIL2/1jTBd60dMsrS3N2yC6ld5Yu/Kna7EjPX6VFf6w2qKtnca5rL6tHE01tNavLBCJWb5VlXqVAAJJwPSr+rPuW8mnbSWvoz6eor5psPHeuyjUZP9P12ext5it5C4toizIQUKZGQCQQ2M8cVxaap4qOhyalfa/rMmrR2e2O3ikaOKOMcebKScHqFBAyT3pxwknuzN5VUTs2fZVFeJeD/AB/dy+A9I1vVbO8is5VS0Uw753mlDbd3+ypxncT1rtnmktdbMKz6rK17m4L4320IRcbAwHy7gcjOckVzTi4NpnNLBtP4jt6K8312LxAPCT2nh28+13WPL866uAkpjbOcOBgOM8EjHFc7JaQXWk66lx411uWLTLSKG6S2YCa0mjUPv+XlicdBkHnk0RSavcTwlr+8e1UV498P21u78L6TM2ruIUleQyushl1GI5Kl1c5izkZA/DiqnjDxt/wi+uQ3HiOx1uOSKDyoPsc+60vfMZV+odSc84IA75ot7zigeFsrtntlFeR6lPc3HxIe3svHbxy6ciSTaHHbBk8vHzb5CcjOc57cVNfQalceMnlk/tk6UbJIoprO5Bt5g7EHcOqupIbKk5ApadRLDN63PVqKKKDlCiiigAooooAKKKKACuE8Df8AI/ePf+vm2/8ARVd3XCeBv+R+8e/9fNt/6KrGr8cPX9Gelgv93xP+Ff8ApcDu6KKK2PNCiiigAooooA8r/Z5/5AXiz/sZtQ/9CWvVK8r/AGef+QF4s/7GbUP/AEJa9UoAKKKKAOb+I1jaah4L1SDUJRDB5RfzD/Cw5B/MCvkeSQJqRF4Q5GOB3x2r6Z+PbbfhtfMCQfNhGc+siivkbWpFKR2kcjrLM4TcjfMHPT8DjFOPvPlR+jcJ1fq2X1K0ndc23nZfn+h0txqIvdRt1OHd2aSCAL/riv8AAPrjFS+HZJ2sb7UdZugto6CSOG+izm6L/NGitkiMKcFsYFbXw60VoFjklt4b+W0lRoHXar+aCNyoSfvAE4zwTXXX0GoQWFvcK8C60rTrHBqieYPskuQIZe+euMnrx0rvb5dFuRmGLq1aidrWWiX5M57wz4Y1rTL1da0J/sYgEsC6deFXyQflWNh95CjkgjuM96u6N4UmubqxFvYrarptwjXN7IVCytHuLqF6lt23rkDnmuggS40HRtOtZpI72W3drePA8sLbg7xkNnb0wOpxj1rX1u+trrw4t7JaTKlzF9o+Zihj25c7jjHbgY+asnUl95wKrJR9ev8AXTcxWvLb7Wt22nwf2pdRbIEjCqzRYIdioJU45AI5wTVzR7WyfW2QR3Md2pWWO3JHlkFAnmAfmoBIqSyvdJtNF0m+1Ax6bZX8BaO41BlhmJLFtpRcbcnnjjHei4u7OzNpcixvbiGeUPDeWhx5CblH3ASWHPXn8CKm97pDVZSVqfX+v6Rj3d7eXmrpY3kYGkOBmW/yFhPO4l1PysGUYxnG6p7m9j1DUrWzs/tIlXy4ZrwKSmQ2AR7HjPQkHNbb3t7famLHUJLubTJUneeJ4ohEFKsESNPvl84Ofep4rOQXLXV6sUMsDtCk00ZzBuA2MCTtGOm0HHrzVKaW6B1rPa39ei+e/Tcx9TIYPHBcWlvd+cALi+gJWePIDRMOrD1I9MHrXLX1vqcsk5ivZNLKT5zhktpNx2qBFgDb0weRjrXQXlm1xe2+i3OpWp1C3JeQ+cyPg4Jcbl+ZcdVU+4q3fQ6zAmpS3Wk29jpukXqvpwiLF57YDc+CMhs+44JxVxko6F+1VP3V9r8v+D/XS+dpmm2dnobW2k3cc89ysd6kF6rREMpIZVHXnBGCCOBiopbf/QTDb2dzZyT7WuXjm3mK1bOArFeivk4ALDAHStOGbT9Ugtv39teyw2ys9nhJJXBPGSCpwuQNw7g1a17y74CAyXT208yi3SONmjkOOSkinIZcE4OOBS5rPUhyTfLf+v6/zMmDX7mz0uKwu9W0d/Ds9q9hBNbxENNcBeqkAhSc5PGKs+G9D1yx0vStO0XS7CO3kmluJpr6TzHkRgvzoyZMbMN3TpgVDqRsp7Owhgs7m2i6EiElQxAAmVAeCCAOQV5watahpMMbnWNR1+O4uLS5CtPjaXj7RPsGVPY8dDUu1rLT+tDKdKyta1/Lr8v8+2hfGjyaHqF9JpkUFhoxUteW62ZaK4b5izI+dxIxyDxXBaWLbXpY7/V4NLvLS0kKpe7/ACywAyqmJmDMp6jHTB61u3M6XItdIhutYtLmzVLy1+2GSXzjIHz84BOEAwM9QTkVnaoyT201x/ZVlax3EBu1iEYjmhKFh5a4yAzcMOOmeKumu+5pQVlb+u39MdqsEurabNrltJZOyypFHbW4VSki8LtY8NGF7DBGT6Vmarrc02tQ3UMeoQ6ndQia9OnNG+18hB8+MuuFJKE1oXtteW+iDSNGgXSGIj8uaeB45PPIy7B2yucYX8c1U0zRFvPCaWfiC4vI1glkleayxcLOm0/I7qcZGGPtWicUrv8ApGjjH5dPT+v63LuleCdWTxFBdxWFtqNosry2yXEmPmILLNIg6kZIAPoBU9j4bi8bW15pcNrq0a3sokv9W1CZS0RT/lkox83JIKLwp71hR6XDpL2tyspNvNAjTXKOySWinJBCq3zFhhQScdAKveFr+40q1tpF02/vpbieSC2Z3G2FN3R1HKZYk4JHAxzSldq6evQwqUZSd1Kz9P8AgmpqF3qOlx6vp2lW93plha266VYR6qu+2u0Ql5GVQPvlQQGPHSuq+HniPSLy0sIdGvJUsL+Fjpumyod8CQ8ON5J3DLDGT06cCuQ1vQ5m17VPF3iPxWLzR7CKW2/s+KNk3ZTa0CA4A4P3gSa5jwiLe1j8Ox6LpskkNtcNf3H2Z8LDJIMRRGY8uuAu4DuPasXTVSHmea6Lk9tf62/4J7BDa6Z4e1e613ToF+z38yQagyXbMsb5PzBeg+fYD6AnpTfB1/ZxXl1o8+mWuka9/r5bFMsSMnaWnPEhOfU4zirngrUzr2iSXsC2ZtZZmCTWy4S4bA8x9uOBvyBnJOM1J4qtpLvwpcWr3ZgnGzF08HnMp3csFH8WCcHt1ricteWW5DV3oP1DVLuys7jWXhuLmzhtgo021jEkxmJAwjqcYHTjpXFaBLPpWpaTp93q81zZNdyiHSYIzeN5hXcFu5nHyurEcADH4ZrrvDyXVlDFpehaW+maVpEwhQztlbu3YFi8Lc5cEk4PfArndMudV0L4axaqY/7CkivJbnVGvLEPPcw+YxDFI8Ycgjrjoe1XBqN0Yys5Jdf6/wCH+ZPD4fm1bSpdQ8US6Xp17eTBtXa2hZUu7IcC3lZjlSe7D0FN1+LxP4ZSe50e9hu7eW6t4bDTsAG3tUA3JEn/AC0Y/XpWxDcPrN/Jb6pb6UNHv4luLASPuknjwGKvG3pnPtVGxsdEuJdB0+01Yy65EZLzTb6VPNYQ+ZmRIw3GMDb6gcjFSpNP3vyuhypqPvRPYqKKKZ5AUUUUAFFFFABRRRQAVwngb/kfvHv/AF823/oqu7rhPA3/ACP3j3/r5tv/AEVWNX44ev6M9LBf7vif8K/9Lgd3RRRWx5oUUUUAFFFFAHlf7PP/ACAvFn/Yzah/6EteqV5X+zz/AMgLxZ/2M2of+hLXqlABRRRQB5h+0NPPF4DEcSKYZrqJZXP8AzkH8WAH4182aXBYt4wWC/sUniGwyTlipTdwCOPfivr/AOIPh5PFHhO/0p3KNIoeNhzh1O5f1Ar44OpS6PrkUjxIt5GXt2W6QFHAOQnP8QIrWhbnsz7jIcTF5dOkrJxld+j0+/8Arc9j8KaLLp1mt4lu13E7J5Xl5IKhcK2wnhjySfYCulu9Rj0tFn1eCdL+aN40kSJjEYyflSUgEBSfWuX8NTy61BaXdmJdNj8srNEVK4JXguMZKEjII9TW/bStJ4gstNXUbhYbMP58MMTGFpM7wBJjnAYCqqayvIyr6uz/AKRrpFFLa3Mdrp/2LVUjDx28lyTGzhQPug9B29q5rUw0mpiw1aa/huHIEN5aTOI7Rgc5IAwOu3GTkdcVtCwnt9ajvLySztVLtIrLYq/ldc7pWbcGIxz+VdQd1za+WJ/3bkMcBT5i91I96y9pyeZye05N9U/N6fn9xwdh4f8AtNpqdh4jvrLVNUYkWn21W2GLIGPNC55PPHTNI3grW7rUEubS/uNAXTLZYbW0tdrJI6sSTx1Rgep/Gu9s7W2srKG2sraC2tos4iRc7Oc8VWutNsdat45JEuN8MvmRTiR4GD9MZXkr6ij6xK7sZyryd2tv6/P5mFc6Tqmm293qQ1LWNZJfzYrGGKLzbcMcsqk/eXtx2rEt/ANu1s0N3d6/eadOpupYLkktg8hAOzqR26139mL90k/t2GxIAz5tlK3K98g4IrjrKK1v9bmTTfsiC4EttJdaffXBkt0IwrFW+UNxzxVQqy1syqNWpG/L0/rf+mc3beFJbjU1udNg1WzvNKthHa29/kl8nIbeTgDkZUDPGKxtTvNT0l9Rk1LxDd6TJa3cbOkxMqHfuBMZHO3OTsPFeparrl9pd1bQ36pPpcNspv8AUXbYN+DgKvqeCa5zxQ51mBL/AErSLXU/PtS9u8hUtIY2yF2N1OfTmt4VZN+8tP6/ruehRqzlrNK3f/h++9typaXGhavoniDxPp9iutalo+lC3i8+Jo0mXaxYgZyc5Iwenaub0mbVl8Oy+LtEtntbOe3S0/s/cJY7OQMA0idxgHqefm61dh8S6g8uk3Vsj6dqW+SO8sxCv2S3Q4+e4Uc7cH06Y6Vp6xfQf8I7KLF7edL+eOC3t4bfyoIQCGZ2jYdCwPJ7VSTjK3QI0/3j1ve3e3n0t5/foUtb0ufWbrda6xBb6i2nxm4QBtyHaBmP+Egt82R3B61kSfbdOuo3k0u1vtQ1KeWzuLgAyJI6bOVVBhJWznfnAwa2tUOkW9uNT06DUNsc0KbbWQPAsy5B8ksCcjcfl4GDU81qdYtkk0vVr2O6ht/PhwrRNujP7wBR8sg6Kw7E1SlZK+w5X5ddOn/A7Faw1X+29Yl0hLmfU7GJpLqK0vMJJdKHK+ZFJu4KkHHIyM8VT1r7OdOnjuDfLArsy3DfKmnOuAPNCkkg7lwR26VG91YR3k2qaVYpFBEUinkeBQ+SM79wcBWDAcL64Pvs60ZPtsTWOlaZceH7uIyyTKhRx8uTI5ztDZHdeoFDvGWhcVKPur+v6/4fQ517hDq+prbX162rjT2ngjgdmgaRUByhzxkIzA44zWTDrW63hMWs3FrLe4u7/TFQlNobBKMo+Z3BxjA71r3OlnSNEVdOv9IuraW7EcVxPdKkky4/eBXJyGyRkA4HbNbGr6ebbWprX+zpdWlu4oxLK4QSLEo3MyTBQoYHK4PJ4quaJDkm7XOTvNRTT57690i8hv7SH7Oqi9OxxGCSsTAYUFGHfknGK1ZLm5udQuoo7iO7v7uBJbp44SHCnDHBGQzA9sZGfar6/bNMvLWzs7KzlgubyOFNMlgj8yNMZDXAAxu39GJyKpL4c8QXoj1I6Hf+HryLUzMJI0yJQSWaSY5yqLwBjjnoKfMuo/bKD16/f+Rkya/e65C1n4guRDDb3IlSxmtWlaOBCS2WXktgKDk81p67remXOiavrs9/Mv2rdpmm6bbWuBbKQCzRKCAGKFsscYJ71Rim1W68T6xcTXltp0T28gvp4ZWMTI3zCVQwOAfl+Veu01T07UbTR7eS6hvYPt9xPJ9ke3hcxxJKMCRkPKnGcADjPNU4p2t+BzShGcbPS39fj1NvWL2706GzsrXVl0jSmtrey021hdpLmES4Mkskad9ofr3biu20n4keH7nTrCfUJzbWElxJZJNejaztEoKyYH3Q59ec15xol7q2h20//CM6LNbalM6Q3GqalGWmuJCQWbe3Cpjk5HTjqafo6pJpfiuW4ls77Wbm7hi3aZp4uQqhiAVzhFDHpjkE+tYzoKa1OOpTmtV93/B2/H1PoBo4p4opIwzINsoTcVwcbgSPXB6GsDxAun6prml6bcX1/FqMCveLaxKxinjHaU42844z+RrgNC8T6lL8VmsF0a7sYTbeddAgJPL5cZ8sSs5weu0HgnPJr1iw1J7q0s5ZIbm1S4jE0lrP8kkA9GX8K8+pSlQaZk735b6o5/XfEFrp+rWM2sadbWljB5gNzK371JMLsMMagllO4gntg+lbGv2EGvwrp76hLb3JdJo57Vwk4VSCQh6hWHBx2NQXFnrk2mXQkl06PWXlf7Pc28RKiDcCiNu5LEDBxxVzUbaz/tKLUbu3i+2Wo8xZvLPmxrjkDHXuMd6yula25KSkr/h2PQaKKK3PDCiiq+oWkd/YXNnPnybiNonwcHDAg4/OhjjZtX2LFFfP/wADtRutB8fav4Y1SV2eXci72z+9iJ6Z7Fdx/AUvxJuJvGHxh0zw5ZzSC2tisMvlsRj+OU8dwoA+q1xLGJ01O2t7W8z6aXDUo42WGdT3FDn57actt7X76bnv9FIihFCqAFAwAOwpa7T5gK4TwN/yP3j3/r5tv/RVd3XCeBv+R+8e/wDXzbf+iqxq/HD1/RnpYL/d8T/hX/pcDu6KKK2PNCiiigAooooA8r/Z5/5AXiz/ALGbUP8A0Ja9Uryv9nn/AJAXiz/sZtQ/9CWvVKACiiigBDXzv8aPh3Naz3ut2NkLu1kl+0MYx88Bx8wIzggnncOQa+iaa6qwKsAVIwQRkGg9DLcxqZfV9pDVPdd0fHngXUrnT0u7WG6SK+dlmtp72fakyg5MBJOFJP516p4fSC/luXtriEX/AJK7ltpAbhW7jOcEgZA9R1qb4hfBmK8lnvfC6wRmTMktjKSUduvyZyAc9jxXjutxXWjP9lvNJFhqkZLsYsW5lHRW24wGGOGTGe4PWtVU5naWjPsYKjmCU8FK/eP2o/L7S9PxPXI7uSO2luNRt7/WjHJ5KxXtmFMZzwevvjnripbCa+gvoL3VprBPMXMMEMBW4UEYwASAo+ozXBSeNNe0+10w+I7KeXSpogI9Qlm3CPcMMPNjO0kbf4gGFdtFrY8R28Voi2riUsIZjNvaGVf+WqsSokxwcKc9eKpxsr9Did2m0u9/Lys7W+5FnWPEmvaf4lhiEUM+lN+8EdrZNLcKOwbJHU8ZFZuneI9QmW4uL+ZoJpGDC0+wSEHDbRtZm+XkjOABnHWr1la3cOrxQG7nGlwgM1sFddzJ94qc5Ys3Od3HQiqmn6PpaSXl3brqenT3zEzjVJSZYnVgT5QLdCCMkHIB4PahciWxmowg0uX+v6/4BAvivUNQSCwtp9S0jUBB5gkks3xcNJkKwJHCL1J71Xv9a1+1t5vDf/CQS3mp3luZkv7Cy3qNoOQzADIJ+XPbvWqiXMy3mmX2pSTJbXKSSRkyNE43neDgbh8uBt6d8nNOOhw2dnqcJvZJnmSZh/DbrCz5IwCSMYwMjr7ValCOlimqezX4ed/X8f8AJee2Laha+ErODxE13NpkkotiJVLAjAJLAkHO7gZPIU4qy9tawXOg3en+cmn2d09xuBVvMAA80bc8DO3HOMZzWzcafdzRwtEkNtbaVcJeW+nqDv8APUfKssiggqAck9icVev7O/1Szl/t91jtZoXtpoUjEYgUx5KKu3eCT82eQM1t7RHR7V7WuvX/AIH46jrm0kfxGdX099OsdJ1KIB9RmcMLmMr8y87gp4UAYrJ1i1s9K0wyuFudQvImiiNiGWV/MOxpEcD5goUAhgBnJzziunngsbzR9P0lpry0sreETZtmVdqeXjG5TxtC5zk89aWK1szPZPb3upJLFCIUa2uAzywkgqxY53gtnn16CsY1LGabSSa1/wCH/r/I4+6gttPltI9FuWNzFbAXvmMjwrEB1XPyFznkDJwaa1tq2oRvbi1tNOv0KyrbW1wUD5yRCpLDG3hyEwDu6cV1ctnYweIrW1sGtPKinVZpDAkswLEl1kyN2ckY24AzzWbdi3stXuf7UaW7s4Q8UEVvL/x4hnJD5bBX0J+bnnI6VoqqfQbm5NO1/wDg9/8AK5kSeITpl4LyKadbcMs88CuZo3RgA6MwGFkO0/KR1PXNWrtb/wAmeeTWIp7FrlXsopHEck0an596BSzeWMZGB+NbelQ6lqMMTXEVzCkaIsQcGKO9Z+qyBhltuPv8huOlUFtotV0y71nwn9j1JEle3msXUebayhv4dxG7PORxkcc4pc8bg6kU9X/X9f5blK60y41XRb+11TRLOSOMzXMCSO0ckb9fPycExsMDaB0ArGsbP+14Uu7W2kvdcijhmmNpKIYPJ+UHemcs3HVTg49a6e8SKy1rTbrVdKW3u57ItdTTXG2CEMvlvtTac4ABK9OgArPhs/s1jf6TpxtLvTrgJFLDDGLnZHuw8gZFVmAP8GSRnJFUptLQIvRyWn9eQiX8R8WTpqhvIWuwIpkityI0w3LiRCSD91skEZPOcVHNIvh/VrqO61S+3W9wZSk95KymHGFO5V288HGeTUlrDrfh9X0zQrjTdPtXVblw8o3xEAqVw/OxiAQMDgnJ4qt4lh1TTbu2ttZeWSGeIq3knKwhi2CDuCsFOzAbI560JpuxpFKTv+H/AAP66akdlqNtrOr/AGfSNYNjpJjkd7RB5MskgAyG3Etg5OM4HtWXpN1rEAis9MZbCWxlMi27qkbTLG+8NLKTgYwBtz36c1e0vwvfalbPceI47m0uLZ/PGobtpKkDPyqc54zntWV4003Tr3Ur/WbjWfs3kyrHDa7XjAcruXeGC7ifvE85xVqUb8qIaVrPX+uv/Dj4L/xV4hvbu4N9Z6tpKqI7wXVyCIg65I/h245BIGRiq2g3Gky2evNa6rc2P2NVuJLXT7ZhHKqYGFYnKnJ4BPJOfo3U4V1fxFZzXgljs0kguo7uOyMCKpGMBV4wTkk4LE+1PsdT1HToBa/2vZ6LpFqcFvsIaS9JlJDvwSw5BySMfhV9NDFxqcunf8C5b2174thudJ1+WGw8Ow2qXkt9f/8AH0sStlfnIyTkgYPYZrU8F61ceGbaCyg8UaHfWLSpPdX1y7OyxNwIt7fx4wFRQcc5xXLaGkdxJqV74gltL+wniMz2jbjd3DI3y+WoJPYdcAAdKyZLGOy8U2HiHVfCmrW3he08qdLMJvMoJwu5mIGWb0pTgpXT/r/gnHiY8rc/6/rqfS9xdaRowvdau764t7W+kiRjPKWhRuURgP8AlmDkbscVmeB5Ly58GNplt4ht21fTrhra7vkzcbWZy/yb+eFO0E8ce1XtCvLvVob6DV/Dn9kx/J5FpMY5RNCy7sMg4Vh3B9avzv8AYY91ppRu5JGjRobJER2xhQzZwCqj1PArxnZe69zi5VJcy2PRKKKK1PGCiiigD58+NVtL4U+JOkeKbJDtnKyMBwGkjIDL7bk2j86v/s+adNquua74rvxulkkaJGPQu53yH8BtH/AjXr/iHw9pXiO1jttas47uGN/MRWJGGwRnIIPQ1LoWjafoNgtlpFqlrahiwjUk8nqcnmuBYRqv7S/u728z6upxFCeVLB8r9rZRcunIndLe/lsaFFFFd58oFcJ4G/5H7x7/ANfNt/6Kru64TwN/yP3j3/r5tv8A0VWNX44ev6M9LBf7vif8K/8AS4Hd0UUVseaFFFFABRRRQB5X+zz/AMgLxZ/2M2of+hLXqleV/s8/8gLxZ/2M2of+hLXqlABRRRQAUU2RljUs7BVHUk4ArkNX+JHhbSp2huNVjeVc7lgUyYI7Hbnmi5vQwtbEvlowcn5Js7A15L8ax4W1UNYarqsVhr1hb/abbzeAyscbffJXtzVfWPjfYKskejadcTS5wss+Ejx6+v4Yrx7xDql34n1l9S1Vw906iNTsCqqjJCj260Wctj6/IuG8bCusRWvTUdtr/drp3uJomuXmjeZ5JWe3lUrPbSrvgnUjkOh4z71PbX8GmXkcejCWTSZ4nNvHdbidGckEurAHeg5x3xwaywsIY+YMbf7jY3fjTptSsbWKMQtJJxh/MO1BwSVOOce9b048r0PtMdl+HrSVVpqXdaX8n3PUZfEtvFapfNPDDpYhYtcTZG4cDzItuQ2epXAIqwjx6vZX7XjyXItYoZILh5VYqJOuDwpX7rjPZh0NeCabqoi1C5k/soPau4vYYrWR1iyEKlQvXBB692A4r1BpHi0N7JGtUuJd9otgzCFkZIVaKQyDDB93ynPGeOK0lRUWrHxqimk/089/mv8Ahzu0uJIVlgn1BvLY5jlLPiIEbtsZG4N0z859hRbbnkm/sUi4huLndcp9nKjzM4ZGU/cAHPPXNc94Y1Ge08I2NjeTwS6paQ4vCqsytgkxqzjkPx94DGcV0EzXVzBb3E09zHlVubpbiVUdiVwI3YAKRywyOenesZRsZ8ri07WXn/X6/iZlqzJoN/Dqmkx28L33leVaxESMrNt6DqT9fetXU7DT2sI47KeZtNmcSG6jmzJHlCGYs/3gRgEHp+FYFrru/Ura3ePUrm1Z3t7tkG6HAHyMjAZDA7Qec1r3NpDb3FvELZ5ollENtbFs7sZZgQwwQcMeT3ptNPsbTg+Z30/L+uvoLDfixgtdLlskD3sTu8ltIjAjkKoPRiejEetZX2aXVEtS32rR7EWvki3niaZoUVuHV1IIJ6DceMHANS6XrdhcRmyvrX7FN57x26RRNKIA7DORgBVLYAx3rfi1G2lnvNMikI1G2h8tVcAPI4HVC3cU2nHpqROLhutev+fbqvT0MSYJeXT39kba7inRQtyrPEYhhVVjIvzHb8xYHA55rDs5p762muNPbSdYklnML3UmE+ylF5xuPzBsFh24PHNdDaayryzNNpt1eR2xJh+RWZpgQGVoz0AJHPGSKyTZ2WmQXKNZxiz1HUIpsWLxkLluFYNkfKSSVI7GtI3WjNE3FWt2/r+vmWdVVVnivHuY4LvMbPcOZs9OdhUkEE5I+XAHWqms/ZFs77Vo7G3hn1BI75zbzBsIpCh1jXrLn+I4UA5OORVhD4Ye3tdP05ry9haW4it5ijgRzFxuGQVBVjkAAbeuDVye4OjwWOpRtbQWEDpA0Js12NG+N0iBdxwQQCM/w0lfQxc+ZRlHfp/X+f8Aw+elppmp6fq15HHqkbwwy27tJdrt8zPzorAEMGYjkDtUBs2utRs7N9Rv9PuJwYpfs8ZQTQuu9rjbu+XOGBc54xwDV3SbF9U1CB11spazRb7axEIEatG+0t5bBdqfMOPXPWp9Pawv3tX0nThdaHN5lrc6hHcR8kkgxOv31XjjGMZHWhtxv/X5ilUSVpO72/q5DH4aWy02HStQ06/utNCH7Fri3ActkcrIqsCqHptPvnrSR6VdWMsNpNqQhuZYv3EaokKQxlgzAIxbeAec84xW74hjea1vIbeS2l0LRbcHybVPOu7ecKTh4zw3HG0+ua4ZNIeCXTPFOqW9jDaW0JaOe+Ja4CseEMSsMHBYgAADjk1NNuSu2Y0qrkt02+j/AK3trb9CO9l0668LK39qatEttdSWrTwxF47hSc4A4J65PTNMDaZqlumk2d5Nr4gbzZC+liGS2ZRjOche3U5/Gtv+zf7PhnvtA1QpBrLrsaVhbvFb4+5GjEkscD5sZIzjrVLXns2tLXQTYa5b5jWaaeCJba5uGVGPzJ1PT73StVLsdDmpu6v/AFuUbm91nWjLZhp5muyoSSU+RH8wA2oDjAAXgcDk80nhW10258QahoytLjO37HCfMVJIscuzDJG7gEYGfzrQ0XVdeTSYbzVrq6vNKaZBaER5cgAgBgw6jAzg5yetZuoaDcafr9zZ6PHcyzXEwlmjZB3wQryZ9/UfnVrrHY1tfZpL+vTyNLxNoH2W5h/4RkfYr8KZJ1tWX7ZOznB/eEkKoyc4rm/FC3eoeCrW0163v7+1jvAtrHaXT3Ewmw3yyScgnIJ6cVcvLRtV8WyaVrxvYprnCzW+mwERrsbIG8EAZ4yeR6mrD63rngzS3j0may0mK5nDJashuFtEBILO4yQ7ZU49uKIxdkt2cVWEeiTdupr/AAuvpbWTUbnWNEn0tLx4R9tuZztkZFKhVMh3vk5zgYFepqZVuf8AVk27AOHDDhs8rj9c18xWd7FfXaEyPrXiC0laU6lrM7GxwTnEasR8wOMA8e1fQvhB4/7HjsxeC7u7Z9t04mRz5hwSPk4A9BXFi6VnznFHRWZ6pRRRUHzwUUUUAeLftB+HNtk3iWO/uY5kEVt9nU4QjJ5z681e+APhwW+hQeI3vriWa/ikiaB+VTbKRkH/AIB+tL+0LrGnr4Sk0k3cY1JpYpRb5+Ypk8/Tir/wF1jT7jwJpulQ3cb6hbLM80APzIpmcgn/AL6H515ijD64/T8T7epWxX+rcd/jtt9i3pte2v4npdFFcTefCzwbeXc9zc6PvnmdpJG+1TDLE5JwHx1NehNzXwq/zt+jPkMPHDyb9vJx7WipfnKP6nbVwngb/kfvHv8A1823/oqj/hUfgj/oCf8Ak3P/APF1S+Ful2ei+K/G2n6ZD5FnBcW4jj3M20GMnqSSeSe9YSc3OHMkte9+j8kerShhY4XEOhOUnyreKj9uHVTl+R6RRRRXUeEFFFFABRRRQB5X+zz/AMgLxZ/2M2of+hLXqleV/s8/8gLxZ/2M2of+hLXqlABSMQASeAKWuY+JOtt4e8G6jfxLmYJ5ceRkbmO0H8zSbsbYehLEVY0YbyaS+Z438aviBBqsr2GmXUy6ZZh/tZHCzsCMAdyBg15nYabrGp2dpdWmm3EFrdZMTuu1XA7ZPA5x19az5Fm1OVdMtGgURt51xPPKsaADkgs3Gelek+C7C4aGyEc5kew/fFHc+SfMbDcHjIG3B98itacVGPNLc/TZ1FllNYXCO0Y7vq3fe/8AX4HI33hmdrFS9/Nb2rNEJH8sFw5BLqo64HXPQ4q9aeHDMqLZpbxWLI7wz3V2VKxouWldcE5PJ2/yruoPDenJrEMxmkh+zQsrnLOyRj5sHJ6843Ad627mPSmvLDfZoZWt5Uhd2YPGMbnVx7jsauVaOiSv8jzpZjVi3KMnzPr5f12PDLvRpbfUvtFxqZntRuYWkCYmRSMqxX+LggkA5A61rWPw4l1R9ObUtQZbDUUWRpTb+XImOqceo6Z64r1Gx0maORI9WewuFSNmt4yBtjLZLvkAnkYwv59Kt2XnwiQ2rh43EciRo6eXBg4O5TyvGMFe4pvEaWiZVMQ6kWpNv1b66f1p6HJ+G9Hs9JmLwQWsNyAsSzTM6wwjBJwMEbmxnvitK6sJ4LRiLe6vE1S5SV3S2bAMZ3IdwG7BbBwQM4rrGk8p7k3EckMCbfLMsYcPnnK8nP485pA0kd/fRRxarPDKqN5qZcY6+ZgdAemAegrL2zbuYTxDk+bp/lb8tNjDit/smhu+oRyx6pPD9ourZgJziJvlwGP3QSTsHHOO1R+I9Ajk8Oy6Ncjfp07CSZtzSSM27cSETJULntwMVraMsF2tx9ovnvEUytKMbIfnAbYrkdACMj3xWbdTXmpXEc0EK29iXlZJHO2K1QKEDeYuDuL7hjJBGcjimm7kqbvZ/l93qN1a6W30/T9L1G6iXQY4g0Vtp0JVNqMAslxIDkKW25A69zWTHb6jqMOtSW9jPLeAxS7bw7lnZSdzJ/dJB4x2HvWzqmnJNYeSbMoiSNDZxmI/vo1OMSMhGM4JweDkE1fv9NlW+keM7kAUSSSSBYmUchWIO7AyCOMetUpqPqaUZ0qS93du/wCK/wCG/wCGKN5bTxx6TDpVjbLqjeXCRKMeQG6gEg4A9+eai8U6Tq8UNjp2mSsCt4bp7ZzGDAvOZC+STnkjjsBTIdSv9KtbWJ7iO41J5gTNIFmjVe7swwApYnA6ipLizt7m9bVrx5bi6uYQ1wlpcR+UuAEby3PXjny8n6Gqi2mmE3KMk21b73f+v611ztaijvpUS0ZIYoJ9rzW0rN9qkEbbN4XkSblGAPUd6jF+l5Y3S6tap4fg1C6IhS+XyJZXC4MrkMSMN0OOdx44rY06X7PfXVhOItKtLWXfbFHzkZJZyODkjBP1GKgm0OHX7e9vr/TV1nU7aRha3EkLxyQYAYIwLAkkOCB0q1JLf+v0InNq13p/n57af8BDtKd0n0dodOh1FbKY20PlOSsKkqxcttXcSG3A8D8apJPf28WvXsf9rtBPcJFbwx2iK1nuGSwcn5ucjB6Eg5HWr9wLCLVrC1stOR5kaUmOK4CpCCUy7rzgZAzggYU+uKp6bqs+kaK+qWsc3iNzdiGN9PwkEL4w+fLGAPmHBBJ+Uk0b62/q5nNvS/5+b8+v/B1KUFrZjxJpWrXml6899o4eKG7e6QCUhS/lsozkdcdznBzWhe3mo6P/AGhe6HY6NHcXbxkQWsRZEixuE8wIBAJyoOAOcmsbxBotxBdadbaVqGpnT2miuby2jRQlmyqGkaablgSCSOMcVQ1fxFH4kur2fRPDpt7S+2tqeoXlx5cslruG1t5OETAwe3OKrl5tVsZtU3O8V6/gb+oXg0S+sMa5YeGYpla91VbKPzBfyuwAZX5P944B4/GqVqumWXieXTnE+o6/dyqJL23xue3IzGGLDafkI3PjoPWi7sbfRvHU0djq+kwWt/Cos7Qxm6Tyyo25ODtBbkA963dQmvrtr5W1nR7u3is/31vcHYd6qFYeYQoI3kEjOByMVOitbr/X9aijCC1hon+v9d7frheLYZpZdJ0uGwt5PNEKXb2EjSwMqMyxAbsYwcdCDmjxJriXt3cRHxLBb6dp0sMV5DHbtNJE4H7yMNty/IPzBgMA5osUutTtrCPShBqOraa8mxI0UIVAAxE5GMKx5+vHSi90i7uLiLV9d0iG3nkLQ3UNqgYGRlK7yq5Jbnoep71SSVk+n9dTdQ2XNt9/rr/XQr6lq2j6ktlrF5b6pplvGjPZzvIWS5CtjaIxjHQfd4xxWktr9v0XzTIbrbbG8hspMWruTyfMmLMWUZGBxnFYV7eaNaaXY6jrNpNNs2wwJHbxsICvVQgIwSSGIIqtc+IdQNpdDU2uHuXia3tF+wBflYcMrKMAYPKnJquRv4S5xsrX2/r+tSe21HVbLQL651u6t7PSp5TJcaTpiEy3Ly8l85O0lVPcAkdKj1PwpPqOmw300sdos0yRxBHWOWO3x8qy4Od4XHQcZ5zS7r7RrZLexuLrSkvNhm2QqlvA7HOXkyWZh3HaqOoxXlpqcFxfXlnKlmfPe50e3AQI/wAuXmkOPqBV63vH+v6+Zz8igklszf8AEN9H4qsmtorBrPwxZ28S21085tknccskfBMgYjG4jjk113wt1LTpbA6PpdjHbHT5d1wbe2lWBWZsbPNcZkf/AGu/auKh1y3i027utNvbrU73SLaZ7SW1Ijt9jDACL90suT27mui+Dvih/EELWtxFqiXNtsZ1vLwTDb2YYAPcDkelcteEvZvsjlq03FpJ9/uPoKiiiuc+bCiioL//AI8bj/rm38qBpXdjE1/wV4d8QXwvNY0yO6uQgjDs7g7RnA4I9TT/AA74P0Hw7dSXGi6dHaTSJ5bsrscrnOOSe4FfK/g7xFq3hvVbbXYGnltYZRDMGclXDAkofcgEj3Ge1ekfGHWItT8SeC77TLlmtLpFkUq2Mgyjgj1HQivLhjKUourye8v163PusTw7jqNaGBeJbpST11snFX5XG9vT/gHv9FFFeofCBXCeBv8AkfvHv/Xzbf8Aoqu7rhPA3/I/ePf+vm2/9FVjV+OHr+jPSwX+74n/AAr/ANLgd3RRRWx5oUUUUAFFFFAHlf7PP/IC8Wf9jNqH/oS16pXlf7PP/IC8Wf8AYzah/wChLXqlABXkP7Rk1ymhaXGvFo9yfMOerBSQD+p/CvXq4r4u+G5vE3g24trKISX0LCaBS2PmHUfUjIpPY9XI8RTw2YUqtX4U/uvpf5Hx5FZPqviIWd5KsDMB5JI+RRnkn1Jx3r23wu6ahokcFuiTNGEWUyEYOwYAOOq5weTzivIPLa11JpLuMxyxSYKytgEjqp9OR0r0HwRrE8sdvZ6dtktY0aTfkBSMbt20dwc/hW7ftIXifdY3DyhKXW7vf+v62PQ9KvVv7ZhHsu7aMC0mlJMZLjr1HKjsQc1PfzQ2tx5lxa/a5SweWSXaWjGNoIHfOMe9c3bCy+y2mm3oimkeczEujYDNnBZDjjnFb0UkC3dlZTq013EX2SBmBVVGSA/G4gdjXNKFmeJOnyyvYbLAEvEKr5ks87TRSTQkGXYP9Wp6BeufWql28YiUWRQzuGSEzBiArcM+EBwoJA+bjmptT1yy0/ULaO4iuYzITEsiDf5TMMKVHXLDim2pttVuIIpUuLp4JnLF0YCJUGRlz15GNvqauKe7QWlFXlt/X9f0i3qFj9kuZ7g+VPGsZ+0CBi5A2hTuBbaAuSQAMnI6YoSziuGjuLiW4hEpyGSV43eMcLkA4AIGQPeqDtDf2LXFzZxQ2V60ck7xkMZIg4+VwApyG4IPPXmqMFhrdrfyYl05LK18xYXaUb40DZVQu4sTjg7hx0pqLtZuzCEG1aUjbsrm2Z7g29jFaRrGikKd6sNvCtjjeMDP1qVJYnAaW9jtrZIMNAq/6rcWXAJ4znJI5INMmit9ajIsZorV4Y1kVljDLsdiQQFOAcrg59eaqX2t209z/ZunTpLdWrmQxLbqvGPnVF4VsZ/X1pb7BFc2i+fl+D3/AAM/UI4bXTLq1gn1QNdX8bXMxVXVmAUInJ2KCpHBPNKLSzZore7snihW6L26LPl7aEJtPnMDg4PIU9cj0qZruztbW0vdet7ee6DuhuFTywXX/VlkyFLAE8c96vWMxS1e9SOzuLWZ1F7cuwhBORlmBJ6A/L61pzaGjTjq/wCn/W3lojMm0GbUNDW1srWzv7fb/pEtyRAJtqKoUruBC7f4hyc5FVdJu9IsraW0sdLh0iyOxpoo8yopQZJTcD8w7tx2Gcmr3iHRvDuvXK2VzolxLqMkIKK08i8Z4ZmGRs6YIyB0p8kd9oVqkGqfZ5P9FeK41DIVniRWbcJSRgLkDG3Jx9KtSutSHUV7yXTTp5vq12toVPthv9Nk1XVdN1i802WyZ/L6yXDiQYjUKBhOpwTyD1qfxBb6hHbwSaVp9za3t28Z8pJQGh5UfvFHB446kDAqK9e8/s2Oa1ursaddrFMI7ZghbegGFTOQDlRncD1PNUbaHVonguYpLJr+NVhsdFhuGljlXkNIzFufvDnnJXrxVpdRQk1LmW3b+vx/yLF3omsL4mGp+H7PSdQcNOg+0Th/s29juVACABnJYtk9hWfpuu+T/wAJBY+G3gtYrZW+yxafHJ5Ut2wBdjkcjCng8Yq5JMkPjKRdCi090tmhm1qSIh5LaZF+6gHITd129STk1a1S41jRNP8AtFvol/fDUJ3uIokSNhJKylgZMHKgdSDyPWqTutSIumk5yt/W/f8Aq/cpaZf6lp9tptu+oSzKsX9palEyqrPbkgY3yYDYwQF54J4rNeHRjb+IhrEIjt7pI4bDSLcorzxyP5qSFlGQ2T0IwBgdq37uGzuUisdVure/8TRo8kMk1sZ0tm2hzEm37yqD1IOfwqjoaDS9O1TVdSv7LUP9DMsSRIZ3K8Bs7gD95eBxt+lF92OyqXb/AK9f6uOsbiG51HT7jQdLXFxamH+04k+zSQ26KSqYbdjB6uOSDjvVuDSX1bXp7JtLsrTQLZkuf7RjufNuzOwDITE2doLk5Urg9fSshLuLxF4QutQSw1CwtZLtIp8TRqpRRgIgbkrlu2R0qxe+ILDRtbuLhbgPqcFs9vA9vbu5SOMcJIM8qmM5IyTk0OMvs7mcqSmv3Tsv63+/+tjQeW08P2WqQeGIY21OUEyXMuVeVycZCj5mwSOQAo9OK4/U/DttFr5v9UvdV09y0Mt5aQSpNHOcKFMnzgBmPbk98CrV1oGPE+j6nEuqf8JHqMqyk25aK3jVgP3rHGcEZJXpzVm+t7bUfGU8Wux3Wr21rctBb+XGguJHCD5SowQvU7myDxVxiovR/wCZpyrZ+vnp1NCe3sTqTW+m6npUduHMlpbxylXVxnczR7T5x3dtw6YqjZeI9VPhjW/7RuZ7qSSTyriVrpYoLaI8jZt5zyOBz27VjadqcLeM4xpTfb76KQrGgkjimYEfdLdPl5+VVHPc1takfEEl1EdUi0nSo7cMVlZFuZl/u/u9xJc8clRjPNHJsmEktnr+P5HOW1tpMbQXIiuNXivJFNvp+nTMEWYDbumUk8FufcVq2OhJdWuqaK3ivSNK1YuJLvT2h3xTzEZCuznGAeBsBxSwzaZqthPo1v8A2fD4nGJTdxMLdbh1OdokUlccchSOc1VsvBOt39lcy3traavJayAf2faX8KyFGy7SSSDJPzAYUc1o3vzOxz15K2rsipa2uraF4rZ10zWREts8TSWQjitZCw2F0H3CuD35Jrqfgz4cfTIVudB1GwlsHv0+0yPARdyRhTvhmBJCYbptPOBVXxDrNlpXh2XTNDsIL/WbaWPZouoSNKMH590ceBuIJOR2x9K7H4TaGdH8OxSXWiWuj6tekXF5Bah1XqdgKsxwQMnjjmuevN+zbfp01OStJSmo2/4B7VRRRXIeAFQX/wDx43P/AFzb+RqemuokRkcZVhgj2oY4uzTPnr4G6Ba+JvCPivSr0fu52h2uBzG4D7WHuD/hXnjWuo6T4ssdF1QsH0+9VBGTkLl1JK+x4I+ue9fWPhzwzo/htJ00SyS0WcgyBWY7iM46k+pqHWPB+gazqkWpalpkU99GFCzFmU/KcjoRnHvXlyy9unFJ+8vyvc+7o8X06eNr1JRbpVNUtLqXKo33tr117G/RRRXqHwYVwngb/kfvHv8A1823/oqu7rhPA3/I/ePf+vm2/wDRVY1fjh6/oz0sF/u+J/wr/wBLgd3RRRWx5oUUUUAFFFFAHlf7PP8AyAvFn/Yzah/6EteqV5X+zz/yAvFn/Yzah/6EteqUAFIaWsvxLrNt4f0O71O9bENuhbGeWPZR7k8UFQhKpJQgrt6I+TviZpjWvjPX7SPaGjuGlVx2L4fv9a4nRxLpGr2Uyqw8uffK8UoYouchtvYD1rd8TawLq9ub69ZvNvJWd1YkldxyBn0A4rGstLvNa1OFtHLM8MW4eTGxCr2Dk4yWxgCtMNtbofrWYRjSpUlN3qRSWj9L6f1+p6pYW1veR/2vqVw0Wn3DRyrLLNunuGRiVdc/dHOMV1V8beKG31qHTpL155WlMYc5G4AFgRwMqPxNc/b2kMWh6XfajbtZyqkkcNpAEjeSNBhvvEhepHXJOK37b7NosWnW1zMUjkgdraEowkK9RG5+6pBYDqTxTnvc+frThJ6bmTrFmtgL6FLcTQzYigZ12uiId/msy8KEPGeprT07SonSztpPEP2u5lklvmAUpFNM4GWDA/MABxjj1q7rqTXlpb2uo+SERw97ZCT/AI+IdhK7GXnG7HHHvWde6pbWVraWskcTXVlEbS5ZJPLAOB+6XAI3YPtkg0k5SStuYKpKb0376fm/0/4avrCyNpby6wZke6uVUKCIvMYLlmZuAqEnauc/jXQ2UUAgTVfsF2pS3YrC5yD2VT3bAHHtisOSHWoZ7v7POotCZ2tJLeVXNydv7n92eCoBCkdM4rRigvYfFNvqmoOYrJ7YLIysflkZCG284AD4yMcetE9t/wCuxcpNpxT6f0idL64j+0m2gs4pjcRZtYQi+arFcyb069TSaUl2dZu4r61iit55GjE8Mao2TnB9So+Uk559OKytJUNe3sfmSW0VrnagUJFMsQ2PICeSwLZyRk8lelXJ9Rtr821vaKUSIZgkdGk83K+WuVI4JLELznKk8VLjbRIlWSsuvXt/Xz/AIb9daui11o9vPHaRSpHe2N0fKlbhVwwxuYEdM5HpWNp93BbeWt9PKtsCY2S9Kj7RJwsoOAQ6KBnnkVZvNR+yaGdP0ywh+0S4vLMFwkdzKG2n5R0YbSGwcZ571LZX+n2+rmPWJrUf2lGPKgELMsExVSY0bnkjg9M+9aRVk9C4zcYuNtP69bbs07WGGz8VyWGnWEiwCPInS7LIkYwQSvQocnj2rGvNH1WSzNvf6oLOCZ0i2XUgl+2XGefLRQTt24wuBkZqlb+bqEUVrpEMdjpi3apq1vNIEDbj8hBAHCgNlRzzW9qmm2NhfWSvM00ruZ4klO4w7AcMgHI4JxkgAZ57U17rt1/yFK8ZavX772+bX5/eY3jeC31axaB7aw1treVRZWFluiazYgZd9mNvHygY6mmatFp2k3ek27JqtpNdNHbpBG4xZogDDDYyQG7ZxVyNLJNLu/7L09UiuVFvdTWgeZ4SRuAkxyyk45HX1p6PdRaHps1rJbT3X9oCO8jDMFg3dIgWyAoPJJPGeK0i7WRKUabutP6/r+nrRjvbi0k1Cy8TW6/bLqcwFLeNY2Cn7zsYwWIAwRnOcGq97bXGoaIPseorZabBHKZY7yUmK4jlAj3kpyjDb8quuTknGau2ktzpkDT6fHd3cepTSPHBBiSRCrEeYTIeQSfvKPuj1pb/AMJEJeSmVG0RoIVe6QbBMkLFnYqCS8rMMZPoelVzRvroRUado7enl2X/AA9xunyQHw3qF7bXGnRQCyj06K6v4CYJJFAG8vjeRy3UDnjpUWlT3ei+LLaz0m50+aOS0t5bm5itX8oRkHeYlUYXH3iXPOelUbG+u9V8LyJorX13JLcr9qt0t/M/ccnZGjKQpztBdgQT3otpzc6tbtoMH9i2JuQlzPOzbYyB8wkjACnngZ+XnpT5dWmTyOV7Pp5eXz/zNK7m1y78P3MkfiJGVrnY897YFbnYqklbcAdSOuOg/GoPEnn6/qOm3GmtMz3DhLNbuZTGyBQMxsBngr828cnPpUvjSHVraDTY7rUhp+jW12wSeCwO9SDw0YTG7dkjjHXk0t/fRPb3viDw0Dc3tkEI0m4jFs0KocGbHJySSefU9aUXazQklCTkv1t2HyXM2vDVRfJ9l01d1w+rxGTy98YA2tk/vEYn7qnj0rNlubHxH4lg8O3z6lZ3NtbebaavBIpjuwvLOwCg5UqQMHIC4NT6jZ3Hh6eyk1TxAHnuI1u5NOaEzbixwYic7GXJ5OAcjIFTa/H4i1LTvtWm31jawWzSKdNhhil+VRlhAwAJXuUOPxpprSz0/r+uxErytOL0v/wP66G1FdaVp+vW9pLdW0viMpvQ6fpgZpBgn/WY54HOTmuJurXT9C8RHWtZN7b61cTGWGS3YzIrNwzMcH5RwNp9fStCzu7m58P6XLa6BeXyJctL5mlzAxxM4wxaJMOq/wCyCBmm3em6pHYXNtpOkaXcWTNNFdTT3YAljbIRHckFD225yNtOFovV/kJ6XTtden6FbxJoMs2tyefdQm2dER59QsYoLKMEggK4IcZY8EAZJqlfalpGmol5BK1hqujqbbUbSzgMUrBXwJY5T8rY4OD171L9vsvDGq6Zp+reEJIHni8i0ubOQ3kEiht4ChicOrj1+o5rZ1/wNq2veONZbW5HtPDl1Gscrz3PHIG2SPnGC6glOxxmq9ol8b0+Rze1esU/uMP4e6LN4r07XtR1K4v9ctmnhW18oLbzjdIGflxlRjG7b8pGQDXteq3p0q7udRvryZ7CNI7aKytYd7vKz4HPUn7oA6dSadMLrTtGt7fTLB9RubSKOCC2Eix7tqhcljwo4yTWVP4mmtvEWkeHtPgjvteuHWW/jWTMWmxEAsWYdSOg9a86rVdaV0tDnbtrJ6/1/X5HrdFFFB4gUUUUAFFFFABRRRQAVwngb/kfvHv/AF823/oqu7rhPA3/ACP3j3/r5tv/AEVWNX44ev6M9LBf7vif8K/9Lgd3RRRWx5oUUUUAFFFFAHlf7PP/ACAvFn/Yzah/6EteqV5X+zz/AMgLxZ/2M2of+hLXqlACNwPavmP44/E77fcXmk2sipolvIFkYp800innB/uggfl6V6T8e/GFx4e0FNNskKTaijq1zux5SDAOMc7jnivk2O2/t2/V4m3Iu6O2ixnc4HJI70owdSXLsj6/IcF9XpfX5xTk/gT8t5P06eZa0lV17XI5Hgku7K3DM5HyLlsBcntzxXsmj2On6XpNpczvbWthlXuJ4ptqRsTjY5Y5LcgDHvVO60+XTLSxs9OsVkuGRRcNBIIT9oYKA+0A78ZPHStnUZL3T7rV7XRrHTZZ3miUrq0fmQONxI79QSSOOPXpW7a5UonbicRVnzS3k9f0Xdmh4i1eSzl1CXWnCW0UZjthaqrtFEy8SBeuckEnPbis5mGoRaPpNhdw6dLBdLe29zPHiO7iI3SpsOSi4YEZ6lW6VYunmOswQ6nPbQPczJdyhIi+ZVTaVVf+eXHf3odwdMu7m91DTr/UHdbSy+yW7CR2Jz5AX7x3cE4PAzUKySOSpFRSb02/r+txsVtpdxbym1+x2tveXTRTRJC7G4SNgy7XJ+UkAjHoOKvyppmo2F9YyStHB53nSyjl0wODK7Ahh/Dg9hVLWrYT3Ez313I93BLHasUjbyWkkTG7GRhgMKScjp3qjPezvdadeQxYsreERXSyOQGVmCFZ84AbB3Z56e1VZy6miSktDQjS3W1s71meOx0uNVU20w2uhbcoBPBGVBIOMdenFWvD5ivpxc/bVBkune2jYbl3ByD8o4ZDxgj0rKs554dFuGtFR7e2u3uIZDbmGKUq20lQvD5UFsDqe2KNVaZL2e+8NzXo/tCJwrW8SyGJAQNqKSNqkgkvjjpihpu6L3TW1zT8MtPd+OfFcRxcWgS3WcXMB3QyY2+XnoCVy2Bng1lHy9f8JQ3eg39zodnZXbwmGSBwBIrE7hkHOFAOOB83UGtDUtZksbCxiGoebeXcClra0jQiSbCpvDY+Zt3B5z17Cqd3Ne3uuR2Wq3txPaRSqJjaZ/0a4MZ3DjIZD0PPfiiKfxf1oZQhUb1kreV+mn9fgacktlqHn6at19vtTF5jW5jEbplf4HzhSSCxX+dZPh2+tL3StUv9F8RzonzRR3UykpDMOpBdQV4wCeCc1Nc6Dp72kseswzJbyJ9oNxZzhZYvKH3WXk8gAHqDWNrGqReJLS103w3Yw2dyk5JtY5EaFxKoBJRQQcqTzkEYqoK+i2NrvmtD4eu39fgW71r42Vxpt1Ne6hexy/aZzsWWS4wnJQH7qEdCOcnAFXtTbS73xLfQ/ZtSGTu3XMcdukmFUBFdjuwMjjHWqhbTNeubHQ5bu1httOC28dubhgZWVdzgcZcBgQPaqdrb3F/DYW2uX1pdSxuiIkkEm2KLOAu4EE5OOPbmtEgUW7NdOn9ei9Cnq9/pmpX7TNLqlpBbxIksZnZXSRZACwC/fdsbdhHTHSt61sNY1u6mN+U0jw7cJ50EcNurMcHIDDJKkrjLMOv0rN8RxpdeI1sLrQQkkd0jWkLT5S5+bO9pGGeB2B9qu6tZSaLf3d/B9t1J4L8pe2twFSW4SQf6yMjJZFyPl6YHam7WViZOMbW0uvV/r5akP9rXEyz3Otx6ONdWQw6ekUheOOHbty7Ic7Qew5yTmrE15rGk+Hrp9VtbPUNWvH/s7T7WyjkWKLA+YMDwDhgRjr3rnNM1ubQ/D7/2bBqWpXC6iEcydBCATuQ8kZyAVHpXT6ZbRHxbOL/WLzT7nY0+n2BlEzKuASJIU4xx0JBPSiUVHfYmcVHZ7f1t/kQ6fPr2nX88HiO6jvdR1C3e3WHSZN08cSryzFSduMcBRjJycVl39nOba40/VrDWNNLXYmtdVgcLJNjaD5qnAVF5w2fesy2sdNS81XUIfEMNrdwTq0t1pEP75Ix8uzZkbcnGQBgV0FvqOl2Pi9bu60i6uNbSFZ7SKSWRyit0JYNtJP3jwAOmOlVs7xM+Vpaf5X30+QzWLtZFs/EN/b6ldafpuA4mQSSKE6FSGC4kOC2RnFZ9le63f6DD4ja5g03UdQviglsLTJlXI3LKG78DAHXmtzSoLbU9U8RXOt+KJoftcRmgjku0laNl7iEAbhjpkA4x3rL8S6lcuLZrS4Qy2RS0YTqUeUMQ4dIsDDKDnOM460RafugrN6q1t/8AhyzALjxHqE+nTS39tbgMs2n6jsSTccktHxgEcHgg1R8LrLqscdibyD7XbyGPTNck3qDh/kRgwyclcZXnt0rP1eTTtd1nUJY/EN/b6ZdXSTR3lzMFjsroZ3IQ3JVtvBGO3Wtbw7aj4j3N/FYafFaaJaSfZLoM+0q5G5byIdpNy5wOCD7mnJ8sbvb8jKpWtG7X/D/1/kY8WsazDDdQ+CbQWXieG8ka6dNzC9Ck7tqvjacnhMciuh0D4eanfeGZDqEMdjda5ew3Op2oYfcUlxLHz8r7j909OfWvRPC3htdERpr29l1HUZ4wtxcMoUXDKTsk24yGAwM5rameO2hlnuZY7e2hQySlvlCKOSST0FctTGa2pr5nLNqb5n+JlaHoOlaNZtp1nG7RxTNeZuHDyCV2yZN2BgnpxgYqHVU0+US6Bq9lYHSbwpFZxeaxe6P3nBUYKhTzkGpNJ1CN7S/1qfV4LvRLgfaLGTyDH9mhXIfP94ZHB71cdI7+FLqzlaC8ngAivPIHmJGw3fKG+7kdf1rkbal7zISVrR2Hxm2OkIli+bUxmKOS2feUA+UbSe4IxzWZoGlT2N0/mOqW0zZ8lj5k83OcyS8YAPRBnFRTeJIW8a6V4a0p7SS4OZdQKwsywwhSdqlRtDk+tPl1G90yW41bxJJHpek205t4bK1QXL3IZtqSu65IySPkA47mkuZadwlVUdP6/r+tD1miiitzwAooooAKKKKACiiigArhPA3/ACP3j3/r5tv/AEVXd1wngb/kfvHv/Xzbf+iqxq/HD1/RnpYL/d8T/hX/AKXA7uiiitjzQooooAKKKKAPK/2ef+QF4s/7GbUP/Qlr1SvK/wBnn/kBeLP+xm1D/wBCWvVKAPm39sDzJP8AhHbaGN5JZRLhUPOAUyfyzXk3hAxXQa2srdo7mCcOuImbCgY2FV5zznjvXs/7T2jyazr3hqC3hkln8i4AVAeQSgOT2HrWRZ6RHpryyaTdWM9rbRiOSONwHeQja+e46cHNbRkoR82fYZbP/Z4c3Zr8W/zf3Fpru5msI1TUra2v7kEzK06xTPkng9Sox2HNRj7XqraXpul3LXNkI2WTULTIkLKoO5nKnAzxt4J4zUsVpp8SwSWdjHIWRRJDHMQ8SqcnIOScN19Khj2R2NpHpc4tLq63X0lqsix3exCQWA6bcA9ucdKlWtodEpRTu3Yct7axXEejSwStBbzR2k1xOrNK5lwcggYABOdufWnwxabYWNpp6XUsrfaHZri2haMLjcHIkIJRT6rz1rMuLsxapFe3bhdPutscGo27eaTJk7ZRGP414BB7dq2p7q9l14rYJpuq6YLE25WF13llHzb0PzAlgeB0PNU9PzFJ3Vt0VYjOdSvLfXDLbzRrBbl4lFwEgIYBi5xjJ2ncB1xmrmnagusT3TXkqw/MYjZnc+0hgQzgggBehPuawFvrOGCS88S2d8Gs/KZTLA2JG37QhC4DHPPPAxkVY1PWL/w/Jetrlhdy2NyGgW5WEJDh/u/MvIDKRnjIOeabV9Ov9bCWjs2aetXcCyWr6nO9pDcBvskRjZ0ieMhQwK9VJbIAHOTzVPdbalJZ3GzSpvE9qjeQyF0aNEzsIweCwOSrZA79aqaVFb6FpNxdGX+07yWFn0zT7wtK1uVPLCTuCMgYPNPbRp9W0rTtR0+S10HXoZCGZISYmZCAd2RuHXj8c0WSVn/X9dR7q0k/6/r8DfurqK1c3UQhWGUiSOxVNwEo+Vipx8u/tiudnsH1ae10oi58P2qubgXdncF4pScZ6gbjwB7ZpPDkU0bvFYaqlnqRlaS6W5G2BvLyCYyBnB4646dT1qnY/wBoW+oXbMzQ6cU80xyS53KG4IlfKhj2ZTjHFOK5b2NlTTVl/X/DFi6XUb+LTrU3N+93Jft5FyrmNYdq4JlyuXIxuAxgD1qw0kEMf9h2GuTLNLPia5tIBCJ3dThUMYywU57Ac84qjZ3l41zc3qMlnpdvAZTcXEnnxseEYY6NuLckHNOgTVdZ8GaomkeIv7SurKSKexi0zdHKOzqVwGK45x3OKtuxFZKmnI0dGiW60yGG+0690m7hge2k1WfcnkvuIACthS7LnJXsc9ai0iGDT9T0rwpZ6lFqWr+S13Gmwi2iG0kEyKAxJ688dMnFWdbuLbTdXsotbv42sXVpYdOu5S87sRsV+TuUFs/KOQM1leKfGd94Uht9B1ywhia6wt1f2kCMrWrYxEjKMjGPun1oXNLRGFSUoq6klru/xIdU1xk8UWMs7w3Him3dUg2/vEUYGA2zI3k8kg4A96teHrSF5/EK3bq+qukmLu3kldYEwS0ZkxznkZA/GlNnPY2d3q+q6eLmJs22nWEyC0aWILuMir947RjPHrjpms6G91Gx0oR/8JLYwafFH9vS0gtvLjvEPyhOB84zhcE569a10atH+v67GimpL3dbdv6/DRFjwHrS6BoMjaNayjUbsm3tLuZ2aEnK/I20np1IH5itKxg1DQPFcZ0a20a91m4kV791naTyWJ+YAE4Rd3PJJJrkG1W20q/8K3ctkr6pb74ZWjLxxxMSDuVD/Em4c98c1FrsjSTaS+nxyrDFcrHc3qX22SUNhlMiKP3fcjI7HNV7O7b7mctXdrXb/L+tfkdZqEGjXv8Ab2tWc09zot5I1veTsPKN1OjoRHEi4KuSw+Y+hqLxXqAg8d6XodtIsGlabBHFtvbRy1mGBUkyKQW+969fpWfqd3f2G6HU9Vj0a91HUne2khcfNEy5V2UAiMtgfMME55q5pXidPFV9oFpLdrfXV3G8d9DO+xsRs2GdcbTheeeuOOalRt7z1RhCya5mtP6/r/LQrTapp99JevrV7A89ncLDaapY2Ya4dQpAE4YZ52hQxHWrujT3Vn4Tu4dQ8J+I76LzgRbshSeOYjh/NGSUK4Un6cVRv9TuNN1i6bRPEN3c3kpEcT2+kqGt4vvqrqVLMGU5U5OcV3Pwzi1XU/FUniZPEcOsaSbd4NyPIjRz7cHdC3Ct3xxU1JckL9P68jKdRqOj0/r7ipa6Bqfja8sYPE/hltC0ZLQylLclNwZ8LDIGAO8bd24ZPIr0SO303w9pmxEtdPtU8tXmKhSzYCqWx95j096SaPU7HQZV08Pq2sFDta4YRCRz/E3OFUA5/CskQ6bobQ2N3p1+ZhLHImo7JLmO4uWGMk8lQCeM4A4rzp1HU06dkc6lryt3t5f1+voW/Heoz6P4aunsRdJqFyfsltNDEZGjmbIVmABwoPtWhaae9roMVlq0wvVihWG4nuJA3nOR82SQOCScD0xWRPPrdr4n1N7LRb5WuIVsrbUJp82sborPvdB0TcQC2CSeKwvEEegafaadL8S9RTUtcWBUe1tZJWhkcSFkcQLjkcDJ4qFH3Uv+HMZVGtje8UXUR0C+ttJmv7i5sJYbe4s9GZTcRgkbYufuAjv2Aq3cqYEmTVpdUvm1iZV8rGVsl28ruT7qrzls81cnguIbyB7H7DGktxv1BpI8PIm09CvVxwOegzVC81LWdO0zWL5tHF0YpFTS7a0YyPcAjG+QDhVyc+wBzSTvohu8XzNmXe+KbfTdKWLwlpNxc6hfztbWcXksvnFcb5iTzsUHOT1xXRaMtzp9rHbXNxd3NxaP9n+23Mex7k8EvgcY5x+FYHh/WPEdlpMh16y1PV7lrplE+mxI0JQJu+QZB2A/JzyTWJ5HxCk8T6fqHhbzoNL1kvcXdrrkHOmlflCnBOMjJAFW6V21+NyXVjFuUme+0UUVoeOFFFFABRRRQAUUUUAFcJ4G/wCR+8e/9fNt/wCiq7uuE8Df8j949/6+bb/0VWNX44ev6M9LBf7vif8ACv8A0uB3dFFFbHmhRRRQAUUUUAeV/s8/8gLxZ/2M2of+hLXqleV/s8/8gLxZ/wBjNqH/AKEteqUAeWfGe8S1vdIU3SWzyJKNzMVyPl4zg98V59q15p9pcaeuoavdSzSr5dqix4tomBwEJAwBuHP617p4j8J6Z4hv7K61JZHe0DBEG0qd2M5BB9BWVpfw30XT4zEJLy5tid3k3TrKobklhlcgknJwaNNz3MLmNGlRjB3uv8zxXVtU1Ow1GF9e0TTfLaZVEljclWSTGAd6kqD/AL2BmotV1CC61m0vYfEOrBreAwR3UdtGWjbIBjdlOOvHzcZ7817Fb/CTw5a/bhbNfRxXrKZo/NVgVByVG5SQp4yAe3an6F8JfC2hAnTYLqKZpfNkm+0MWl/2X7MvsRWiklqv6++5f9pUO34HjNhfeLb5r6bwndQpqcTJDd2d/aCGb5TlXTJ2EnkEA+mK1BoOpWZs/E5tLbTtcKtLfWsjrDCXJwVDMflZsAjgj6V762h2bziWUNI6ncpfB2n24rFPw/0OSwhtbtLi88ieS5hlupPNeORyTuG4YOMnAIIFZ88n0SM/7TgnzdTgo9Il06yuYYJb63vLvDw2t7LBIzz/AHmMWTyU9+PSsfW/C+o3upoNStrW+0q+RPtNzNqBtbi0mXGZgpJG7HZeOtexHwlp01raR35lv7m1JaG8ugjzI+c7wduAfw7CmjwlZzWUlpqtzdarDLuEgvfLYurDBUlUHHfjFZx9onch5lzJ3/4PoeXjwto+h28uo3GqavqOnQfvUt5SsoA6MyHG5vXiqFz4Ptb621D7T4lvY9KuvLmWAptaMnpuRhgH3BGe4r1eH4e+Gbe60u4t9MSKbS4/LsmV2/cLnOAM4P45qex8H2FtbTW0tzf3cD3JukS5nLeS2c4QgA7c9iTVJzWqeppDNFHRtnzvr3hhdI8L3h0G/uNb8PXL7Z2swrSrIpBIJyAq5H3RW+NJdvB3n32pW9jodtYDcLi0InBBydy5xkcdDjnNe43PhbSbq2NvdWkc1uTu8pkXbu9cAdfeifwzp0tnLalCIJFKsm1WUg+oZSD+NV7Sbtc2jnMVFR6+i/r8D5otvAd94jh0nXdBmR7GckXMVxKsUhjVgMAZ2sD978a09N8Px6X8RH8KW39oERI2qhrVkjZhyVRmzyvXtjNfQo8M6abCOykhElsihfLKqFIHsAB+QqDVPB+k6nbSQ3Mcg8xBE8sTeXKYwciPzFAbbntmr9tN6PYmWcX/AOG/r9Dx7XvA2q3F1d28dkL97W1V9Kv7zbGUeXPmQuR9/b94EYwTiuT0rwBrGmy2T/2Tqzwy2Nyb21vtjq08ahoSignGXxjPPFfRGjeCtM0iymtbaXUJIZDyJ7t5So9FLHgc9qvweH7SGFI0e4IQYBaQsT9SeTSVapFWRj/aKsk5Pvtv+P6HjEHhOZ9Ft9Z8YX+p6rqltt1CWExACI7MPEo+9gDqOATVRIIfEv8AY93ottYxW9zd+YtveWzxCa0hDFzGuPl5cnHcr3r3f+xbbduDSg+u6n/2TB5hk3zbyME7h/hUKpPqSswjFWiz5a8Oadb+I9Iv7Pw9q9nPc3V3NdzG/j8yTT7FS2EUMCQ5O3gex9at2vhPxNc2d1YWtlFHoGqiO41HVXkCzSQFAQEBIO5cHIxnkV9Ip4b0uKWWW2to7aaYhpZYEWN5D6sQMmny6FayFW3Sq6tuDgjOT16itfbzWy0F/aCatff5nyBo9rqc+i6L4h+1aZYT2lvNBDLd2zPPKisBHIM53cnbuHSuq8LeD7/U7nVdJuNPtY3vLRbiG8MBinsr7BYCcEl1Bw3swxX0anhXSwmyaBZ0G5UWWNCI0YAMijbgKcdKLnwrpdyJhLEx81QDtIUqQCAQwGQcHrmreJk1ZIJY6EtL2+XU8/8ADnh+XTrr7bPdTwSjTINKkhtioUvCeJg467h0BHANa9zFbadp9+9slrYvNl5JVGwNKw2hmx1Occ11Gm+E9K02zhtrKJ44o0VOGyWwMbm9WPc06fw1azNcB7m7EE0BgaFXAQZ6uOMhvfNcklKT1ehMcVRj3/r7zlpIXi01Y1e4lmtIgWitZgTMwX7mW67jnGSKwtVXxNeeHln0H7ZZs1gsS6bLIkN0shOHklkYEZVRkAcnNd/png3StJ0WDTNKE9pDCAFeN8yE5ySWYHJJ659asaj4Z0/UtNuLG/8AOmguIzFL8+1nB68rjH4UKLTvuTLFQktzzPQ7fUrzRYL631W/fWbYT2todTRrZCp2gPNEMiQgZIcdfrW1pVpqukjxDLbRWt21w4ntooZCklw+zDeYzcICcYA6Cu2Xw9aRW0MFo81tFCqRoI2BwiDAT5geMDHr71Dd+GLS5vtPuDcXsaWbtIIIpdscrEYzIMZbHYZxSak79iPrNNLS+pzOlzXFzZW0+r2h0u5KeZcW8kiuIyOp3Dt+tYOmwXWs6RPqMesmCXVIWjku7feqW8SswQQxvjBPGWOM9RXe674M0vW9Gu9LvTcfZbpPLk2sNxHsSDgjqDUdl4D0K0E5jglea4t47a4lkkLtMiKFXdnjOAOgFKNNpN9TR4qk2r3sc3fRajBptlZeG7q0tDA0cLTX8bS4hVcEqFxuk6HnAzWUvh9tU1Bm1y/16cWKJbm4W6FtDf8AO8yGNOm04XtmvS/7AtM53TZxjO4dOnpUM3hbTJzH56SSqjBtrP8AKSOmR3/GiMZoTr0H3N2iiitjzAooooAKKKKACiiigArhPA3/ACP3j3/r5tv/AEVXd1wngb/kfvHv/Xzbf+iqxq/HD1/RnpYL/d8T/hX/AKXA7uiiitjzQooooAKKKKAPFtD8FfE3wtPrMHhrV/Co06+1K41BReQzNIplbOCRgdAK1fsXxn/6C/gj/wABrj/Guf8ACNz8S/Gz69e6b4zsdMs7PV7qwit30mOUhY34O7IzwQPwroP+EW+K3/RRdN/8Ecf+NAB9i+M//QX8Ef8AgNcf41v+Crf4gQ6rK3jS+8O3GnGEiNNNhlSQS7lwSX4243fjisD/AIRb4rf9FF03/wAEcf8AjW/4K0bxtp2qyzeK/FdprNi0JRLeHTltysm5SH3A8jAYY9/agDtaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuE8Df8AI/ePf+vm2/8ARVd3XCeBv+R+8e/9fNt/6KrGr8cPX9Gelgv93xP+Ff8ApcDu6KKK2PNCiiigAooooA8r/Z5/5AXiz/sZtQ/9CWvVK8r/AGef+QF4s/7GbUP/AEJa9UoAKKKKACiiigAooooAKKKKACiiigDL8Ua5Z+GfDuoa1qZkFnYwtNL5a7mIHYD1PSuN8LfELVtdghvm8JS2uj3Nu88F/wD2lBLGMIXAlCEmPIAHfBODXYeLLW8vfDeo22m29hc3csJRINQBNvLnqkgHO0jI/GvE/Cfwl1az8Vy6tYaNYeErM6fcW1zY2mqS3a38skbKpIKgIik7sc8gcUAenwfEbw9beH9O1HxFq+kaXLeW/wBoWIXyyqVBwSj4G8Z7gVoaR458L6zqsem6Tr+m3l/JD56QQTq7FMZzx7HOOuK818M/CzVrK68GNqaadNDpGhXOnXCly4MshO0qCvIwevFHgj4WavoV38LJ5005ZPDkeorqTxOd0hnQiPado3YJ5zjFAHodj8Q/B9/q1tpll4k0qe/uSVigjuFZmIJGOO/B461meHfiZpV74e1jWdee20Oz0/VZ9L3z3IYSNGQAwOBy3J2jPTqa8f8Ahj4W8R+KfB/hTT/7PsbHRNM1+TVpNRkuCbhzHO58tItg2k5xu3EYwfatzUPhF4l/sqOe0uLc6hZ+JLzWIreO8eATQzYxiUKSkoxwcEDJ5oA9ftPG/hi7s9Pu7bXdOkttQm+z2sgmGJZeP3Y/2uR8vWtHRdb0zXIp5dHv7e9iglMEjwOHVZB1UkcZGRx714jdfCzxBqXgHUPDyaZp2mnWNXW+up7nUXvpbdQF3Sq2xd0rFSOMDGcnmvSPg54d1Pwl4GtNA1iCwSWwd4opbInZcR7iRIwIBVzk5HPPOecAApeHfjF4O1l9XV9XtbBtOvJLVhdTovmqjKomXB/1bMwAJ711eo+KdC02a/iv9WsreSwiSa6WSUKYEYgKz+gJIxmvJ4fAWoWOlfErR/EFhpo8N61c3+rR6ok+ZIN4VkQxbM/IUDZzjK9DXE2eiaof2YvF3iHXFlm17X0gd2ZT5hgheOKFSPorN9GoA+g9J8deFtYOof2Z4g0y5GnoZLpo7hSsSDqxOcbeOvSpfC/jHw74rNwPDms2WotbkeasEgZkz0JHXB9eleO698MfE/xAbVr/AFSPTvD7S6FHpNlFb3LTmUrMkweVwi4Q7NuMZAPTjnpPhX4M1vSfGMuta7pi20v9mmwa4fWXvWlw6MoVCihEG1upJGQPWgD12iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuE8Df8AI/ePf+vm2/8ARVd3XCeBv+R+8e/9fNt/6KrGr8cPX9Gelgv93xP+Ff8ApcDu6KKK2PNCiiigAooooA8r/Z5/5AXiz/sZtQ/9CWvVK8r/AGef+QF4s/7GbUP/AEJa9UoAKM0UUAGaKKKACiiigAzRmiigAooooAKKKKACiiigAzRmiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAM0ZooPQ0AFFFFABRRRQAUUUUAFFFFABXCeBv+R+8e/9fNt/6Kru64TwN/yP3j3/AK+bb/0VWNX44ev6M9LBf7vif8K/9Lgd3RRRWx5oUV5po/xVi1S5Hk6LcxWUl5aW0M8soBkjuHkRJQmOBujxjOcHNel1rVozpO01YiE4zV4hRRRWRZ5X+zz/AMgLxZ/2M2of+hLXqleV/s8/8gLxZ/2M2of+hLXqlABRRRQAUUUUAFFFFABRRRQAUUZooAKKr319aWEPm311BbRZxvmkCD8zXJ6l8S/DVm8kdvdy6jMn3o7GIy4/4F939aVzWnRqVdIRbO0ozXm8nxPNwv8AxKPDWrXLeWZD5wSIYxxzkj+VUpvGXi2+l22tlpemQPGCGmdp5UJ9htAP4GlzHRHL673Vvmv+HPVarXt/Z2MTS3t3b28ajJeaRUA/E14tqg1i9jl/t3UNV1OFyI1gsWWISJgHcyZUdcjHPaslPCdmYyy2uowyTyM8dldupM5I+633gPw6U1r1OyllcG/3lT7l/nY9vsvE2i3lnDd22pW8lpKXCThsIdpKt8x46g/XtVqHWdMmuI4IdRs5J5M7I1nUs2OuBnmvBofD+neRI+m2bR3yMUe4lnZIYzkb0ZgQcjtwAfWr2oeEpbY232K4nSW3kF3HJDdLK0jKeFOVJ2nPXPTjmh6O1wlltLVRm7+n/BPeqK8ZvB4g1K3uIdWuxNZo6OSHmQh9uc5XbtAbPByDgHioLPXPEehZiuLhri0ncIC8+8/MAFEbkghiccZNCu9iI5TOcG4TTa6bfnb8j2a8vLaxgM17cQ28IIXzJnCLknAGT6mnwTxXEQkt5Y5YzkBkYMOOvIryqTxFLd6ctp4jt4b0Qzb2DxrgrztLAjkrx0xnbXK3K6daJfq+nPcWF3KhNrFI5j8sdfLUsAjDJPcelHvX2HDJ6zT5k7rtZp+mqPd73U7Kytbu4urqKOG0TfO27PlLjOWA5HFLpuo2ep24n0+5iuIjj5o2Bx3wfQ+xrwQ3UWkaw11pF1NJpsloEd7uQMQVblZFPGNp4OTxxVmy1LSYNOuI9KGj6dZNG1nJLFHIHKscld6P8pDH8KGpLoazyWajeF366et1/kz32jNeLWniPXjC6PrtxBb2xCnzII5HkQDAwwBOT7knvmtPwz411s30aXs+m3unyruSRiYp0JOArAccYJPGfek3bVownk9eMHNWdvX9Uj1bNFcV4P8AGkuratNo+taZJpuqorSx4dXhuIg2AyOD1weV6jrXaCmnc82cHB2kLRSEgdSBS0yAoPQ0UHoaACiiigAooooAKKKKACiiigArhPA3/I/ePf8Ar5tv/RVd3XCeBv8AkfvHv/Xzbf8Aoqsavxw9f0Z6WC/3fE/4V/6XA7uiiitjzT518JW2ip4w0nV/7I8TQeHLy9SPTJLidGtRMGcQ5iA3KoZ32ZJwW96+iq+edPsPD93dR6TqfjPxZoN1DP50NhqbLbqrhiVaMldvU5BBzXvWj2xstKtLZrua8MUSp9omYM8uB95iOpNejmFm07/nt8/xOXDaJouUUUV5x1Hlf7PP/IC8Wf8AYzah/wChLXqleV/s8/8AIC8Wf9jNqH/oS16pQAUUUUAFFFFABRRRmgApksiRRtJK6pGoyzMcAD1JrmPFfjnR/DsaI8v22/lUtDZ2rBpJADjPXAGe5P5nivLPEEuqeM9Me78S3U1rYsR5Gk6fIHGcggOf+WjDgkHgelRKoonTRws6uuyO61H4r6HFd3FrpFvqGsTxIWL2cQ8nI7eYxA/EZrmdU8VeLtfFvFCi6LaXILbLSVZLkKFzgs2ACfRR9TWFZ6o8Qgs9Og1Kxt7WR43ubqLahCgttPGW34IBDA9ODkVW1a/vrsbxcNJcQo06Pp7IktpG0ZGX8xsqSDkdePQ1DbkehTp0KWqV/N6/8D52NeLw3a+VIL22F1qLRuX+2uJJZhn7xPbPH0q5Yw7U+zW0crBUaISRsoIbPJwOMDseenIFZ2l25SyJ2XtpNA6xSvNKZZGlABbedxB5Pt19Kr3uY9CiTEcCXEZkf7SJBMNsgeQkqwYIFB4HXIpa7HZKbVPmdzftpfK1Qwz2aWtxPH9nmu1lBAnC5WMKyjzDg5yAR1z0qa6a4ils7A3lub+8s2ZbaKVWDKqZacSoqsnzcYG4dwOuKniWWWW10nWre5uhJblzbxTW5lR2d/3crovOdjDa3GOc5ORTbq/uIL+a7lWHQoo5N7ROxPn4QphjuAKsdu0L+POKnc85OpU67mil0yPdyTKVhE22MWykMI9oO8gMQQcgjAB55Hc5F2qxT5iv7u9jmkae3t5Z3aNyAMqWwQFG3I75yKzNKecXFvJJapBLHunj821SBkjMK4QKGypByPmycAZq9HqF5IY47aW2vre4xPDbx3ItZ4y33Y1PQkkN9a0j7p6FKUYwVST08/8AgF+eayvlube6mtrX5RNPG0rwCQgAnDOi7wMc4J96nv8A+xXM0jzz/aUVPNm09fMdMEMkbGIlhuySMjBAOayr/Uwb3TrFpp7K61UkBbScSywqCd5wV2hcA8gZJK49a17CbUIvP1JFhvQRKbeOIlJJiV+UMu1VhCgc7sk+ozik7vY5K1aUZb6Euno1tLN5Ms6xyfu2V7o3EikjO2TnC8Hp9KillT7PNaiM2juzNhIlyNo5kUfQAZx6Vko8m6X7JLb20cKyuJdNtQiXUyjDBckkMGDAhsBtwx2q+/2G21E2SSf2bqOoqy28zHc8jlBuKg5CkYBweKpLXU6aNTS9tv6RJd6VbahZE2ckliJY1kE9sxBwcEHb1Hv+NYX2y5tOJ7dXCljLNBISoyvDYPQey/lW7a/aP7KgS/kY34LwJ9oVY3fHfCnvgniobiG4FnJG961h5W2KIwqhEKj7vbqR1yKuLa0Z6FKtZvmXN82YlvrNpLDHbtNHNCse1vMIaTGOCwJzz71Wsrqxubqdo5I40ATEXlBTHknOeMndgflXQBLO5jtmu4PtNrIr5ugBmIhjwxI3EZ6Gs/UPD8N6sTxX1xEZSNswQfOD0xgA/jWilHY66WIpNe8rfkVLi0nuLoPLErRRBgHS5cMckHC/3cEKc+3SkuXh09mvvLuGuFBjR51EhJY5IHODk46+gpwsNQtL6CCGUzLIzhY0Z/QAsxPDMcDA69auWY1GWFvOgNsMEMlwhyMd+M4zj60NjU6b3ZZ0eKSGS0Gk3GmRfZZvMja8hJEchA+VCCCFOSODjk12Wm+NNZumWxg8PNf6nHOY7mSGXybWJCzBH3tknKjOFDfXtXnTaYJ7qYSwTwW6IrANBujLBs7wjAHcMd+DWy2vahZ6hZ+T50dmXkme9QBPuqSEnRcZGCxwOBiud3i9NTxMfhYVZc8P8l+Bkp4lF7rXiLw9qlzBqKx3MksEGqXH7yIltuMjA2jI2quTjtmtawkuNF06dtG1+e70+ZCxhnmMU6sMjEaMA6kZAwOCFrjZtHtPD15qesW2hXNzfXF08koG6doY2yQ6HAKl24JDEqG49a0xpp1GRimoa/bW5to5RAmoxypBGQfmErKTtHTGeq45puCcrvRCjCNowjG+iutN9L7tferGpBrHiew0+dbbU52udzK1tqG6U7SNoxKvzo2cHHIyO2a6j4Savr82mT6ffxXV/LaPtku7+7TzGJ6YCIcrxnk5GcVyHhvQppvGOn6cdbu/sTZnkjcrvu8AZDsO5AznA4U4wea7PWPD3izQFvX8F6gJbSRVdba7bzZEdd2QrPkYbK8dsdeaajqkmcuNjQ5nCMeWT+SX9fM9LoooqzxwooooAKKKKACiiigArhPA3/I/ePf+vm2/9FV3dcJ4G/5H7x7/ANfNt/6KrGr8cPX9Gelgv93xP+Ff+lwO7qnq2pWekadNf6lcJbWcIBklfooJxz+JFXKy/Emp6TpOlPceIJ7eHTywRmuBlCSeARXRBXkla55jdlc8K0S78C61/ZNzrM934m1/U71bT7LfXjSG2WSQqWVQAoUDDY7DuK9+0nTrbSdMttPsI/KtLaMRRJuLbVHAGTya43w74o+Ha3tpZaDeaMl07+XAkEQVizHoDjvmu9rrxlSUmlZpdn+iMaEUle6foFFFFcRueV/s8/8AIC8Wf9jNqH/oS16pXlf7PP8AyAvFn/Yzah/6EteqUAFFFFABRRWfrerWmi6e95fs6wJ1KIWOfw/rxSbSV2OMXJ2W5fOAMk8CvMvG3j8yi50rwsbaa4AKy31wR9ni9QueJGA7A4Hf0rI8Qa3qPjW3e0kiu7DQXjZpIYjiW7XcQF3A5A46D72cdOuK0KWegW93HZ3kaGRGjjeNZHihIxloQwIXgLgE8nmsZVb6I9GjhY0/er/JE2hWGmWeqLbNeRnULtTc3FyV+eRcn5uBhQSflXj2qHWml1ObSrqzWRN1uYASQrJlxhZcMsiMV2kKoGcgHOao3VsbTSjeC7uJ/PdxDcxuZoSFJIDkjEYILDbxtbkda0rOaWyvre8jnkvrZZE+0NJasPP3RALOHRT82VyQehjHI61m97m1SfM/L+v6Zn3sANxJqUo1e1s2uPtDRXUcYTz8BI5IySCoXKjAwSB0Nbfg3QJFvv7UvpYpLy8C27vGxyY87i245zzjCjbxwc1S1IxXGk3UjNJLctar++SH7VFaRqx2By2N+7aWzzyO1b1nczWum6a2lrLHatCJwzRhjJC6k/u1LZ+UEfQYpNvlsXGMUmmc7Ddabd6hfXyTxW8cd5PG0UqC3IkCqHMyjqSFLA9CD7VJrdq+2CH7JLcpKzf6H5i/MR83mKSfmQAZxWZptuut6Bq11cPOkVw5jt7m1Uq06gk5b0LKmCx9cVvavYy2mJtAtMX22aKNp5BLuMcJUEtnCgg9Cc1tdJpF8/u8iZq3As7zVoTZ29qlxA0cLXKy4a42EhkdQAxVXHTvmuZ8QzpqmuarBeSWN7CVRb6K4jOI4N5AeEnPzZA691yafrk11Kvh260m9NnNJEWuZZW3xxhwVbAb53AkbAGcZ29sVT8PQ2/9oXVjeXL31tZwyTCYxMJGaJdpTcfvoNwODnrxnNZq8dTCL05bC2l3o0UNuzxJb3ltcy20kj3C3jmLyVQSMFxkMFXpkircvnxSFbGP7PqEEUlrbzNIrwosRGQI3AIZwHzgEKMdayNJubWy0gR3Mduk86x2llZqqo21sncHA3jcpOQRwc81oCziCXk1xc29xJfWtxdldjvBE7FI/wDXAbguFwV9DntW17j5nyJGhZTi21e51CcRLe+VHZQW0jGOOOVFR32tjaxIKhemQvemadJHaQjTvC8kLTTyyXjwSxSiCZMZJ3Nyq7vlA/hJPBqe7lt9H0uKW7ls7S+kjLLKyyTLGXLsX+YksSEABUZUdeOKb4ou3hNtbWcVvYWl2E+1tNcoEmJZjLEGxuJ+8cqB04qYq5lzWb7k2lOf7H0qSVIzMXkkdZY93nNjOAxLYG4ffGOFXgVajS9Olwy3UUb3TKWubdUEgJ5JVWPIwDjNZO99NghuI45rmwnnOxVDMFjYgZVSclt24lv7v0rVvTqNhqQ4mubQMqw2iqEkZycM7MeBGB7Vra2p6FFqELssRSRtbyyQ2l3lIopHEgB2AjgLg4yOhx3p8nkKZH2BTIAXx1bH+FY51CK1uov7SkMEEsSBwzK8UMwHMcZHJJLDnnpU6bL3S5bizvZkWI8TiIBpGQ/P8pHOeR09andnTSld2LMsbtDMq3DIJE27woOAexHQ1nTQCO5tfILzWybY440IXyQBgcdx0p9jJJdadLqa6XeQzu2EtDICzqMYcDgDqfypurSTR3kksUsz2tvaO8lrFDuMrdhuHOR/dHNNJ3sae6/eZK6ZmWPy7qSZYiPtEhG2PBHXHO7PI4/Go3vpvNuhdvLDbRNGiSyTh1uCwwcg8rg4GDnOarFGt7bQJFOpQo0ip5SgtwUPExPIUepq5DeQqkc06BEHDOoJDtuwMK2T2FPlCMVfX57DNMnTyrdrJY51iRkiyuSg3EMvscj8sVo3U7rprXMtk7eayl4rf5HBJKAHJyOBkkYIzWZLDdak2zUrdoY1aUQwfaSpkGPvHZgk4556VHqNlPb3emGaC3jmudqx3cp8xlHZQh5O9Q3OfwrBpXOSdrdF+pc1G2iub65jtolsRBGY7S4gbLski/OYx1HPBBPJyaxG06K00IaZqGh6PMIoobWFrUtvKxuWzI2cDkhiuTkk9M1fecyNYvZNLFAs7Lct9lbYcZwpL4ZeeAcEZqza3X2ycC3j+zxeXvWadT+8fdgxbQRg7Q3zepHarTasLlg1F727f59u5jzv9liuJjbX1usmGzDK6SDBIXGw5UgnIGe5r0n4e+L4r0QaLeG9e/iUok9yVZrgKM7iVAHt0ycV5prVtci41MRvIloWtVgEs++OV933MHoScDJPpVVCl6d7WqMYZisltN8rbgRht/p159MVtbmV0dtTC0cdF8ytJdevzXmfSdFFFI+OCiiigAooooAKKKKACuE8Df8AI/ePf+vm2/8ARVd3XCeBv+R+8e/9fNt/6KrGr8cPX9Gelgv93xP+Ff8ApcDu6iubaC7iMV1DFNGTnZIgYZ+hqWittjzT5+8NW9zDq+keHlvvCzWmjatEG1O3Ym5lO52SE4GA7hWU89j36/QNfOvhTw5d2F1o073mlL4Wm1GySC+ijkE13JBNMYlKbcq7PJhmOB8vX1+iq9DMLc6s7/1r879OhzYa9ncKKKK886Tyv9nn/kBeLP8AsZtQ/wDQlr1SvK/2ef8AkBeLP+xm1D/0Ja9UoAKKKKAK9/dQ2NnNdXTiOCFC7sewFeV65rM+v388l0v2PT7VB5NnO3zzO2Cu9AcZORxkkD3PHQfFeaUw6BZRkCO61JDKWHASMGU59vkrhVvp/Oggu7by7rzC8kszhvPcnAK7eMlRnHbiuas29D18voLl9q9yw2myyg3BtLCaPy2uWttrGaWVeCY+cAqvQc02yurHT9OnC6Yv2C3hilt4HjknwHxvj2nBRgwJPAAznvWRrMrahdTWtteSTfZpd4ZQjmQFXBT0VkJBGeuD6Uy8sDa3GbS4jt7ZY3abgAxsQCzklT8xIGfaskrq19zaVNuTk+hZuL4+IdMheBIbC2hkEskWFaxmVX3GNgcfMfUZGe5qfN/Y4uLG0FvLdXT71DLbwsuA+HQOVaV87QVBI68Vj3EB1OaaS50zZO0SmSESRxxxoHDCVGGWxgAnjnirUsEMcMNpcxwW+j2t294Z5pEuMKASnl5H7p2HHAz755rTl6ETg4a2uzkmbVLi7mmnhuYpYrrzIkfe/lyFQ0cQKtg7hjkjuRXW6PrNyNRW/wBSlEtobEIUkja3FuoJWR+flU5wPU7MYFL/AGvCLrF3AbfR7iEXYFzau0fzJtRGYkiOQHkBB07HNbGlx3cFnpf2u1tppFsmt3vbqcMqufvl4+A4yqAHPfoKurO8UrWNatVVHdRMS0tblfC/iqSQyNBfjy7aVW+SaMqMDA5VkGe4GXOKmt3ttYezsH0/ZbSzQ5ud3ls0keI8YGcgDdljgE8c1HbNcX8PiHQxHfRF7eOEbSojhJ348uAgccc1U06K5mMcMsCpPaw/apDcqzOwX5YWAGU4dj+7/wBlamPX+uhg4pNv1Lt7ME86TS55b1LOS6t1jmjLIweXcxZOCFUnaCMg1Lpctlo+leIpw897byExCWdlW1VMbkUHjAJcLjk/L6Vc0K1mn8Svfoispto2Z5d0XmYUbi0QOG+V2IAGNxxnis3Sbqe6tJ4NKsWnt9QmZI7C7WODdJ5asbkowLBVHDbQckdKryJlJQ0LFkmy6tby9t72XUCIhbmTynB2MdwgU9RtYnJIOE4HFSa/dDVb+6t0ge+S2dIpUsS0EgSUPG0rNjDqMnAX0PpTtJTT5Lu71H7LBPuQGW6toTPGskSKxCDcdo+ZhtwGJOMDFXtbu7O/itLC2e0mjv5DOiYaJo49pxGPm/1u/IPYcjGaPtaBf3bJmbcS/abvQbS+tLPUJoEksZUWBpmCmQIDuA/dBkySx6YxS6Jb3kZuC0VukscsSzEQCeFSQyrFJJuy20bDxtK596WdYtLe0QXt5p06rgw6aqxAYYF5JDk4BckYyDtboaSRltbkXMBhS9vnM955UzLHCzbdoMQ4MhXblG6sBzWqVkZ8tpXKVvcadDompj53itZjLb3F4Csb3TkvmNRnO1CuAMkg84q1Jb3lnCkMFzLdzpbslw8qqfNckPJ878hmKsBgAZHfFVJntrFdSdkm02BbhItNG0qsTz4DSRoBueTYxJO0bc7e2a10eDTdJ1nVdHvfsdpJeSC5F5DuFuj5BCbsjO8huN3TBGcinKWoKq2xjJPqFiPs9pFJHJaxT2sYkDW6OpUKA4HXaBke3FX75bOzgmuIF3COMKhJ2gsp4UemSc1WFjYxwwQGd7n7MjS+Sjf65lZTlVGAMY6AACnTTTu225sf+JfJskTaFMiTMwPzqOiqOSfeklroetQvGyZW1KG3axYyS3Wn37onnS24zIGYbc8feAzgntV6z0+LTIGh82a4nYBZJm6sQMbvaiy+z3NwsxmkklYb4HdeQrAblXvjjp2qyYVthKLdG4YyD5vvMck03fY6It7MrwoYJbC0E7FhnmV/3jADrj+LtTLe5jvdQnt1jAZCTMSmADjPGeuRzkU21hMhM1xHKly7GTMr7jCSANinsOM/U1HdSXKCa6iE8pMYVraHasgYd1b+YNS9dA1UbklglpJNHca5FNFaRl5IYVnCtInIViMgnccDHesbSLHSYNZ1DXJLq4ktY3aJ4DBvuEmY5jCH74RcsBwPu5AxzWk8cE2omABEv5ceU8cxWQsFJUsM9F64I9D2rIu1vZLmPVLJ9Wm2GONFu5Y0jaXf5IJ3g7wysXB5Py8HkVD1PNxDtLV/1/X4l7SreW2063h0uW4BacRXN3byRyln3FmZ1Y5wSWBB3HAz61aNtdXNyTeCOQOzPE8XymLbgou0cSL7g5ANZbQ3Gnandq+qahd3iToIIbGGOO3mTcWQnJ2sQodWY4B3AZzU0MJhGnRJFDG0Rkb7LHMCcFmzMkZyUZc9ASpG7B6U9gp1dbWLtpfwXUjW7HzI5V5WPKiTa2GGD6EYqlc6TeSayxtZo44WkD28Mo2jyx95A3XcM5wc5A4q+EH2hrS5EkmYj/pICgbxgMwxyN2cj6Gm2jzvHbWtwHlWMEq9zzOxBxnjqcd+taQdndHo06ri1OGnc90ooopnyAUUUUAFFFFABRRRQAVwngb/AJH7x7/1823/AKKru64TwN/yP3j3/r5tv/RVY1fjh6/oz0sF/u+J/wAK/wDS4Hd1Q13SbTXNJuNN1BXa1uAFcI5QkAg8EcjkCr9UtUvJrNLdoLOa7MtxHCyxEDy1ZsGQ57KOTXRG/MuXc8x2tqfO3gGPwwniLSG0/wAJatLbRXsIt9RvtS4UyM3lSGIYHO1sDHbuTz9LV4fpOl2U3iTw+f8AhCNfsrexmjihma8UwYWRmjZxk7tjOxHcdOnFe3S7zE4iKiTadpbpntmu7MJqck1+d/1Zz4aNk1/X5DqK8r+xfGf/AKC/gj/wGuP8aPsXxn/6C/gj/wABrj/GvPOkP2ef+QF4s/7GbUP/AEJa9UryL9mgXS+EvEQ1BonvR4ivRO0IIQyZXcVzzjOcV67QAUGimTMyROyKXYKSFBxuPpQB598TbZtXubSBGsFi0yQXd2LuXarW7pIjkAeme/Brg13TKqWADu4ygmztiGzb8g9BjpTtb13V9W8czu9umkXaaQIntJnEhidpQ21nQ852LwexPrUFxF/aaTMt5ciFdyCJFBQvn5y+OXBBI2+9cdW7d/6/rQ+jwlGpSo69bW+eo+/0V/7M8vUZ4byCOMI1hDB5Chdwy+9cHJ5OTnGeayX1CCy0+Waa0nsLC0bLXMcnmuzMF+RCSP1+8MY60mqf2jKfJu7m4trcuIxatbmELDj/AJZOM4BGASTnjpUlhq95axNFdxXF81sC6yoFFxkEEq4cgbMDaG9aUG+5nJyhG0b2IrzVbCW4lmsoLhb/AE+Y+d/o7RwlXHCyl3zjjuDjtVnU7gWurQslho63LBYJCId8UzHDbwuNzgBeqnGe1bVxFHrFxplxDE2katNCftbK4nBgRs7TyRk54PbkZNYyOyxLBZeIba0tBOFh8hS3A+9Hu67mznp2q4yuOCcouTf3m3pZnuruXVrnfGxdxaQFmWN1AwMjlQWI4bGQCOBWHew6hDflZp7SWe4QvbXF1cIrWLMCzNtIA2gYX3PvxUWl3mmSadcDSdNNtpUA8zM9wY3kdZARlHztXqCTz0xW4bG41O3uZ7tYJ9PmhdRA0QhBRj8g8zhuTzkYzk+1HwyuyJJyXn/XoZmsXM9h4iv4bidhBHPFb6bmQxhAEVlCBRlj13ZPTA5Bqw0muSR30MjzwaffSG4sjb2XnJ/rso0kqAnJ5+UD5R1NVpbbUbDULmzT+xrzT1mtjHY3UkzTQXB+UkFj8iYBbdk8KB61qeFtfuvC0DyaDprXlldASXSykRRQXLS/NmTJBGHyNueAOp6aJKxzy5rNw1fW/wDn/wAMVbK6ae21NrN7e81CCOSO7FrAzMiSABVhcdtwOQwzwRjio7Xw7Y38JhRbkw2ds0kdibvMaLgLMqSDc+3Ln5TtyRg1U1nxPd+IdXmv57WS00q13bxFbqYEVXdGYzlThySBhRkda6FNLnj1a11CC/mhmeFY7uOzeN0CryryYUF1b5sjByWHpQ/dC3Ok2LFqdh9gthbRW+baOX7MbK1BeF2cjBIbAIG1SBzkdcYqhH9km1qzF3NBO+IybhlXHmoSJAwbBXCjduJ4I71v6dG+oPBcRtKQFLJYqi7I33EhgNoYHHrTZLG4j1GK2vJrJLM27RT2/npG5z65JLZ9yKI7tJG0qVkrGDZJb2Alsra6RjeM8gjS08wSPG3zTGUj94hVhwAcHhTxVm8vprtp7aWxiuYLmNJ0e1ciZmi2iRlQqOrBQAzg8Zq1LYqn9lWt1fTW0k9yxjtLxxGVgDbjDDg8glVGCx4PHHFZlhAy22qymS1jEt21xeWsczNG5IJQFnGV+cEfLjIXFaJJu/UxhTcnZbmd4k0+DVrZre/uDJGLz7cjwx7WtnaBkd3IyPlkG4gn+HAz32XuibGTRlntLfUhIbWe4jMjhAI8iRQANhJ2kqcKCcgk1We4W40WRdS/tZB8ljPFYNEIplXc4AV2DhW+6cHJA69auyTP/Zl5Gtubi5m3W97BPCsWyclVSM7QWKBX3cMTtPJobvozJL33YnE8ltquq393FC1vDGrW13GnLRM2AnHUcHn3zS3eli+gsrqWR7OeJzczGJ+PM27CpPfFU9Ka+sjqEF6YJLBVbBkcovmr9+KNSPuA7AvU8nrVu0ae+s7q3u7l5zMxnTcgUKkgU7Aw+9gg4OAcGndp3PWwtR8ytsRXFrfWIEmkhEu28t8TrvgWPOHIx/GRj8q1HC2od1laRGBwz8nGScVm2k4guHtbWBgjbilwjF0yoUHeD91icjHtSwqyXcsUbwwXksguiineZY8AE4PC9McUN9zqitb9yeW7iSVibW6JjuEi3GMhckZ3e6jPX1rOY3Gl2FwbS3UTyXyl2vJDgq5AJXH6D2qxqramYTEIo1YrJN9pDZ8pVxtGzBJyM/lSxW6fa5Z5LiSdZUiujbyHm2BHDbeoB64PQ0nsJ+bMaW2SzuNRgssWurX5iupy8f8AqUUtGxDYwMkj8DUklnNNd3MFpOPO0a7js7JXlKRpEqKzsybTubCDH3jk5GKs3qeZc6rLeRCYlcoIpWBeJVGAe4O4+mK5+60pre4+0aVLbSabEiyX0kihVjXO5Q2VLtJtdvmGAce2KHqefiltJrf/AIH5f8E2LO5W1vU1O9gspUls0WV7ciOFLPa5ZU3fOzIVUsDk89FqHUZm06/tdMjt7CzEdq0aXUtu7CdVUNGpmP3UyUHy5JbNOu7r7Ba2ekmLTopoLdt0moQM7yIAu7eCuFBDbAwLAlhwO1vVDc2WuWTwWV5HDqCI72twgMVp9nGCgGPlG0ttO4gkCpXc5E7tRT6j9PvFtrX/AE+/iaz+0tbxvInlvGcKUjyMhuGGDxnHStGGB5THHOVaRJdgcHG7kcjHQ/4Vh6f5khFtsW6gudt/iQbWtotpEZ2jowbjJ6gVqwtdSSSw3dtBAysjW8wO8TcDecdsHtTv2PWpT93e57jRRRVnyoUUUUAFFFFABRRRQAVwngb/AJH7x7/1823/AKKru64TwN/yP3j3/r5tv/RVY1fjh6/oz0sF/u+J/wAK/wDS4Hd1Q121vr3Sbi30nUP7NvpABFd+Qs3lHIJOxuDxkc+tX6K3Ts7nmNX0PnHwdPpr6n4f8P33xKjv47LUUlh0y20hgjzLIWUC428gsc56c/Q19HV4Z4A1W60i+ttE0/xfos+kWWoJaSW0GnSkhpndljEuNvO1wGzjgAnJGfc678wfvr/hv/bV+vqc+G+H+v8ANhRRRXnnSeV/s8/8gLxZ/wBjNqH/AKEteqV5X+zz/wAgLxZ/2M2of+hLXqlABUF7I0VnPJGCXSNmXAycgccVPWB441yTQPDtzeWkSz32NltC2cSSH7oOO3rUzkoRcmaUqcqs1CCu2zwPF5D41N9qNsw1LVbG3e7V0IIkKk71UEbfuqPrkEVbv4V0/QrmJ7P7Q0krNNFaN5RlZjyVOeuMdOuK57Qb+71bxI2o6tAz3RuN7SSsxO4c7Uz/AArwBXUSNcSahcxRW0T22fPDt8zIQDnAJ9xjGaxd2l/XW6/M+8q4X2FONJ9Ek/XZlFvE+pWVvPaLLFeM7RQyCcussaN8uArHbuweWHcZwafaOXlj0rTbWeQ2wKlmkXy1Vs/u2z97ueeadOC8bzJd215prRvGbeV3Z4pMAuSSchMFTxwpIovIn/smGG/sluLWSRWhe1ZlkZx0YdicEDrzRyrseaqOjlFLr17dP8x1vCt0NYh0Yhra0MSSzRKxWPGQyqvAKLz39eKsQxXVxYlrGKwVW3Em2tg00ccgADpjaFJOCwY5Ap13IuyKe+H2eaBSiIU+eLnlCqY3ZHGc9KzW04K0tjby20iwL5io42tOcqUwFcOMDI5B4FTqzkqQqKNv0JH09F05YL6ESW8aiKO3S4O2Y/N5kk7NwseeQtWZZ7m48vT7K5SKeCEvc36lgscYzmGPgIxVWY57AevNV9T/ALOvp57i+0/7DePAHS7RzcII0bjcr4AY4Y9O/eq/krPLZ6dq+o3gDQg3CxKfs8pAIViT0Dhu4PfpxVRV9zNpz269zQsrldSgtodDsnlit4f3cmor5paPzBsbLEYJKsfmGQOlMvLeLUbC3dbKyt9RaSaWSK6lchvLPzIzbQGDMQOT0PGaSKxhMFsjpcLeMQRpr6krnKMoz83BwoHA6Amqjt/xM7uWC0t7ky7LV4jNtMmQFkRVBwFjA4OO/BNWlZ3RFnFrqT2X2izFmv2CINbNJL9ktcPbwTgM0pfLY5DLgj17kYq7YWoutVW8vREJryGOQmN2WR8EBVTBC+UCM45JPWoLu+h1CK3Ok6dO105Ony2hfKNCflaUSI21W6DcQSTwaXSrq2OsR3ti8culCd7NGGVEBKHlVbBUZG1uo4yO9N66jbg5JJaFLxBr763qV7p1nKI9Hg8z7SIZBC1w6/eMjjkIMe2enpXKubEMkJh0a1l2h3zaxz+VEfulnlBZyfQZNW57SbR31fTfLWWYSm6UH/l4iLhghYfj1GMrT7Zrm11C01SwuEspIQV+aJJlEe0Kdp/DvmtHyp+XT+v6X5H0lLBxnT9yKb9P6Xls2rdbieF9Z1C3QSDTWtmGJJIQCkQjPy5KZwvUZZQGXOeQCK74eXM1pdwNbpp06Kvl3J+edEDKQxz99COv+9mvPZGjtriRrmWSS7mPnCQ/xgnG1uuScnI9K9C0+zt7jw7ZTTLDMtvc3Cr50YYFeVcgnpl1c5HXPvUSlzLmPNzPCRw1WLp6X1+61/6+4deW0rzxtcqbuwa5JGdriJBHtV1HBx8zZ65ArN8Qz29lpVlPBcbLOSCYSR3JljSOVB5atG+PkJ4G3uD6gGpkSxxZyXZbZNL9ot/lYsgUYdWPQp8rHAxjJplpd3Folj5GnbtPvg7XFvuLEhS5WRFO4xsVUsMn5sY9MJHjVNrl23s57VLO21C2srNBdfbzEZzOEUOSzgNyzEsOenTFPAupIbqG9litxK3l6erKA0cm0/KR1IIAwPXiqurXdtd6zZ6hfNLcC2864IyXeSMRApHGVUKFIGSrDcCT9asT2ipb2d5Hb+fMksV5I1wckxswctGM/eX5ePrVLzN6Hw/cG631RLXeUlRyGYBCm6cAFT9MjpVgTy/2eJbiaLTLmbbCDuDGORjwoPcZ7VFkW9lYSXmbh4HUiW1GPMDHIbH0YZpNQa7nuRBHbQ+V5wzI/wAzDjhwOxBoPUiude6Nv7+SznlW+Ty4FtzNNdyt8quvAXA7HrxVK4eZ5LDVb2+WG9jhFneHTI9xkd/uBs/wDdnB+tX2XUFllhlH2+CS7USM+FWGEr29cEfrVXV5IpIg8VrciQXcRL2pxu28ZcHkrxg01LUzk77f1/wB99paS2dml1f48ySGJrmNjulfcqFGK9A/NY0a3EM8qp4nm+13Be2hW4sd9vbwIFP7xWHDCM43HrnNaUMFvb3zR6JJ9lW6laC5kgDM0aKj/vFwCMq5z0qvp817PPdXF+BMsb+QfNSaSNrV4yfM2kfMxUg4IwdvIzUSk1ocGJbk3pov+AVLhtUthp2k3KR/Zoyt2ywAzTXUSfKokATC42KcDHT1rSbUdWj1Jr6O1nuIZUaRDK2ZGV2DRlkOAzeWW29cEKD0ounjtw2pSwS26TqIjbllia6jKMA0asoIfLudhz90gYyM1nkkg06G3uo77U3tbky2VwL7y0QxDZEMthkdnZVKkY457movdHDL3db/ANbfoXLy00yDVJbM2TJPJJBZtdKNj3MmWlGcYByVOQM5LHoKms1t1KXaN50odDJDFKfLMg+UfKfutjacHoaz7p47DzLq58xpvNQyeZP5pa+cRqXhjBwApzk4HBwBzTtIuWl1u6Gm7bZUjSe5iuAI7a6fcAZlkJ54xjA9a2irxuehQlam7n0TRRRTPnwooooAKKKKACiiigArhPA3/I/ePf8Ar5tv/RVd3XCeBv8AkfvHv/Xzbf8Aoqsavxw9f0Z6WC/3fE/4V/6XA7uiiitjzTwvwB4E1K6urC6tdVsJfCkFzC0W2CSO6k+yTTFEdWGBiR23HvtHvn3SvnTwhNog1631Kx0nWre2Op2f2eSbV2ImW5klVZjEFx9+PlSeQ2c+v0XXoZhzc/vfp+nU5sNbl0CiiivPOk8r/Z5/5AXiz/sZtQ/9CWvVK8r/AGef+QF4s/7GbUP/AEJa9UoAK8/+MBWPTNMnnZIbaK5PmXUg3CAMjKGwDknJAAHrXoFeV/HDXLW1Gj6LdW6zrqDSMyv02quPQ85YVFRXVrXO/K4SnioKO55XpFov9sSLClwqeYxCzZ3GMNgHHbOe1dVNpttqU8i3Egijt90z4JKhOmWPU4OOB1rN8Of8SvRvtWqCKGIxBfMfJlWJBjOOSQePfirP9pBY0eV1t7RpkkXTrdT9pkBGIlHzAtnliAMHODWUrx0j0Prcyxrei32v+f6lfTtTutWTUbnU00eCx1NWs5tT0JkkksIg5AWQEFiHwACBnjNFrBqVkLzRrvUpFEEEkcOpbCFcgA7tg9hj8D7VS17Uja6m8AtJpJ4ZVDWsEoYfZwvIaJCSoyV5yTjJ6CmxzWiyG1soreeKSALcyw35YlvvB1ZiWBC7gEIPJApxldaLQ8CjUVOTUm3f+vvNHUILYadYwWs8tzq5tx5Nujs1q+FBLCVh8rjJxz7VMj3CH7XeWbpNmMxT29olx5YOSWyCCwPcgYBPSmWj2NzPD9l2zRQEMI3jMZZyATlSP3UgBBIHynHar1jPqqwT2FhJZQXjSupQJ5rvCCD5j5wdzDK8Y7fWpldI6PejFSjLR/l5/wBeXQx4GYW9zDp6ajFaCE/Z3QoJlAOZOGyVUHnBzx0FW5pLaxggvIrn7Z5snmRBrpcyy527SR1OO2farOkQQ6/El/pd/tma3JdHVY1gUEZheMtkEkPhgM+9UtKsNNnMkJvEE7LFPIbeSLkAB2ZQmQqhjt25HPOTTvq7kxra6PyHX9pbvfG3hsFjt5XlUAQfMA/+s8uQMfnJ4JJAqDfDvW3udOVkFq8Mj3kYtpHiYcKsq7gQO49+tTQhGe/bSLi8aLzCqxXUMc0k0u8DfGNwJXBfLEgYAxVi8gvNN1axsrGGC681J4oV2MEdAAy8uMn738Leg9apSWzE6kJq2xGlzNp9jolgn2Aae262fMgiEGQSgdFIGXOclQM8EVUu4LLUVS+eJktre8ZVkCg7cOFG5CTiNjvBbIIz061ozXosfPhimuY9RFvHJJE8BlIzxuIxyM5AY9MdKyFvGRDd6gZUvI5kaxia+W4LlmHDgDG0l9uDwOKaV9UYz918sHoXbvSP7a06FtSWTS7hZ2dZtuTDuY/umYgblIXrjB7GsK58C6q0ryQ2aJaFioZZXd1KnqisVABGfvMa6m2n1iC2uE8N6Q2rxW6b3llmaOSRixJjyBsIU7iEXOO5B4rOtrzUdE0yO5XS9Q0qWYNHNGZjPKp29QTvH3jwuzIxjpzTU30ZpTx1WjpGTVuzdvu2+9Gd4S8N3UzxxpHLHGHeNriYhcFSSBFgnzZMc5ztU9iRXZSXEDoLGyWa3jhtlSSGVFPkRqG2kAnljjvnrUdlq1rfiykaa7Fu7MrRSJsmJVchxEg7kMOoH48UmoqHvIZby5/stLVZpVinSMPLG2FDIw7AZOzqc85ocnJ6iqYiVV88pXbKcItzY6AyXk2nxlmljunRZGmglcu0e1mzGRjrjopx6VMsnl+E4J/MS1tC8iJOYmkEyI7lXwDhfkBGTznJ71Rnka4bzoVnsYRA1vLJIw8118wmPcwwwLfwjIABAIrR1S6nsNPsbqWOR4Z4pAWmt8SJKmVIVPuoJMPyfXjrSe9jm21Kflz2cAsXvIgYZCYJraMKZUaNQWHG2RiMkkcAHrUd/wCWYrm2Ro7pIY2uJbiMFZHwFlijJ6DIJx7D3qXWoho0J1Cz0+2itLLzvssclwG2qu7fuTqRliCo5HFWjFJYeGtO066VIEuLWVr2GFPnz5bPsRduCM5PUYC8U+a1i3J8nK3oizBbSNJFcx3TXsTW0SvhsRrwTvXtnkfhini8t7a0mvGDn7KjK+07nYhc429zz0rFt4YVvbZbqM2i+RIkapIMhWRYxMoHy+W6plfTvV7S40ubG3mmtZEkWEOFlcearhQrbgOrDg/jTsup6NGpzxsyC5tor8mKW1nm0+S3S5EeTH5jt+OeByQa3oMPdy75GZmUBcDof8eazrGziigtrYXQupEADyyTEyYJyCfYkYpkjzSwy28l5Fbaq7GVmiGAsasO3vgDND1NtWt9TPttWg0saXcoZbYTxusjn9zG5LHCsecbnKg/Wo9fuZbiJ9gurG+MSwrHgxOZON59JFVWzjoRupdSnuLywLyiCKUz+V9gkUhGTzGQuNvIUllOe2BW5qEKarp8FvrgMU1tE17FJCHfyPLVdrRyE/N94Zz15GMc1E7JpnnV9Jcz67r9PuOT0jTbuK/tbi6066FykyeYYIGkW3KBQdgc/IrFgCRuBAOMU/T7G7WO2W1vrrTb6NpPsi3FoGaSMiQK7JjCMSe5wdg4yadqV8r2byK0G/SLSONI76HIk3xqzEqMvEFDAHPBZgO1WraaK2upY5bknTjKhaeKRQYztEYLbMkrjBU9MgcClra7OZJVN3ov6/P8yrqFrLpOpy6X9mt7q9ljjSCYLI92YSvzPJKq4Vt4wDjoMcUrabHDcW9tJFcmzTUGkuZJswm0gjchEXPLh9pwAcHIHBp5eCO/t2utSNveSL5JnlbN5NEjqBI0mQuOQSD096UMU1aJ7saTIzzxpez3N8kiRlY0aPzSAMyGSMHaBztPTJzrG99f6/roKTcev9fP8T6PoooqjygooooAKKKKACiiigArhPA3/I/ePf8Ar5tv/RVd3XCeBv8AkfvHv/Xzbf8Aoqsavxw9f0Z6WC/3fE/4V/6XA7usDxtq9/oeiDUNN0+TUDFPF58MUZkk8ksBIyKCMsByB+db9cx8Q9OXVNChtxqyaTdfbIHtLl1DL54cFFKnhsnjHf36V1UbOoubY8ud+V2PH/hz/wAItfeItL1OPRfFsU81wGhtijSadbuHcIwOBwpdiM8KWavoevEPh5qGp2dxpOm3HxJ0K5Cz7H0+ONJJJcuSUEhO7Jz6cdO1e3115g26n/D/AKpGGG+H/hv0CiiiuA6Tyv8AZ5/5AXiz/sZtQ/8AQlr1SvK/2ef+QF4s/wCxm1D/ANCWvVKAA188/EjULjW/ibIskUcdjpC/Zonl6vI4DEpj/gI59DX0DcyiC3lmb7saljz6Cvmfw7/pc0l28YZri8a7ZSSVUSsSPmPXC4+lLrfsfRcO017WdaX2V+Z0txFcyzW0dlcwxNIQlyZofNcxKvIRD/Os27Wd5ZYLm8srV1iIuNQWCSaSIsvyqg6oXGTxjGMCrepPHDqunm6uobiJfMkFmsG4SEYKszDoF9O/GaIJ5r2/h+1QyX6XFp50kkMZFwNp3LGuCqEHJGVHbHWuS+zNMXLmkzmL/T5blg9u5XTrFdvks5aYJGwy0SN82WI4DEk4A6c1NaWsN3PJJZvJbL9q/cJ9n8tmiMbSFn3DoCCSq917cV0lpdXfnQ6jqFzHYm4hC4edmZi8uAhjYcAA4ySWzwDgCsK60nX7eK5uYEE9rp4N2imJIkdyrblCEkMG55G0jcM5PSubWzZ584cqvFaGtb3T3lxHH9veKa3w0t0u3EplGY4mUgtvOc5zjjqBgVWvI4ZtRcau9ys7rFHFMZFtWAZiJM9iwAXjJzjtmobRb2TRbdkht5RaYuLm2GSYMhvKV1OSwABOB0wCOKS2vJDpYuru4tJbWZHF7aRz7fLy+fPUEkBskccEhvahaP8Ar+tTenVlFK39f1/mW7iZ77ULYJDMt9b3CRwzPaCRJxndvYDaMjG0E56n1qvc2UE8+nxWVq01tHN57fZnCtJOH2+SBwqBMglenXrWits+n2csKRG1ijlUWaBTMv3cvIwPIJ55PPNWruEvrEN3Y3rC5UMRbvEIlKMMO2MHJ7jvV3tt/X9fgdTou2i/r7tidLq00rVLkSadHPNcSOwvo5hI8jKfmiCdgvPQ4G01n65cQraJb3esBriDajx+U6rCv3uAuSRgqBj161JPJ/xNINPht9NW2h+aSLBgZbZgVOTwpYljwPX3qvdCG3jgh0dJ3ui5gRInK+aqJtJdhnIReMMcHOalRtZszlSko3urssWbSW8uoaTp+pwm6aAS+XBEvmodpZt0JyuSRjapH3+meuLe6ui6imnppFrZ2af6Gpa1JuI1CBkZXTlWJKYU85HB7Vd0y0gj+yaftaC4tiY7SdJw8gRgfm80L82DgYznC9xTLnT9TjeGSxjae2hneVoLOLfkls/Jvxs5YHB5+U4xmqVk7MwlTlHQu3GsPHYxuq3MhkBaAXTbZEXblpTI68bT2OCeeOK0YJtIubK1aa+F+FKSrdvJvkDLwZAADtPIG7jAI6cVzenS3CYSzt5rSO3ttkEupW7GSdWkYGNd/IKqGYqCSRzkCtbSreW+ku5k+3Ja/ZNg1vTZo/nQMpK+WuQGO1QcDOE6miUUt/6/r1E5txel+n5GNHZrpN1bapbSm6SO4jRbkXSReSjKSWcEeW5PKny+cBfWksxPbT2/2yyu3sZSAks6mSQFmwzhACEQgkbckEHORW1e6lPPq90Y77TU0SVA0KywSIIk2qzOUKDHy5AbOOe5GKpaBNpOlam1jHNMNGuImvI0W4kt0KqN3mO5UDDZVME8jBxng2m7WMXJQV07oZpN3bXmr2NvE9tLZ/bQiJAJI2mkiBKgAgfLkKT1H86ctxK9lHb6jcRCNJ5rlCl6wVkw6GIu7blbnPGehxjFJovjK3n8TaXey2Nnb+GJomRHib99HIDgGVm6DduVclcgnjisfxbrt1Y+NNW07T7ECCHAiF7bKqzrgh8N8px8xwwPVquEJTlbyOjD0/rL5Vvb7/6+S8zc03U1GrrZR/Z5pUkB1C1kb5rbcoMhRnC/KBngZGOc1fk1e007xMLQ2OpXFxGA0U8MaEShQNiCRSBtw0mQwG7cetcrpus6fqOtWD306z3UObQaW/MZAwRJ57E5BwM5JJxt71pWN3Y6ZaO1srQafP500kFxE8TRTKwKkJ99gTvxljgfQ1M6dnbqKrTanyTVrf1/TJIbWO+1e6uZ3trbUbiFJI5ZIGVYJCwjEZzwfl2kA/NktwBxWrLFp6TXN2gZ/LklLyocNHMQAyAdSWwMAHqaY62ENhKbuGb9yVEZu42d5pE+csFLc8v8p46YNQ3c0+nR7IpYbS3JVhDJDhmKYbzgeedvXtwaW500ouKVn/XUsW0gnit5L6WaKWSMyKIRsGzqquf4W56HqaWylaeBJVk8udNnnLOQ1wkeTkSHrg4BqK9tIJr25BeF41KC8hwQ03AKNk9dvOAM9qkjhuGuYLk+ZPPNutpGtIwYpWYnYX5zhV//AFUOxop3eo1lu/sayfa4Uv0glEN1OxUTSyLuRBjoBtB9cgVTlmN/NqL3OqrLrNpYOsN2GMNvEcKfKLR/3WByeMoecgGrF3GNzWtxMl3dCZWhjlH+o2Jhio7gAnr/AHqbHIY9Wt4IoogJGM1rbH7jkKDkkDIbjGDj0oOevQ9o9Pl+ZJp+rW6aXp17qC29reiFDNeLbvLbXcDDLKJcHaCFTO8DbimS6TrCCO5uEhLmWS7jkiiE6tGEbG3BVQcFCvBBK81Nc6wdTt7LUbOCO3njWSDO8KbdQwEvAyAcBflIOAMetclbRWUIuItVu7e3Gq2wF1O7mLMcsx2PGqIAZVIB6DIfBAxmlGFjjmqsE3JE9uJ7HSbGe7s77VLSVkuje22nifAYEnH7wgHnkEEDHFWdPl1PQtVt02WL2887h5LhzHB5ZKsW2kEtKS4weRk446VYtvDuNT0u7spVvp2EqSXsVu6rG4TbuYsSPl24CnIyWyRxjFS40TTPFqTPeXhmeUIIoI0QqTh1KwAYkGVILN1GOD1q0+a/9f1/Wg5TfLd7f1b+vxPqaiiiqPJCiiigAooooAKKKKACuE8Df8j949/6+bb/ANFV3dcJ4G/5H7x7/wBfNt/6KrGr8cPX9Gelgv8Ad8T/AIV/6XA7uuY+JWsL4f8ABl/q32OG8mtDG1vFMoK+cZFWNvbDMDng8dRXT1k+KdBsvE+g3OkaoJGs7jZvEb7W+VwwwfqorqpOKnFz2vr6HlzTcWo7nlmnaVrng3xN4fufEq+H9TtdUvFtCbbTYoJLS4ZWZCjKoLDKnk817TXnek/CHwxpeq2WoW/9otcWkqzxebds6hlPBINeiVviqsKjTi7/ACt+BnRhKKaf+YUUUVyGx5X+zz/yAvFn/Yzah/6EteqV5X+zz/yAvFn/AGM2of8AoS16pQBXvwTZXAUgExtycenvXzz4emgjtGxdwRGLmSSORZEVfU4+9kkLhQeeBxXs3jnxVaeHbRYZZkjvrtHFr5oPl7gONxHQZIH4141YafcQ3GmOt+TcW8kd9JI8QAZvm3cj5fm3dDyB6VLV372iPfylVo0anIvita+ztc6yXwdrEMGrF3hg3HAiRjMgXgrMQ6kEjaflHasG71OG3t9PtwlvPe3SmVGt5PMDRq7fvTkYQYx8pPfHauosNfv9IbUrmDT11CW7KyOst0I8kZGAcHoD39Kx5tQ0iVDBqHgVLSK6ia2ke3uFfy9xLALhQOSc5yOfWuflT1v8rlezxCqNTTfpbr5X6FGC9in1S5ivJbK5ju5zxEqQzQgYwjgk+ZjcOhPOMVSubVNOkGmfLf3MsjxPGEYO1sxzJ5rAbU6DDewp0WmW8Hhy6ZLzVftFo8awwwSRGWYqfkfc0aiPb04PbvxVm3uLLU9CjguPD2rXOp3MrTPaPqm+NFDL+8cg4CbuQhGOvajkS1i9Pl8iJ80Ytcr/AK9RmjXdxNM1xpdnA9hcRNLbFU5gBGQswU/NllbDDpk84qrpV35ep3kQaOxtZ1jlkW3iVVlAAwhaQYUcnjIY9KqGeyvJLWG+iRZpTDb3N4t1IgEpBkk2RquwYyMNggg4Oc1qPbeHtTjn/s7xFHClsmxY7+1DLJD93aw+UlQ4XCnoV9DT5Hu1uTLRWZTsmiluLu3tlvLiWFJPOLIR9oKtj5XPIbODj0rcnM00lnd219Jb2vlNsideGLcDcDzkGsi7ku9E1Oz8ONqVnLrLFZXa4g8kvDsOCNh2/Jgnnr68UNdW9pK/9sWc7WxkAuLsO8kKEAEOvBAORg8+lXe/9f5nfSxMbK/9dizEotrOOCC1dftErq9tkL5j9SdzcqvGeKV7ZNRuL50urQMn+g26K29HlA3HzExyRweD61pRCK9vbaRWuZoE3ThZoMMS3Iw3Y9Mj36VBY2zR3rtATJIj+ZJLNJk7Scn5Bjaw6ZpJ9Te0ajunp+BJFEkdjGk6Wr+c8dvMlucRsxyHCLglPQ1JeeHrK/0e0ha0DWCt8skV2YvsUahlMqsMhm6DnHIpbWJAJJl08w2bRvI9wWLESbiRwPXcelZGnwS2D3P9l6dLbJcz5eSGb7VHKzA7v3ZIC467enqKaXW9n/Xn+RyVYX03/MhvNHguYpby6tNReC2hE1tLduzebKrKBKTEctlTlWHYtmrs8rQ675Nnb/YL+G18yM2dwVhLPtBd87hz8wXcuaS5kEsV3bRRaXPZSlNPaGWzliMrRgkHIyoXJb7oGfWq0aai08lpa2OjW0tkzxJvt5G+UMDFgk7WbgYzznFWk7a/qc/s276Fi/kupNF1NtFtr27uIn2T3bO3mNHuzJAGIDDBwQPu/NxwDWQiiCc2Umk3l6beBGtV1FnK2xcLmMum7CAJls4zkjGKs2lnJAt2Z9auYPPf7VPJeHAVnIUHcrAP0K7ecfKPXNiaezTVwnn3Nw8MV1tuJHJlzsJYSpjIOFBUnkgYHFNR0stvmZyp3VtF9xzfivVNPv8AVbnZa21kLhRpuo3Vt+++dosqVXHCAHsAcjvjFaviS3XUdB0uGDVYLg2ai5MrMZzuIyCfusMKMBenBLDNRGxv9Y1Oe8nYRSxpCGvmXasHyjLbmJIDBtuxhgHLtW/4f06x0jRNdt9N1HRVs5JVm2y3omKSLgAbyNuXxnG08nuKLpL3d/wIpP2Uua2qf9MqeHbHVbbTpLW2gsbjTIZkup4IpsvHKzKWjJwzrgAuvOOcHirV3pckMpvtNvJHW4uTeyRgNFMyg/ONw6AL8uOOp7mr0F3Dod9Gt5YG2mv7hbRBZLiFIgflkk3Hs0pG5cBvTpVzTrYsRM8/2q3h3QeXbvHxKX5dinOcAgj9Kz5nds6IqNW7lv8A1/TMOzuxeXKpp8HmWTF5PtFxIUlkcjoA6gnhBknqCetRXjFmt7Wxe4t52EblplU7ir5aJnGdrY4I6YHvWXt1XT9Zms4Ln+0pmuJZJArCRIRuO1JRndsCY9FzxWq2nXV0rRecsSyZlkaRdqTq2cqPQ4KjI5+Wt+VROmiuaHkvSxNM1pbvC19JFqF8cXMhGWaIBiIyvqMlPSkcjU9TigukupLmKAWdzBbnZEJm+ffIB7KOR61XSS0gs9Ims5ZotHUtFviXkIgYP5hPzFAcEYHaodXuLyysLxYdi+aAtjJEAZpHCDY4U4L9TkHsKXL23FNxa5ra/wBfI3VSZJzdWOI1KHC7QVVj1JOcgkdqy2juMCKwk2qC8ypGzZDnDLIWUqVPXjPIPSsfRrQ6ZqZWPVBLG0X2l3eEhZAcqyt/DlfTqK6OSSKaSaGKaXesY80pIyuFxlAuANyn2JxxUQ9PwG/fVpLU52xaKe7nuZ43t7rfILJtLTEc8jE5YNIdpDkg7MnJ657VdfXVNOv5F1FXEQZpYUihLQrGmW+aQHAfOGZWBGRgVs3Nnbzhfs4hmuJYFCf2gSxDRgsN2eAxBIOBu9KzIL3VbC4tNLZJoNI3sJDuYyLHkFcMn/Ahh+3UVpbS/Q5HCUVa5Wur6LUktLbWJpbvTJg18jRXhYSFGJZWRSR02nHueetaUF2r69Zea1w0qPHBHLBsZraU9d4XOAEYbeo+U9OtRWx0TUtNntdPsbeLULByYdLuMI0bMW/eBTtySDuwpx2rJ0K6TRBEj2t9p1410/2xZ0Ukxp91nBPz4Dkgp6VDjfRrX+n/AF3MvdTs7WZ9W0UUVR4wUUUUAFFFFABRRRQAVwngb/kfvHv/AF823/oqu7rhPA3/ACP3j3/r5tv/AEVWNX44ev6M9LBf7vif8K/9Lgd3RRRWx5oUUUUAFFFFAHlf7PP/ACAvFn/Yzah/6EteqV5X+zz/AMgLxZ/2M2of+hLXqlAHC/E/wnd+IoILixkiMtpG5W3kX/Wk443Z+XpXi1tJNpMjmAlZGnaE4bzEZ1GSHB9M4/CvefGuoT6K0GqWunW95OimFA9yIpGLMv7tAR8xIBPXqBxXlXxZSW1utK1WPTfsFneo6GJ4wsscxOW3BSQxYDj/AOvWTbhK66/1/wAA+v4fx05JYSrrB3t+bXf+mXLPWrW7jSSBmULIIZkKkBWI/UVb3LJbOunXb2/UJIoBwcnjB6/SuV8MyuqX0uJESPBeJxlWGCV4/v5H5GugK72imZS8aKkgiKjKuRnIzzkVFSCi9NP6/r5HbXpKM5QWo5JYPKvYd4uwGUSsq/PE+PRfzqleWsN/bxCW1kvMbQjO/wA3Bzwe30q3NbpqFrJFBcvZvI+5prRxG+4H+968c1HqS3U19Z+XqslnFGwNwkqhluFxg5z0Pv71Ed+z/rsZ8vToVtQhufIMMmmbiXEcMc0ix26t0U7jkMePu+uKzrvz7iC0tbN0h8m6IEd5aCRXnGCUj+9sjGPvcYP1rZsdKSzWeyhijNuT5qtFJkgjlf3bZ596gESWL2n2y5ia9kcpHczRnzSG/gUjPTA4ORVReun9fLU5ZUHN+7r8iidMmPm2kMV1Bpd4jtciHUFMcCEbSHMgyh6EBcZz7ZqtLeXN9PpN9NBOFtZp42Al+z+dE/yCZigxlMKc55Hcmt5oPKmgguAbqSWbzmukiABcD7zlCp3D6fhVcwxpZ3Pl3EtpEWZmRkLFjsKgsFH3ec/Wqu79zD6lq5NK3kcjOdVt1jutUNxG5LG6vrNzeTE7gY/3TDakYJKnJ6Kce/VWr3lpc3EN2+lamUSN7lLC7kCGMkbJXVjsTKkuVB9McUmqsNRi08wyNMZJOI2TnO3a7YbquDwCcc/Wl0CC4QobS3tLe2Zfs97NNIogmhA2ojpkjeuSAQcA8YwcU5Sk1qc9SnOnLS9u39WKwuolXTIbmCKFi6TrKfOeNmYfu1hZCVYjHORtGa0hDJZTXEWnThbaSNJDHKVWJpmb5hGgx82Rgtx1HXNVJNBs9P0y3Fm8omcSWsiSHbbT3BUBWZ8kxgso4Xgk9h0z/ENrq2j3yrrGrXEemNBEZzcBTb+Xu5S3AXCkYDZ3E4Xkd6qLv1/4JcatRKzV38v6+5o17rUmvtPllSMLbXE8TweUdrQqpAdXXaSWLfwjqM+lXNEsU+2bb29vtS1RI/tD28VyqW7ESYLdcbkBBPAIBHtWD4qkjuNQaysbiV1mke6uL+KUT27RMhIzxjK4AEa5bHOa6lrhXWK5a1Jgk8yKFbFNuYJuWZhuxu3ENuAHpRKOl1oTUbqe9S2v62/z9SnJeaNa6reXVhageXDK8yQ2wufPdtpQlxu244O0HnrVmzuLeOxt0tdM0xrqZ3Z5rtFgLT7CHkVVALEkHjjhhzWNp2nvYaVcQ2ttu0q3MUwaOQxskYUDLqFLMw2ucY7irK3UemSNHehxIF+1yTTIqBVkX5WI2ggsVPyjng5ximoxYoQhe05a+rFmt7gL/wAT6WfUYvIMUplk8qB1cbcGAZJAG0ZOSTk1Zm0nR2j8m5sLRLOJlbzY4/LLBY9gbjvyQDxVG5vIIdWaCWK2nFuFW4na6CwRMSpAYY3MecgDr60r2camb7fqZuGO8hbKH7PujwNqA8kjOMEEHitHHr/X/A/A6GqUE4wV/kVtJtYNPvorbR1uLfyom+22u5/uCNzlhlmIBKhcc5Ira18XK+ZcW9jpllpc8Uf2jUNTiMZIfk4iX+I7sc4wQabpupx6Yt7p1nZz2Mty4uI5ktxcSoDkyFy55AYYzg/eB78Y8qWEGmT6TBPc3UF3PJLDG8zfudz+Y26PoERV4U8kM2OuKi0pSv8A1/X3nGuaMrxVl9xR1SGwivtVZruaGOSPKm5ZhHxIQFdjjOSw4Hao49QihtUg1Jb+extp/JeR02bssWV1UHLBmAVR2CkmoUuJbnwymqXTKbcutu7bxcLCqMHEgAXCsM7cEZyAccVPBqr7bfULi6kEZuX86FVZl3yDbHGwIHyDJ547Vur2sdcZXtymo/m22ozy6lb+TPZqyxPAmFmSRm/dKMduCT71katt0u90yF7iG4jS583zL3a/2dtzNsO3LAtvBBH3QOetQi31Y3tu1pbLLLYMPM8uddtuFTa4TcSNpU8Hnk+1J4fee+1a/wBT0u0XTbuSx3XH2uMSRvKCBlnYdCoKkqMDk8EVLXKm7omrJuKa/D/MLO/1pp4nSSR3nXLIzsLeGZQVcbRjA27n2HOSM8VhrqlxY3LRwaZd28aozRzF06eYSZFkK4VSQflPPStbX4dI09kvrLULmDSo4EfT7eCY7C5lyzpjqEOSSeu4DPGK0LDULe4luLjTtQurKKa9kC6dcxCaGechiRHj/d3E8DJxnvTi2tbX/ry/rc5lUu9H/X3fqYc/iLzp4Ltl0pFDv9ptJpDm6wvAiYnrhjg8elULLxXZ+VLBeWtxvQvbPbLIflPCsGOcFcNnPOMHJ5qXSbu31XXo4dDGm3Gi24eCSaWxjLspyRuJ7MwI4A/Oty71+e2NxqJle3cI1o32aBGRGP8AErfdPIK896ttp8qX5/5GkZSmnNPT8/Pr/XmYEq3sFml9FpUljJY/u4LoMt0iylWyrN8xKge3UYFbCSJ4ps9J123ezvPsMvmP5TMkskahY3kZnyE2MUIGcEHpnpN590muvNpcjHWI8WsfkoEgQkFi0uVCsHHUYODWrJ9v0W40B/DtlC2m6neBL2wt4SdtySBPHuYYMRHIyR90YNc0273/AKt/Xn3Oeto/y/rRfn+B9G0UUVR5AUUUUAFFFFABRRRQAVwngb/kfvHv/Xzbf+iq7uuE8Df8j949/wCvm2/9FVjV+OHr+jPSwX+74n/Cv/S4Hd0UUVseaFFFFABRRRQB5X+zz/yAvFn/AGM2of8AoS16pXlf7PP/ACAvFn/Yzah/6EteqUAcb4+vvC2mXWmXviS3S4v7ZmmsEEJkk3rgkp2B6dSK8o8ReMJvE2uXb/ZvK0p4lhS1uI/3rsMMJCM/KVOcMK7n4yWV3dXWlPZ29zNsSTcYYy2OV64rzY6TqxkcxaVdphR8727nd6jGKyk3eyX9f18z7fI8vwvsYYmo7yfd7a9BIJ/InYySssbTDdtJHGRya6K51NWiju7Te7PJsVlUFj82NxDfj17ViDRNUltnSXTJ5JGYhcW8gGPQ5H60Q6ZqkLJOdEv5X3ABPLdSOe5HbvV2T0l0PYxEaVVcylr6rU37u3tpbKWCQBbRsu20gbeclT/jUt4kM1kI7pYjZtHgbjuDDt0/pWZFa+IAtxCdOmuljaOQgxOhZCcOoJHzceua2pLLUZIEWysJApxgTQMAg7jA74rJwsebK0HZSWnmU5dE0m6a6W4gQSSRJHceWx8wAH5RwcgcfpV+3d7LTlWdNkcKFImBztA4GT/WraWNytyj/YrokjYxWIgle2TjnGTUd3p2qPc26olwkEBxInkkrKh6DpwRUWb0e39f1/wxzuceuxQVb2byitzaw2mDuRB+8JI+UqTxkH2Oazra+uLwwAWlwLcFiLpLpVkeQHG0qvBB9DW5c2GoHULWGHSXZExKZGVgAAeg461mQ+FtVtrhjbPLb2Ubl0iS2JK5yePU5PetE0t/6+79TRVKbT1/r7x99u+wu86eZOuGeHGEGejDJ4x35qvbWTpFC11MyTtu3RoAYiDzyB16KfWptO0zWLOJYPsl9cW4gxunjO4vnqeDwR2qWbT9VtLa1vGgumlhJWVEgZxIhPTbjrjoe1FmtmZ1ORK8mvvRiCGS1nd7dTppRQk0YtywYH7rDkjgk8EE4NWLDWSYoQsOsaVBHEUnktVWa2xkBDslywyueRyO9bEWl3TLMrR3zR3T+dGJ4HYKpGdp4yMenrVVtIuLhmkbTb8Fx5M8MkbMs8Z5DA44+mKtSfVf1/XqctSlGouVSt8/8/u2+Zm2r/abqY6ff2urX1rdRvI9o5tZRI2UG6GX93Iu3nC4B/Grqadq1nrIRtPs2uj/AMsfsxgmNuzfvfLO8xsQBnqCd2eMVLcaBOrTN/Z948n2cRLceWWcxlgc9Ad644zmr2lR+Io7ZraFtTlgkgkVodQzI8G4Y3q+3J4HCZwN1Ulppp6nHKnOmrQafzt/Xpp5Ge5SeK+leyuZ7W4tzaSLZszeSVONjMoJBIIwwU455qvpn22a4/sq4hnMcEIW2s/MZmRk4UiU4Y8HG7t0qxf6JdPpVtZHTZLmGLy43kbzraV7cJ5e3dEvLhjkbgeueK1pNJu7ixNun2uwEZhWKO5ilmJZSQ2JFPO7j5io75zTvp/X9fd95TrpNua+f9XMJ5rS0vLa1vpD59vCHb7QFcThjld7uck5AA5P4Uj6pp4uJ7q9TT/JMyLIMxzlNm4hwQ3JIHCgZBIrS1Xwt4nt9O+zJbLqEMwt4QIIo8+UqtkMW2le3I6dl5NV/sF+3iSGC78Cxm3z5V1dbUJkl2ECVXUA4OBzt4J9qIuLX9L8wWJbsoy0+QyZ5GuWRY08y53fZQtyYpSDkiPc2VLEg5A6YrLuoHkkWS/Md3FJIrsDAscd08Zc7fMP3cbecAcjg81tDwtP/Z+mW8FpBG8H2m1WK7tZ51HHGJQwYDG4Buhzxiqv/CM6hDbyf2PZ6hBbzXARVa1W4WdyrBmeORh5ca9ODk5BOaOdf0v6/AmeJ5rplDVNRtby9vNDvzfsmqoIo47dd0cU+8As65JQBhgcnPPBrBtHhga5g1N5otRkmMUubgvbvKmBgJgMAxKc4xz1rvNI+H2t/wDCWWWt+IFimNqRHFHZgAbtpIlYHGMOxbAPp6VMfCsi6faXMlldwavNBLHdXIYtOjoDh0wCN7DuTxuxk4o9rFLlitDFVIp2v/XyPPZLDxNF5lxptnBaXLz21u9vDCszvEAzF9meo7hiMg+uK0bHTr+zutXuL+U2kAi+y3JtbZUuHUBn80RqThWYEY43ZOai1fRtb1q1tp3tr1tQkiGzz7VojOcHHnbF++vyYJbB9M1q6WPEs2gR6tLFqltc4U6jY3dsZiUGeI2xvYnIxk8bj6VpKTatdfd/TEpJt329f6/4PYwvGVrJNPa31o8LaTIryRsd8dvbNsDIrFCPLOWfsQScNzisazvLzwxb6C6vYW+m2TSO11dB5TOJR1ijKh+MMew5616XY6FrGr22tC7066eSRo5rfT2uGjhjTYCi52gbjhtw5564qrqHhTXHkg1KVBp2s35aGR7GyMr2duRkozlgCw4w4BIOQMislK2+y/r+v6ZlaPPeD1Zys9hFJBDqVpbajoOnzR/ap3t7ZVglnRSTIylS+CWyFxj+dYWtarqFvY2MPki5jcI0VzbMEgvIMElj1Ct6qeck9a9TSGfQ5LkjT9WnRpP3l20TzOEKjrnJY5HRQBzVX4ffDabXNNtW8Qwahp1hbXLTpZuy7L1XbduePnZzzt7Zpqbjra/9ev6nRUlTpStz+p5Lpx1PXhbwRCawt7dsTXDSEs0gxs2E9SemMdRivoj4SeEb7w680jxrZ6W8CRR2TgNK8in/AF8jDo5BIIHtXYaF4U0XQ4lXT7CFHA5kK5duSeSfcmtwVLcpu8tuxy4nF05x5Kcfm9/8kFFFFUecFFFFABRRRQAUUUUAFcJ4G/5H7x7/ANfNt/6Kru64TwN/yP3j3/r5tv8A0VWNX44ev6M9LBf7vif8K/8AS4Hd0UUVseaFFFFABRRRQB5X+zz/AMgLxZ/2M2of+hLXqleI+GvD/wAUvB8ut2ug2XhS6sL3VLnUI5Lu4mEmJGyAQoA6AVtfbfjP/wBAjwR/4E3H+FAHqlFeV/bfjP8A9AjwR/4E3H+Fb/gq4+IE2qyr40sfDtvpwhJjfTZpXkMu5cAh+NuN344oA7WiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAryy21i68L+OvFktx4c8Q30F9NA8MthZGVCFjwecgdT2r1Ois6lNzs07NHbg8VHDqcZw5ozVmr26p/mjhP+Fjf9Sb4z/8Ff8A9lR/wsb/AKk3xn/4K/8A7Ku7oqeSp/N+Br9awf8Az4/8mZwn/Cxv+pN8Z/8Agr/+yo/4WN/1JvjP/wAFf/2Vd3RRyVP5vwD61g/+fH/kzOE/4WN/1JvjP/wV/wD2VH/Cxv8AqTfGf/gr/wDsq7uijkqfzfgH1rB/8+P/ACZnCf8ACxv+pN8Z/wDgr/8Asq6zQtS/tbSoL37He2Pm7v8AR72LypkwxHzLk4zjI9iKv0VUIzT96VzDEVqFSNqVLlfe7f5hRRRWhyBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    2004 International Society for the Study of Vulvar Diseases (ISSVD) modified terminology for vulvar intraepithelial neoplasia (VIN): the term VIN applies only to histologically high grade squamous lesions (former terms, VIN 2 and VIN 3 and differentiated VIN 3).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_35_36409=[""].join("\n");
var outline_f35_35_36409=null;
var title_f35_35_36410="Treatment of advanced stage (IIB to IV) mycosis fungoides and Sézary syndrome";
var content_f35_35_36410=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/35/36410/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/35/36410/contributors\">",
"     Richard T Hoppe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/35/36410/contributors\">",
"     Youn H Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/35/36410/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/35/36410/contributors\">",
"     Timothy M Kuzel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/35/36410/contributors\">",
"     John A Zic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/35/36410/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/35/36410/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/35/36410/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/35/36410/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mycosis fungoides (MF) is an extranodal, indolent non-Hodgkin lymphoma of T cell origin that primarily develops in the skin, but can ultimately involve the lymph nodes, blood, and visceral organs. S&eacute;zary syndrome is a more aggressive leukemic variant of cutaneous T cell lymphoma (CTCL) in which circulating malignant (S&eacute;zary) cells are observed in the peripheral blood.",
"   </p>",
"   <p>",
"    The management of advanced stage MF and S&eacute;zary syndrome will be discussed here. The management of early stage MF and the clinical presentation, diagnosis, staging, and prognosis of MF and S&eacute;zary syndrome are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17017?source=see_link\">",
"     \"Treatment of early stage (IA to IIA) mycosis fungoides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/32/4618?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard staging system for MF is based upon an evaluation of the skin (T), lymph nodes (N), visceral involvement (M), and blood (B) (",
"    <a class=\"graphic graphic_table graphicRef75768 graphicRef53711 \" href=\"mobipreview.htm?6/60/7119\">",
"     table 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75528 \" href=\"mobipreview.htm?18/6/18541\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/1\">",
"     1",
"    </a>",
"    ]. Details are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4713?source=see_link&amp;anchor=H1118879#H1118879\">",
"     \"Staging and prognosis of mycosis fungoides and S&eacute;zary syndrome\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TUMOR (STAGE IIB) LIMITED EXTENT DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited stage IIB disease includes tumors that involve an area of skin surface that can easily be managed with a limited amount of local electron beam therapy (generally much less than 10 percent of the skin surface) with or without concurrent",
"    <span class=\"nowrap\">",
"     patch/plaque",
"    </span>",
"    disease of any size (",
"    <a class=\"graphic graphic_table graphicRef75768 graphicRef53711 \" href=\"mobipreview.htm?6/60/7119\">",
"     table 1A-B",
"    </a>",
"    ). Patients with the folliculotropic variant or large cell transformation, with",
"    <span class=\"nowrap\">",
"     patch/plaque",
"    </span>",
"    disease or tumors, are treated as extensive IIB disease, while patients with blood involvement are treated as stage III disease.",
"   </p>",
"   <p>",
"    Patients with limited extent tumor (stage IIB) disease can be treated with localized radiation to the tumors followed by other skin-directed therapies for concurrent",
"    <span class=\"nowrap\">",
"     patch/plaque",
"    </span>",
"    disease. Alternatively, they can be given systemic therapy similar to that given for extensive stage IIB disease. With either approach, patients with stage IIB disease have a median survival of 3.5 to 4.0 years, and the majority will die from complications of MF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These two approaches have not been compared directly in a prospective trial. However, a randomized trial demonstrated that there is no advantage to early aggressive combination therapy with radiation and chemotherapy when compared with conservative sequential topical therapies in the management of advanced disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For most patients with limited tumor (stage IIB) disease, we suggest treatment with localized radiation to the tumors plus skin-directed therapy as needed for concurrent",
"    <span class=\"nowrap\">",
"     patch/plaque",
"    </span>",
"    disease. For those who cannot or opt not to receive radiation, systemic therapies are an acceptable alternative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Localized treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our preferred treatment for limited stage IIB disease is the combination of localized radiation (ie, electron beam therapy or x-ray therapy) to the tumors plus skin-directed therapy for concurrent",
"    <span class=\"nowrap\">",
"     patch/plaque",
"    </span>",
"    disease. Electron beam therapy is preferred to x-ray therapy for most patients.",
"   </p>",
"   <p>",
"    MF is extremely sensitive to radiation therapy and ionizing radiation in the form of x-rays results in complete clearance of the tumor in more than 90 percent of cases. However, short and long term toxicities limit the use of x-rays. In comparison, electron beam therapy (EBT) uses energies that confine the dose of radiation to the superficial layers of the skin to avoid damage to deeper tissues. Total skin electron beam therapy can be considered in patients with limited tumors and extensive",
"    <span class=\"nowrap\">",
"     patch/plaque",
"    </span>",
"    disease, but is associated with more side effects then the combination of localized EBT plus other skin-directed therapies. The administration of radiation and associated side effects are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17017?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of early stage (IA to IIA) mycosis fungoides\", section on 'Electron beam therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17017?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of early stage (IA to IIA) mycosis fungoides\", section on 'Radiation therapy'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H9\">",
"     'Total skin electron beam therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Radiation can be supplemented by other skin-directed therapies to treat concurrent",
"    <span class=\"nowrap\">",
"     patch/plaque",
"    </span>",
"    disease. Options for skin-directed therapy (eg, topical nitrogen mustard or ultraviolet light) are the same as those used for early stage (IA to IIA) MF. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17017?source=see_link\">",
"     \"Treatment of early stage (IA to IIA) mycosis fungoides\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Systemic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic therapy with systemic retinoids or biologics can be offered to patients with limited stage IIB disease who are not candidates for localized radiation or in conjunction with topical approaches. These treatment options may also be appropriate for patients with limited extent tumor disease of the folliculotropic variant or with transformation to a large cell variant. Other systemic treatment options, including Interferon, histone deacetylase inhibitors,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/57/918?source=see_link\">",
"     denileukin diftitox",
"    </a>",
"    , and low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    are typically reserved for patients with relapsed or refractory disease (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TUMOR (STAGE IIB) EXTENSIVE DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with extensive stage IIB disease include those with generalized cutaneous tumors, with minimal, if any, lymph node involvement (N1 or N2) and no visceral involvement (",
"    <a class=\"graphic graphic_table graphicRef75768 graphicRef53711 \" href=\"mobipreview.htm?6/60/7119\">",
"     table 1A-B",
"    </a>",
"    ). In addition, patients with limited extent tumor disease in the presence of histopathological evidence of the folliculotropic variant or with large cell transformation are treated as extensive IIB disease. Patients with blood involvement are treated as stage III disease.",
"   </p>",
"   <p>",
"    Treatment options for generalized tumor (extensive stage IIB) MF include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Total skin electron beam therapy (TSEBT)",
"     </li>",
"     <li>",
"      Systemic retinoids",
"     </li>",
"     <li>",
"      Interferon",
"     </li>",
"     <li>",
"      Histone deacetylase inhibitors",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/57/918?source=see_link\">",
"       Denileukin diftitox",
"      </a>",
"     </li>",
"     <li>",
"      Systemic chemotherapy",
"     </li>",
"     <li>",
"      Combinations of topical approaches and the above",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    TSEBT is a skin directed therapy, while the others are systemic therapies. There have been no prospective trials comparing these various treatment options. However, a randomized trial demonstrated that there is no advantage to early aggressive combination therapy when compared with conservative sequential therapies in the management of advanced disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients with stage IIB disease have a median survival of 3.5 to 4.0 years, and the majority will die from complications of MF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with generalized stage IIB disease or limited extent tumor disease with blood involvement (B1) or histologic evidence of folliculotropism or large cell transformation, equally acceptable treatment options are the use of TSEBT, systemic therapies (biologics, histone deacetylase inhibitors, single-agent chemotherapy) or combination therapies (systemic plus skin-directed or systemic plus systemic). TSEBT can be followed by other skin-directed therapies or systemic therapies to prolong response duration. Choice among these treatments is made based upon patient characteristics. As an example, in patients with aggressive generalized IIB disease with large cell transformation, single agent chemotherapy such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    is highly effective, though not approved for this indication by the United States FDA. Alternatively, TSEBT can be administered followed by systemic biologic therapies.",
"   </p>",
"   <p>",
"    The majority of patients with stage IIB disease will relapse after an initial response to treatment. Patients with relapsed stage IIB disease may respond to treatment with systemic retinoids, interferon alfa, histone deacetylase inhibitors,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/57/918?source=see_link\">",
"     denileukin diftitox",
"    </a>",
"    , other systemic chemotherapies, or combination regimens. A choice among these depends upon patient characteristics and the side effect profiles of the various agents. Focal resistant tumors may respond to booster doses of local electron beam therapy. In addition, patients with relapsing disease should be considered as potential candidates for allogeneic hematopoietic cell transplantation (HCT). (See",
"    <a class=\"local\" href=\"#H46\">",
"     'Hematopoietic cell transplantation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Total skin electron beam therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total skin electron beam therapy (TSEBT) results in a complete response (CR) in 44 to 74 percent of patients with stage IIB disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. TSEBT is typically followed by the use of an adjuvant therapy, either skin-directed (eg, nitrogen mustard or PUVA) or systemic (eg, interferon-alfa, retinoids, or photopheresis), in order to prolong the response duration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. It remains unclear if such adjuvant therapy improves overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     TSEBT administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;A full cycle of TSEBT is administered over two days using a six-field technique that delivers a dose of 1.5 to 2.0 Gy to anterior, posterior, and four opposed oblique fields [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/11\">",
"     11",
"    </a>",
"    ]. On the first day, treatment is applied to the anterior and two posterior oblique fields, while the posterior and two anterior oblique fields are treated on the second day. A total dose of 30 to 36 Gy is administered over a 9 to 10-week period. A one-week break may be given after a dose of 18 to 20 Gy has been delivered to provide relief from the generalized skin erythema associated with treatment. Of importance, some areas, such as the top of the scalp, the perineum, the underside of the breasts, panniculus folds, and the soles of the feet, are \"shadowed\" and may require supplemental treatment.",
"   </p>",
"   <p>",
"    The ideal total radiation dose used for TSEBT is unknown. Initial studies used doses as low as 8 Gy and demonstrated high response rates and minimal toxicity, but significant relapse rates. The doses used were gradually increased over time to 30 to 36 Gy, a dose that is associated with greater toxicity, but longer remission durations. Subsequent studies have attempted to define an equally effective dose with minimal toxicity. Trials investigating doses less than 4 Gy have demonstrated unacceptably short response durations (&lt;3 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. A single center retrospective analysis of TSEBT dose in 102 patients with advanced stage MF demonstrated that TSEBT doses of 10 to &lt;20 Gy and 20 to &lt;30 Gy resulted in similar rates of overall response, survival, progression-free survival, and relapse-free survival when compared with doses of &ge;30 Gy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/14\">",
"     14",
"    </a>",
"    ]. These lower doses of TSEBT need to be compared with higher doses of TSEBT in a prospective trial to confirm efficacy prior to general application.",
"   </p>",
"   <p>",
"    After the completion of TSEBT, adjuvant therapy with topical nitrogen mustard (in an ointment base) with or without systemic agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/10/31904?source=see_link\">",
"     bexarotene",
"    </a>",
"    , photopheresis) is administered for 6 to 12 months. This therapy provides the dual role of treatment for any residual disease and acts as an emollient of the skin, which is often chronically dry after completion of TSEBT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     TSEBT toxicities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects of TSEBT include desquamation, xerosis, and erythema of the skin. These are presented in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17017?source=see_link&amp;anchor=H27#H27\">",
"     \"Treatment of early stage (IA to IIA) mycosis fungoides\", section on 'TSEBT toxicities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Systemic retinoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic (oral) retinoids result in response rates of 45 to 55 percent (10 to 20 percent complete) depending upon the dosing and severity of MF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/15-18\">",
"     15-18",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/10/31904?source=see_link\">",
"     Bexarotene",
"    </a>",
"    (Targretin) is approved by the United States FDA for use in patients with advanced MF (stages IIB to IVB) who are refractory to at least one prior systemic therapy. There are other systemic retinoids commercially available but not FDA approved for this indication: oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    (Amnesteem, Claravis, Sotret, formerly Accutane) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    (Soriatane) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/6\">",
"     6",
"    </a>",
"    ]. Etretinate is available only in Japan.",
"   </p>",
"   <p>",
"    A phase",
"    <span class=\"nowrap\">",
"     II/III",
"    </span>",
"    trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/10/31904?source=see_link\">",
"     bexarotene",
"    </a>",
"    in 94 patients with advanced stage MF (stages IIB to IVB) who were refractory to conventional therapy reported overall response rates of 45 and 55 percent of patients started on oral doses of 300 and greater than 300",
"    <span class=\"nowrap\">",
"     mg/m(2)",
"    </span>",
"    per day, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/15\">",
"     15",
"    </a>",
"    ]. No serious adverse events occurred; the most common toxicities included hyperlipemia (primarily hypertriglyceridemia, 82 percent), hypercholesterolemia (30 percent), hypothyroidism (29 percent), and headache (20 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/15,19\">",
"     15,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/6/18536?source=see_link\">",
"     \"Central hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Retinoid administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended initial starting dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/10/31904?source=see_link\">",
"     bexarotene",
"    </a>",
"    is 200 to 300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day orally. Liver function, serum lipid levels, thyroid function (serum free T4), and complete blood counts should be monitored in each patient during treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/20\">",
"     20",
"    </a>",
"    ]. We measure these levels before starting the drug. Lipid levels are then monitored weekly until a plateau in the lipid response and then at four to eight-week intervals thereafter. A comprehensive metabolic profile, CBC, and serum free T4 (",
"    <strong>",
"     not",
"    </strong>",
"    TSH) are checked monthly. Bexarotene must be used with caution in patients with hypertriglyceridemia, liver dysfunction, or risk factors for pancreatitis. Lipid lowering agents",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thyroid hormone replacement are commonly required to mediate these side effects of bexarotene; however, patients taking bexarotene should not be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    because coadministration results in increased serum levels of bexarotene. Omega-3-fatty acids may be initiated prior to treatment with bexarotene to lessen the hypertriglyceridemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/51/28474?source=see_link&amp;anchor=H2#H2\">",
"     \"Lipid lowering with diet or dietary supplements\", section on 'Fish oil and omega-3 fatty acids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial dose for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    is 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day and for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    is 25 to 50",
"    <span class=\"nowrap\">",
"     mg/day;",
"    </span>",
"    subsequent doses can be adjusted according to clinical response and the severity of adverse effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Retinoid toxicities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most toxicities due to systemic retinoids are reversible after cessation of therapy. The most common adverse effects of retinoids include photosensitivity, xerosis, myalgia, arthralgia, headaches, and impaired night vision. Retinoids have potential hepatotoxic and hyperlipidemic effects, necessitating monitoring. Patients receiving treatment with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/10/31904?source=see_link\">",
"     bexarotene",
"    </a>",
"    are also at increased risk for hypertriglyceridemia and central hypothyroidism, and may require anti-lipidemic and thyroid replacement therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/19\">",
"     19",
"    </a>",
"    ]. The well-known teratogenic effects of retinoids must be carefully addressed in female patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/42/22184?source=see_link\">",
"     \"Oral isotretinoin therapy for acne vulgaris\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/6/18536?source=see_link\">",
"     \"Central hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Interferon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon (IFN) alfa is used primarily for the palliative management of relapsed or refractory advanced disease with overall response rates from 53 to 74 percent (21 to 35 percent complete) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/21\">",
"     21",
"    </a>",
"    ]. However, the majority of patients will relapse during maintenance therapy.",
"   </p>",
"   <p>",
"    IFN may be administered alone or, more commonly, in combination with topical or other systemic treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. As an example, the combination of IFN alfa plus PUVA (psoralen + ultraviolet A photochemotherapy) results in complete and partial response rates of 75 to 80 percent and 6 to 20 percent, respectively, in patients with generalized",
"    <span class=\"nowrap\">",
"     patch/plaque",
"    </span>",
"    disease (stages IB and IIA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Although the clinical response and response duration appear to be better with the combined regimen of PUVA and IFN, as compared with either treatment alone, randomized prospective clinical trials are needed to confirm this impression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An additional benefit of combined therapy may be the suppression of anti-interferon-alfa antibody formation. None of the 24 patients with MF assayed in a clinical study developed antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/27\">",
"     27",
"    </a>",
"    ], compared with a reported incidence of 4 to 46 percent in a variety of other cancer settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     IFN administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of interferon-alfa (IFN) for MF is usually initiated at a dose of 3 to 5 million units SQ given three times a week. This dose is gradually increased, depending on the clinical response and the severity of adverse effects. For a regimen combining IFN and PUVA, the two treatments are initiated concurrently, each given three times per week. When a patient's skin clears completely, IFN is stopped and maintenance therapy with PUVA treatment at a reduced frequency is begun.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Romidepsin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/2/3110?source=see_link\">",
"     Romidepsin",
"    </a>",
"    (also known as depsipeptide) is a histone deacetylase (HDAC) inhibitor with activity in cutaneous T cell lymphoma (CTCL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/29\">",
"     29",
"    </a>",
"    ]. It has demonstrated overall response rates in CTCL of 35 percent in two separate studies and is approved by the United States FDA for the treatment of CTCL in patients with progressive, persistent, or recurrent disease on or following at least one prior systemic therapy.",
"   </p>",
"   <p>",
"    A multi-institutional phase II trial evaluated the use of single-agent intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/2/3110?source=see_link\">",
"     romidepsin",
"    </a>",
"    in 71 patients with CTCL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/30\">",
"     30",
"    </a>",
"    ]. The patients had received a median of four prior therapies and 87 percent had advanced stage disease. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall and complete response rates were 34 and 6 percent, respectively. The median duration of response was 11.1 months. Among those with a major response, the median time to progression was 15.1 months.",
"     </li>",
"     <li>",
"      Severe (grade",
"      <span class=\"nowrap\">",
"       3/4),",
"      </span>",
"      yet transient, granulocytopenia and lymphopenia were seen in 14 and 21 percent of patients, respectively. Nonhematologic side effects were generally mild, but included nausea, vomiting, fatigue, electrolyte abnormalities, and electrocardiographic changes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An international phase II trial evaluated the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/2/3110?source=see_link\">",
"     romidepsin",
"    </a>",
"    in 96 patients with CTCL who had received a median of two prior therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/31\">",
"     31",
"    </a>",
"    ]. Seventy-one percent had advanced stage disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall and complete response rates were 34 and 6 percent, respectively. The median time to response was 2 months and the median duration of response was 15 months.",
"     </li>",
"     <li>",
"      Of the 65 patients with moderate to severe pruritus at baseline, 28 (43 percent) had clinically meaningful improvement in pruritus, including patients who did not achieve objective disease response.",
"     </li>",
"     <li>",
"      Approximately half of patients had mild (grade",
"      <span class=\"nowrap\">",
"       1/2)",
"      </span>",
"      gastrointestinal side effects (mostly nausea, less commonly vomiting or diarrhea). Severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      side effects were uncommon. The most common dose-limiting adverse effects were",
"      <span class=\"nowrap\">",
"       fatigue/asthenia",
"      </span>",
"      and thrombocytopenia. A prolonged corrected QT interval was seen in two patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/2/3110?source=see_link\">",
"     Romidepsin",
"    </a>",
"    is administered as a single agent at a dose of 14",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    administered by intravenous infusion over four hours on days 1, 8, and 15 of a 28-day cycle. Full prescribing information is available separately [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several treatment-emergent morphological changes in ECGs (including T-wave and ST-segment changes) have been reported in clinical studies with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/2/3110?source=see_link\">",
"     romidepsin",
"    </a>",
"    but which have not been shown to be clinically significant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/31,33,34\">",
"     31,33,34",
"    </a>",
"    ]. In patients with congenital long QT syndrome, patients with a history of significant cardiovascular disease, and patients taking anti-arrhythmic medicines or medicinal products that lead to significant QT prolongation, appropriate cardiovascular monitoring precautions should be considered, such as the monitoring of electrolytes and ECGs at baseline and periodically during treatment. Romidepsin is metabolized by CYP3A4. Co-administration of strong CYP3A4 inhibitors or potent CYP3A4 inducers should be avoided if possible.",
"   </p>",
"   <p>",
"    Potassium and magnesium levels should be in the normal range before drug administration. There is no required monitoring of ECGs in patients who do not have the above risk factors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40138?source=see_link&amp;anchor=H52#H52\">",
"     \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\", section on 'Histone deacetylase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Vorinostat",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/29/27093?source=see_link\">",
"     Vorinostat",
"    </a>",
"    (suberoylanilide hydroxamic acid, SAHA, MSK390, Zolinza&trade;) is an orally active histone deacetylase (HDAC) inhibitor, with partial response rates in MF of 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/35-39\">",
"     35-39",
"    </a>",
"    ]. It is approved by the FDA for the treatment of CTCL in patients with progressive, persistent, or recurrent disease after two systemic therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The activity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/29/27093?source=see_link\">",
"     vorinostat",
"    </a>",
"    (starting dose 400",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    was evaluated in 74 patients with stage IB or higher CTCL who had failed a median of three systemic therapies, one of which included",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/10/31904?source=see_link\">",
"     bexarotene",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/41\">",
"     41",
"    </a>",
"    ]. Thirty percent of subjects experienced a partial response as measured by a modified skin severity weighted assessment tool, 32 percent had pruritus relief; one patient attained delayed complete remission on day 281.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Vorinostat toxicities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxicities of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/29/27093?source=see_link\">",
"     vorinostat",
"    </a>",
"    included diarrhea (46 percent), fatigue (49 percent), nausea (43 percent), anorexia (26 percent), and dysgeusia (24 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/41\">",
"     41",
"    </a>",
"    ]. Hematologic abnormalities included anemia, thrombocytopenia (22 percent), and neutropenia, most of which were grade 1 or 2 in severity. The most common severe adverse event was pulmonary embolus, seen in four patients (5 percent).",
"   </p>",
"   <p>",
"    Several treatment-emergent morphological changes in ECGs (including T-wave and ST-segment changes) have been reported in clinical studies with HDAC inhibitors but which have not been shown to be clinically significant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/33,42\">",
"     33,42",
"    </a>",
"    ]. In patients with congenital long QT syndrome, with a history of significant cardiovascular disease, or taking anti-arrhythmic medicines or medicinal products that lead to significant QT prolongation, appropriate cardiovascular monitoring precautions should be considered (ie, monitoring of electrolytes and ECGs at baseline and periodically during treatment).",
"   </p>",
"   <p>",
"    Potassium and magnesium levels should be in the normal range before drug administration. There is no required monitoring of ECGs in patients who do not have the above risk factors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40138?source=see_link&amp;anchor=H52#H52\">",
"     \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\", section on 'Histone deacetylase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients enrolled in clinical studies were also instructed to drink at least 2 liters of fluid daily to avoid dehydration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Denileukin diftitox",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/57/918?source=see_link\">",
"     Denileukin diftitox",
"    </a>",
"    (Ontak&reg;,DAB389IL-2) is a recombinant interleukin-2 (IL-2)-diphtheria toxin fusion protein that is approved by the United States FDA for patients with persistent or recurrent MF, whose malignant cells express the alpha component of the interleukin-2 receptor (CD25) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. It demonstrates an overall response rate (ORR) of approximately 30 percent (10 percent complete) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/45\">",
"     45",
"    </a>",
"    ]. Durable complete remissions have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A phase III trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/57/918?source=see_link\">",
"     denileukin diftitox",
"    </a>",
"    in 144 patients with stage IA to III CD25 positive MF and &ge;3 prior treatments randomly assigned treatment to up to 8 cycles of high-dose (18",
"    <span class=\"nowrap\">",
"     microg/kg)",
"    </span>",
"    or low-dose (9",
"    <span class=\"nowrap\">",
"     microg/kg)",
"    </span>",
"    denileukin diftitox or to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/48\">",
"     48",
"    </a>",
"    ]. When compared with placebo, denileukin diftitox resulted in the following significant findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Superior overall response rates (49, 38 versus 16 percent, respectively)",
"     </li>",
"     <li>",
"      Longer median times to progression (greater than 32 months, 26 months, and 4 months, respectively)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another phase III trial in 71 patients with relapsed or refractory stage IB to IVA CD25 positive MF randomly assigned treatment with one of two different doses (9 versus 18",
"    <span class=\"nowrap\">",
"     microg/kg)",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/57/918?source=see_link\">",
"     denileukin diftitox",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/45,49\">",
"     45,49",
"    </a>",
"    ]. Treatment was administered daily for 5 consecutive days, repeated every 21 days for up to 11 courses. The overall response rate was 30 percent (10 percent complete). The median duration of response was approximately 8 months. Patients with higher than stage IIB disease demonstrated a possible dose response effect with ORRs of 38 and 10 percent for the high- and low-dose levels, respectively.",
"   </p>",
"   <p>",
"    A third study of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/57/918?source=see_link\">",
"     denileukin diftitox",
"    </a>",
"    (18",
"    <span class=\"nowrap\">",
"     micrograms/kg",
"    </span>",
"    daily for 5 days) in 24 patients with MF reported higher ORR in patients whose tumors expressed CD25 when compared with those who had little or no CD25 expression (78 versus 20 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/57/918?source=see_link\">",
"     Denileukin diftitox",
"    </a>",
"    is associated with systemic side effects that may be severe. The vast majority of patients receiving denileukin diftitox experience flu-like symptoms with chills, fever, asthenia, arthralgia, myalgia, and headaches. Serious and fatal infusion reactions have occurred. Premedication regimens have varied among studies and have included",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , antihistamines and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    . This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=see_link&amp;anchor=H62#H62\">",
"     \"Infusion reactions to systemic chemotherapy\", section on 'Denileukin diftitox'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/57/918?source=see_link\">",
"     Denileukin diftitox",
"    </a>",
"    has a black box warning for a potentially severe, including life-threatening, capillary leak syndrome, which also may be ameliorated by pretreatment with corticosteroids. Physicians should monitor the patient's weight, edema, blood pressure, and serum albumin prior to and during treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Systemic chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most chemotherapy agents that have been used for other types of non-Hodgkin lymphoma have been investigated in patients with MF. These agents may be considered in patients with relapsed or resistant MF or those with extensive tumor disease, especially when evidence of large cell transformation is present. These agents are described in more detail below. (See",
"    <a class=\"local\" href=\"#H37\">",
"     'Single agent chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     STAGE IIIA DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with stage IIIA MF include those with generalized erythroderma (covering at least 80 percent of the body surface area), without any lymph node, visceral, or blood involvement (",
"    <a class=\"graphic graphic_table graphicRef75768 graphicRef53711 \" href=\"mobipreview.htm?6/60/7119\">",
"     table 1A-B",
"    </a>",
"    ). Stage IIIA MF can be treated with skin directed therapies, systemic therapies, or a combination of the two. Caution must be used in this group because they often have severe pruritus and skin inflammation that can be irritated further by many topical therapies. Standard electron beam therapy (EBT) is generally not used because these patients may suffer severe desquamation with total doses as low as 4 Gy.",
"   </p>",
"   <p>",
"    Treatment options for patients with stage IIIA MF include one or a combination of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Topical corticosteroids",
"     </li>",
"     <li>",
"      Topical nitrogen mustard",
"     </li>",
"     <li>",
"      Low dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"     </li>",
"     <li>",
"      Systemic retinoids",
"     </li>",
"     <li>",
"      Histone deacetylase inhibitors &mdash; (see",
"      <a class=\"local\" href=\"#H18\">",
"       'Vorinostat'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Romidepsin'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      PUVA (psoralen + ultraviolet A photochemotherapy)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These treatment options have not been compared directly in prospective trials. Treatment of stage IIIA MF is palliative and the median survival is 3.5 to 4.0 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For most patients with stage IIIA MF, we typically administer both a skin directed therapy (eg, topical steroids) and a systemic therapy (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/10/31904?source=see_link\">",
"     bexarotene",
"    </a>",
"    ). Others use skin-directed therapy alone and then proceed to systemic therapies upon progression of failure of response.",
"   </p>",
"   <p>",
"    The majority of the patients relapse after initial treatment. Relapsed disease may respond to repeated treatment with the same agents. Alternatively, other skin-directed or systemic therapies may be used for relapsed or resistant stage IIIA MF. In addition, patients with relapsing disease should be considered as potential candidates for allogeneic hematopoietic cell transplantation (HCT). (See",
"    <a class=\"local\" href=\"#H46\">",
"     'Hematopoietic cell transplantation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Topical therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical therapy with nitrogen mustard or corticosteroids are the same as those used for early stage (IA to IIA) MF. Caution must be used in patients with stage IIIA disease because topical therapies can exacerbate pruritus and skin inflammation seen in these patients. The use of topical therapies is presented in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17017?source=see_link\">",
"     \"Treatment of early stage (IA to IIA) mycosis fungoides\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Retinoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic retinoids (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/10/31904?source=see_link\">",
"     bexarotene",
"    </a>",
"    ) also can be used alone, or more often, in combination with topical steroids, PUVA (RePUVA), or IFN for stage III disease. The type and doses of systemic retinoids used for stage III disease are similar to those used for recalcitrant plaque or tumor disease. However, patient numbers are limited in the reported studies, with variable response rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Systemic retinoids'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     PUVA therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;PUVA (psoralen + ultraviolet A photochemotherapy) results in complete response rates of 33 to 70 percent in patients with stage IIIA MF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/25,53-56\">",
"     25,53-56",
"    </a>",
"    ]. In such cases, PUVA must be started at a low dose followed by a very slow and cautious increase of UVA dose to avoid phototoxic reactions. Despite a good clinical response with PUVA alone, the majority of the patients relapse during maintenance therapy.",
"   </p>",
"   <p>",
"    The combined regimen of PUVA plus interferon-alfa (IFN) can be used as primary therapy or when patients fail to respond to IFN or PUVA alone. In one study, the complete and partial response rates in stage III disease for the combined regimen of IFN and PUVA were 62 percent and 25 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/22\">",
"     22",
"    </a>",
"    ]. This combined regimen may result in improved clinical response and response duration beyond that observed with IFN or PUVA alone, although prospective randomized studies will be needed to confirm this impression. At this time, there is no clear evidence that prolongation of response duration leads to improvement in overall survival.",
"   </p>",
"   <p>",
"    The administration of PUVA and associated side effects are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17017?source=see_link&amp;anchor=H21#H21\">",
"     \"Treatment of early stage (IA to IIA) mycosis fungoides\", section on 'PUVA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Low dose methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with stage IIIA MF, low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    results in complete and partial response rates of 41 and 17 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/57\">",
"     57",
"    </a>",
"    ]. The administration and side effects of methotrexate are discussed in more detail below. (See",
"    <a class=\"local\" href=\"#H38\">",
"     'Methotrexate'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     STAGE IIIB DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with stage IIIB MF include those with generalized erythroderma, with limited, if any, lymph node involvement, no visceral involvement, but with limited involvement of the peripheral blood (",
"    <a class=\"graphic graphic_table graphicRef75768 graphicRef53711 \" href=\"mobipreview.htm?6/60/7119\">",
"     table 1A-B",
"    </a>",
"    ). In addition, patients without generalized erythroderma but with limited blood involvement are treated as stage IIIB disease.",
"   </p>",
"   <p>",
"    Patients with stage IIIB MF require systemic therapy to target the malignant cells circulating in the blood. Skin-directed therapies may be added as adjunctive treatment if needed to control cutaneous lesions. Systemic treatment options for stage IIIB MF include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Extracorporeal photochemotherapy (ECP, photopheresis)",
"     </li>",
"     <li>",
"      Systemic retinoids &mdash; (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Systemic retinoids'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Interferon &mdash; (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Interferon'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Histone deacetylase inhibitors &mdash; (see",
"      <a class=\"local\" href=\"#H18\">",
"       'Vorinostat'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Romidepsin'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/57/918?source=see_link\">",
"       Denileukin diftitox",
"      </a>",
"      &mdash; (see",
"      <a class=\"local\" href=\"#H20\">",
"       'Denileukin diftitox'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Low dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      &mdash; (see",
"      <a class=\"local\" href=\"#H38\">",
"       'Methotrexate'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with stage III disease have a median survival of 3.5 to 4.0 years, and the majority will die from complications of MF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. There is no advantage to early aggressive combination therapy when compared with conservative sequential therapies in the management of stage III disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For most patients with stage IIIB MF, we recommend the use of a systemic therapy with or without skin directed therapies rather than skin directed therapies alone. A choice among these options is made principally upon a review of the patient's comorbidities and treatment-related issues. As an example, ECP has a low toxicity profile, but requires a significant patient time commitment with travel to an expert center. In comparison, systemic treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/10/31904?source=see_link\">",
"     bexarotene",
"    </a>",
"    , interferon, or low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    can be easily administered at home, but may be complicated by hyperlipidemia, fatigue, or liver toxicity, respectively.",
"   </p>",
"   <p>",
"    The majority of patients will relapse after initial treatment. At the time of relapse, patients can be retreated with ECP or with other systemic therapies. In addition, patients with relapsing disease should be considered as potential candidates for allogeneic hematopoietic cell transplantation (HCT). (See",
"    <a class=\"local\" href=\"#H46\">",
"     'Hematopoietic cell transplantation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Extracorporeal photochemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extracorporeal photochemotherapy (ECP, also known as photopheresis) is a method of delivering PUVA (psoralen + ultraviolet A photochemotherapy) systemically by using an extracorporeal technique. It is often used as the primary therapy for stage IIIB MF or S&eacute;zary syndrome (leukemic variant of cutaneous T cell lymphoma with high numbers of circulating S&eacute;zary cells) with overall response rates of 41 percent (21 percent complete), but is not widely available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/58-62\">",
"     58-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one series, 83 percent of patients with erythrodermic MF and S&eacute;zary syndrome experienced greater than 25 percent response to photopheresis. The complete response rate was only 21 percent, but 41 percent of patients experienced at least 50 percent improvement in their skin disease (partial response) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/61,63\">",
"     61,63",
"    </a>",
"    ]. In one study, a higher baseline S&eacute;zary cell count as a percentage of the total white blood cell count predicted for a clinical response at six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the response to photopheresis alone is partial or slow, IFN or systemic retinoids can be added as a combined modality regimen. Patients who had partial or no response to photopheresis alone experienced improved responses when IFN",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    systemic retinoids were added to their regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/60,65,66\">",
"     60,65,66",
"    </a>",
"    ]. In addition, skin-directed therapies such as topical corticosteroids, topical nitrogen mustard, phototherapy, or total skin electron beam therapy can be combined with ECP if additional skin directed therapy is needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     ECP technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's white blood cells are collected via leukapheresis, liquid psoralen (8-methoxypsoralen, Uvadex) is mixed with the leukapheresed white blood cells, and irradiated with ultraviolet A. Uvadex acts as a photoactivating drug. The irradiated cells are then returned to the patient intravenously. Photopheresis is usually given every four weeks, but in patients with severe disease, it can be given as often as every two to three weeks. Once complete clearance is achieved, the frequency can be gradually reduced and then discontinued.",
"   </p>",
"   <p>",
"    If necessary, interferon (IFN) alfa or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/10/31904?source=see_link\">",
"     bexarotene",
"    </a>",
"    can be administered with ECP. The dose for IFN is usually low, 3 to 5 million units SQ three times weekly, gradually increasing the dose if patient tolerance permits, but not exceeding 10 million units per dose. Oral bexarotene is the most commonly used retinoid for the combination therapy. The bexarotene dose for combination therapy ranges from 150 to 300 mg per day. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Systemic retinoids'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H15\">",
"     'Interferon'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The mechanism of action of photopheresis remains unclear, although there is some evidence that it may act as an immunomodulating, transimmunization process. This treatment is believed to induce apoptosis of circulating tumor cells (S&eacute;zary cells). The released tumor antigen is then processed by peripheral dendritic cells, leading to the augmentation of systemic antitumor responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     ECP toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The advantage of photopheresis is that adverse effects are minimal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/70\">",
"     70",
"    </a>",
"    ]. Some patients may experience nausea, mostly as the result of the ingested psoralen, and some experience a transient low-grade fever or slight malaise after treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     STAGE IV DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with stage IV MF are generally divided into three main subgroups (",
"    <a class=\"graphic graphic_table graphicRef75768 graphicRef53711 \" href=\"mobipreview.htm?6/60/7119\">",
"     table 1A-B",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage IVA1 &mdash; Major involvement of the peripheral blood (S&eacute;zary syndrome), with limited, if any, lymph node involvement, and no visceral involvement.",
"     </li>",
"     <li>",
"      Stage IVA2 &mdash; Partial or complete effacement of the nodal architecture by abnormal cells, but no visceral involvement.",
"     </li>",
"     <li>",
"      Stage IVB &mdash; Visceral involvement present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Stage IV disease is principally treated with systemic therapy, although most regimens result in temporary palliative control only. Chemotherapy can be used alone or in combination with other skin-directed therapy (eg, radiation) or biological response modifiers (eg, interferon-alfa). With combination chemotherapy regimens, overall complete and partial response rates can reach 80 to 100 percent. However, in most cases, the median duration of response is less than one year, and, in many patients, less than a few months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. In addition, patients with stage IV disease are potential candidates for allogeneic hematopoietic cell transplantation (HCT). (See",
"    <a class=\"local\" href=\"#H46\">",
"     'Hematopoietic cell transplantation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Our approach to the management of a patient with stage IV disease is stratified by whether the patient has S&eacute;zary syndrome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most patients with S&eacute;zary syndrome, stage IVA1 MF, we recommend the use of a systemic therapy with or without skin directed therapies rather than skin directed therapies alone. Where available, we prefer nonimmunosuppressive therapies, such as extracorporeal photochemotherapy (ECP), for this patient population. In patients with high blood tumor burden, combination systemic biologic therapies or histone deacetylase (HDAC) inhibitors are usually needed. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Stage IV disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with stage IVA2 with S&eacute;zary syndrome, management is similar to those with stage IVA1. For patients with non-S&eacute;zary IVA2 or for patients with solid organ IVB disease, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/2/3110?source=see_link\">",
"       romidepsin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/57/918?source=see_link\">",
"       denileukin diftitox",
"      </a>",
"      , or systemic chemotherapy. Combination chemotherapy may lead to faster responses, but there is no advantage to early aggressive combination therapy when compared with conservative sequential therapies in the management of advanced stage disease. Local radiation therapy may be used in conjunction with systemic therapy for local control of visceral disease or lymph node involvement. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Stage IV disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Extracorporeal photopheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extracorporeal phototherapy (ECP), also known as photopheresis is the preferred initial therapy for patients with S&eacute;zary syndrome (stage IVA1 disease). In contrast, its use in stage IIIA disease, ECP is generally combined with biologic regimens (eg, interferon or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/10/31904?source=see_link\">",
"     bexarotene",
"    </a>",
"    ) at the time of initial treatment. Details regarding ECP are presented above. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Extracorporeal photochemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Single agent chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most chemotherapy agents that have been used for other types of non-Hodgkin lymphoma have been investigated in patients with MF. The most commonly used single-agent chemotherapy regimens in MF and S&eacute;zary syndrome include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/71,72,74\">",
"     71,72,74",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"       Pegylated liposomal doxorubicin",
"      </a>",
"      (Doxil)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"       Chlorambucil",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/75\">",
"       75",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Purine analogs (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      , 2-deoxycoformycin)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       Etoposide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/76,77\">",
"       76,77",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       Bortezomib",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"       Alemtuzumab",
"      </a>",
"      (Campath-1H)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/43/29366?source=see_link\">",
"       Pralatrexate",
"      </a>",
"      (low dose)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These agents have never been compared directly in a clinical trial. Of these,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    has been used the longest and is therefore associated with the greatest clinical experience for the treatment of MF. Other agents may be associated with higher response rates, but may also demonstrate increased toxicity. A choice among agents depends upon the patient's comorbidities and the physician's comfort with these agents.",
"   </p>",
"   <p>",
"    When considering the response rates seen in uncontrolled trials, it is important to recognize that some patients with MF will experience spontaneous remissions following treatment with placebo. This was illustrated in an analysis of 44 patients with previously treated recurrent or persistent CD25+ MF or S&eacute;zary syndrome randomly assigned to receive placebo within the context of a phase III trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/78\">",
"     78",
"    </a>",
"    ]. A minority of patients (32 percent) had advanced stage disease and the majority (68 percent) had received at least two prior therapies. The overall response rate was 16 percent and one patient had a complete response. The median estimated duration of response and progression-free survival were 81 days and 124 days, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low dose oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (approximately 5 to 50 mg per week) results in overall response rates (ORR) of 30 to 50 percent in patients with MF. Alternatively, methotrexate can be administered intravenously at doses of 25 to 50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    once per week with similar response rates.",
"   </p>",
"   <p>",
"    A retrospective study of patients with T1 (2 patients), T2 (60 patients), or T3 (7 patients) MF treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    reported an ORR of 33 percent (12 percent complete); only one of seven patients with T3 disease responded.",
"   </p>",
"   <p>",
"    A study of 29 patients with stage IIIA disease reported complete and partial response rates of 41 and 17 percent of patients of patients with stage IIIA MF, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/57\">",
"     57",
"    </a>",
"    ]. Patients remained free of disease for a median of 31 months.",
"   </p>",
"   <p>",
"    Common side effects of low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    include mucositis, gastrointestinal effects, and myelosuppression. Methotrexate can also result in hepatic, renal, and pulmonary toxicity. Methotrexate is an abortifacient that can also induce congenital anomalies if taken during pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Pegylated liposomal doxorubicin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"     Pegylated liposomal doxorubicin",
"    </a>",
"    (Doxil) has demonstrated overall response rates (ORRs) of 40 to 80 percent in patients with relapsed or refractory cutaneous T cell lymphoma (CTCL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/79-82\">",
"     79-82",
"    </a>",
"    ]. Patients with refractory stage IV disease have demonstrated an overall response rate of 33 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retrospective and uncontrolled prospective studies have evaluated the use of pegylated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    in relapsed or refractory CTCL. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective, multi-center study evaluated the use of pegylated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      (20 to 40",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      as second-line therapy in 34 patients with relapsed or refractory CTCL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/79\">",
"       79",
"      </a>",
"      ]. The ORR was 88 percent with 15 percent obtaining a complete response. Toxicity was generally mild and transient. Median overall survival was approximately 18 months.",
"     </li>",
"     <li>",
"      A prospective, non-randomized, multicenter trial examined the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"       pegylated liposomal doxorubicin",
"      </a>",
"      (40",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every four weeks) in 25 patients with",
"      <span class=\"nowrap\">",
"       relapsed/refractory",
"      </span>",
"      CTCL that had failed two previous lines of treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/80\">",
"       80",
"      </a>",
"      ]. The treatment was well tolerated. Objective responses were seen in 56 percent of patients with five complete responses and nine partial responses. Median overall survival was approximately 44 months.",
"     </li>",
"     <li>",
"      In a prospective, international multicenter phase II trial, 49 patients with stage IIB, IVA, or IVB relapsed or refractory MF were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"       pegylated liposomal doxorubicin",
"      </a>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 and 15 of a 28-day cycle for up to six cycles) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/83\">",
"       83",
"      </a>",
"      ]. Treatment was well tolerated. The ORR was 41 percent (6 percent complete). Patients with lymph node or visceral disease had a lower response rate than those with skin-only disease. At a median follow-up of 10.6 months, the median duration of response was six months (95% CI 5.0-10.4 months).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"     Pegylated liposomal doxorubicin",
"    </a>",
"    is commonly administered in CTCL at a dose of 20 to 30",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    given every three to four weeks. Although it has not been directly compared with other agents in",
"    <span class=\"nowrap\">",
"     relapsed/refractory",
"    </span>",
"    disease, it is an acceptable treatment option in this setting.",
"   </p>",
"   <p>",
"    The most common side effects include mild anemia, lymphopenia, and palmar-plantar erythrodysesthesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Gemcitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     Gemcitabine",
"    </a>",
"    has demonstrated overall response rates (ORRs) of 47 to 70 percent in patients with relapsed or refractory MF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/84-86\">",
"     84-86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase II trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      in 30 patients with previously-treated refractory or relapsed MF (stages T3 or T4) and 14 patients with peripheral T cell lymphoma, unspecified (stage IV) reported an ORR for both groups of 70 percent, with 10 percent complete remissions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/84\">",
"       84",
"      </a>",
"      ]. Median durations of complete and partial responses were 15 and 10 months, respectively. The drug was given on an outpatient basis on days 1, 8, and 15 of a 28-day schedule at a dose of 1200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV over 30 minutes for a total of three courses.",
"     </li>",
"     <li>",
"      Another phase II study of the same dosing and schedule of single agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      administered for six cycles to 19 patients with advanced stage MF reported overall and complete response rates of 48 and 16 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When six courses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      (same dosing schedule as above) were employed as initial therapy in 32 patients with advanced cutaneous T cell lymphoma, complete and ORRs were 22 and 75 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/87\">",
"       87",
"      </a>",
"      ]. For both groups of patients, treatment was well tolerated and hematologic toxicity was mild.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Purine and pyrimidine analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    have demonstrated clinical activity against MF with response rates as high as 50 to 70 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/88-91\">",
"     88-91",
"    </a>",
"    ]. Common side effects with these agents include",
"    <span class=\"nowrap\">",
"     significant/prolonged",
"    </span>",
"    immunosuppression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/17/4378?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of hairy cell leukemia\", section on 'Purine analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Alemtuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     Alemtuzumab",
"    </a>",
"    (Campath-1H), a humanized monoclonal antibody directed against CD52, was tested in 22 patients with previously treated MF, most of whom had stage III or IV disease, reduced performance status, and severe pruritus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/92\">",
"     92",
"    </a>",
"    ]. Complete and partial responses were noted in 32 and 23 percent, respectively, with a median time to treatment failure of 12 months. Serious infections (CMV, generalized herpes simplex, fatal aspergillosis and mycobacterium pneumonia) were noted, especially in patients who had received at least three prior treatment regimens. Alemtuzumab therapy requires antibiotic and antiviral prophylaxis as well as close observation for the development of infection and cardiac toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A low-dose, intermittent administration schedule of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    may reduce infectious complications in patients with MF. A prospective dose escalation trial of subcutaneous alemtuzumab found the following schedule to be effective and well tolerated: 3mg on day 1 followed by 10mg on alternating days until reaching a target reduction of S&eacute;zary cells (&lt;1000",
"    <span class=\"nowrap\">",
"     cells/mm3)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/94\">",
"     94",
"    </a>",
"    ]. None of the 10 patients who received this dosing schedule developed infectious complications or severe hematologic toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     Bortezomib",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proteosome inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    was evaluated in a phase II trial of 12 patients with relapsed or refractory CTCL or peripheral T cell lymphoma unspecified with isolated skin involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/95\">",
"     95",
"    </a>",
"    ]. Patients were given six cycles of bortezomib (1.3",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV days 1,4,8, and 11 of a 21 day cycle). The drug was well tolerated and demonstrated an overall response rate of 67 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5654579\">",
"    <span class=\"h3\">",
"     Pralatrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/43/29366?source=see_link\">",
"     Pralatrexate",
"    </a>",
"    is a novel antifolate that has demonstrated clinical activity in T cell lymphomas. High rates of thrombocytopenia and mucosal inflammation seen in trials of pralatrexate in peripheral T cell lymphoma resulted in an interest in using lower doses for the treatment of mycosis fungoides. A prospective dose de-escalation trial design was used in a study of 54 patients with relapsed or refractory cutaneous T cell lymphoma to identify a pralatrexate dose with significant activity in MF, but with an acceptable toxicity profile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/96\">",
"     96",
"    </a>",
"    ]. The preferred regimen was low dose pralatrexate 15",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per week administered for three out of four weeks along with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    1 mg by mouth daily and vitamin B12 injections every other month. Of the 29 patients treated with this regimen of low dose pralatrexate, responses were seen in 13 (45 percent) after a median of four treatment cycles. Toxicity was generally mild. The most common adverse effects seen at this dose and schedule were stomatitis, fatigue,",
"    <span class=\"nowrap\">",
"     nausea/vomiting,",
"    </span>",
"    skin toxicity, edema, anemia, and pyrexia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h3\">",
"     Other treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biological response modifiers, IFN, and retinoids have been used alone, together [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/51\">",
"     51",
"    </a>",
"    ], in combination with topical therapy (eg, IFN and PUVA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/22\">",
"     22",
"    </a>",
"    ], or in combination chemotherapy regimens for stage IV disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/71,97\">",
"     71,97",
"    </a>",
"    ]. Further studies are needed to determine the efficacy of these less frequently used combination regimens in patients with extracutaneous disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As an example, the combination of IFN and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      resulted in a response rate of 46 percent with a median response duration of 6.5 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/98\">",
"       98",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A subset of patients with erythrodermic (T4) MF with limited nodal disease may respond well to photopheresis alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/63\">",
"       63",
"      </a>",
"      ] or in combination with IFN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/60\">",
"       60",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Extracorporeal photochemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Megavoltage (4 to 15 MeV) photon irradiation can be used for palliative control of lymph node disease. Total doses of 30 to 36 Gy are delivered over three to four weeks providing local control of lymph nodes or visceral disease. This is often combined with systemic chemotherapy or IFN, depending upon the severity of the extracutaneous involvement.",
"     </li>",
"     <li>",
"      Total skin electron beam therapy (TSEBT) may be used in combination with systemic agents in stage IV disease, especially when the cutaneous involvement is very extensive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/6,99\">",
"       6,99",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Total skin electron beam therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Combination chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with refractory or frequently relapsing tumor disease may require a combination of systemic therapies, either with biologic therapies or a combination of biologic therapy and chemotherapy, with or without topical therapy. Combination chemotherapy may result in faster responses, but there is no clear advantage to early aggressive combination therapy when compared with conservative sequential therapies in the management of advanced stage disease.",
"   </p>",
"   <p>",
"    The most effective and commonly used combinations include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/4,100-102\">",
"     4,100-102",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , and adriamycin (CHOP) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/100\">",
"       100",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (CVP) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/100\">",
"       100",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      , adriamycin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      (CAVE) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/4,101\">",
"       4,101",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      CVP with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (COMP) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/102\">",
"       102",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Interferon-alfa, systemic retinoids, or photopheresis may be used as an adjuvant agent after completion of the chemotherapy regimen. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interferon-alfa has been used in combination with systemic retinoids with a response rate of approximately 55 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/51,52\">",
"       51,52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Various chemotherapy regimens have been used in combination with TSEBT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/4,73,99\">",
"       4,73,99",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with hematopoietic cell transplantation (HCT) in MF is limited to a small number of case reports and case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/1,103-113\">",
"     1,103-113",
"    </a>",
"    ]. Responses to autologous HCT appear to be common yet short-lived with a median estimated time to disease progression of a little over two months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/1\">",
"     1",
"    </a>",
"    ]. By comparison, allogeneic HCT may offer durable remissions in a subset of patients, perhaps due to a graft-versus-tumor effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/1,109,112\">",
"     1,109,112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complete remission following allogeneic HCT has been described in several single patient case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/107-110\">",
"     107-110",
"    </a>",
"    ] and small case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/1,106\">",
"     1,106",
"    </a>",
"    ]. Eligibility and preparative regimens used have varied across studies.",
"   </p>",
"   <p>",
"    The largest study was an international retrospective analysis of patients with MF (36 patients) or S&eacute;zary syndrome (24 patients) who underwent related (75 percent) or unrelated allogeneic HCT with myeloablative (27 percent) or reduced intensity (73 percent) conditioning regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/103\">",
"     103",
"    </a>",
"    ]. After a median follow-up of 36 months, the following outcomes were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The estimated overall survival rates at one and three years were 66 and 53 percent, respectively. Survival was worse in patients who had an unrelated donor, myeloablative conditioning regimen,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      advanced phase disease at the time of transplantation.",
"     </li>",
"     <li>",
"      The estimated progression-free survival rates at one and three years were 42 and 34 percent, respectively. Relapse occurred in 26 patients at a median of 3.8 months after HCT. Of these, 17 underwent donor lymphocyte infusion (DLI) and 10 achieved a complete or partial response after DLI.",
"     </li>",
"     <li>",
"      The 100-day cumulative incidence of acute graft-versus-host disease (GVHD) was 40 percent. The cumulative incidence of chronic GVHD was 32 and 48 percent at one and two years post-HCT, respectively.",
"     </li>",
"     <li>",
"      Non-relapse mortality was 20 percent at one year. Factors associated with non-relapse mortality were myeloablative conditioning regimens and poor performance status at the time of HCT. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Allogeneic HCT appears to be most successful after initial disease control with induction therapy and before disease progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/35/36410/abstract/68,103\">",
"     68,103",
"    </a>",
"    ]. Patients with stage IIB or greater MF who have failed multiple systemic therapies and are not candidates for or have failed an adequate trial of skin-directed therapy should be referred for possible allogeneic HCT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h1\">",
"     EMERGING NOVEL THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with refractory skin involvement or extracutaneous disease should be considered candidates for enrollment in a clinical trial of novel agents. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mycosis fungoides (MF) is an extranodal, indolent non-Hodgkin lymphoma of T cell origin that primarily develops in the skin, but can ultimately involve the lymph nodes, blood, and visceral organs. S&eacute;zary syndrome is a more aggressive leukemic variant of cutaneous T cell lymphoma (CTCL) in which a significant number of circulating malignant (S&eacute;zary) cells are observed in the peripheral blood.",
"   </p>",
"   <p>",
"    Advanced stage (IIB to IV) MF is a heterogeneous group that encompasses those patients that present with extracutaneous disease or advanced skin lesions (eg, tumors) (",
"    <a class=\"graphic graphic_table graphicRef75768 graphicRef53711 \" href=\"mobipreview.htm?6/60/7119\">",
"     table 1A-B",
"    </a>",
"    ). Patients with advanced stage disease generally require systemic therapy. In addition, patients with early stage disease who demonstrate the more aggressive folliculotropic or transformed large cell variants of MF and those with blood involvement are treated as more advanced disease.",
"   </p>",
"   <p>",
"    The standard staging system for MF is based upon an evaluation of the skin (T), lymph nodes (N), visceral involvement (M), and blood (B) (",
"    <a class=\"graphic graphic_table graphicRef75768 graphicRef53711 \" href=\"mobipreview.htm?6/60/7119\">",
"     table 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75528 \" href=\"mobipreview.htm?18/6/18541\">",
"     table 2",
"    </a>",
"    ). Details are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4713?source=see_link&amp;anchor=H1118879#H1118879\">",
"     \"Staging and prognosis of mycosis fungoides and S&eacute;zary syndrome\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most patients with limited extent tumor (stage IIB) disease, we suggest treatment with localized radiation to the tumors plus skin-directed therapy as needed for concurrent",
"      <span class=\"nowrap\">",
"       patch/plaque",
"      </span>",
"      disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For those who cannot receive radiation, systemic therapies are an acceptable alternative. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Tumor (stage IIB) limited extent disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with generalized stage IIB disease without blood involvement or those with large cell transformation, equally acceptable treatment options are the use of total skin electron beam therapy (TSEBT) or systemic therapies. TSEBT can be followed by other skin-directed therapies or systemic therapies to prolong response duration. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Tumor (stage IIB) extensive disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with stage IIIA MF, we typically administer both a skin directed therapy (eg, topical steroids) and a systemic therapy (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/10/31904?source=see_link\">",
"       bexarotene",
"      </a>",
"      ). Other clinicians use skin-directed therapy alone and then proceed to systemic therapies upon progression of failure of response. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Stage IIIA disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with stage IIIB MF, we recommend the use of a systemic therapy with or without skin directed therapies rather than skin directed therapies alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Stage IIIB disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approach to the management of a patient with stage IV disease is stratified by whether the patient has S&eacute;zary syndrome:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For most patients with S&eacute;zary syndrome, stage IVA1 MF, we recommend the use of a systemic therapy with or without skin directed therapies rather than skin directed therapies alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Where available, we prefer nonimmunosuppressive systemic therapies, such as extracorporeal photochemotherapy (ECP), for this patient population. In patients with high blood tumor burden, combination systemic biologic therapies or histone deacetylase (HDAC) inhibitors are usually needed. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Stage IV disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with stage IVA2 MF with S&eacute;zary syndrome, management is similar to those with stage IVA1. For patients with non-S&eacute;zary IVA2 or for patients with solid organ IVB disease, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/2/3110?source=see_link\">",
"       romidepsin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/57/918?source=see_link\">",
"       denileukin diftitox",
"      </a>",
"      , or systemic chemotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Combination chemotherapy may lead to faster responses but there is no advantage to early aggressive combination therapy when compared with conservative sequential therapies in the management of advanced stage disease. Local radiation therapy may be used in conjunction with systemic therapy for local control of visceral disease or lymph node involvement. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Stage IV disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Relapsed or refractory MF is generally treated according to the stage of disease at the time of relapse. In addition, patients with stage IIB or greater MF who have failed multiple systemic therapies and are not candidates for or have failed an adequate trial of skin-directed therapy should be referred for possible allogeneic HCT. (See",
"    <a class=\"local\" href=\"#H46\">",
"     'Hematopoietic cell transplantation'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/1\">",
"      Duarte RF, Schmitz N, Servitje O, Sureda A. Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant 2008; 41:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/2\">",
"      Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/S&eacute;zary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 2010; 28:4730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/3\">",
"      Kim YH, Liu HL, Mraz-Gernhard S, et al. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 2003; 139:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/4\">",
"      Kaye FJ, Bunn PA Jr, Steinberg SM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989; 321:1784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/5\">",
"      Jones GW, Tadros A, Hodson DI, et al. Prognosis with newly diagnosed mycosis fungoides after total skin electron radiation of 30 or 35 GY. Int J Radiat Oncol Biol Phys 1994; 28:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/6\">",
"      Wilson LD, Licata AL, Braverman IM, et al. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. Int J Radiat Oncol Biol Phys 1995; 32:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/7\">",
"      Chinn DM, Chow S, Kim YH, Hoppe RT. Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int J Radiat Oncol Biol Phys 1999; 43:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/8\">",
"      Navi D, Riaz N, Levin YS, et al. The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides. Arch Dermatol 2011; 147:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/9\">",
"      Jones GW, Kacinski BM, Wilson LD, et al. Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol 2002; 47:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/10\">",
"      Wobser M, G&ouml;ppner D, Lang SC, et al. Durable complete remission of therapy-refractory, tumor-stage cutaneous T-cell lymphoma under radioimmunotherapy with electron beam irradiation and denileukin diftitox. Arch Dermatol 2010; 146:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/11\">",
"      Hoppe RT, Fuks Z, Bagshaw MA. Radiation therapy in the management of cutaneous T-cell lymphomas. Cancer Treat Rep 1979; 63:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/12\">",
"      Kamstrup MR, Specht L, Skovgaard GL, Gniadecki R. A prospective, open-label study of low-dose total skin electron beam therapy in mycosis fungoides. Int J Radiat Oncol Biol Phys 2008; 71:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/13\">",
"      Neelis KJ, Schimmel EC, Vermeer MH, et al. Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas. Int J Radiat Oncol Biol Phys 2009; 74:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/14\">",
"      Harrison C, Young J, Navi D, et al. Revisiting low-dose total skin electron beam therapy in mycosis fungoides. Int J Radiat Oncol Biol Phys 2011; 81:e651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/15\">",
"      Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19:2456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/16\">",
"      Talpur R, Ward S, Apisarnthanarax N, et al. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2002; 47:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/17\">",
"      Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001; 137:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/18\">",
"      Abbott RA, Whittaker SJ, Morris SL, et al. Bexarotene therapy for mycosis fungoides and S&eacute;zary syndrome. Br J Dermatol 2009; 160:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/19\">",
"      Sherman SI, Gopal J, Haugen BR, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 1999; 340:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/20\">",
"      Scarisbrick JJ, Morris S, Azurdia R, et al. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J Dermatol 2013; 168:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/21\">",
"      Olsen EA, Rosen ST, Vollmer RT, et al. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol 1989; 20:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/22\">",
"      Kuzel TM, Roenigk HH Jr, Samuelson E, et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the S&eacute;zary syndrome. J Clin Oncol 1995; 13:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/23\">",
"      Chiarion-Sileni V, Bononi A, Fornasa CV, et al. Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma. Cancer 2002; 95:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/24\">",
"      Gardner JM, Introcaso CE, Nasta SD, et al. A novel regimen of vorinostat with interferon gamma for refractory S&eacute;zary syndrome. J Am Acad Dermatol 2009; 61:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/25\">",
"      Roenigk HH Jr, Kuzel TM, Skoutelis AP, et al. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol 1990; 95:198S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/26\">",
"      Mostow EN, Neckel SL, Oberhelman L, et al. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA. Arch Dermatol 1993; 129:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/27\">",
"      Kuzel TM, Roenigk HH Jr, Samuelson E, Rosen ST. Suppression of anti-interferon alpha-2a antibody formation in patients with mycosis fungoides by exposure to long-wave UV radiation in the A range and methoxsalen ingestion. J Natl Cancer Inst 1992; 84:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/28\">",
"      Itri LM, Campion M, Dennin RA, et al. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa-2a by intramuscular injection. Cancer 1987; 59:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/29\">",
"      Woo S, Gardner ER, Chen X, et al. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res 2009; 15:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/30\">",
"      Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009; 27:5410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/31\">",
"      Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010; 28:4485.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022393lbl.pdf (Accessed on November 06, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/33\">",
"      Munster PN, Rubin EH, Van Belle S, et al. A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. Clin Cancer Res 2009; 15:7077.",
"     </a>",
"    </li>",
"    <li>",
"     Romidepsin: Treatment of Cutaneous T-cell Lymphoma (CTCL), including Relief of Pruritus, in Patients who have Received at Least One Prior Systemic Therapy. Sponsor's Background Package for the Oncologic Drugs Advisory Committee Meeting Scheduled for September 2, 2009. (Available at file://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM180633.pdf, accessed February 11, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/35\">",
"      Zhang C, Richon V, Ni X, et al. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 2005; 125:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/36\">",
"      O'Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006; 24:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/37\">",
"      Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/38\">",
"      O'Connor OA. Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma. Br J Cancer 2006; 95(S1):S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/39\">",
"      Duvic M, Zhang C. Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma. Br J Cancer. 2006; 95(S1):S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/40\">",
"      Mann BS, Johnson JR, He K, et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res 2007; 13:2318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/41\">",
"      Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25:3109.",
"     </a>",
"    </li>",
"    <li>",
"     Zolinza prescribing information file://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021991s004lbl.pdf (Accessed on February 11, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/43\">",
"      Williams DP, Snider CE, Strom TB, Murphy JR. Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J Biol Chem 1990; 265:11885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/44\">",
"      LeMaistre CF, Saleh MN, Kuzel TM, et al. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 1998; 91:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/45\">",
"      Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/46\">",
"      Kazin R, Bujanauskas P, Vonderheid EC. Durable complete remission of mycosis fungoides following erythroderma induced by denileukin diftitox. J Am Acad Dermatol 2008; 58:S31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/47\">",
"      Carretero-Margolis CD, Fivenson DP. A complete and durable response to denileukin diftitox in a patient with mycosis fungoides. J Am Acad Dermatol 2003; 48:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/48\">",
"      Prince HM, Duvic M, Martin A, et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 2010; 28:1870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/49\">",
"      Olsen E, Duvic M, Martin A, et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak&trade;) for the treatment of cutaneous T-cell lymphoma (CTCL). J Invest Dermatol 1998; 110:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/50\">",
"      Talpur R, Jones DM, Alencar AJ, et al. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol 2006; 126:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/51\">",
"      Dr&eacute;no B. Roferon-A (interferon alpha 2a) combined with Tigason (etretinate) for treatment of cutaneous T cell lymphomas. Stem Cells 1993; 11:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/52\">",
"      Knobler RM, Trautinger F, Radaszkiewicz T, et al. Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids. J Am Acad Dermatol 1991; 24:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/53\">",
"      Herrmann JJ, Roenigk HH Jr, Hurria A, et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol 1995; 33:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/54\">",
"      H&ouml;nigsmann H, Brenner W, Rauschmeier W, et al. Photochemotherapy for cutaneous T cell lymphoma. A follow-up study. J Am Acad Dermatol 1984; 10:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/55\">",
"      Abel EA, Sendagorta E, Hoppe RT, Hu CH. PUVA treatment of erythrodermic and plaque-type mycosis fungoides. Ten-year follow-up study. Arch Dermatol 1987; 123:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/56\">",
"      Herrmann JJ, Roenigk HH Jr, H&ouml;nigsmann H. Ultraviolet radiation for treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995; 9:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/57\">",
"      Zackheim HS, Kashani-Sabet M, Hwang ST. Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. J Am Acad Dermatol 1996; 34:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/58\">",
"      Holloway KB, Flowers FP, Ramos-Caro FA. Therapeutic alternatives in cutaneous T-cell lymphoma. J Am Acad Dermatol 1992; 27:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/59\">",
"      Lim HW, Edelson RL. Photopheresis for the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995; 9:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/60\">",
"      Gottlieb SL, Wolfe JT, Fox FE, et al. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution. J Am Acad Dermatol 1996; 35:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/61\">",
"      Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 1987; 316:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/62\">",
"      Arulogun S, Prince HM, Gambell P, et al. Extracorporeal photopheresis for the treatment of S&eacute;zary syndrome using a novel treatment protocol. J Am Acad Dermatol 2008; 59:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/63\">",
"      Heald P, Rook A, Perez M, et al. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol 1992; 27:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/64\">",
"      Evans AV, Wood BP, Scarisbrick JJ, et al. Extracorporeal photopheresis in S&eacute;zary syndrome: hematologic parameters as predictors of response. Blood 2001; 98:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/65\">",
"      Suchin KR, Cucchiara AJ, Gottleib SL, et al. Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution. Arch Dermatol 2002; 138:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/66\">",
"      Richardson SK, Lin JH, Vittorio CC, et al. High clinical response rate with multimodality immunomodulatory therapy for S&eacute;zary syndrome. Clin Lymphoma Myeloma 2006; 7:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/67\">",
"      Wilson LD, Jones GW, Kim D, et al. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides. J Am Acad Dermatol 2000; 43:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/68\">",
"      Horwitz SM, Olsen EA, Duvic M, et al. Review of the treatment of mycosis fungoides and s&eacute;zary syndrome: a stage-based approach. J Natl Compr Canc Netw 2008; 6:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/69\">",
"      Edelson RL. Cutaneous T cell lymphoma: the helping hand of dendritic cells. Ann N Y Acad Sci 2001; 941:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/70\">",
"      Knobler R, Jantschitsch C. Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphoma. Transfus Apher Sci 2003; 28:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/71\">",
"      Bunn PA Jr, Hoffman SJ, Norris D, et al. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the S&eacute;zary syndrome). Ann Intern Med 1994; 121:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/72\">",
"      Rosen ST, Foss FM. Chemotherapy for mycosis fungoides and the S&eacute;zary syndrome. Hematol Oncol Clin North Am 1995; 9:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/73\">",
"      Duvic M, Apisarnthanarax N, Cohen DS, et al. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2003; 49:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/74\">",
"      Sarris AH, Phan A, Duvic M, et al. Trimetrexate in relapsed T-cell lymphoma with skin involvement. J Clin Oncol 2002; 20:2876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/75\">",
"      Coors EA, von den Driesch P. Treatment of erythrodermic cutaneous T-cell lymphoma with intermittent chlorambucil and fluocortolone therapy. Br J Dermatol 2000; 143:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/76\">",
"      Onozuka T, Yokota K, Kawashima T, et al. An elderly patient with mycosis fungoides successfully treated with chronic low-dose oral etoposide therapy. Clin Exp Dermatol 2004; 29:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/77\">",
"      Rijlaarsdam JU, Huijgens PC, Beljaards RC, et al. Oral etoposide in the treatment of cutaneous large-cell lymphomas. A preliminary report of four cases. Br J Dermatol 1992; 127:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/78\">",
"      Prince HM, Duvic M, Martin A, et al. Incidence of spontaneous remission in patients with CD25-positive mycosis fungoides/S&eacute;zary syndrome receiving placebo. J Am Acad Dermatol 2012; 67:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/79\">",
"      Wollina U, Dummer R, Brockmeyer NH, et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 2003; 98:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/80\">",
"      Quereux G, Marques S, Nguyen JM, et al. Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or S&eacute;zary syndrome. Arch Dermatol 2008; 144:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/81\">",
"      Di Lorenzo G, Di Trolio R, Delfino M, De Placido S. Pegylated liposomal doxorubicin in stage IVB mycosis fungoides. Br J Dermatol 2005; 153:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/82\">",
"      Pulini S, Rupoli S, Goteri G, et al. Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas. Haematologica 2007; 92:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/83\">",
"      Dummer R, Quaglino P, Becker JC, et al. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol 2012; 30:4091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/84\">",
"      Zinzani PL, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 2000; 18:2603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/85\">",
"      Duvic M, Talpur R, Wen S, et al. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 2006; 7:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/86\">",
"      Zinzani PL, Venturini F, Stefoni V, et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 2010; 21:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/87\">",
"      Marchi E, Alinari L, Tani M, et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 2005; 104:2437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/88\">",
"      Von Hoff DD, Dahlberg S, Hartstock RJ, Eyre HJ. Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: a Southwest Oncology Group study. J Natl Cancer Inst 1990; 82:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/89\">",
"      Mercieca J, Matutes E, Dearden C, et al. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 1994; 12:2588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/90\">",
"      Greiner D, Olsen EA, Petroni G. Pentostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1997; 36:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/91\">",
"      Tsimberidou AM, Giles F, Duvic M, et al. Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series. Cancer 2004; 100:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/92\">",
"      Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003; 101:4267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/93\">",
"      Lenihan DJ, Alencar AJ, Yang D, et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/S&eacute;zary syndrome. Blood 2004; 104:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/94\">",
"      Bernengo MG, Quaglino P, Comessatti A, et al. Low-dose intermittent alemtuzumab in the treatment of S&eacute;zary syndrome: clinical and immunologic findings in 14 patients. Haematologica 2007; 92:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/95\">",
"      Zinzani PL, Musuraca G, Tani M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25:4293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/96\">",
"      Horwitz SM, Kim YH, Foss F, et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2012; 119:4115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/97\">",
"      Duvic M, Lemak NA, Redman JR, et al. Combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1996; 34:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/98\">",
"      Foss FM, Ihde DC, Breneman DL, et al. Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/S&eacute;zary syndrome. J Clin Oncol 1992; 10:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/99\">",
"      Winkler CF, Sausville EA, Ihde DC, et al. Combined modality treatment of cutaneous T cell lymphoma: results of a 6-year follow-up. J Clin Oncol 1986; 4:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/100\">",
"      Grozea PN, Jones SE, McKelvey EM, et al. Combination chemotherapy for mycosis fungoides: a Southwest Oncology Group study. Cancer Treat Rep 1979; 63:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/101\">",
"      Braverman IM, Yager NB, Chen M, et al. Combined total body electron beam irradiation and chemotherapy for mycosis fungoides. J Am Acad Dermatol 1987; 16:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/102\">",
"      Case DC Jr. Combination chemotherapy for mycosis fungoides with cyclophosphamide, vincristine, methotrexate, and prednisone. Am J Clin Oncol 1984; 7:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/103\">",
"      Duarte RF, Canals C, Onida F, et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and S&eacute;zary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28:4492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/104\">",
"      Bigler RD, Crilley P, Micaily B, et al. Autologous bone marrow transplantation for advanced stage mycosis fungoides. Bone Marrow Transplant 1991; 7:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/105\">",
"      Olavarria E, Child F, Woolford A, et al. T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement. Br J Haematol 2001; 114:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/106\">",
"      Molina A, Zain J, Arber DA, et al. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol 2005; 23:6163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/107\">",
"      Koeppel MC, Stoppa AM, Resbeut M, et al. Mycosis fungoides and allogenic bone marrow transplantation. Acta Derm Venereol 1994; 74:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/108\">",
"      Molina A, Nademanee A, Arber DA, Forman SJ. Remission of refractory Sezary syndrome after bone marrow transplantation from a matched unrelated donor. Biol Blood Marrow Transplant 1999; 5:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/109\">",
"      Burt RK, Guitart J, Traynor A, et al. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graft-versus-tumor effect. Bone Marrow Transplant 2000; 25:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/110\">",
"      Masood N, Russell KJ, Olerud JE, et al. Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantation. J Am Acad Dermatol 2002; 47:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/111\">",
"      Hosing C, Donato M, Khouri IF, et al. Allogeneic hematopoietic stem cell transplantation for cutaneous T-cell lymphoma (CTCL) (abstract). J Clin Oncol 2006; 24:432s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/112\">",
"      Duvic M, Donato M, Dabaja B, et al. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J Clin Oncol 2010; 28:2365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/35/36410/abstract/113\">",
"      Schlaak M, Pickenhain J, Theurich S, et al. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. Cochrane Database Syst Rev 2012; 1:CD008908.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4759 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-77.94.48.4-8E67DEBC9C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_35_36410=[""].join("\n");
var outline_f35_35_36410=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H48\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TUMOR (STAGE IIB) LIMITED EXTENT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Localized treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Systemic treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TUMOR (STAGE IIB) EXTENSIVE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Total skin electron beam therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - TSEBT administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - TSEBT toxicities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Systemic retinoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Retinoid administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Retinoid toxicities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Interferon",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - IFN administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Romidepsin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Vorinostat",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Vorinostat toxicities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Denileukin diftitox",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      STAGE IIIA DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Topical therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Retinoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      PUVA therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Low dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      STAGE IIIB DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Extracorporeal photochemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - ECP technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - ECP toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      STAGE IV DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Extracorporeal photopheresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Single agent chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Pegylated liposomal doxorubicin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Gemcitabine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Purine and pyrimidine analogs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Alemtuzumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - Bortezomib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5654579\">",
"      - Pralatrexate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      - Other treatments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Combination chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      EMERGING NOVEL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4759\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4759|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/34/11822\" title=\"table 1A\">",
"      Mycosis fungoides TNMB classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/56/15245\" title=\"table 1B\">",
"      Mycosis fungoides clinical staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/6/18541\" title=\"table 2\">",
"      Pretreatment evaluation MF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40138?source=related_link\">",
"      Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/6/18536?source=related_link\">",
"      Central hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/32/4618?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=related_link\">",
"      Infusion reactions to systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/51/28474?source=related_link\">",
"      Lipid lowering with diet or dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/42/22184?source=related_link\">",
"      Oral isotretinoin therapy for acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4713?source=related_link\">",
"      Staging and prognosis of mycosis fungoides and S&eacute;zary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17017?source=related_link\">",
"      Treatment of early stage (IA to IIA) mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/17/4378?source=related_link\">",
"      Treatment of hairy cell leukemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_35_36411="Collagenous v lymphocytic";
var content_f35_35_36411=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinicopathologic features of lymphocytic and collagenous colitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lymphocytic colitis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Collagenous colitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Median age and range, years",
"       </td>",
"       <td>",
"        58 (55 to 77)",
"       </td>",
"       <td>",
"        58 (41 to 84)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Female-to-male ratio",
"       </td>",
"       <td>",
"        3:1",
"       </td>",
"       <td>",
"        15:1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Type of diarrhea",
"       </td>",
"       <td>",
"        Secretory",
"       </td>",
"       <td>",
"        Secretory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mean fecal weight, grams",
"       </td>",
"       <td>",
"        712 (317 to 1269)",
"       </td>",
"       <td>",
"        565 (246 to 1438)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Pathologic features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Percent of lamina propria space occupied by inflammatory cells (normal 47&plusmn;2)",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        68",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Types of inflammatory cells in lamina propria",
"       </td>",
"       <td>",
"        Mainly plasma cells and neutrophils",
"       </td>",
"       <td>",
"        Mainly plasma cells and neutrophils",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Subepithelial collagen band (normal &lt;3.65 &micro;M)",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Abnormally thick",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Lee, E, Schiller, LR, Vendrell, D, et al, Gastroenterology 1992; 103:1790.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_35_36411=[""].join("\n");
var outline_f35_35_36411=null;
var title_f35_35_36412="Indicators of Clostridium difficile infection in children";
var content_f35_35_36412=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71790&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71790&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indicators of Clostridium difficile infection in children*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Signs of invasive illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever (&ge;102&deg;F [38.9&deg;C])",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        White blood cells: Neutrophilia (&gt;10,000 neutrophils/microL) immature neutrophilia (&gt;500 bands/microL), or increased immature to total neutrophil (&gt;0.15)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevated ESR ( &ge;40 mm/) or CRP (&ge;4 mg/dL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fecal leukocytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoalbuminemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unusually severe (volume, frequency [&gt;3 stools/day], abdominal pain), persistent (&ge;5 days), or bloody diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute abdomen with no stool due to ileus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Radiographic evidence of colitis:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        a. Plain film: Bowel wall thickening, dilatation, thumb-printing, ascites, pleural effusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        b. Ultrasound: Bowel wall thickening; ascites, pleural effusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        c. CT: Bowel wall thickening, dilatation, accordion sign, mural enhancement, fat stranding, ascites, pleural effusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pseudomembranous colitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Predisposing conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antibiotics in the past 6 weeks (note that about one-third cases had no prior antibiotics)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        More than one antibiotic in the past 6 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recent hospitalization, particularly in a unit known to have had patients with C. difficile disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proton pump inhibitor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammatory bowel disease, Hirschsprung's colitis, hemolytic-uremic syndrome, or anaphylactoid purpura. Early recognition of C. difficile in IBD flares can be life saving.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunodeficiency. The child may have a known immunodeficiency, or C. difficile disease may be the first suggestion of an immunodeficiency, eg, transient hypogammaglobulinemia of infancy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Structural or post-operative intestinal disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cystic fibrosis with distal intestinal obstruction syndrome plus inflammatory signs above",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infant botulism or other motility disorders",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Although there is no established standard, we suggest at least two or more of these indicators should lead to diagnostic testing for children older than five years, and that three or more should be present if the child is younger than five years. Simultaneous isolation of a plausible alternative enteric pathogen greatly reduces the likelihood that identified C. difficile toxin is meaningful.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael S. Cooperstock, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_35_36412=[""].join("\n");
var outline_f35_35_36412=null;
var title_f35_35_36413="Atom with electrons orbiting the nucleus";
var content_f35_35_36413=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atom with electrons orbiting the nucleus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 239px; height: 246px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With excitation, an electron moves from an inner shell (1) to an outer shell (2), thereby defining the atom at ground state and excited state.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_35_36413=[""].join("\n");
var outline_f35_35_36413=null;
var title_f35_35_36414="Staging uterine sarcoma";
var content_f35_35_36414=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59860&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59860&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Staging uterine sarcoma (TNM and International Federation of Gynecology and Obstetrics [FIGO])",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Primary tumor (T)*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       TNM categories",
"      </td>",
"      <td class=\"subtitle2\">",
"       FIGO stages",
"      </td>",
"      <td class=\"subtitle2\" colspan=\"2\">",
"       Definition",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"4\">",
"       Leiomyosarcoma and endometrial stromal sarcoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       TX",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td colspan=\"2\">",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       T0",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td colspan=\"2\">",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3_start\">",
"       T1",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       I",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"2\">",
"       Tumor limited to the uterus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       T1a",
"      </td>",
"      <td class=\"sublist_other\">",
"       IA",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"2\">",
"       Tumor 5 cm or less in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       T1b",
"      </td>",
"      <td class=\"sublist_other\">",
"       IB",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"2\">",
"       Tumor more than 5 cm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3_start\">",
"       T2",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       II",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"2\">",
"       Tumor extends beyond the uterus, within the pelvis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       T2a",
"      </td>",
"      <td class=\"sublist_other\">",
"       IIA",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"2\">",
"       Tumor involves adnexa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       T2b",
"      </td>",
"      <td class=\"sublist_other\">",
"       IIB",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"2\">",
"       Tumor involves other pelvic tissues",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3_start\">",
"       T3",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       III&bull;",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"2\">",
"       Tumor infiltrates abdominal tissues",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       T3a",
"      </td>",
"      <td class=\"sublist_other\">",
"       IIIA",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"2\">",
"       One site",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       T3b",
"      </td>",
"      <td class=\"sublist_other\">",
"       IIIB",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"2\">",
"       More than one site",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       T4",
"      </td>",
"      <td>",
"       IVA",
"      </td>",
"      <td colspan=\"2\">",
"       Tumor invades bladder or rectum",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"4\">",
"       Adenosarcoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       TX",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td colspan=\"2\">",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       T0",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td colspan=\"2\">",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3_start\">",
"       T1",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       I",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"2\">",
"       Tumor limited to the uterus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       T1a",
"      </td>",
"      <td class=\"sublist_other\">",
"       IA",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"2\">",
"       Tumor limited to the endometrium/endocervix",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       T1b",
"      </td>",
"      <td class=\"sublist_other\">",
"       IB",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"2\">",
"       Tumor invades to less than half of the myometrium",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       T1c",
"      </td>",
"      <td class=\"sublist_other\">",
"       IC",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"2\">",
"       Tumor invades more than half of the myometrium",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3_start\">",
"       T2",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       II",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"2\">",
"       Tumor extends beyond the uterus, within the pelvis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       T2a",
"      </td>",
"      <td class=\"sublist_other\">",
"       IIA",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"2\">",
"       Tumor involves adnexa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       T2b",
"      </td>",
"      <td class=\"sublist_other\">",
"       IIB",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"2\">",
"       Tumor involves other pelvic tissues",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3_start\">",
"       T3",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       III&bull;",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"2\">",
"       Tumor involves abdominal tissues",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       T3a",
"      </td>",
"      <td class=\"sublist_other\">",
"       IIIA",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"2\">",
"       One site",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       T3b",
"      </td>",
"      <td class=\"sublist_other\">",
"       IIIB",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"2\">",
"       More than one site",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       T4",
"      </td>",
"      <td>",
"       IVA",
"      </td>",
"      <td colspan=\"2\">",
"       Tumor invades bladder or rectum",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Regional lymph nodes (N)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       TNM categories",
"      </td>",
"      <td class=\"subtitle2\">",
"       FIGO stages",
"      </td>",
"      <td class=\"subtitle2\" colspan=\"2\">",
"       Definition",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"4\">",
"       Leiomyosarcoma and endometrial stromal sarcoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       NX",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td colspan=\"2\">",
"       Regional lymph nodes cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       N0",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td colspan=\"2\">",
"       No regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       N1",
"      </td>",
"      <td>",
"       IIIC",
"      </td>",
"      <td colspan=\"2\">",
"       Regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"4\">",
"       Adenosarcoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       NX",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td colspan=\"2\">",
"       Regional lymph nodes cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       N0",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td colspan=\"2\">",
"       No regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       N1",
"      </td>",
"      <td>",
"       IIIC",
"      </td>",
"      <td colspan=\"2\">",
"       Regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Distant metastasis (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       TNM categories",
"      </td>",
"      <td class=\"subtitle2\">",
"       FIGO stages",
"      </td>",
"      <td class=\"subtitle2\" colspan=\"2\">",
"       Definition",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"4\">",
"       Leiomyosarcoma and endometrial stromal sarcoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       M0",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td colspan=\"2\">",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       M1",
"      </td>",
"      <td>",
"       IVB",
"      </td>",
"      <td colspan=\"2\">",
"       Distant metastasis (excluding adnexa, pelvic and abdominal tissues)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"4\">",
"       Adenosarcoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       M0",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td colspan=\"2\">",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       M1",
"      </td>",
"      <td>",
"       IVB",
"      </td>",
"      <td colspan=\"2\">",
"       Distant metastasis (excluding adnexa, pelvic and abdominal tissues)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Anatomic stage/prognostic groups",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Uterine sarcomas",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Stage I",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Stage IA&Delta;",
"      </td>",
"      <td>",
"       T1a",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Stage IB&Delta;",
"      </td>",
"      <td>",
"       T1b",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Stage IC&loz;",
"      </td>",
"      <td>",
"       T1c",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Stage II",
"      </td>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Stage IIIA",
"      </td>",
"      <td>",
"       T3a",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Stage IIIB",
"      </td>",
"      <td>",
"       T3b",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Stage IIIC",
"      </td>",
"      <td>",
"       T1, T2, T3",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Stage IVA",
"      </td>",
"      <td>",
"       T4",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Stage IVB",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: Uterine carcinosarcomas are staged using the system for uterine carcinoma.",
"    <br>",
"     Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"     <div class=\"footnotes\">",
"      * Simultaneous tumors of the uterine corpus and ovary/pelvis in association with ovarian/pelvic endometriosis should be classified as independent primary tumors.",
"      <br>",
"       &bull; In this stage lesions must infiltrate abdominal tissues and not just protrude into the abdominal cavity.",
"       <br>",
"        &Delta; Stage IA and IB are different for leiomyosarcoma / endometrial stromal sarcoma than for adenosarcoma.",
"        <br>",
"         &loz; Stage IC does not apply for leiomyosarcoma and endometrial stromal sarcoma.",
"        </br>",
"       </br>",
"      </br>",
"     </div>",
"     <div class=\"reference\">",
"      Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_35_36414=[""].join("\n");
var outline_f35_35_36414=null;
var title_f35_35_36415="Shoulder stretch";
var content_f35_35_36415=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flexibility exercise: Shoulder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 302px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This exercise to stretch your shoulder muscles will help improve your posture.",
"    <ol>",
"     <li>",
"      Stand back against a wall, feet shoulder-width apart and arms at shoulder height.",
"     </li>",
"     <li>",
"      Bend your elbows so your fingertips point toward the ceiling and touch the wall behind you. Stop when you feel a stretch or slight discomfort, and stop immediately if you feel sharp pain.",
"     </li>",
"     <li>",
"      Hold position for 10 to 30 seconds.",
"     </li>",
"     <li>",
"      Let your arms slowly roll forward, remaining bent at the elbows, to point toward the floor and touch the wall again, if possible. Stop when you feel a stretch or slight discomfort.",
"     </li>",
"     <li>",
"      Hold position for 10 to 30 seconds.",
"     </li>",
"     <li>",
"      Alternate pointing above head, then toward hips.",
"     </li>",
"     <li>",
"      Repeat at least three to five times.",
"     </li>",
"    </ol>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: file://go4life.niapublications.org (Accessed December 2, 2011).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_35_36415=[""].join("\n");
var outline_f35_35_36415=null;
